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Genome-wide association studies (GWAS) have successfully identified thousands of 
single nucleotide polymorphisms (SNPs) associated with complex traits and diseases 
of human. Meta-analysis of multiple GWASs has become a popular method since it 
increases the statistical power and reduces false positive findings. In the genetic 
field, fine mapping is a process of identifying independently associated variants 
within a genomic region, which improves our understanding of the causal 
mechanisms underlying human diseases. However, data sharing among different 
studies is usually unavailable for meta-analysis of a large number of studies. Fine 
mapping of genetic variation under the current meta-analysis system is 
administratively onerous and time consuming. Therefore, statistical approaches 
which can process fine mapping analysis using meta-analysis summary statistics are 
assuming increasing importance.  
This thesis is concerned with the development of two fine mapping methods using 
meta-analysis summary statistics: Sequential Sentinel SNP Regional Association 
Plots (SSS-RAP) and haplotype-based regional association analysis program 
(HAPRAP). SSS-RAP detects SNPs with independent effects conditional on the top 
associated signal using meta-analysis summary statistics and summary pair-wise 
SNPs haplotype frequencies obtained from reference genotype panel. I 
demonstrate that SSS-RAP is as powerful as conditional analysis and ten model 
selection methods in individual-level. I applied SSS-RAP to meta-analysis of 
Electrocardiography (ECG) traits, gallbladder disease (GBD) traits and GIANT BMI 
database. In addition, HAPRAP is an empirical EM style approach, which extends 
multiple regression and conditional analysis to meta-analysis levels. I demonstrate 
that HAPRAP is statistically outperforming existing methods in meta-analysis level. I 
applied HAPRAP to meta-analysis for ECG traits. Finally, I discuss the position of 
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CHAPTER 1. INTRODUCTION 
1.1. Background of human genetics 
Human genetics is the study of inheritance as it occurs in human beings. Here, I will 
give a brief overview of the human genetics concepts, including human genome, 
Deoxyribonucleic Acid (DNA), gene, gene expression, genetic variation and genetic 
disorder.  
1.1.1. Human genome  
The human genome is composed of approximately 3 billion base pairs 
(International Human Genome Sequencing Consortium, 2004). The human genome 
is composed of 23 pairs of chromosome (Figure 1-1). 22 autosomes and the one 
pair of sex-determining chromosomes: X/X (female) or X/Y (male). Each 




Figure 1-1. Human Genome 
(http://www.edinformatics.com/math_science/human_genome.htm).  
1.1.2. Deoxyribonucleic Acid (DNA) 
Human genome is encoded by deoxyribonucleic acid (DNA). DNA is a double 
stranded biopolymer composed of nucleotides. Each nucleotide includes a ribose 
sugar, phosphate group and one of four nitrogenous bases: Thymine (T), Cytosine 
(C), Guanine (G) or Adenine (A) (Levene, 1919). The nucleotides are paired up to 
one another (noted as base pair) in a chain by covalent bonds between the sugar of 
one nucleotide and the phosphate of the next, resulting in a backbone. According 
to base pairing rules, A will only bind with T and C will only bind with G.  
1.1.3. Genes 
The term gene together with the laws of inheritance was illustrated by Gorger 
Mendel around 150 years ago (MENDEL, 1950). His famous experiment on pea 
plant hybridization illustrated that a certain genomic region controlled the 
inheritabilities of some phenotypic characteristics, such as seed shape and pod 
colour. A simple definition of gene is a region of DNA that encodes for a protein. 
The pathway is DNA transcript to RNA and ribonucleic acids (RNA) translate to 
amino acid. The Encyclopaedia of Genetic Elements (ENCODE) consortium have 
recently updated definition of a gene as “a union of genomic sequences encoding a 
coherent set of potentially overlapping functional products” (Gerstein et al., 2007). 
This definition takes into account the considerable genomic complexity in the 
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human genome, for example, the non-genic regions of the genome which shows 
high conservation and the enrichment of non-coding RNA.  
1.1.4. Gene expression 
Gene expression is a procedure in which DNA and genes are used to synthesise 
gene products, i.e. ribonucleic acid (RNA) and proteins. The Central Dogma of 
Molecular Biology described this process as a one-way system consists of two steps: 
firstly DNA is transcribed into RNA, and secondly RNA is translated into proteins 
(Crick, 1970). 
Transcription 
Transcription is the first step in gene expression. In this step, the linear nucleotide 
sequence of DNA is copied by a RNA polymerase into a linear nucleotide sequence 
in RNA (Strachan and Read, 2011). RNA is classified into several categories based on 
functions: if the gene is translated (as explained below) into a protein, the gene 
product is called messenger RNA (mRNA); otherwise, the gene product is called 
non-coding RNA (ncRNA), i.e. transfer RNA (tRNA) or ribosomal RNA (rRNA) (Storz, 
2002). 
Translation 
After DNA has been transcribed into mRNA, the linear nucleotide sequence of 
mRNA will be decoded by cellular ribosome three bases at a time. This process will 
produce a linear sequence of amino acids, and then amino acids will bind into a 
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protein. Recently, with the understanding of open reading frames (ORF), the new 
estimate of the number of protein-coding genes are ~ 21,000 (Clamp et al., 2007).   
 
Alternative splicing  
The underlying assumption for the above process is called the one gene-one 
enzyme hypothesis, which assumes that a single gene encodes for one RNA or one 
protein. In fact, it is possible for a single gene to produce multiple functional 
transcripts, which is called alternative splicing. There are several different ways 
where alternative splicing forms, i.e. alternative 5-prime donor, 3-prime acceptor 
sites and exon skipping (Black, 2003). Chen et al estimated that ~ 90% of genes 
within human genome go through alternative splicing (Chen et al., 2012).  
1.1.5. Genetic Variation 
The sequence of human genome is changeable during generations (Strachan and 
Read, 2011). The change of sequence, called genetic variation, are normally caused 
by a number of sources: i.e. errors during DNA replication or environmental 
exposures. Genetic variation provides the basis of natural selection mutations 
(Duret, 2009). Mutations can either neutral, beneficial or deleterious to people / 
causal to diseases (Chapter 1.3.1).   
The human genome is highly analogous: 99.9% of the entire genome of two 
unrelated individuals are the same at the nucleotide level (Collins and Mansoura, 
2001). The remaining 0.01% genome was classified into three main categories: 
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single nucleotide polymorphisms (SNPs), Insertions and deletions (termed INDELs) 
and structural variation.   
Single nucleotide polymorphisms 
Single nucleotide polymorphisms (SNPs) are genomic variants changing only one 
single nucleotide base. Approximately 90% of sequence variants in human are SNPs 
(Collins et al., 1998). In human genome, SNPs occur approximately once every 1000 
bases averagely (Wang et al., 1998). In fact, SNPs are tend to be clustered in the 
genome instead of randomly distributed (Koboldt et al., 2006).  
SNPs fall either within or outside protein-coding regions in the human genome. 
There are three possible effects on the translation of a protein sequence of SNPs 
within protein-coding regions:  
1. Silent or synonymous SNPs are variants which change the nucleotide 
sequence, but do not modify the amino acid sequence of a protein.  
2. Missense or non-synonymous SNPs are variants which modify the 
nucleotide sequence and the amino acid sequence.  
3. Nonsense SNPs are variants which change the nucleotide sequence so that 
the codon is substituted by a codon encoding for a premature stop. The 
consequence of a nonsense SNP is usually producing of a shorter and 
unfinished protein or longer, completely destroys function  
Although coding variants are important, recent estimates of human exome only 
accounts for little more than 1% of DNA in the human genome (Maher, 2012). On 
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the other hand, SNPs falling outside exon regions are called non-coding SNPs. SNPs 
occur in non-coding regions more frequently than in coding regions, in general, 
where natural selection is acting and fixating the allele of the SNP that constitutes 
the most favourable genetic adaptation (Barreiro et al., 2008). Non-coding SNPs 
have no effect on the translation of a protein sequence. However, the activity and 
expression of protein-coding genes can be regulated by a variety of DNA elements 
called regulome, i.e. promoter, enhancer, transcriptional regulatory sequences, 
regions of chromatin structure and histone modification (ENCODE Project 
Consortium et al., 2012). It is thought that changes in the regulation of gene activity 
can disrupt protein production and cell processes and result in disease (ENCODE 
Project Consortium et al., 2012). Mapping the position of these regulatory elements 
and how they influence gene transcription could show associations between 
variations in the expression of certain genes and the development of diseases 
(ENCODE Project Consortium, 2004).  
As described above, the primary goal of the ENCODE project is to determine the 
role of the remaining component of the genome, much of which was traditionally 
regarded as "junk" (Maher, 2012). 
Insertions and deletions 
Insertions and deletions (also note as INDELs) are the second most common class of 
genetic variation in human genome (Montgomery et al., 2013). They are defined as 
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a gain/loss of up to 50 nucleotide bases. Similar to SNPs, INDELS can fall within or 
outside of protein-coding regions of the human genome as well.  
INDELs that fall within protein-coding regions have two possible effects on the 
translation of a protein sequence: 
1. INDELs consisting of a number of nucleotides that cannot be evenly divided 
by three will cause a shift in Open Reading Frame (ORF), which is called 
frame-shifting (FS). FS will result in translation of a different amino acid 
sequence. 
2. INDELs consisting of a number of nucleotides that can be evenly divided by 
three will not cause a shift in ORF, which is called non-frame-shifting (NFS). 
NFS will not alter the translation of the remaining protein sequence.  
In addition, INDELs outside protein-coding regions, i.e. intronic and intergenic 
regions, are called non-coding INDELs. They will not cause any downstream effect 
on the translation of a protein sequence. But, same as non-coding SNPs, non-coding 
INDELs can affect the regulation and splicing, which could be associated with the 
development of diseases. 
Structural variation 
Structural variations are large variation with in the human genome. Both copy 
number variants (CNVs), inversions and translocations are in this category 
(Weischenfeldt et al., 2013).  
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1. CNVs occur when a segment of DNA sequence appears in variable number 
of copies compared to the reference genome.  
2. Inversions occur when a segment of DNA sequence is reversed in direction 
in comparison to the rest of the chromosome.  
3. Translocations occur when a segment of DNA has modified its position 
within the genome 
Based on their feature, large structural variations are often cause serious 
phenotypic consequences, which include human diseases such as Down’s 
syndrome-where an extra copy of chromosome 21 is appeared; and DiGeorge 
syndrome-where a part of chromosome 22 is deleted.  
1.1.6. Genetic disorder 
One key research field in human genetics is to understand the inheritance of 
disorders as it occurs in human beings. A genetic disorder is a disease caused by 
abnormalities of the human genome. It can be classified into two classes based on 
the number of gene involved in the disorder.  
Monogenic disorder 
A monogenic disorder is the result of a single mutated gene. In reality, monogenic 




They normally show familial aggregation with Mendelian pattern (term Mendelian 
disease) of inheritance model, which include:  
1. Autosomal dominant, where only one mutated copy of the gene will be 
needed for a person to be affected by an autosomal disorder. Each affected 
patient usually has one affected parent. The chance that a child inherits the 
mutated gene is 50%. Autosomal dominant disorders sometimes have 
reduced penetrance, which means the percentage of individuals who inherit 
the mutation develop the disease is less than 100%, i.e. Huntington's 
disease (Kay et al., 2014).  
2. Autosomal recessive, where two mutated copies of the gene are needed for 
a person to be affected by an autosomal disorder. In the family pedigree, an 
affected child usually has unaffected parents who carry a single copy of the 
mutated gene (called carriers). For a child of two carriers, the chance of 
him/her affected by the disorder is 25%. Example of autosomal recessive 
disorder includes wet versus dry earwax (Yoshiura et al., 2006) (Rodriguez 
et al., 2013). 
3. X-linked disorders, which are caused by variation on the X chromosome. 
Males and females are both influenced by these disorders. But males will 
affected by them more seriously since male have only one copy of the X 
chromosome. Examples of X-linked dominant disorders includes Rett 
syndrome (Chattopadhyay and Arora, 2014) and Aicardi syndrome 
(Prontera et al., 2013). For X-linked recessive disorders, the sons of a man 
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with an X-linked recessive disorder will not inherit the disorder, but his 
daughters will inherit one copy of the variant. For a woman carrier, the 
chance of her son/daughter will carry the copy of the variant is 50%. 
Example of X-linked recessive disorder incudes some serious diseases, i.e. 
hemophilia A (Aledort et al., 2014) 
4. Y-linked disorders, where are caused by mutations on the Y chromosome. 
This disorder can only be passed from the men to their sons. Y-linked 
disorders are rare. A typically Y-linked disorder is infertility (Krausz and 
Chianese, 2014)                                                                                
Individual monogenic diseases are relatively rare, and affect fewer than 200,000 
people for each disorder. However, the most famous database for Mendelian 
disorders-Oline Mendelian Inheritance in Man (OMIM) have involved 5188 
phenotypes, of which the molecular basis is known until early 2014 
(http://www.ncbi.nlm.nih.gov/omim).  
Polygenic inheritance  
The majority of human diseases and traits with high prevalence are polygenic 
inheritance (term multifactorial or complex inheritance), i.e. cardiovascular disease, 
cancer and so on. They can be caused by the effects of multiple genes together with 
the effect of environmental and behavioural factors. Unlike monogenic disorder, 
researchers cannot classify their pattern of inheritance simply into several 
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categories. Polygenic inheritance patterns normally follow a normal (bell-shaped) 
distribution curve. It shows continuous variation 
In early 1900s, Fisher claimed that the heritability of quantitative human traits can 
be explained by Mendelian patterns of inheritance if they were the result of a 
combination of variation at many genetic loci and the interaction between loci, 
including the influence of environmental factors which affect these traits (Fisher, 
1918) (Plomin et al., 2009).  
An classic example of polygenic inheritance is the human skin colour. Globally, we 
can observe continuous variation in skin colours. The colour of the skin is the result 
of pigments, such as melanin. As far as we know, the skin colour is controlled by at 
least three separate genes, each with their own alleles. Assume that three 
"dominant" capital letter genes (A, B and C) control dark pigmentation because 
more melanin is produced. The "recessive"alleles of these three genes (a, b & c) 
control light pigmentation because lower amounts of melanin are produced. The 
words dominant and recessive are placed in quotation marks because these pairs of 
alleles are not truly dominant and recessive as in some of the garden pea traits that 
Gregor Mendel studied. A genotype with all "dominant" capital genes (AABBCC) has 
the maximum amount of melanin and very dark skin. A genotype with all 
"recessive" small case genes (aabbcc) has the lowest amount of melanin and very 
light skin. Each "dominant" capital gene produces one unit of color, so that a wide 
range of intermediate skin colors are produced, depending on the number of 
"dominant" capital genes in the genotype. For example, a genotype with three 
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"dominant" capital genes and three small case "recessive" genes (AaBbCc) has a 
medium amount of melanin and an intermediate skin color. This latter genotype 
would be characteristic of a mulatto. In the following cross between two mulatto 
genotypes (AaBbCc x AaBbCc), each parent produces eight different types of 
haplotypes and these haplotypes combine with each other in 64 different ways 
resulting in a total of seven skin colours. The skin colours can be represented by the 
number of capital letters, ranging from zero (no capital letters) to six (all capital 
letters). 
 
1.2. Population genetics concepts  
Population genetics is the study of the distributions and changes of allele frequency 
in a population. Changes of allele frequency can be either caused by chromosomal 
recombination during meiosis or by mutations (Hartl, 2007).  
1.2.1. Allele frequencies 
Allele frequency, which is the core concept in population genetics, represents the 
proportion of a particular alleles (of a genetic variant) at a given locus in the allele 
pool of a certain population (Klug, 2012). 
Hardy-Weinberg Equilibrium (HWE) 
Hardy-Weiberg Equilibrium is a common assumption for population genetics, which 
states that frequencies of allele and genotype-which is the genetic makeup of a 
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person-in a population will remain constant from one generation to next 
generation given that there is no other evolutionary influence. Other influences 
include non-random mating, mutation, selection, genetic drift, gene flow 
and meiotic drive. But in fact, one or more of these influences are typically present 
in real populations (Ewens, 2004). In a simple example of one single locus with 
two alleles, A and a. Assume the allele frequency of allele A is: 
!(#) = &  
And allele frequency of allele a is:  
!(') = ( 
Under HWE, the estimated genotype frequencies then become: 
!(##) = 	&* for the AA homozygotes, 
!('') = 	(* for the aa homozygotes, 
!(#') = 	2&( or !('#) = 	2&( for the heterozygotes. 
The sum of three genotypes is: 
&* + 2&( + (* = 	 (&	 + ()* 
Since the sum of the frequencies of allele A and a are equal to 1: 
& + ( = 1 
Then the sum of the genotypes will be equal to 1 as well. These genotype 
proportions (p2, 2pq, and q2) are called the Hardy-Weinberg proportions.  
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Calculation of allele frequencies 
For biallelic SNPs (where the locus only has two alleles), the allele frequencies of 
the locus can be calculated as a reverse calculation of HWE genotype proportions:  
If f(AA), f(Aa) and f(aa) are the three genotype frequencies at a locus with two 
alleles, then the frequency p of the A-allele and the frequency q of the a-allele are 
obtained by calculating alleles counts. Because each homozygote AA consists only 
of A-alleles, and because half of the alleles of each heterozygote Aa are A-alleles, 
the total frequency p of A-alleles in the population is calculated as follows: 
& = !(##) +
1
2
!(#') = !./(0/123	4!	# 
In the same way, the frequency q of the a-allele can be calculated as:  
( = !('') +	
1
2
!(#') = !./(0/123	4!	' 
As explained above p and q sum to 1, so: 
( = 1 − &	 
& = 1 − ( 
Based on allele frequencies, genetic variants can be classified into several 
categories: variants with minor allele frequencies (MAF) > 1% are called common 
variants; variants with MAF < 1% are normally called rare variants. More specifically, 
Alharbi et al have defined the rarer variants with MAF between 0.1%- 5% as 
“paucimorphism” (Alharbi et al., 2005).  
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1.2.2. Disease-variant Hypothesis and 
missing heritability 
Thousands of genome-wide association (GWA) studies (details in Chapter 1.3.4) 
have been carried out with the common disease common variant (CDCV) 
hypothesis. It assumes that common genetic variants, each with small effect (Reich 
and Lander, 2001), sum up to account for a reasonable proportion of the variance 
in the phenotype (Lander, 1996). In addition, as discussed above the selective 
disadvantage conferred by highly penetrant monogenic mutations results in their 




Figure 1-2. Relationship between allele frequencies of genetic variants and 
penetrance of diseases/traits. 
Typically, only variants with minor allele frequency (MAF) greater than 1% are 
followed up in such studies. There are two reasons for this cut-off:  
Firstly, there is an inverse relationship between sample size and the MAF that 
maximizes the power to detect a true association (Figure 1-3) (Gorlov et al., 2008).  
 
Figure 1-3. Relationship between power and sample size with different MAF (Gorlov 
et al., 2008) 
Secondly, as listed in Table 1-1, SNP genotyping panels are typically designed for 
common SNPs, therefore they contain a relatively small number of rare variants 
(Asimit and Zeggini, 2010). These common variants explain at most 5%–10% of the 














MAF<0.05 55k 106k 9k 32k 35k 62k 
MAF<0.01 17k 35k 1k 7k 8k 22k 
Table 1-1. Approximate-low frequency / rare variant GWAS platform content. K 
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means thousand and M means million (Asimit and Zeggini, 2010).  
To address the “missing heritability” problem, researchers further developed 
Fisher’s polygenic inheritance theory (Chapter 1.1.6), which assume that may small 
genetic effects (most of them not reach the genome-wide significance) working 
together influence the total heritability of complex traits in human populations 
since 2010. Based on this theory, Peter Visscher’s lab developed a user friendly 
method called Genome-wide Complex Trait Analysis (GCTA), which estimate the 
proportion of variance for complex traits using a restricted maximum likelihood 
model (REML) (Yang et al, 2011). The same group estimated the proportion of 
variance for human height explained by SNPs across the whole genome on 3,925 
unrelated individuals using REML, and validated the estimation method with 
simulations based on the observed genotype data. The analysis show that 45% of 
variance can be explained by considering all SNPs simultaneously. They concluded 
that most of the heritability is not missing but has not previously been detected 
because the individual effects are too small to pass stringent significance tests (Yang 
et al, 2010). This method together with the example on height open a door for 
population genetics field. Another major application of the polygenic inheritance 
theory is polygenic score. The first successful application of polygenic score analysis 
to GWAS data was in schizophrenia. Later in 2013, Frank Dudbridge estimated the 
power and predictive accuracy of polygenic risk score (Dudbridge, 2013). 
Furthermore, Speed et al claimed that if variance explained is correlated with MAF, 
the estimates of heritability and genetic covariance can be biased and developed a 
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method, LDAK, to address such issue (Speed et al, 2012). Utilising a similarly idea, 
Benjamin Neale’s group developed an approach, LD Score regression, that 
quantifies the contribution of each SNP by examining the relationship between test 
statistics and linkage disequilibrium (LD). The LD Score regression intercept can be 
used to estimate a more powerful and accurate correction factor than genomic 
control. The model is a simple fixed effect model, which regress test statistics 
(square of Z score) from GWAS against LD score (Bulik-Sullivan et al, 2015 a). 
Another advantage of such setting is that LD score regression can be applied to 
meta-analysis summary statistics directly. The meta-analysis data is also the major 
resource I will going to use in my work, which I will explained in more detail in 
Chapter 1.3.6. The LD score regression model was further developed so that it can 
process the bivariate genetic correlation analysis later on (Bulik-Sullivan et al, 2015 
b). 
In contrast to common variants, rare variants have larger effects than common ones. 
As shown in Figure 1-4, the advantage of testing rare variants association is that the 
effects of rare variants tend to be larger than those of higher frequency SNPs 
(Bodmer and Bonilla, 2008). In addition, the identification of rare variants may 
facilitate pinpointing causality. It will be easier to infer causality at a locus that 




Figure 1-4. Comparison of odds ratio between rare and common variants (Bodmer 
and Bonilla, 2008).  
1.2.3. Linkage disequilibrium, haplotypes 
and haplotype phasing  
A central issue in population genetics is whether it is possible to map causal genes 
to diseases. Linkage disequilibrium (LD) plays a key role in this issue.  
Linkage disequilibrium 
LD refers to correlation between neighboring alleles, reflecting combination of 
alleles (noted as haplotypes) descended from single, ancestral chromosomes (Reich 
et al., 2001). Several factors will affect the degree of linkage disequilibrium, which 
including genetic linkage, selection, the rate of recombination, the rate 
of mutation, genetic drift, non-random mating, and population structure. To 
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estimate the amount linkage disequilibrium, we used the difference between 
observed allelic frequencies and the expected allelic frequencies from a randomly 
distributed population.  
If the haplotype frequencies of several genetic variants fit the expected proportions, 
they are noted as in linkage equilibrium to each other. 
Haplotypes and haplotype phase 
In population genetics field, a haplotype is a combination of alleles at a certain 
genomic region (or loci) (Reich et al., 2001). A haplotype can be one locus, several 
loci, or even an entire chromosome depending on the length of genomic region we 
are interested in and number of recombination events that have occurred inside 
the region. 
For a simplest model containing two SNPs, SNP A and SNP B, the haplotype will be 
A1B1, A1B2, A2B1 and A2B2 with haplotype frequencies X11, X12, X21 and X22 
respectively. The allele frequencies of A1 A2 B1 and B2 are p1, p2 q1 and q2 
respectively (Table 1-2).  
  A1 A2 Total 
B1 X11=p1q1+D X21=p2q1-D q1 
B2 X12=p1q2-D X22=p2q2+D q2 
Total p1 p2 1 
Table 1-2. Example of a 2X2 haplotype table 
If SNP A and SNP B are in LD, X11 is equal to p1 * q1+D, where D is the quantity of 
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linkage disequilibrium between the two SNPs. A more common measure of LD is 





Where 89:; = <
min(&1 ∗ (1, &2 ∗ (2) 	Bℎ/1	8 < 0
min(&1 ∗ (2, &2 ∗ (1) 	Bℎ/1	8 > 0
 
Another commonly used measure of LD is called r2 (Hill and Robertson, 1968). R2 is 
the correlation coefficient between a pair of SNPs, which is equal to: 
.* = 	
8*
&1 ∗ &2 ∗ (1 ∗ (2
 
For a certain GWAS, if individual-level genotype data is available, the four haplotype 
frequencies (denoted as X11, X12, X21 and X22 in this chapter) can be easily 
calculated using programs such as PLINK (Purcell et al., 2007), CubeX (Gaunt et al., 
2007) and MIDAS (Gaunt et al., 2006).  
For the same 2 SNPs model shown in Table 1-2, assume locus 1 has alleles A or T 
and the locus 2 has G or C. For each locus, there are three possible genotypes: AA, 
AT and TT for locus 1; GG, GC and CC for locus 2. For a certain individual, the 
genotype may not define the haplotype uniquely, since there are 10 possible 
genotypes but there are only 9 possible haplotypes at these two loci (Table 1-3). 
The double heterozygote A1B1-A2B2 have two possible genotypes (eithr AG-TC or 
AC-TG). This unknown middle cell is called haplotype uncertainty and the technique 
to infer the haplotype is therefore called haplotype phase.  
 
  Locus 1 
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A1A1 A1B1 B1B1 
(AA) (AT) (TT) 
Locus 2 
A2A2 (GG) AG AG AG TG TG TG 
A2B2 (GC) AG AC 
AG TC or 
AC TG 
TG TC 
B2B2 (CC) AC AC AC TC TC TC 
Table 1-3. Haplotypes and haplotype uncertainty 
Haplotype phase can be generated through laboratory-based experimental 
methods, or it can be estimated using computational approaches. The lab-based 
methods need to spend extra fees to genotype members in the family. On the other 
hand, computational approaches can phase haplotypes accurately from genotypes 
without any further cost (haplotype phasing tool will be introduced in Chapter 2).  
Haplotypes phasing tools 
As described in Chapter 1, haplotype phasing is an important process to estimate 
the haplotype uncertainty. In this chapter, I shall describe some well-known 
computational haplotype phasing tools, including PHASE (Stephens et al., 2001), 
BEAGLE (Browning and Browning, 2007), MACH (Li et al., 2010) and IMPUTE2 
(Howie et al., 2009).  
PHASE 
PHASE is a haplotype phasing algorithm, which is useful for small genomic regions 
(up to coupe hundred SNPs) and small sample sizes (up to one thousand 
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individuals) but relatively slow compared to the other tools I shall describe below 
(Stephens et al., 2001) (Stephens and Scheet, 2005). PHASE was considered to be 
the gold standard amongst population-based haplotype phasing algorithms for a 
long time (Marchini et al., 2006) before updated tools were developed. Two 
important updates / refinements of PHASE algorithm is fastPHASE (Scheet and 
Stephens, 2006) and SHAPE-IT (Delaneau et al., 2012). FastPHASE is the first 
method that is capable of phasing genome-wide SNP array data. SHAPE-IT includes 
PHASE algorithm but much faster and can be applied to high-throughput 
genotyping chips data and whole genome sequencing data.  
BEAGLE 
BEAGLE is a hidden Markov model (HMM) based algorithm to infer haplotypes 
(Browning and Browning, 2007). It is faster and more accurate than fastPHASE for 
medium and large sample sizes (i.e. more than 1000 individuals) but it is not as 
accurate as fastPHASE for small sample sizes (100 or less individuals). This is 
because fastPHASE uses Expectation-Maximization (E-M) algorithm which is more 
accurate than the HMM when a small number of SNPs in a short gene are to be 
studied. When the number of SNPs in the model increase, the number of haplotype 
will increase rapidly. This will cause two problems, a) the haplotype frequencies of 
rare variants will be too small to estimate directly; b)the computational time will 
become intractable since all haplotypes need be considered (Browning and 
Browning, 2007).   
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MACH and IMPUTE2 
MACH (Li et al., 2010) and IMPUTE2 (Howie et al., 2009) are designed for genotype 
imputation of untyped variants (I will introduce imputation in the next section). 
However, these algorithms can also be used for haplotype phasing. These two 
methods can be used for much larger datasets than PHASE and can return more 
accurate results for large sample sizes when compared to fastPHASE. The accuracy 
of both methods can be improved by increasing the complexity of the model, for 
example increase the number of HMM states so that the methods can make better 
use of the information in the data. But that will cost more computational time 
(Browning and Browning, 2011).  
 
1.2.4. Genotype Imputation 
The success of HapMap and 1000 Genome project has enabled researches to 
identify tagging SNPs (smaller subset of SNPs) across the whole human genome. 
Using HapMap and 1000 Genome data as reference panel, we can now then impute 
the haplotypes, haplotype frequencies and allele frequencies of hundreds of 
thousands un-typed SNPs. This process is called genotype imputation. As, shown in 
Figure 1-5, for unrelated individuals in a population, the raw data consist of a set of 
genotyped SNPs that has a large number of SNPs without any genotype data (part 
a). Testing for association at just these SNPs may not lead to a significant 
association (part b). Imputation attempts to predict these missing genotypes. 
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Algorithms differ in their details but all essentially involve phasing each individual in 
the study at the typed SNPs. The figure highlights three phased individuals (part c). 
These haplotypes are compared to the dense haplotypes in the reference panel 
(part d). Strand alignment between data sets must be done before this comparison 
takes place. The phased study haplotypes have been coloured according to which 
reference haplotypes they match. This highlights the idea implicit in most phasing 
and imputation models that the haplotypes of a given individual are modelled as a 
mosaic of haplotypes of other individuals. Missing genotypes in the study sample 
are then imputed using those matching haplotypes in the reference set (part e). In 
real examples, the genotypes are imputed with uncertainty and a probability 
distribution over all three possible genotypes is produced. It is necessary to take 
account of this uncertainty in any downstream analysis of the imputed data. Testing 
these imputed SNPs can lead to more significant associations (part f) and a more 




Figure 1-5. Example of genotype imputation (Marchini and Howie, 2010) 
Imputation has now become an essential process during GWAS studies. Imputation 
has the potential to increase the power of GWAS and provide a high resolution 
overview of an association signals across a locus (which is meaningful for fine 
mapping) and is particularly useful for combining the GWAS results across studies 
that rely on different genotyping platforms (i.e. meta-analysis) (Li et al., 2009).  
We can classify imputation tools into two categories: computationally intensive 
tools and computationally efficient tools.    
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Computationally intensive tools: MACH, minimac and 
IMPUTE2 
Computational intensive tools, such as MACH (Li et al., 2010) and IMPUTE2 (Howie 
et al., 2009), take into account all observed genotypes when imputing each missing 
genotype.  
Typically, tools that consider all available markers and all available haplotypes 
require intensive computation but do better at estimating missing genotypes, 
particularly for rare SNPs (Li et al., 2009). Both MACH and IMPUTE2 are based on 
coalescent models to impute the missing genotypes. These models are based on 
the fact that new haplotypes are developed from old haplotypes by the processes 
of mutation and recombination. Since mutations and recombination are quite rare 
inside small genomic regions, haplotypes tend to look similar to each other. So, for 
instance, if we see two haplotypes, e.g. 1000 and 0010 in a sample (where 0 and 1 
are the two possible alleles at the four loci), we have better chance of observing the 
haplotype 1010 (caused by recombination) or 1100 (caused by mutation) than 
observing the haplotype 1110 (caused by both a recombination and a mutation) 
(Browning and Browning, 2011). The approximate coalescent gives rise to a HMM, 
and its parameters are estimated with the use of iterative algorithms such as the 
stochastic E-M algorithm (Tregouet et al., 2004). One advantage of IMPUTE2 is that 




Minimac (Howie et al., 2012) is a low memory, computationally efficient 
implementation of the MACH algorithm. Now, a two-step procedure is recommend. 
The first step is a pre-phasing step using MACH. This step is time consuming step 
but it is only need once. The second step is the actual imputation into phased 
haplotypes using minimac and is very fast (i.e. one million markers for 1000 
individuals using 100 reference haplotypes takes about an hour, and computing 
time increases linearly with all these parameters) 
(http://genome.sph.umich.edu/wiki/Minimac:_1000_Genomes_Imputation_Cookb
ook).  
Computationally efficient tools: PLINK and BEAGLE  
Computationally efficient tools, like PLINK (Purcell et al., 2007) and BEAGLE 
(Browning and Browning, 2007), typically only focus on genotypes for a small 
number of nearby markers when imputing each missing genotype. PLINK used an 
E-M algorithm for genotype imputation function while BEAGLE used an HMM 
model to impute the missing genotype.  
Performance comparison 
In a comprehensive comparison between BEAGLE, IMPUTE, MACH and PLINK, 
Nothnagel M et al concluded that BEAGLE, IMPUTE, and MACH yielded nearly 
identical trade-offs between imputation accuracy and efficacy whereas PLINK 
performed consistently poorer (Nothnagel et al., 2009). A more recent comparison 
made by “GoldenHelix” compared BEAGLE, IMPUTE2 and Minimac for accuracy, 
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computational time and memory usage (http://blog.goldenhelix.com/?p=1911). 
They concluded that IMPUTE2 is the most accurate method; however one of the 
disadvantages of the method was it’s the intensive memory usage. BEAGLE and 
Minimac use much less memory but need more computational time. Besides, 
pre-phasing will decrease the accuracy while save a lot of time. On the other hand, 
BEAGLE seems like the most user friendly program with good manual. So choosing 
the most appropriate imputation programme is a trade-off between imputation 
quality, computational time and memory usage.  
 
1.3. Mapping genetic variants to complex 
traits 
For each human being, on average approximately 3.5 million SNPs and 610,000 
INDELs have been identified in the whole genome averagely (Pelak et al., 2010). 
Characterising the relationship between genetic variants and complex human 
disease/trait susceptibilities will lead to a better understanding of the aetiologies of 
human diseases. Here I will explain the background knowledge of genetic mapping 
first.    
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1.3.1. Phenotypes and phenotype 
standardization 
In human genetics field, a phenotype is a composite of a human being’s observable 
characteristics or traits, i.e. type 2 diabetes or height.  
A phenotype is normally caused by the expression of human genes, the influence of 
environmental factors, and their interactions: 
Genotype (G) + environment (E) + genotype & environment interactions → 
phenotype (P) 
Almost all of the traits can fall into two major distinct classes: binary outcomes and 
continuous traits.  
Binary outcomes (disease status) 
Binary data is a data type which can take on only two possible values: i.e. “success” 
or “failure”, “yes” or “no”, “true” or “false” and “present” or “absent”. In the 
human genetics field, binary outcomes often represent the disease status. 
Numerically, these two values are normally coded as 0 and 1, where 0 means 
absent and 1 means present. Binary data is the simplest type of categorical data. 
Randomly selected binary variables follow the Bernoulli distribution. Regression 
analysis on/given outcomes that are binary variables is mainly accomplished 
through logistic regression. 
31 
 
Continuous traits (quantitative traits) 
Most of traits do not fall into discrete classes. Rather, when a certain population is 
analysed, a continuous distribution of phenotypes can be identified. These 
continuous values are called quantitative traits. Many human phenotypes can be 
classified into this class, which including height, weight, blood pressure and so on. 
Regression analysis on predicted traits that are continuous variables is majorly 
accomplished through linear regression. Most quantitative traits can be attributed 
to polygenic disorders, i.e. product of multiple genes and environmental factors. 
Quantitative traits from random selection need follows the approximately normal 
distribution so that linear regression can be used to analyse these traits. 
Standardization 
In probability theory, the normal (or Gaussian) distribution is a very common 
continuous probability distribution. The normal distribution is sometimes informally 
called the bell curve. For most of the statistical analysis in population genetics field, 
we need a phenotype which follows an approximate normal distribution. For raw 
phenotype data which are not normal distributed, we can standardise them using 
the following ways:   
1. Standard score, also called Z-score, is the number of standard deviations 
an observation is away from the mean. The use of “Z” is because the 
normal distribution is also called the “Z distribution”.  







Where μ is the mean of the population and σ is the standard deviation of 
the population. 
The value of z represents the difference between the observed value and 
the mean of the population in units of the standard deviation. Z is negative 
when the raw value is smaller than the mean and positive when bigger 
than the mean.  
One advantage of Z-score is that it does not have a unit, therefore we can 
compare traits with different units after we standardized them.  
2. Logarithm transformation, the logarithm of a number is the exponent to 
which the base must be raised to produce that number.  
3 = K; 	<=> L4MN(3) 
The logarithm transformation can only be applied when data are strictly 
positive. Two kinds of logarithms are used frequently: “natural” logarithms 
(irrational number e as its base) and base-10 logarithms. 
The log transformation can be used to make highly skewed distributions 
less skewed. This can be valuable both for making the data more 




1.3.2. Association analysis for candidate 
genes 
Another classic method, which is still a useful follow-up approach nowadays, is the 
candidate gene analysis (Westaway et al., 2011). The scientists will select a gene (or 
a group of candidate genes) based on their biological knowledge and prior 
experience. Then they will sequence the gene (genes) for genetic variants in a 
group of people with / without a phenotype (or some relative phenotypes). Finally, 
they will try to identify the association between the variants and phenotypes. This 
approach is highly possible to be failed in certain genes and also lacks of replication 
since the knowledge on the molecular mechanisms of these phenotype is uncertain 
(Richardson et al., 2013). 
1.3.3. Genome-wide association study 
(GWAS) 
Genome-wide association study (GWAS) extend the association analysis approach 
to the whole human genome. The formal definition of GWAS is a statistical test 
which are performed using dense maps of common SNPs (or note as single 
nucleotide polymorphism-SNP) on a group of participants from a study. The study 
can be either a disease-based cases-control design or exposure-based cohort 
design.  
GWAS offered the opportunity for the “hypothesis-free” analysis to understand the 
disease pathophysiology, which will overcome the difficulties and obstacles of the 
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traditional candidate gene approach (Kitsios and Zintzaras, 2009). Since GWAS 
includes a huge amount of genetic markers, it is more likely to identify the truly 
causal variant or the proxy variants in strong LD with the causal variants. But the 
side effect of GWAS-multiple testing-will increases the chance of false positive 
findings. In statistics, the multiple comparisons, multiplicity or multiple testing 
problem occurs when one considers a set of statistical inferences simultaneously 
(Benjamini, 2010). Bonferroni correction is the most common way to counteract the 
problem of multiple testing (Bonferroni, 1936), which is simply divide the test-wise 
significance level (O) by the number of tests (N), the significance level after 





For GWAS, N is the number of SNPs involved in the test. So given the large multiple 
testing in GWAS, very few signals exceed the genome-wide significance threshold 
and those that do not exceed this stringent statistical requirement are generally 
neglected (Kitsios and Zintzaras, 2009).  
The first GWAS were proposed by Risch and Merikangas in 1996. This study showed 
that the tests between common genetic variants were better powered than linkage 
analysis to identify causal variants (Risch and Merikangas, 1996). Later, scientists 
found that genetic effects underlying complex traits and common human diseases 
are small, and their detection requires typing of single nucleotide polymorphisms 
(SNPs) in large samples (Cardon and Bell, 2001) (Colhoun et al., 2003). Then, the 
completion of the Human Genome Project provided a platform for identifying and 
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characterizing common genome-wide genetic variation (International Human 
Genome Sequencing Consortium, 2004). After that, GWASs have identified 
thousands of single nucleotide polymorphisms (SNPs) associated with human 
complex traits and diseases (Hindorff et al., 2009) (Manolio, 2010). The National 
Human Genome Research Institute has established a catalog of published GWAS 
studies (https://www.genome.gov/gwastudies). As of 01/10/14, the catalog 
includes 1788 publications and 12329 SNPs. 
1.3.4. Regression analysis  
In this section, I will explain the concepts of regression analysis since association 
analysis, such as GWAS, is highly related to it.   
Linear regression 
In statistics, linear regression is an approach for identifying the approximate linear 
relationship between a dependent variable (Y) and one or more explanatory 
variables (X or X1…Xn). The dependent variable should be a quantitative variable 
while the explanatory variable can be either continuous or categorical variable.  
In linear regression, data are modelled using a linear model. For example, the 
relationship between an explanatory variable X (i.e. a SNP) and a dependent 
variable Y (i.e. a certain phenotype) can be identified by a linear regression model:  
R = 	ST + HSU + V 
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Where ST is the intercept of the regression; SU is beta coefficient of the 
regression. V is the error variable (which means an unobserved random noise to 
the linear relation).  
Figure 1-6 shows an example of the simplest linear regression model. ỹ is the 
mean of the outcome variable. “Yi” is the predict value of the regression for event i. 
“yi” is the observed value of event i. yi − Yi is the residual about regression 
(noise). Yi − ỹ is the signal due to regression. The green line is the line of the best 
fit.  
 
Figure 1-6. Example of scatter plot and linear regression of a continuous 
explanatory variable. X is the predictor variable (independent variable) and Y is the 
outcome variable (dependent variable). The regression line is in green.  
Logistic regression 
On the other hand, logistic regression is a kind of generalized linear model (GLM). 
GLM is a flexible generalization of ordinary linear regression that allow for response 
variable that have distribution other than a normal distribution. Like linear 
regression, it also predicts the linear relationship between a response variables (Y) 
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and one or more explanatory variable(s) (X or X1…Xn). The dependent variable of 
logistic regression should be a categorical variable (i.e. binary disease status). 
Meanwhile, the explanatory variables can be either categorical or continuous 
variables.  
Logistic regression uses a link function to link response and explanatory variables. In 
genetic epidemiology field, the simplest link function is: 
ZQ(4[[\	.']^4) = 	ST + HSU + V 
Where LN is the natural logarithm. ST is the intercept of the regression; SU is 
beta coefficient of the regression. V is the error variable. The odds ratio is the odds 
of cases divided by the odds of controls for a disease, where odds of an outcome D 
is given by probability of D occur (P(D)) divided by probability of D not occur (P(not 
D)).  
Model fit: least squared method 
The least squared method is an approach to the approximate solution of over 
determined systems. “Least squares” means that the overall solution minimizes the 
sum of the squares of the errors made in the results of every single equation.  
Hypothesis test: testing the significance  
The next step is to test the significance of the association using a hypothesis test. 
For association analysis, we want to test whether there is an association between a 
SNP (or between a set of SNPs) and a trait, which means whether the slope (effect 
size =SU) is equal to zero.  
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So the null hypothesis H0 will be: 
SU = 0 
While the alternative hypothesis H1 will be:  
SU ≠ 0 
Normally the t statistics (details in Chapter 3) will be an intermediate parameter for 
the hypothesis test (either one-sided test or two-sided test). A large value of t 
statistic, either negative or positive, would provide evidence against the null 
hypothesis. Therefore, the decision rules to reject H0 if the absolute value of t is 
greater than the critical value of the student’s distribution on n-2 degrees of 
freedom for a specified confidence level (95%, 99% or even more confident).  
Assumption of regression analysis 
The following are the major assumptions of regression analysis: 
1. Lack of measurement error is important.  
2. Linearity, which means the mean of the dependent variable is a linear 
function of the explanatory variables. 
3. Equal variance of errors, where the different dependent variables have the 
same variance in their error, regardless of the predictor variables.   
4. Lack of multicollinearity in the explanatory variables. If two or more 
explanatory variables are in a strong correlation to each other, this will 
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cause a problem called multicollinearity for standard least squares 
estimation approaches.  
Example of regression analysis: testing the association of a 
SNP and a trait 
For association analysis of a certain SNP A, the linear relationship between its 
genotypes and a quantitative phenotype can be represented using a regression 
model. In the example shown in Figure 1-7, I used an additive model, which assume 
the effect of the phenotype will increase / decrease a certain amount with the 
increase of per rare allele. The genotypes are coded as 0, 1 and 2 for TT, TA and AA 
respectively. Each dot represents the effect on the phenotype of an individual with 
one of the genotypes. The slope of the green line (line of the best fit) is the beta 
coefficient. The baseline is the intercept of the regression model.   
 
Figure 1-7. Example of association analysis between a biallilic SNP and a 
quantitative phenotype. TT, TA and AA are the three genotypes of SNP A. The green 
line is the line of the best fit. The red line is the line of baseline effect.  
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1.3.5. Meta-analysis of Genome-wide 
association analysis 
One problem with GWAS is that many stand-alone GWAS studies lack sufficient 
power to obtain precise results (Zeggini and Ioannidis, 2009) (Cambon-Thomsen, 
2003)  so the synthesis of available open resources and data pooling remains 
important. In statistics, a meta-analysis refers to methods that compare and 
combine results from different studies. Meta-analysis is normally done by 
identification a weighted average of a common measure of effect size (in regression 
analysis effect size means beta coefficient). The major advantage of meta-analysis is 
that it increases the sample size so that the precision and accuracy of estimates can 
be improved. More importantly, the statistical power to detect an effect will 
increase as well. Commonly used software for meta-analysis include METAL (Willer 
et al., 2010) and STATA (StataCorp, 2013) and PLINK.  
Numerous examples of meta-analyses have identified disease and quantitative trait 
susceptibility loci that small individual level studies did not identify reliably 
(Ioannidis et al., 2006). It is, therefore, desirable to utilize the published and 
on-going studies.  
Data synthesis models for meta-analysis 
There are several data synthesis approaches for meta-analysis. Two of them are 
widely for GWAS meta-analysis: 
1. Fixed effect model is the most popular approach for synthesizing GWAS data 
since it is the most powerful approach for discovering phenotype-genotype 
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association (Pfeiffer et al., 2009). The assumption for fix effect model is that the 
true effect of each risk allele is the same in each individual study. This 
assumption is quite hard to achieve, but fixed effect model will maximizing 
discovery power compared to random effect model (Pereira et al., 2009). 





Where SEi is the standard error of effect size for each study “i”. Based on this 
weighting system, bigger studies will get more weight than smaller ones. 





2. Random effect model assumes the true treatment effect varies between 
studies. Random effect models are not designed for discovering association 
since they will return far more limited power than fixed effect models. However, 
random effect models will performance better than fixed effect models when 
the aim is to synthesize heterogeneous studies and estimate the average effect 
size of the associated variant and its uncertainty across different populations 
(Ioannidis et al., 2007).  





Where SEi is the standard error of effect size for each study “i” and I2 is the 
heterogeneity term of the meta-analysis. The definition of heterogeneity is 
variation between the true intervention effects underlying the different studies. 
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Heterogeneity can cause by difference between patients, intervention, 
outcome definition and design of each study of the meta-analysis.  
An example of a meta-analysis results is shown in Table 1-4:  
ID  A1       A2      
 Frequencies 
of A1       
b se       p       N     
SNP1 A   G 0.8493  0.0024  0.0055  0.6653   129850  
SNP2 C G 0.0306  0.0034  0.0115  0.7659   129799  
SNP3 A   C 0.5128   0.0045   0.0038   0.2319    129830 
Table 1-4. An example of meta-analysis summary statistics. For each SNP, A1 is the 
alternative allele and A2 is the risk allele.  
 
Polygenetic inheritance, missing heritability, estimating heritability using REML, 
LDSC etc 
1.3.6. Genetic fine mapping 
Current GWAS studies have identified a huge amount of genomic regions that cover 
causal variants for different complex traits. Although GWAS studies have much 
greater resolution than linkage analysis, it is still difficult to know the uncertainty 
between statistical “distance” and physical distance. We need further analysis to 
refine the location of causal variants as sharply as possible so that follow-up 
functional studies and hypotheses regarding mechanism can be processed 
(McCarthy and Hirschhorn, 2008). The process of this kind of further analysis is 
often noted as “genetic fine mapping.” As shown in Figure 1-8, this terminology is a 




Figure 1-8. Relationship between linkage analysis, association analysis and fine 
mapping. TDT refers to transmission disequilibrium test, which is a family based 
association test for unrelated families. It is out of the range of this thesis. For details 
please read the paper (Spielman et al., 1993).   
There is strong LD throughout most of the genome (International HapMap 
Consortium, 2005), so a genotyped proxy variant and the untyped causal variant 
could be tens of thousands base pairs away from each other, and the region in 
between them could contain tons of alleles, none of which are strongly correlated 
with the causal allele. Moreover, it is quite often that some variants show more or 
less equivalent evidence of association for a certain association signal. It is also 
possible that multiple independent association signals exist at a certain locus, for 
example, protein tyrosine kinase 2b (PTK2B) associated with Alzheimer’s disease 
(Lambert et al., 2013). For a set of potential causal variants, fine mapping, which 
utilises the LD pattern across a region, to test which variant (or subset of variants) is 
(are) most likely to explain the signal of association.  
Fine mapping can not only help narrow down the list of possible causal variants and 
simplify future functional studies, but also increase the power of association if the 
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dense set of SNPs use for the GWAS is reasonably high (Wiltshire et al., 2008) 
(Sanna et al., 2011). In my point of view, common and rare variants that are poorly 
represented in common genotyping arrays (which means an array with low density 
but cover the whole genome) may account for a large proportion of trait heritability. 
Ignoring these variants might exclude identification of casual trait associated loci so 
that we are underestimating the heritability. Fine mapping (using either a high 
density gene centric genotyping array or a high coverage sequencing data of 
candidate regions) should be the logical next step after GWAS. 
1.4. Existing model selection approaches for 
identifying independent SNPs 
associated with polygenic traits 
As explained above, the major aim of genetic fine mapping is to identify the “casual” 
(or state more clearly the independent) variant(s) in a candidate genomic region. To 
achieve this aim, we need to select a subset of possible causal variants (term 
independent SNP) from the entire association analysis results. For such selection 
procedure, there are four types of statistical approaches exist:   
1. Select SNPs for follow up based on their ranked beta coefficient of the single 
regression analysis (i.e. the most significant SNP, the second most significant 
SNP and so on) 
2. An approximate Bayesian procedure, based on posterior probabilities that each 
marker is the causal marker. 
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3. A Least absolute shrinkage and selection operator (Lasso), which is a shrinkage 
based selection method for linear regression. 
4. A stepwise procedure, which recalculates regression coefficient conditional on 
the most (second most etc.) significant SNP of a genomic region to find out the 
independent effect SNPs.  
The first strategy has drawbacks since the selected markers for follow up are based 
on statistical significance (rather than the real functional variant). There is high 
chance that the causal SNP is excluded from the follow up study because of 
experiments cost, time issue or labor intensive. So I do not recommend using this 
strategy anymore.  
On the other hand, the Bayesian analyses produce an estimate of the probability of 
association. Bayesian methods can combine information from both GWAS results, 
SNP information derived from bioinformatics databases, empirical SNP weights, and 
the researchers’ subjective prior opinions. There are different ways to implement 
Bayesian procedures (Wellcome Trust Case Control Consortium et al., 2012) (Valdar 
et al., 2012) (Thompson et al., 2013). The advantage of the Bayesian analysis is that 
Bayes factors, although not as well known as p value, for different SNPs can be 
compared quantitatively. For instance, for a certain genomic region, if we assume a 
certain number of causal SNPs in the selected set of SNPs, it is straightforward to 
calculate the posterior probability that any particular SNP is causal taking into 
consideration data from the fine-mapping analysis (Wellcome Trust Case Control 
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Consortium et al., 2012). There are two problems that may prevent a researcher 
using Bayesian approach: firstly, these approaches are relying on have a reasonable 
prior distributions which can be difficult to determine 
(http://www.bayesian-inference.com/priors). Bad prior distribution may lead to 
poor estimation of posterior distribution. Secondly, Bayesian approaches are 
normally computational expensive and time-consuming (Grzegorczyk, 2010).  
The third strategy a step-wise procedure, is the most commonly used one. Compare 
to Bayesian analysis, step-wise procedures are computational fast and easy to 
understand. In the following section, I will introduce some popular step-wise based 
fine mapping methods used for complex human traits.  
The third approach, LASSO, is a relevant new statistical method which is proposed 
by Tibshirani in 1996 (Tibshirani, 1996). The Lasso minimizes the residual sum of 
squares subject to the constraint on the sum of absolute value of coefficients. In 
2004, Efron et al. proposed the Least Angle Regression(LARS) (Efron et al, 2004) 
which is a computationally efficient model selection algorithm. There is a close 
connection between the LARS and the LASSO. A simple modification of the LARS 
algorithm can yield all the LASSO solutions. Due to their popularity and usefulness, 
the LASSO and the LARS have drawn intensive research interest in the statistical 
field. Later in 2005, the Elastic Net proposed by Zou and Hastie (Zou and Hastie, 
2005) uses a novel regularization penalty. The naive Elastic Net uses a combination 
of the LASSO and the Ridge regression penalty. However, the Elastic Net uses a 
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scaled version of the naive Elastic Net estimate to reduce the over shrinking of 
parameters. It has been shown that the Elastic Net outperforms the LASSO (Zou and 
Hastie, 2005). In a GWAS (SNP based association analysis) point of view, The above 
LASSO methods can be used to identify genetic variants that associated with 
variation in the phenotypes. Some successful model selection methods using LASSO 
or using combination of Bayesian approach and LASSO have been developed since 
then (Wu et al, 2009, Li et al, 2011, Motyer et al, 2011).  
 
1.4.1. Stepwise regression and 
Conditional analysis 
Stepwise regression is a classic scheme for sequentially adding or removing 
variables from the model. In genetic field, conditional analysis, which is the most 
commonly used model selection method, has been used as a tool to identify 
secondary association signals at a locus (Lango Allen et al., 2010) (Schizophrenia 
Psychiatric Genome-Wide Association Study (GWAS) Consortium, 2011) (Psychiatric 
GWAS Consortium Bipolar Disorder Working Group, 2011).. A more general and 
comprehensive strategy would be to perform a conditional analysis, starting with 
the top associated SNP, across the whole genome followed by a stepwise 




A more common and expended strategy would be to perform a conditional analysis 
as follows: 
1. Firstly, test the association between a trait and test SNPs conditional on the 
most significant associated SNP, across a certain genomic region  
2. Then, follow a stepwise procedure of selecting additional SNPs, one by one, 
according to their conditional P values.  
3. Finally combine all the reminder SNP in the model and process a step-wise 
regression to remove SNPs highly correlated to each other. 
Such a strategy would allow the discovery of more than two associated SNPs at a 
locus (Galarneau et al., 2010) (Trynka et al., 2011). 
1.4.2. Model selection approaches 
Model selection is a way of selecting a good statistical model from a group of 
candidate models. The word “good” is kind of a balance between fitness and 
simplicity of the model. Consider the specificity, we need to include the main 
effects and interactions in the model. On the other hand, parsimonious will reduce 
the computational time of our analysis.  
In order to select the best model, we firstly need a criterion or benchmark to 




1. The coefficient of determination (R2), which measures the goodness of fit of a 
statistical model. It is not a good criterion since it always increase when extra 
explanatory variables are added to the model. Adjusted R2 is an attempt to 
take account of the phenomenon of the R2. It is better than R2 but it penalized 
bigger models.  
2. Mallow’s Cp (Mallows, 1973), which is used to assess the fit of a regression 
model that has been estimated using ordinary least squares.  
3. Akaike’s Information Criterion (AIC), named for Akaike Hirotugu, is a measure 
of the relative quality of a statistical model (Akaike, 1974). It offers a relative 
estimate of the information lost when a given model is used to represent the 
whole data.  
For any statistical model, the AIC value is: 
#pq = 2r − 2ZQ(Z) 
Where k is the number of parameters in the model and L is the maximized 
value of the likelihood function of the model. LN is the nature logarithm.  
4. Bayesian Information Criterion (BIC), which was first developed by Schwarz 
(Schwarz, 1978), is a criterion for selection among a finite set of models. It is 
partly based on the likelihood function and is closely related to AIC. In 
comparison to BIC, AIC penalizes the number of parameters less strongly.  
For a large statistical model, the BIC value is: 
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spq = 	−2 ∗ ZQ(Z) + r ∗ ZQ(1) 
Where n is the sample size. k is the number of free parameters to be estimated. 
L is the maximized value of the likelihood function of the model. LN is the 
nature logarithm.  
Search strategies  
1. Best subset, where search all possible models and take the model with highest 
R2, lowest Cp or other information criteria.  
2. Stepwise (forward, backward or both), where choose an initial model and plus 
or minus one parameter from the model until the best model is found. It is 
useful when number of predictors is large.  
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1.5. Materials 
In this section I will briefly overview the sample datasets, bioinformatics tools, 
scripting programme and statistical tools I am going to use in this work.  
1.5.1. British Women’s Heart and Health 
Study (BWHHS) 
The British Women's Heart and Health Study is a prospective cohort study of 
cardiovascular disease in older British women (Chapter 9.13 BWHHS). The samples 
were randomly selected from British women aged 60-79 and were drawn from 23 
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towns in England, Scotland and Wales. Most of them are European originals. 
Information was collected using general practitioner record reviews, a 
self-completed questionnaire, research nurse interview, and physical examinations. 
The study aims to provide information about the existing patterns of treatment for 
heart disease, and further the understanding of risk factors and disease prevention. 
In total, 7173 participants were approached and information pertinent to 
approximately 60% of participants (4286) is available. 20% of women had a doctor 
diagnosis of either myocardial infarction, angina, heart failure, stroke, or peripheral 
vascular disease. 50% of participants were hypertensive and more than 25% of 
them were obese. 50% have a total cholesterol level greater than 6.5 nmol/l. For all 
4286 participants, 3800 have DNA samples (Lawlor et al., 2003). The structure of 




Figure 1-9. Structure of the BWHHS study 
BWHHS “Metabochip” 
Of the available BWHHS participants, 2024 were genotyped using the Illumina 
Cardio-Metabochip (called “Metabochip”). The Metabochip is a custom genotyping 
array design for fine mapping additional loci associated with cardiovascular disease 
(CVD) related traits. It covers ~200,000 SNPs which are selected based on the 
knowledge of previous GWAS studies for type 2 diabetes, coronary artery disease, 
53 
 
myocardial infarction, body mass index, glucose and insulin levels, lipid levels and 
blood pressure (Voight et al., 2012).  
BWHHS “Cardiochip” 
Of the available BWHHS participants, 3443 were genotyped using 50 k HumanCVD 
BeadChip (called “Cardiochip”) (Illumina, San Diago, CA). The CardioChip consists of 
~50,000 SNP markers that capture genetic regions across ~2,100 genes identified as 
being associated with CVD from the literature (Keating et al., 2008). 
1.5.2. HapMap and the 1000 Genome 
Project 
HapMap 
The aim of the international HapMap project is to determine the common patterns 
of DNA sequence variation within the human genome (a haplotype map, so called 
“HapMap”) and to makes these precious data freely available in the public domain. 
Using the haplotype map in a genomic region, scientists can then identify tagging 
SNPs that could be used as representatives to represent haplotypes uniquely 
(http://hapmap.ncbi.nlm.nih.gov) (Chapter 9.13 HapMap). Moreover, HapMap 
provides a landscape of precious linkage disequilibrium (LD) information of human, 
which is the foundation for fine-scale analysis of genomic variation. It enhances our 
ability to fine map associations between common variants and complex diseases / 
traits (Slatkin, 2008). 
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The original HapMap project genotyped more than one million of common genetic 
variants (SNPs) in 270 individuals from four human populations (Chinese, Japanese, 
European and Nigerian) (International HapMap Consortium, 2003). The allele 
frequencies and the degree of association (LD) between these SNPs were also 
measured for each population. At the time of writing, HapMap (Phase 3) has 
identified ~ 1.6 million SNPs in 1,184 individuals from 11 different populations 
(International HapMap 3 Consortium et al., 2010). In Chapter 3, I will use the 
genotype data of HapMap Utah Residents with Northern and Western European 
ancestry (CEU) and Toscana in Italia (TSI) population to process an admixture 
population simulation.  
1000 Genomes 
The 1000 Genome project has similar goals to the HapMap project, which is to 
provide a well-annotated haplotype reference map (1000 Genomes Project 
Consortium et al., 2010) (Chapter 9.13 1000 Genomes). In contrast to the HapMap 
project, the 1000 Genomes project has sequenced more than 1000 individuals from 
26 different populations in order to enable them to discover low frequencies 
variants (MAF between 1% and 5%). The 26 populations used within the 1000 
Genomes project are from many different locations around the world. They can be 
classified into 5 super populations: African, admixed American, East Asian, 
European and South Asian. In order to reduce costs, the 1000 Genomes project 
opted to use low-coverage whole genome sequencing (WGS) (~5X). Although 
variants with low frequencies can be identified using low-coverage WGS, but with 
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such limited sample size and coverage issues, the approach is limited to detecting 
variants with a population allele frequency of ~1% (1000 Genomes Project 
Consortium et al., 2010). In this work, genotype and haplotype data of 1000 
Genome CEU and British in England and Scotland (GBR) population will be used as 
reference genotype data in Chapter 5 for a performance comparison of fine 
mapping methods. I will also use them as a reference panel to impute genotypes of 
BWHHS individuals in Chapter 6.  
1.5.3. Avon Longitudinal Study of Parents 
and Children (ALSPAC) 
The Avon Longitudinal Study of Parents and Children (ALSPAC), which is also known 
as Children of the 90s, is a population-based cohort study (Fraser et al., 2013) 
(Chapter 9.13 ALSPAC). The major aim of the study is to establish a 
trans-generational, prospective, observational birth cohort and use it to understand 
how genetic and environmental characteristics influence health and development. 
More than 14000 mothers were enrolled during their pregnancy in 1991 and 1992, 
and the health and development of their children has been followed in great detail 
ever since (Golding et al., 2001). The study maintains a huge amount of genetic and 
phenotypic data, including genetic, epigenetic, biological, psychological, social and 
other environmental exposures from across participant life course (Boyd et al., 
2013). In this work, 9233 ALSPAC individuals were genotyped using the Illumina 
HumanHap550 quad genome-wide SNP genotyping platform (Illumina, San Diego). 
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ALSPAC individual-level genotyped data will be used as a reference panel for fine 
mapping atopic dermatitis associated loci in Chapter 6.  
1.5.4. Meta-analysis of cardiovascular 
disease traits 
The University College-London School-Edinburgh-Bristol (UCLEB) consortium is 
comprised of a set of population-based prospective studies with dense CVD related 
phenotypes ((Chapter 9.13 UCLEB)). All participating studies have genotyped their 
individuals using a new high-resolution custom SNP array (“Metabochip”, see 
Section 2.1.1). The array have a much higher SNP densities in genomic regions 
linked to cardiovascular and metabolic diseases / traits.  
The overall aims of the UCLEB consortium include, a) follow-up studies of genomic 
regions reported to be associated with CVD traits by previously GWAS studies and 
understand the unknown mechanisms for healthcare; b) to fine map functionally 
relevant SNPs inside these regions; c) to estimate the CVD risks for individuals and 
population separately based on individual SNPs and their interactions; d) to 
understand the mechanisms leading to altered CVD risk factor profiles; e) to 
process Mendelian Randomisation to identify the causal role in CVD of a range of 
cardiovascular biomarkers to inform public health policy and help develop new 
preventative therapies, i.e. new drug targets (Shah et al., 2013b).   
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1.5.5. Meta-analysis of gallbladder disease 
The meta-analysis of gallbladder disease is a collaboration based project between 
Candidate gene association resource (CARe) consortium (Musunuru et al., 2010a) 
(Chapter 9.13 CARe) and UCLEB consortium. It consists of three independent 
cohorts: the Atherosclerosis Risk in Communities Studies (ARIC), BWHHS and 
Women’s Health Initiative (WHI). ARIC is a prospective epidemiology study 
designed for atherosclerosis and cardiovascular disease (CVD) researches. In total, it 
has recruited 15,792 individuals between 1987 and 1989 (The ARIC investigators, 
1989). The WHI is a National Institutes of Health (NIH) study and has recruited 
161,808 women with ages between 50 and 79 years. The aim of WHI study is to 
prevent diseases (i.e. heart diseases) in women (The Women’s Health Initiative 
Study Group, 1998).Participants from these three cohorts were genotyped using 
the “Cardiochip” (see Section 2.1.1)   
1.5.6. Meta-analysis of Atopic Dermatitis 
The EArly Genetics and Lifecourse Epidemiology (EAGLE) Consortium is a 
collaboration between various cohorts and aims to investigate the genetic basis of a 
range of phenotypes in antenatal and early life and childhood (Paternoster et al., 
2012). The participating cohorts within the EAGLE consortium includes: the 
Australian Asthma Genetics Consortium (AAGC) replication cohort, the Avon 
Longitudinal Study of Parents and Children (ALSPAC), BAMSE, British 1958 birth 
cohort (B58C), the Children’s Hospital of Philadelphia (CHOP), the Copenhagen 
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Prospective Study on Asthma in Childhood (COPSAC), Danish National Birth Cohort 
(DNBC), the European Community Respiratory Health Survey (ECRHS), Generation 
R, Genetics of Overweight Young Adults (GOYA) women’s study, the Danish 
Glostrup Cohort (Health2006), KORA, LISA/GINI, Manchester Asthma and Allergy 
Study (MAAS), the Norwegian Mother and Child Cohort Study (MoBa), the Northern 
Finland Birth Cohort 1966 (NFBC66), Northern Finland Birth Cohort 1986 (NFBC86), 
Netherlands Twin Register (NTR), PIAMA, QIMR discovery cohort, Western 
Australian Pregnancy (Raine) cohort, SAPALDIA, the Department of Twin Research 
and Genetic Epidemiology at King’s College London (TwinsUK). Meta-analysis 
summary results of the EAGLE consortium of Atopic Dermatitis were conducted by 
Paternoster and colleagues. I will use them together with the ALSPAC genotype 
data to run a regional association analysis in Chapter 6.  
1.5.7. Meta-analysis of Body Mass Index 
The Genetic Investigation of ANthropometric Traits (GIANT) consortium is an 
international collaboration based consortium 
(http://www.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium) 
(Chapter 9.13 GIANT). It aims to identify genetic loci that modulate human body 
size and shape, including height and measures of obesity. The GIANT consortium 
consist of investigators from many different cohorts, institutions, countries, and 
studies, and the results represent their combined efforts (i.e. meta-analysis 
summary statistics). The primary analysis has been meta-analysis of GWAS data and 
other large-scale genetic data sets. Anthropometric traits that have been reported 
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by GIANT include body mass index (BMI), height, and traits related to waist 
circumference (such as waist-hip ratio adjusted for BMI, or WHRadjBMI). So far, the 
GIANT consortium has identified more than hundreds genomic regions with 
common genetic variants that are associated with anthropometric traits. The GIANT 
meta-analysis summary results of BMI (Speliotes et al., 2010) will be used for a 
further fine mapping analysis in Chapter 4.  
1.6. Bioinformatics tools 
1.6.1. Variants database: dbSNP 
The National Centre for Biotechnology Information (NCBI) dbSNP database is a 
general catalogue of genetic variation (mainly single nucleotide variations and small 
INDELs) which is open access to the public (Sherry et al., 1999) (Sherry et al., 2001). 
The web link of dbSNP database is http://www.ncbi.nlm.nih.gov/projects/SNP/. The 
dbSNP database is the central repository for genetic variation and contains both 
polymorphisms and clinical mutations. At the time of writing, the most up-to-date 
database (dbSNP Build 140) contained ~249 million variant submissions (ss#s), of 
which ~161 million are unique positions in the genome (rs#s) and ~45 million have 
been validated (data obtained from 
http://www.ncbi.nlm.nih.gov/projects/SNP/snp_summary.cgi).  
Day et al summarized that data quality is a big issue for dbSNP since various studies 
provide evidence for a high number of false positive ‘multisite’ variants which arise 
because of genotyping errors associated with paralogous (duplicated) genes (Day, 
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2010). Although the number of submissions to dbSNP has increased over the last 
few years, it is estimated that up to 8.3% of the unique coding variants could be 
false positives (Musumeci et al., 2010).  
 
1.6.2. SNP Annotation tools: Variant Effect 
Predictor (VEP) and SNP Annotation 
and Proxy Search (SNAP) 
Variant Effect Predictor (VEP) 
Variant Effect Predictor (VEP) is a tool to predict the consequences of genomic 
variants and annotate variants onto known transcripts (McLaren et al., 2010). The 
VEP web interface is: http://www.ensembl.org/Homo_sapiens/Tools/VEP 
VEP will be used to annotate variants significantly associated with Atopic Dermatitis 
in Chapter 6.   
SNP Annotation and Proxy Search (SNAP) 
SNP Annotation and Proxy Search (SNAP) is a bioinformatics query tool for SNPs to 
identify and annotate nearby SNPs in LD (called proxies) based on HapMap and 
1000 Genome (Johnson et al., 2008). It can be used to find proxy SNPs as well as 
pairwise LD information. Moreover, it can be used to visualize the regional 
association analysis among variants with in a genomic region.  
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1.6.3. Batch Coordinate Conversion 
(LiftOver) 
Batch coordinate conversion (liftOver) converts genome coordinates and genome 
annotation files between assemblies (http://genome.ucsc.edu/cgi-bin/hgLiftOver). 
To conduct a LiftOver, we need an input file called BED file. An example of the BED 
file is shown in Table 1-5.  
Chr Start POS End POS Name 
chr7 127471196 127472363 Region 1 
chr7 127472363 127473530 Region 2 
chr7 127473530 127474697 Region 3 
chr7 127474697 127475864 Region 4 
chr7 127475864 127477031 Region 5 
chr7 127477031 127478198 Region 6 
chr7 127478198 127479365 Region 7 
chr7 127479365 127480532 Region 8 
chr7 127480532 127481699 Region 9 
Table 1-5. Example of BED file. 
In addition, a chain file that links different assemblies (i.e. hg18 and hg19) is 
needed. Both files can be downloaded from the UCSC webpage. The code of 
LiftOver were shown in Chapter 9.1.1.  
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1.6.4. Linkage disequilibrium tools: 
Haploview, CubeX and MIDAS 
Haploview 
Haploview is a tool developed by the Broad Institute (Barrett et al., 2005). It is 
designed for analysing and visualizing haplotypes and LD. As illustrated in Figure 
1-10, the interface of Haploview is simple and user friendly. In this work, I used 
Haploview as a tool to draw linkage disequilibrium (LD) plots. The input of 
Haploview can be either HapMap haplotypes data or our own data in a PLINK input 
format (e.g. PED and MAP file).  
 




CubeX is a tool to estimate the pairwise haplotype frequencies using cubic exact 
solutions (Gaunt et al., 2007). As shown in Figure 1-11, the inputs to CubeX are the 
number of individuals of each genotype for the 3x3 genotype table. The output will 
be all possible haplotype frequencies for the two test SNPs. CubeX will be used in 
Chapter 3 to calculate the haplotype frequencies (X11) from reference genotype 
panel (i.e. HapMap and BWHHS individual-level genotype data).  
 
 
Figure 1-11. Web-based tool of CubeX.  
MIDAS 
Multiallelic Interallelic Disequilibrium Analysis Software (MIDAS) is a software for 
LD analysis with a comprehensive graphical users interface. It illustrates the 
patterns of LD between all types of multiallelic and biallelic markers (Gaunt et al., 
2006) (Figure 1-12). In this work, MIDAS will be used in Chapter 3 and Chapter 4 to 




Figure 1-12. Example of MIDAS results plot 
1.6.5. Functional prediction tools: 
FATHMM and RegulomeDB 
Functional Analysis through Hidden Markov Models 
(FATHMM) 
The Functional Analysis through Hidden Markov Models (FATHMM) is a 
high-throughput n algorithm capable of predicting the functional, molecular and 
phenotypic consequences of protein missense variants using hidden Markov 
models (HMMs) representing the alignment of homologous sequences and 
conserved protein domains (Shihab et al., 2013). In this work, FATHMM will be used 




RegulomeDB is an approach and database that guides interpretation of regulatory 
variants in the human genome. RegulomeDB uses high-throughput, experimental 
data sets from ENCODE (ENCODE Project Consortium et al., 2012) and other 
sources. It also includes computational predictions and manual annotations to 
identify putative regulatory potential and to identify putative functional variants 
(Boyle et al., 2012). The RegulomeDB scoring system was listed in Table 1-6. 
RegulomeDB will be used in Chapter 7 for functional prediction of non-coding SNPs 
associated with QTc interval.  
Score Supporting data 
1a eQTL + TF binding + matched TF motif + matched DNase Footprint + DNase peak 
1b eQTL + TF binding + any motif + DNase Footprint + DNase peak 
1c eQTL + TF binding + matched TF motif + DNase peak 
1d eQTL + TF binding + any motif + DNase peak 
1e eQTL + TF binding + matched TF motif 
1f eQTL + TF binding / DNase peak 
2a TF binding + matched TF motif + matched DNase Footprint + DNase peak 
2b TF binding + any motif + DNase Footprint + DNase peak 
2c TF binding + matched TF motif + DNase peak 
3a TF binding + any motif + DNase peak 
3b TF binding + matched TF motif 
4 TF binding + DNase peak 
5 TF binding or DNase peak 
6 other 
Table 1-6. The RegulomeDB score system. 
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1.7. Statistical genetics tools and 
programming languages 
1.7.1. PLINK  
PLINK is an open source C/C++ tool set for handling and analysing GWAS data in 
computational efficient manner (Purcell et al., 2007). The original functions such as 
data management (PED/MAP files, BED/BIM/FAM files and data filtering), 
population stratification (principal component analysis), summary statistics 
(estimating allele frequencies) and association analysis (for both binary traits and 
quantitative traits) will be used in the next few chapters. More importantly, I will 
use some of the updated functions included in version 1.07, such as LD calculation 
(estimating LD block, calculating LD measures D’ and r2), multimarket haplotype 
analysis (haplotype phasing) and conditional analysis (for fine mapping 
individual-level data). I will use these functions for my novel methods development 
in Chapter 3 and Chapter 5.   
1.7.2. GCTA conditional and joint SNP 
effect analysis 
Genome-wide Complex Traits Analysis (GCTA) is a multiple function tools originally 
designed to estimate the proportion of phenotypic variance explained by genome 
wide SNPs for complex traits (Yang et al., 2011). It has now been extended for many 
other analyses to understand the genetic architecture of complex traits. In this 
work, I will focus on its conditional and joint genome-wide association analysis, 
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which can use summary-level statistics from a meta-analysis of genome-wide 
association studies (GWAS) and estimate linkage disequilibrium (LD) from a 
reference sample with individual-level genotype data. The command and options of 
the conditional and joint SNP effect analysis can be found in the following webpage: 
http://www.complextraitgenomics.com/software/gcta/massoc.html  
1.7.3. R and Python 
R is an implementation of the S programming language and is a free software 
environment for both high-level programming, statistical analysis and plotting 
graphics (http://www.r-project.org/). With the help of Rstudio 
(https://www.rstudio.com/), it has now become one of the most popular and user 
friendly language all over the world. In this work, R will be used in four respects: 
data managing, graphics plotting, processing statistical analyses and novel 
algorithm scripting.  
On the other hand, Python is a widely used high-level programming language 
(https://www.python.org/). It is attractive since supports programming paradigms, 
including object-oriented, imperative and functional programming. Python can also 
be used with a wide range of third-party tools such as “matplotlib” and “RPy2”.   
In this work, Python will be used in three respects: transforming data format, 
programming web-based tools and scripting a novel E-M algorithm.  
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1.8. Major aims and objectives 
As I described in Section 1.4, applying existing variable selection methods, such as 
conditional analysis and model selection approaches, requires individual level data. 
Single GWAS lack power to obtain accurate association results (Zeggini and 
Ioannidis, 2009). Meta-analysis of multiple GWAS studies is a good way to increase 
the power of the association analysis. But pooling of individual genotype and 
phenotype data are normally not available from meta-analyses. As a consequence, 
the bulk of this thesis concerns the development of two novel 
approaches/algorithms so that meta-analysis results can be used directly for fine 
mapping analysis. Both methods will combine statistical concepts of regression 
analysis with population genetics concepts of allele frequencies, LD, haplotypes and 
haplotype frequencies. Furthermore, these two methods will be applied to real 
meta-analysis summary statistics to identify secondary signals associated with 
complex traits of human beings.        
1.8.1. Objectives 
l Use concepts of pair-wise LD and simple regression analysis to develop an 
approximate conditional analysis methods using meta-analysis summary data  
l Investigate the performance of the approximate conditional analysis and 
compare it with conditional analysis and model selection methods  
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l Apply the approximate conditional analysis to cardiovascular disease (CVD) 
related meta-analysis to identify independent effect SNPs in the candidate 
regions 
l Extend multiple regression analysis to group level and use E-M algorithm to 
develop an approximate joint SNP effect approach using meta-analysis 
summary statistics 
l Perform an independent benchmark to compare the performance of the 
approximate joint SNP effect approach against other existing fine mapping 
methods.  
Identify independent SNPs of 12 complex quantitative traits and 2 disease 
outcomes using the approximate joint SNP effect approach to identify more 
multiple SNPs associated with these traits / diseases.   
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CHAPTER 2. SEQUENTIAL 





Genome wide association studies (GWAS) have been successful in identifying over 
twelve thousand SNPs involved in the development of human complex traits and 
disease outcomes (Hindorff et al., 2009) (Manolio, 2010). A considerably larger 
number of SNPs show significant associations (with respect to the genome-wide 
significance threshold) with these traits, but this can be caused either by the own 
effect of these SNPs or they are in LD with the causal variant (i.e. SNPs shown in 
Table 8-1). Moreover, with the increasing in sample size and the number of 
meta-analyses of multiple GWASs carried out, an increasing number of genetic 
variants associated with different traits will be identified consequently. With these 
in mind, fine mapping, which is an approach taken to identify secondary association 
signals at a certain genomic region, will become statistically feasible and a 
potentially powerful tool in the future. However, there is an untested assumption of 
GWAS which contradicts this idea and therefore slowed down the development of 
fine mapping approaches.  
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2.1.1. One Limitation of single SNP 
model GWAS, conditional analysis 
and model selection approaches 
For GWAS, a single SNP model is usually used to test the association between 
phenotypes and genotypes. The most significant (noted as top-hit) SNP will 
represent the association of a genomic region such as a gene and/or a linkage 
disequilibrium (LD) block. In the following situations, this untested assumption may 
not be met: Firstly, this design does not take into account the possibility of multiple 
casual variants at a region. Secondly, the real causal variant maybe untyped or with 
low imputation quality; and the best genotyped (or imputed) SNP with LD to the 
real causal variant may not capture the total amount of variation at the region. 
Therefore, a GWAS based on a single SNP model will result in an underestimate of 
the total variation that could be explained at a locus (Yang et al., 2012). 
To detect multiple potentially causal sites for GWAS, several statistical stepwise 
procedures exist for identify SNP independence using individual level data, which 
include statistical packages for conditional analysis (Purcell et al., 2007) and model 
selection criteria such as Akaike information criterion (AIC), Bayesian information 
criterion (BIC), Mallows’ Cp, Cross-validation, adjusted r2 and stepwise regression 
(Smith et al., 2010a). Among these methods, conditional analysis is the most 




2.1.2. Meta-analysis and limitation of 
current meta-analysis system 
As previously described in Chapter 1, meta-analysis of multiple GWASs has been 
shown to increase the power to detect genetic variants associated with complex 
disease risk traits such as blood lipids (Teslovich et al., 2010) (Asselbergs et al., 2012) 
and Electrocardiographic (ECG) traits (Arking et al., 2006) (Pfeufer et al., 
2009) (Newton-Cheh et al., 2009) (Marroni et al., 2009) (Gaunt et al., 2012). The 
common meta-analysis design requires different research groups to manage 
individual level analyses of the same phenotype and then collaborate on detailed 
meta-analyses of this phenotype (Seminara et al., 2007). In fact, meta-analysis 
provides an improved platform for regional fine mapping with respect to GWAS. 
Meta-analysis summary statistics 
For a certain SNP, the most notable information one gets from a meta-analysis is the 
effect size of the SNP (noted as beta coefficient, beta or b), standard error of the 
effect size (SE) and the p value against the null hypothesis in regards to the SNP’s 
association with the trait under analysis (p). Beta represents the overall effect of the 
SNP, where p value shows the level of significance of the SNP. On the other hand, 
the risk allele (A2), alternative allele (A1) and allele frequencies of the risk allele 




Limitation of conventional meta-analysis system 
Meta-analysis has proven to be a powerful method to identify disease susceptibility 
and quantitative trait loci which single GWAS did not identify or provide enough 
evidence due to lack of power (Ioannidis et al., 2006). As abovementioned, 
meta-analysis is based on collaboration, so data sharing is an issue amongst 
different institutes. Normally only standard summary statistics (as shown in Table 
1-4) might be available for researchers needed data in the trait(s) of interest. 
Unfortunately, statistical approaches like conditional analysis and model selection 
methods are only applicable when individual-level data is available.  Before I 
developed the novel method SSS-RAP (Zheng et al., 2013), if analysts from different 
institutes wanted to fine mapping a candidate region, they needed to processed 
conditional analysis in each single study and combined summary results together 
through a second round of meta-analysis.  As we can imagine, it normally takes 
months for a single round of conditional analysis under the current meta-analysis 
system (Zheng et al., 2013). 
To overcome the limitation of GWAS and increase the efficiency and accuracy of fine 
mapping under the current meta-analysis system, a biological point of view is 
necessary. Haplotypes, which contain all LD information for a certain genomic 
region, will be a good choice. Using rule of thumb “Simpler the better”, I started 
analyzing the simplest haplotypes, ones which contained two SNPs. Digging the 
correlations between pair-wise SNPs, especially correlation between top significant 
SNP and a query dependent SNP, became the first priority of this project.   
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2.1.3. Haplotype, haplotype frequency 
and r2 measure of linkage 
disequilibrium from open access 
resources  
For a meta-analysis combining data from a major ancestral group, for example, East 
Asian, the individual-level data will, most of the time, not be available. We are not 
able to estimate haplotype, haplotype frequencies and LD correlation (r2) without 
individual level data. But through utilizing available resources such as the 
International HapMap Consortium (International HapMap 3 Consortium et al., 2010) 
and the 1000 Genome project (1000 Genomes Project Consortium et al., 2010) 
access to reliable individual level data can be possible. These open resources 
provide users with hundreds of well-defined references with individual-level phased 
haplotypes for each ancestral group. Previous studies have proven that a reference 
panel from the same population as the meta-analysis individuals will share similar 
LD correlation between a pair of SNPs (Ke et al., 2004). Under this assumption, two 
loci haplotype frequencies can be estimated freely using these data. 
2.1.4. Limitation of considering r2 as the 
standard of SNP independence  
As discussed in chapter 3.1.2, fine mapping under the current meta-analysis system 
is time consuming. Since r2 is a good representative of LD correlation and easy to 
calculate, some of the early meta-analysis papers used the LD correlation (r2) as the 
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only standard to test SNP independence. But r2 is a measure of pair wise LD, which 
cannot take into account the correlation among multiple SNPs. Besides, I 
hypothesized that, even in the two SNPs model, only considering the r2 would not 
be adequate to detect the independent signals between the two loci. I used the 
following examples to prove the hypothesis: (i) Two SNPs in Low LD and (ii) Two 
SNPs in linkage equilibrium (which means there is no LD between the two SNPs).  
Two SNPs in Low LD 
In this section, I would prove that even if two SNPs are in low LD to each other, one 
can still be dependent to the other. Here I listed some real case example from two 
published papers (Gaunt et al., 2012) (Shah et al., 2013b), which, in my point of 
view, will be the best observational proof for my assumption. As illustrated in Table 
2-1, I listed the conditional analysis p values of some pairs of SNPs reported in the 
above two papers. Amongst all these pairs, the conditional analysis suggested that 
these SNPs are dependent to each other although their r2 is lower than 0.15 








QTc NOS1AP rs7534004 rs4657154 0.144 0.116 
PR SCN5A rs12053903 rs7374540 0.172 0.198 
QRS SCN5A rs7374540 rs11710077 0.113 0.166 
HDL CETP rs3764261 rs12708967 0.111 0.066 
TG LPL rs3735964 rs7016529 0.002 0.224 
TG LPL rs3735964 rs1121923 0.002 0.608 
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Table 2-1. Examples of query dependent SNPs with low LD (r2<0.223) to the top hits 
but dependent on the top hits 
Two SNPs in linkage equilibrium (No LD) 
I simulated one extreme case of two SNPs in linkage equilibrium. In this case, I 
assumed that SNP1 (allele frequency of minor allele=0.3) and SNP2 (allele 
frequency of minor allele =0.4) were two significant SNPs associated with a trait and 
there is no LD between them (Figure 2-1 a). Then I estimated the haplotype 
frequencies between SNP1 and SNP2 (Figure 2-1 b). Then I introduced a hidden SNP, 
SNP3, with allele frequency of minor allele equal to A or Ā. Since the haplotype of 
SNP3 is known, I listed the haplotype frequencies between SNP1~SNP3 and 
SNP1~SNP2 in Figure 2-1c and d. Using these information, I calculated A, Ā, D and 
D-bar. Interestingly, both A andĀ was 0.28. This means when allele frequency of 
minor allele of SNP3 is 0.28, this SNP will be in LD to both SNP1 and SNP2 although 
there is no LD between SNP1 and SNP2.  
This special case proves that even if two SNPs are in linkage equilibrium, both of 
them can still be in LD with a third SNP. If the third SNP is the untested causal signal, 





Figure 2-1. A special case using the three SNPs model. a, the three SNPs model; b, 
rs327 and rs328 are in linkage equilibrium; c and d, estimating allele frequencies for 
rs263 with certain haplotype frequencies. Values at the bottom of each grid are the 
haplotype frequencies. D and D bar were the LD measures between rs263 and 
rs327/rs328 
2.1.5. Aims and objectives 
At the time I wrote this chapter, the step-wise regression analysis (Efroymson, 
1960)-the most widely used method for identify SNP independence-required 
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individual-level genotype data, which is normally not achievable in the current 
meta-analysis system (Seminara et al, 2007). On the other hand, I also proved that 
only consider LD relationship (r2) is not a ideal way of identifying SNP independence. 
Before the end of 2012, this is a blank area in genetic fine mapping field, which 
worth digging more. So in this chapter, I shall describe the development of a novel 
fine mapping method, which shall only use meta-analysis summary statistics. It 
should be highly automated and computational fast. The method is called 
sequential sentinel SNP regional association plots (SSSRAP, pronounced 
(es,es,es-rap)), which is a step-wise elimination method to detect the independent 
effect of query dependent SNPs conditional on the top significant signals. The 
dependence between top signal and the test SNPs shall be shown be depicted in a 
plot. The method shall be applicable to group-level data as well as individual-level 
data. It shall only require meta-analysis summary information and the haplotype 
frequencies information estimated from a reference panel. In addition, different 
functions shall be developed so that the method can be applicable to both 
quantitative (i.e. continuous) traits and binary (i.e. disease) outcomes.  
Objectives 
l Develop a novel fine mapping method using meta-analysis summary statistics 
of complex quantitative / disease traits  
l Investigate how the standard error of beta depends on minor allele frequency  
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l Compare the performance of the program against the performance of ten 
existing fine mapping methods using samples from 1) BWHHS individual-level 
data, 2) 1000 Genome individual-level data and 3) several simulated datasets 
l Develop a user friendly web-based tool for the novel method 
2.2. Methods and Materials  
2.2.1. Formulation of problems: linking 
meta-analysis summary statistics to 
pair-wise linkage disequilibrium 
measures 
For a pair of SNPs significant associated with a complex trait, for example lipids, it is 
not possible to detect whether the two SNPs are independent of each other using 
the meta-analysis summary statistics (single SNP effects) directly. As illustrated in 
Figure 2-2, the haplotype and haplotype frequencies of two SNPs can be used to 
link the observed beta (marginal SNP effect) of the top hit (top significant SNP) to 
the dependent effect (noted as the transformed beta) of the query dependent SNP 
by using a 2x2 table transformation. Then for the query dependent SNP, I compared 
the observed beta and its transformed beta. If two betas are statistically different, 
then I concluded that the query dependent SNP is independent conditional on the 
top hit and vice versa. The assumptions and notations of the SSSRAP program were 





Figure 2-2. Two SNPs 2x2 haplotype table and regression coefficient transformation  
Assumption: 
l Linkage disequilibrium between pair wise SNPs (or it will be meaningless to test 
the SNP independence) 
l For disease outcomes, the log odds increase equally with each addition of the 
minor allele (for each SNP) 
l For quantitative traits, the difference of effect between homozygous wild type 
genotype and heterozygous genotype is equal to the difference of effect between 
heterozygous genotype and homozygous mutant genotype 
l Participants are from the same population in the meta-analysis I applied 
l The top hit selected for the first phase tags a single causal signal. 
l Although the observed beta and transformed beta are not totally independent of 
each other, I still use the two samples unpaired T test.  
l Assume normal distribution of the phenotype, so I need to do the normalization 
of the phenotypes  
Definitions: 
p1 and p2 represent the major and minor allele frequency of the top significant SNP 
q1 and q2 are the major and minor allele frequency of the possible dependent SNP 
X11, X12, X21, X22 represent the four haplotype frequencies for the two respective SNP 
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loci    
Oddsmaj and Oddsmin represent the disease odds of each major and minor allele 
respectively 
‘e’ and ‘b’ represent the effect per minor allele and per major allele for the top hit 
respectively. 
βobs_top is the observed beta of the top hit  
βtrans is the beta estimation of the possible dependent SNP  
Oddsmaj_top and Oddsmin_top are the odds of major and minor allele for the top hit 
respectively 
Oddsmaj_trans and Oddsmin_trans are the odds of major and minor allele for the possible 
dependent SNP respectively 
‘m’  is the number of SNPs in the test group 
SEobs is the observed standard error for each possible dependent SNP 
SEtrans is the transformed standard error for each possible dependent SNP 
SEsim is the simulated standard error for each possible dependent SNP 
Notes: 
 X11 should be smaller than both p1 and q1 
Table 2-2. Assumptions and notations 
2.2.2. Relating regression coefficient to 
minor allele frequencies and 
haplotype frequencies 
As explained in Chapter 1, in the association analysis field, regression coefficient 
(beta) is the core value of the genetic association analysis, which is the gradient of 
the regression line of a single SNP model analysis.  
For disease outcomes, the regression coefficient for a specific SNP is the nature 
logarithm of the odds ratio:  
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As illustrated in Figure 2-2, for a pair of SNPs, the observed beta of the top hit, 
noted as βobs_top, can be transformed into the estimated beta of the query 
dependent SNP, noted as βtrans, through the 2x2 table transformation.  
Using equation 1, theβobs_top and βtrans can be extended to:  
βÅãÄ_çÅé = LN(OddsÉeÑ	 _çÅé/OddsÉÜâ_çÅé) (2) 
βçÖÜÑÄ = LN(	OddsÉeÑ _çÖÜÑÄ	/	OddsÉÜâ _çÖÜÑÄ		) (3) 
Where Oddsmaj_top and Oddsmin_top are the odds of major and minor allele for the 
top hit respectively; Oddsmaj_trans and Oddsmin_trans are the odds of major and minor 
allele for the query dependent SNP respectively.  
The above odds of alleles can be represented by the four haplotype frequencies X11, 
X12, X21 and X22:  







The haplotype frequencies X22, X12 and X21 can be represented as a combination of 










For quantitative traits, beta of a locus is the slope of the regression line. For a pair 
of SNPs, the top hit beta is: 
βÅãÄ_çÅé = e − b 
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Where e represents the effect per allele of homozygous mutant genotype and b 
represents the effect per allele of homozygous wild type genotype (Figure 2-3). 
Assume the effect of homozygous mutant genotype (AA) is 2e, meanwhile the 
effect of homozygous wild type genotype (TT) is 2b. The slope of the regression line 
(beta) will be e-b. 
 
Figure 2-3. Example of a linear trend line for a single locus. The grey dots are 
phenotype values (QTc interval) for 2686 participations, the black dashed line is the 
linear trend line, the x axis is the genotypes of SNP rs4657139, y-axis is the 
normalized QTc interval (normalized by Z score).  
As illustrated in Figure 2-2, the beta transformation formula becomes: 
βçÖÜÑÄ =
e ∗ N ∗ X22 + b ∗ N ∗ X12
N ∗ X22 + N ∗ X12
−
e ∗ N ∗ X21 + b ∗ N ∗ X11
N ∗ X21 + N ∗ X11
	(6) 
Where N is the number of participants, X11, X12, X21 and X22 are the four haplotype 
frequencies for this pair of SNPs. 
N cancels, and representing X22, X12 and X21 using p1, q1 and X11, gives:  
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2.2.3. Estimating standard errors of 
transformed betas  
To estimate the standard error of the transformed beta for each query dependent 
SNP, I separated the total uncertainty (where is the reason of the beta getting a 
specific standard errors) to two parts: phenotype uncertainty and haplotype 
uncertainty. The phenotype uncertainty is the errors caused by the randomness of 
the phenotype. The haplotype uncertainty, as illustrated in Chapter 1, is the 
proportion of the middle cell haplotype phase is unknown in a 3 × 3 table for a 
biallelic marker (Table 1-2). I assessed both phenotype uncertainty and haplotype 
uncertainty separately using a simulated dataset. The dataset was a group of SNPs 
that significantly associated with three ECG traits and three lipid traits in BWHHS 
(Table 8-1A and 9-1B). These data was chosen since previous reported multiple 
association signals in these regions, and these regions are genotyped using a 
high-throughput chip. The phenotypes of these traits were standardized using a Z 
score, which made the unit of the betas the same among these traits, so that I can 
combine them together for this simulation. For the phenotype uncertainty, I 
transformed the 95% CI of observed beta for each possible dependent SNP through 
the 2x2 contingency table directly and get the “95% confidence limit” of 
transformed beta (noted as SEtrans). To explain the haplotype uncertainty of the 
transformed beta, standard errors (noted as SEsim) were derived from a distribution 
generated by 10,000 simulations.  
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2.2.4. Two tailed t test and stepwise 
elimination  
Extending the pair-wise SNPs situation to a model containing ‘m’ loci, I estimate the 
transformed beta (different formula for disease outcomes or quantitative traits) for 
each pair of top significant SNP and query dependent SNPs. So I will derive ‘m-1’ 
transformed betas (from βtrans_1, to βtrans_m-1).  
For each query dependent SNP “i” (i =1 … m-1), the difference between its observed 
beta (βobs_i) and its transformed beta (βtrans_i) will be quantified using an unpaired 
two tailed t test. The reason of choosing the two tailed t test is that the effect of 
SNPs can be either risk increasing or protective. 
As the estimation results suggested in Results section and Figure 2-8, the observed 
standard error for the query dependent SNP (SEobs_i) will be used instead of the 






The t-statistics will then be transformed to t test p values using R code: 
2 x pt (-abs (t-statistics), df = N-1), 
Then a step-wise elimination procedure is used to remove SNPs highly dependent 
on the top hit. The p-value threshold will be set (for example: 0.01) and SNPs with t 
test p value higher than the threshold will be removed from the model. For the 
remaining SNPs, the SNP with the lowest t test p-value will be used as the second 
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independent SNP and it will be used as the top hit for the next phase step-wise 
elimination (Figure 2-4).  
Although the remaining SNPs are significant conditional on the top hit, the top hit 
may still have minor effect on them. To remove the effects of the top hit from the 





Whereβobs_adjusted, βobs and βtrans are adjusted observed beta, unadjusted observed beta and 
transformed beta of the SNP. “g” is the number of current phase of elimination, 
whereas g+1 is the next phase of elimination 
The step-wise elimination will be continued until all SNPs with independent effects 




Figure 2-4. Flowchart of the SSSRAP approach
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2.2.5. SSS-RAP web-based tool 
A web-based implementation of the SSS-RAP program was developed using Python CGI (for 
details please see Appendix, Chapter 9.3). I illustrated the homepage in Figure 2-5. The URL 
is: http://apps.biocompute.org.uk/sssrap/sssrap.cgi 
 
Figure 2-5. Homepage of SSS-RAP programme.  
2.2.6. Sample datasets 
The BWHHS sample data 
The SSS-RAP program was applied to the analysis of BWHHS individual level data (Gaunt et 
al., 2012) (Shah et al., 2013a) for three ECG traits (PR interval, QRS duration and QTc interval) 
and two lipid traits (triglycerides and HDL cholesterol). SNPs selected for the performance 
comparison were listed in Table 8-1A and 9-1B.  
To prepare the input data required, I controlled the quality of data for individuals with 
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missing genotypes and phenotypes using PLINK code --geno and –prune. I standardized 
phenotype using Z score, which is explained in Chapter 1. Using PLINK, I calculated MAF, 
conducted an association test using the additive SNP model and estimated haplotype 
frequencies for each pair of SNPs.  
Using model selection methods, I aim to identify one subset of SNPs providing the best fit to 
the data among all the possible models. The model selection methods were selected using a 
number of criteria in R (http://www.r-project.org/, 2.14.1), which included Akaike 
information criterion (AIC), Bayesian information criterion (BIC), Mallows Cp, Cross 
Validation, leave-one-out-cross-validation (LOOCV), adjusted r2, stepwiseAIC, stepwiseBIC, 
stepwiseCp, stepwise regression with p value threshold of 0.05. The concepts of these 
methods were explained in Chapter 1. I listed the data and R code I used in Chapter 9.1.2. 
Besides, the conditional analyses were run in PLINK with a p-value cut-off value of 0.001.  
Admixed population simulation using 1000 Genome data  
To analyse whether minor departures of LD (e.g. two sub-populations in one major ethnic 
group) affect the SSS-RAP assumption of one ancestral group, I combined the genotype data 
of HapMap unrelated Utah Residents (CEPH) with Northern and Western European ancestry 
(CEU) unrelated individuals and the Toscana in Italia (TSI) individuals. SNPs associated with 
PR interval and QRS duration in the ECG meta-analysis were selected (Gaunt et al., 2012). I 
applied SSS-RAP to the summary statistics (betas and SEs) of the meta-analysis and allele 
frequencies and haplotype frequencies estimated using individual-level genotypes of CEU 
individuals as well as the admixed population of CEU and TSI. Then I compared the results of 
these two designs. 
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Simulation to test relationship between r2 and beta 
I conducted several simulated datasets to test the relationship between r2 and beta. For the 
top hit, I assumed that it has a MAF of 0.1. To test whether the method performed 
differently with different marginal SNP effects, I set three different marginal effects for the 
top hit: 0.5, 1 and 4. For the query dependent SNP, I varied allele frequencies and r2, 
increasing 0.01 per time in the range of 0.5 to 1 for allele frequencies and in the range of 0 
to 1 for r2.   
Admixed population simulation 
For the BWHHS genotype data of LPL gene, I imputed the region using IMPUTE2. The 
HapMap genotypes were used as a reference panel for the imputation. I selected three SNPs 
with varying associations with triglyceride (TG): rs328, which is a well replicated top 
significant signal associated with TG; rs327, which is a significant SNP associated with TG 
and rs263, which is a bystander SNP not associated with TG. For these three SNPs, I used the 
four commonest haplotypes among them (Figure 2-6). We assume the frequencies of these 
four haplotypes change 0.1 each time. Haplotype 1 is the commonest haplotypes with 
frequency change between 0.5 to 0.8. The frequencies of the other three haplotypes are 
changing between 0.1 to 0.4. Totally there are 55 possible haplotype frequencies 
combination. Amongst these haplotype frequencies combinations, 20 were not in perfect LD 
(Table 2-3). These 20 combinations were used in this simulation. I simulated the genotypes 
for 10000 individuals for each set of these 20 haplotype frequencies combinations. The 
phenotypes for the 10000 individuals were estimated using the true effect plus a random 
baseline effect. These 20 simulated populations were noted as “pop_1”. The whole process 
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was repeated again and the second 20 simulated populations were noted as “pop_2”. Then 
for both pop_1 and pop_2, I picked the first population and combined them together as an 
admixture population. Using the same way, I created 210 admixed populations.  
 
Figure 2-6. The three SNPs model for the admixed population simulations. I assumed rs328 
was the top hit, rs327 was an independent effect SNP and rs263 was a by stand SNP. Alleles 
in red means they were the effect / minor alleles. 
 
ID haplotype 1 haplotype 2 haplotype 3 haplotype 4 
5401 0.5 0.4 0 0.1 
5311 0.5 0.3 0.1 0.1 
5302 0.5 0.3 0 0.2 
5221 0.5 0.2 0.2 0.1 
5212 0.5 0.2 0.1 0.2 
5203 0.5 0.2 0 0.3 
5131 0.5 0.1 0.3 0.1 
5122 0.5 0.1 0.2 0.2 
5113 0.5 0.1 0.1 0.3 
5104 0.5 0.1 0 0.4 
6301 0.6 0.3 0 0.1 
6211 0.6 0.2 0.1 0.1 
6202 0.6 0.2 0 0.2 
6121 0.6 0.1 0.2 0.1 
6112 0.6 0.1 0.1 0.2 
6103 0.6 0.1 0 0.3 
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7201 0.7 0.2 0 0.1 
7111 0.7 0.1 0.1 0.1 
7102 0.7 0.1 0 0.2 
8101 0.8 0.1 0 0.1 
Table 2-3. Possible haplotype frequencies combination for the 3 SNPs model 
2.3. Results 
2.3.1. Estimating standard errors of 
transformed betas  
Previously in Chapter 3.2.3, I have explained my way of finding out the appropriate standard 
errors for the beta produced by SSS-RAP (noted as transformed beta). Here is the result of 
my hypothesis that minor allele frequency (MAF) has a major influence on the standard 
error of beta. 
Relationship between minor allele frequencies and standard error 
of beta 
As shown in Figure 2-7, with smaller numbers of individuals in the variant allele group (i.e. 
lower MAF), the errors (both observed SEs and simulated SEs) on estimates are wider, which 
can also be supported in a statistical way: the residual variance of the regression is a 




Figure 2-7. The influence of minor allele frequency on the standard error of beta. 
a, relationship between the observed standard errors and the minor allele frequencies 
(MAF). b, relationship between the simulated standard errors and MAFs 
Standard error of SSS-RAP betas 
The total uncertainty (which is represented by the SE) of SSS-RAP beta was combination of 
the phenotypic uncertainty (transformed SE) and haplotypic uncertainty (simulated SE). I 
tested the relationship between the observed SE and both transformed SE and simulated SE 
in different r2 ranges. When the r2 is between 0 and 0.5, the observed SE of the possible 
dependent SNP was similar to the simulated SE and total SE (Figure 2-8a and 3-7b). In 
contrast, when r2 is between 0.5 and 1, the observed SE was more similar to the 
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transformed SE and total SE (Figure 2-8e and 3-7f). So for the query dependent SNP, the 
observed SE of the single SNP regression is an appropriate representative of the SE of the 
SSS-RAP beta.  
 
Figure 2-8. Comparison of the observed standard errors to the simulated standard errors and 
the transformed standard errors in different r2 ranges 
2.3.2. Relationship between r2 and beta 
estimation  
I illustrate the relationship between r2 and the two beta estimations in the r2 simulation I 
mentioned in Methods section. As shown in Figure 2-9, beta estimation value varies with 
different r2, and the shapes of these two beta estimations are similar when the observed 
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beta is smaller than 1.  
  
Figure 2-9. Relationship between r2 and beta estimate of the possible dependent SNP for a 
given major allele frequency of the top hit and observed beta for the top SNP. Different colors 
refer to different intervals of major allele frequency of the possible dependent SNP (called 
q1): red for 0.5< q1 <=0.6, blue for 0.6< q1 <=0.7, green for 0.7< q1 <=0.8, yellow for 0.8< q1 
<=0.9 and grey for 0.9< q1 <1. 
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2.3.3. Example of a SSS-RAP plot 
The SSS-RAP plot can visually show the relationship between each pair of SNPs. Figure 2-10 
illustrated an example of the SSS-RAP plot. The top hit is the one on the right side with a bar 
of the observed beta only, whereas 6 test SNPs were in the left side. For each test SNP, the 
SSS-RAP plot compared the difference between the observed betas and the transformed 
betas. If two bars were overlap, this will suggest that the test SNP have some dependence 
conditional on the top hit. Otherwise, it suggests that the test SNP has certain level of 
independent effect conditional on the top hit. In this example, all test SNPs are suggested to 
be independent conditional on the top hit. However, the plot did not correct the multiple 
testing. In reality, we need to check whether the SSS-RAP p-value is smaller than the p value 
cut-off to conclude the independence of the test SNPs.  
 
Figure 2-10. Example of a SSS-RAP plot 
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2.3.4. Performance comparisons of SSS-RAP, 
model selection methods and conditional 
analysis using BWHHS individual level 
data 
The SSS-RAP program was used to analyse significant SNPs associated with lipid traits and 
ECG traits in BWHHS individual level data, which include SNPs in the lipoprotein lipase (LPL) 
(associated with both triglyceride and HDLc), cholesteryl ester transfer protein (CETP) 
(associated with HDLc), sodium channel, voltage-gated, type V, alpha subunit (SCN5A) 
(associated with PR interval and QRS duration) and nitric oxide synthase 1 (neuronal) 
adaptor protein (NOS1AP) associated with QTc interval (Table 2-4). Since the purpose of this 
analysis is a performance comparison rather than a discovery study (in which we need to be 
very careful about false positive), we selected a quite loose p value threshold so that we can 
include more SNPs into this analysis. Results from SSS-RAP were compared with ten different 
model selection criteria and conditional haplotype analysis.  
genes quantitative traits mean SD  N significant SNPs p-value threshold 
LPL TG (mmol/l) 1.873 1.251 3175 10 1x10-03 
LPL HDLc (mmol/l) 1.660 0.453 3169 10 1x10-04 
CETP HDLc (mmol/l) 1.658 0.455 3035 17 1x10-05 
NOS1AP QTc interval (msec) 0.419 0.024 2686 24 1x10-04 
SCN5A PR interval (msec) 0.159 0.023 2867 6 1x10-02 
SCN5A QRS duration (msec) 0.091 0.015 2980 9 1x10-02 
Table 2-4. Summary information of BWHHS participants. P-value threshold is the cut off 
value of the SNP significant test. Abbreviations: mean, mean of quantitative traits; SD, 
standard deviation of quantitative traits; TG, triglycerides; HDL-C, high-density lipoprotein 
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cholesterol, QTc = QT/√(RR interval); N, participants after exclusion with missing genotypes 
and phenotypes. 
BWHHS ECG traits:  
For three ECG traits, I set the t test p-value of 0.05 as the elimination standard for SSS-RAP.  
Generally, the SSS-RAP program selected the same optimal SNPs model as conditional 
analysis in all ECG traits. For NOS1AP loci associated with QTC interval and SCN5A SNPs 
associated with PR interval, the SNPs selected by SSS-RAP were also chosen by the other ten 
model selection methods (Figure 2-11 and Figure 2-12a). For SCN5A SNPs associated with 
QRS interval, BIC, CV, stepwise BIC and stepwise regression (Figure 2-12b) selected SNP 
rs10154914 instead of top hit rs7374540. This SNP is in some LD with the top hit (r2=0.153).  
BWHHS lipids traits: 
For the three lipids traits, I set a t test p value of 0.01 as the threshold for backward 
elimination. As shown in Figure 2-12c, 3-11d and 3-11e, the results were consistent among 
the ten model selection methods, conditional analysis and SSS-RAP. The only exception was 
the top hit of LPL associated with TG, rs3735946. Stepwise AIC stepwise Cp, stepwise BIC and 
stepwise regression selected a coding SNP, rs328, instead (Figure 2-12c). Rs328 is in strong 
LD with top hit rs3735946 (r2=0.911). Thus this finding is inconclusive in that this exception 




Figure 2-11. Comparison of model selection approaches, conditional analysis and SSS-RAP 
using BWHHS individual level data in NOS1AP region. All the methods and criteria used to 
select NOS1AP loci most likely to be tightly associated with QTc interval. For all the methods, 
cross (×) denotes inclusion in the best model. Top hit is represented by yellow background in 




Figure 2-12. Comparison of model selection approaches, conditional analysis and SSS-RAP 
using BWHHS individual level data in other regions. All the methods and criteria used to 
select: a, SCN5A loci most likely to be independently associated with PR interval, the P value 
cut-off of 0.05 was used in this analysis; b, SCN5A loci most likely to be independently 
associated with QRS duration, the P value cut-off of 0.05 was used in this analysis; c, LPL loci 
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most likely to be independently associated with a TG variant, the P value cut-off of 0.01 was 
used in this analysis; d, LPL loci most likely to be independently associated with a HDL 
variant, the P value cut-off of 0.01 was used in this analysis; e, CETP loci most likely to be 
tightly associated with a HDL variant , the P value cut-off of 0.01 was used in this analysis. 
For all the methods, cross (×) denotes inclusion in the best model. 
2.3.5. Applying SSS-RAP to an admixed 
population using 1000 Genomes Project 
data 
For the analysis conducted on an admixed population using the 1000 Genome Project data, 
the principal components analysis (PCA) applied by the HapMap Consortium indicated that 
CEU and TSI populations are from a relatively homogeneous ancestry and can be grouped 
together under larger group of ‘European ancestry’ (International HapMap 3 Consortium et 
al., 2010).  
In both populations SSS-RAP selected the same sets of independent SNPs in SCN5A for both 
PR interval and QRS duration (Table 2-5). Therefore, the minor departures in LD did not have 
a major effect to the SSS-RAP results. 
  Step-wise stage CEU only CEU+TSI 
SCN5A - PR 
step 1 rs7372712 rs7372712 
step 2 rs7374540 rs7374540 
step 3 rs7624535 rs7624535 
step 4 rs12053903 rs12053903 
SCN5A - QRS 
step 1 rs7374540 rs7374540 
step 2 rs6797133 rs6797133 
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step 3 rs1805126 rs1805126 
step 4 rs7624535 rs7624535 
Table 2-5. Test of one ancestral group assumption for SSS-RAP. The SSS-RAP was applied 
using meta-analysis summary statistics of SCN5A associated with two traits. The reference 
panel was either HapMap CEU unrelated individuals or HapMap CEU plus TSI individuals. 
The SNPs in Step 1 to Step 4 refer to the independent SNPs selected by step-wise procedure 
1 to 4.  
2.3.6. Applying SSS-RAP to 210 simulated 
populations  
The performance of SSS-RAP and conditional analysis were compared using 210 admixed 
populations using simulations (Chapter 3.2.3). For the three SNPs in this simulation, the top 
hit rs328 and the secondary independent signal rs327 was identified as independent by both 
method in all 201 populations. Interestingly, the performance of eliminating bystander SNP, 
were different for these two methods. In this simulation, the bystander SNP, rs263, was 
eliminated in 68.6% (144/210) of the simulations when applying the SSS-RAP algorithm 
(Figure 2-13a). In contrast, the conditional analysis did not eliminate the bystander SNP from 




Figure 2-13. SSS-RAP and conditional analysis results for the three SNPs haplotype simulation. 
a, represents the result for SSS-RAP. b, represents the result for conditional analysis. Since 
both methods working well for identifying the independent signals, so I only shown the 
difference in eliminating bystander SNPs in this plot. For each cell, light grey means the 
bystander SNP was eliminated by the method, which means the method return a result fit 
our setting perfectly. Dark grey the bystander SNP was not eliminated by the method, which 
means the method fail to achieve its function. 
2.4. Discussion 
In this chapter, I have utilized the basic concepts of LD measure (r2) of pair-wise SNPs and 
regression coefficient (beta) to solve the problem of detecting independent SNPs conditional 
on the top hit using summary statistics from meta-analysis and reference genotype panel. 
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2.4.1. Advantages of SSS-RAP 
Scope of SSS-RAP 
Before the SSS-RAP program was developed, the researchers had to perform the conditional 
analysis at the level of individual studies; and then summary statistics from each of the 
individual-level studies are combined together through a second round of meta-analysis (Ma 
et al., 2010). Meta-analysis nowadays combines more and more single GWASs together, 
which makes the abovementioned process administratively laborious and time consuming 
(Zheng et al., 2013). The SSS-RAP algorithm extends the scope of fine mapping to 
group-level and enabled determining multiple associated variants using meta-analysis 
results directly.  
Accuracy and inherent automation of SSS-RAP 
Comparison between SSS-RAP and model selection methods 
In the performance comparison using BWHHS individual-level data, all SNPs selected by 
SSS-RAP were chosen by most of the established model selection methods (Smith et al., 
2010a) (Figure 2-11 and Figure 2-12). Only two top hits which were classified as 
‘independent’ by SSSRAP were not replicated by the model selection methods. These 
methods chose SNPs in LD with the top hit instead. These differences can be attributed to 
the downsides of the other methods and not to SSS-RAP, since, (i) the results of SSS-RAP and 
conditional analysis were highly consistent using the individual-level data and (ii) SSS-RAP 
considers the biological correlation-LD, whereas model selection methods only consider the 
statistical correlation of the SNP models. 
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Comparison between SSS-RAP and conditional analysis  
Among all the SNPs which were tested using BWHHS individual-level data and meta-analysis 
summary datasets (Figure 2-11 and Figure 2-12), 95.44% (293/307) of SSS-RAP results were 
consistent with conditional analysis results. This proves the highly accurate nature of 
SSS-RAP. Further analysing the inconsistent results, only two independent SNPs (rs1805126 
and rs11710077) selected by conditional analysis which were not included in the SSS-RAP 
results. For SCN5A associated with PR interval, the coding SNP rs1805126 (D1819) was 
statistical significant conditional on the top hit rs7372712. But it is in strong LD with the 
second independent signal, rs12053903 (r2=0.827). Similarly, rs11710077 is in modest LD 
with the second independent effect SNP rs6797133 (r2=0.386) associated with QRS duration. 
As abovementioned, conditional analysis is administratively burdensome and time 
consuming. For the ECG meta-analysis, only the association analysis conditional on the top 
associated SNP at the loci were processed. So these two SNPs were still included in the 
model. In contrast, SSS-RAP is a step-wise elimination method. Like other step-wise 
regression strategy (Knüppel et al., 2012), it not only considers the independence 
conditional on the top SNP, but also considers the correlation between each possible 
independent effect SNP; and consequently excluded these two SNPs, which highlighted a 
major advantage over previous methods is the inherent automation in SSS-RAP.  
Population structure causes genome wide LD between unlinked loci, which will cause 
statistical confounding in GWAS based fine mapping (Segura et al., 2012), so an additional 
performance comparison was conducted using admixture populations. Both SSS-RAP and 
conditional analysis shows the ability to detect the secondary signal in an admixture 
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population. Moreover, SSS-RAP shows the ability to eliminate bystander SNPs where 
conditional analysis failed to eliminating the bystander SNPs in any case (Figure 2-13). So I 
suggested that SSS-RAP is a more suitable fine mapping approach for admixture population 
analyses. This comparison illustrates the potential value of SSS-RAP when conducting fine 
mapping analysis using admixture populations who belong to the same ancestral group (e.g. 
European).  
Computational time of SSS-RAP 
As discussed above, conditional analysis using the conventional meta-analysis system is time 
consuming, which will normally take months for each round. Compared to conditional 
analysis, SSS-RAP is simple to use and yields results speedily. For SSS-RAP, there are no 
computationally unfeasible and/or expensive processes such as iterations and simulations 
thus the analysis usually takes a few seconds for each genomic region. Table 2-6 shows some 
examples of the number of SNPs in each model and the computational time of each analysis 
(the analysis result include the conducting of result table and the SSS-RAP plot) using a 
computer with 2.53GHz CPU and 2 GB RAM. 
Loci traits number of SNPs computational time (Second) 
SCN5A PR 6 2.54 
SCN5A QRS 10 3.1 
ABCG5-8 GBD 10 3.99 
NOS1AP QTc 60 4.26 
Table 2-6. Computational time of SSS-RAP 
The web-based tool and visualization  
As a user friendly program, SSS-RAP provides a lot of options for different user requests. Not 
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only can the users carry out analyses by using the SSS-RAP source code written in R, but also 
can use the web-based interface to analyze regions with less than 20 SNPs. As illustrated in 
Figure 2-10, SSS-RAP also provides a plot which shows the difference between expected beta 
and observed beta in the context of a regional association plot as well as the t test p-value. 
The plot shows the dependence effect of each test SNP “borrowed” from the top hit and 
helps the users to pick out the statistical independent effect SNPs easily. 
2.4.2. Assumptions and limitations of SSS-RAP 
One ancestry assumption 
Different racial and ethnic and ancestral categories of human show differences arise directly 
through differing allele frequencies, which will influence LD patterns and haplotype 
frequencies (Race, Ethnicity, and Genetics Working Group, 2005). So the major assumption 
of SSS-RAP program is that participants of both the meta-analysis and the reference 
genotype panel are from one major ancestral group. Although I have proven that minor 
departure of LD will not affect the result of SSS-RAP significantly in section 3.3.5, users need 
to avoiding using meta-analysis results from trans-ethnic analysis.  
Assumption of the top hit 
When applying SSS-RAP, I assume that the most significant SNP inside a genomic region 
represents a tag of a single causal signal or is itself the causal site. Conditional analysis 
shares the same assumption of the top hit. To fit this assumption better, it would be 
necessary to impute the genotypes before progressing to the meta-analysis so that the 
possibility of detecting the causal signal or a suitable proxy signal will be higher.  
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Limiting conditions for SSS-RAP and conditional analysis 
The results of the admixed population simulation suggested that SSS-RAP and conditional 
analysis performs quite well if the top hit is the only independent effect SNP in the genomic 
region. If there are two or more independent loci in the region, SSS-RAP will eliminate most 
of the dependent SNPs. However, it is impossible to explain which loci are truly independent 
for the remaining SNPs. In fact, only haplotype-based analyses may be able to discriminate 
between causal sites, for example in the (most likely infrequent) situation where one 




Figure 2-14. An example of one ‘bystander’ efficiently represents two separate causal sites 
themselves in LD. In Model 1, bystander C shows the most signal. However, the haplotype 
effect scores are not consistent with C being causal because not all C bearing haplotypes 
show the same effect score. On the other hand, effect scores A=B=1 would be consistent 
with observed haplotype effects. In Model 2, C shows the most signal (same as in model 1). 
In this model, the haplotype effect score are consistent with C being causal, whereas A and B 
would not be. 
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2.4.3. Conclusion  
In this chapter, I have successful develop a novel fine mapping method, SSS-RAP, using 
meta-analysis summary statistics directly. I compared the performance of SSS-RAP to 
conditional analysis and model selection methods, most of the results are consistent among 
these methods, which proves the accuracy of SSS-RAP. A user-friendly web interface was 
developed by the same time. During the development of SSS-RAP, I also verified the linear 
relationship between MAF and the standard error of beta. Last but not least, the limitation 
of SSS-RAP made me realized that a haplotype-based fine mapping method was needed, 
which will be discussed in Chapter 5.  
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CHAPTER 3. FINE MAPPING OF 
CARDIOVASCULAR DISEASE 
REALTED TRAITS AND 
APPLICATION OF SSS-RAP 
3.1. Introduction 
Cardiovascular diseases (CVD), mainly coronary heart disease (CHD), stroke and rheumatic 
heart disease, are the leading cause of mortality and morbidity globally. The World Health 
Organization (WHO) reports that CVD deaths increased from 14.4 million in 1990 to 17.5 
million in 2005. Among the CVD deaths, 7.6 million were caused by CHD and 5.7 million by 
stroke (WHO, 2009). The WHO further estimate that there will be about 20 million CVD 
deaths in 2015, accounting for 30% of deaths worldwide (WHO, 2005). CVD is the largest 
current contributor to global mortality and will continue increasing its percentage mortality 
in the future (WHO, 2009).  
Finding the biological mechanisms of CVD and developing prevention strategies are of 
paramount importance. 
Classic family and twin studies provide evidence that there is a heritable component 
contributing to CVD (Lloyd-Jones et al., 2004) (Marenberg et al., 1994) (Murabito et al., 2005) 
(Bachmann et al., 2012). In contrast to the above candidate gene approach analyses, GWAS 
provides a hypothesis free method of discovering novel molecular mechanisms of CVDs.  
Previous GWAS studies investigating the impact of CVD looked at a range of different traits 
including Electrocardiography, body mass index and gallbladder disease. To contribute to this 
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cut-edge research field, I shall briefly introduce the background of these traits and the 
relative GWAS studies for these traits in the following section.  
3.1.1. Electrocardiography (ECG)  
Human heart beats regularly over a period of time. ECG is a quantitative measure of 
the electrical activity of the heart beating. It is measured by electrodes attached to the 
surface of the skin and recorded or displayed by a monitoring device external to the body 
(Cooper, 1986).  
As shown in Figure 3-1, ECG traces the cardiac cycle, the quantitative measurement of ECG 
includes PR interval, QRS axis, QRS duration and QT interval (Hurst, 1998).  
Electrocardiographic traits are important in predicting CVD morbidity and mortality (Lawlor 
et al., 2003) (Gaunt et al., 2012). A prolongation of QTc interval or QRS duration are linked to 
heritable determinants of risk of arrhythmias and sudden death (Mann, 2008). The 
mechanism of the common genetic variants contribute to ECG traits are unclear. Recent 
GWASs and meta-analyses successfully identified several genomic regions associated with 





Figure 3-1. ECG waves and intervals.  
PR interval 
The PR interval is a measurement of the period from the beginning of the P wave to the 
beginning of the QRS duration. The PR interval represents ventricular depolarization. 27 
SNPs were previously reported to be associated with PR interval (Pfeufer et al., 2010) (Smith 
et al., 2011) (Butler et al., 2012) (Jeff et al., 2013). As illustrated in Table 8-2, SNPs in SCN5A 
and SCN10A region got the strongest signals. SCN10A gene encodes the voltage-gated 
sodium channel Nav 1.8, which is essential for pain at low temperatures (Zimmermann et al., 
2007). Moreover, the neighboring SCN5A gene encodes the main cardiac sodium channel, 
Nav 1.5. The mutations in SCN5A is related to Brugada syndrome, long-QT syndrome, dilated 
cardiomyopathy, cardiac conduction disease, idiopathic ventricular fibrillation and atrial 
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fibrillation (Remme et al., 2008). Moreover, Pfeufer A et al reported that there are more 
than one signal associated with PR interval within this region (Pfeufer et al., 2010).  
QRS duration 
QRS duration, also called QRS complex, reflects the rapid depolarization of the right and left 
ventricles. The ventricles have a large muscle mass compared to the atria, so the QRS 
duration usually has much larger amplitude than the P-wave. As listed in Table 8-3, 9 SNPs 
were previously reported to be associated with QRS duration (Jeff et al., 2013). In addition, 
Gaunt TR et al claimed that SNP rs7374540 in SCN5A is associated with QRS duration as well 
(Gaunt et al., 2012).  
QT interval 
The QT interval is measured from the beginning of the QRS complex to the end of the T wave. 
It represents ventricular repolarization and varies with heart rate and, for clinical relevance, 





RR is the interval from the onset of one QRS duration to the onset of the next QRS duration, 





Totally 77 SNPs are associated with QT interval (Arking et al., 2006) (Pfeufer et al., 2009) 
(Newton-Cheh et al., 2009) (Nolte et al., 2009) (Marroni et al., 2009) (Kim et al., 2012) 
(Smith et al., 2012) (Jeff et al., 2013). As shown in Table 8-4 A and B, SNP rs12143842, which 
is 6kb 5’ of NOS1AP, got the strongest association with QT interval. NOS1AP (CAPON) is the 
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C-terminal PDZ domain ligand to neuronal nitric oxide synthase and it affects NMDA 
receptor-gated calcium influx (Jaffrey et al., 1998). NOS1AP expression in human left 
ventricular heart tissue (Arking et al., 2006). Common genetic vairants inside NOS1AP are 
linked to sudden cardiac death in European population (Kao et al., 2009). Moreover, 
Newton-Cheh C et al claimed that, except top hit rs1214382, there are two additional 
independent SNPs associated with QT interval, rs12029454 and rs16857031.  
3.1.2. Body mass index (BMI) 
The BMI is a well-known index of measuring human obesity. It is defined as the body mass 





As represented in Figure 3-2, the BMI provides a simple numeric measure of people’s level 
of adiposity. A BMI less than 18.5 may indicate underweight. The BMI range between 18.5 
and 25 are optimal weight. A BMI over 25 and under 30 is classified as overweight, whereas 




Figure 3-2. Body mass index chart. The scope of underweight, normal, overweight and obese 
are shown (http://en.wikipedia.org/wiki/File:Body_mass_index_chart.svg).  
Obesity is one of the leading cause of preventable death in industrialised world (Richardson 
et al., 2013). The prevalence of obesity is increasing worldwide. In 2003 to 2004, the 
percentage of overweight and obese population in US was 66% and 32% respectively 
(Ogden et al., 2006). It is associated with an increased risk of diseases such as type 2 
diabetes, heart disease, metabolic syndrome, hypertension, storks and so on (Frayling et al., 
2007). Understanding its genetic influences will enhance insight into molecular pathogenesis. 
19 studies identified approximately 150 SNPs associated with BMI. As listed in Table 3-1, 
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multiple SNPs near Fat mass and obesity associated (FTO) and melanocortin 4 receptor 
(MC4R) gene were reported to be associated with BMI (Thorleifsson et al., 2009).  
Chr Position Gene lead SNP Risk Allele beta p-Value 
16 53769677 FTO rs6499640 A 5.25 4.00E-13 
16 53816275 FTO rs8050136 A 8.04 1.00E-47 
18 57884750 MC4R rs12970134 A 4.38 1.00E-12 
Table 3-1. FTO and MC4R SNPs reported to be associated with BMI in the GIANT 
meta-analysis 
3.1.3. Gallbladder disease (GBD) 
The prevalence of gallstones is 10% - 40% in developed countries (Johnston and Kaplan, 
1993). Gallstones lead to gallbladder disease (GBD), a major cause of morbidity, hospital 
admission, surgical intervention and economic burden. Causes of morbidity include biliary 
colic, cholecystitis, choledocholithiasis and pancreatitis (Kalloo and Kantsevoy, 2001). In 
developed countries, most gallstones are formed of cholesterol. In contrast, pigment stones 
can be found in regions where bacterial and parasitic infections of the biliary tree, and 
hemolysis occur (Wang and Afdhal, 2004). Therefore, it will be interesting to see the 
relationship between lipids traits loci and GBD loci. Genome-wide association studies 
identified coding variant rs11887534 (D19H) in ABCG5 and ABCG8 region as the leading SNP 
affecting GBD (Buch et al., 2007). The head-to-head gene pair ABCG5 and ABCG8 together 
encode a heterodimeric transporter responsible for apical cholesterol secretion from both 
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hepatocytes and enterocytes. Rodriguez et al suggested multiple independent signals 
associated with GBD in this region (Rodriguez et al., 2014). 
3.1.4. Aims and objectives 
In chapter 3, I developed SSS-RAP and determined its accuracy using the performance 
comparison of conditional analysis, model selection methods and SSS-RAP. SSS-RAP is design 
for group-level data, so I shall focus on its application in group level in this chapter. Before 
the real case applications, I shall compare the SSS-RAP meta-analysis results to its 
individual-level results using different data sets as reference panel. For the CVD related 
traits I introduced above, SSS-RAP shall be applied to the candidate regions that have been 
associated with multiple signals by previous GWASs and meta-analysis, such as NOS1AP and 
SNC5A associated with ECG traits, FTO, MC4R and other regions associated with BMI as well 
as ABCG5 and ABCG8 region associated with GBD.  
Objectives 
1. Verification of the performance of SSS-RAP in meta-analysis level using summary 
statistics of ECG traits and GBD outcomes. Compare the meta-analysis level results with 
its individual-level results using different data sets as reference panel, for example, data 
from a specific study and publically available data 
2. Discover the relationship between correlation coefficient, effect size and p value using 
GBD meta-analysis data 
3. Fine mapping the genetic variants in NOS1AP and SCN5A regions associated with ECG 
condition traits using meta-analysis level data 
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4. Developing a transformation method so that the GIANT BMI meta-analysis summary 
statistics can be applied to SSS-RAP 
5. Detecting LD pattern of SNPs significantly associated with GBD in the meta-analysis and 
identifying independent signals of GBD outcomes in ABCG5 and ABCG8 region using 
SSS-RAP 
3.2. Methods and Materials  
3.2.1. Sample datasets 
The BWHHS individual-level genotypes 
Among all the BWHHS individuals, I used genotype data of 3445 individuals who were 
genotyped using the Human cardiovascular disease (HumanCVD) BeadChip (Illumina, San 
Diego, CA). MAF were calculated using PLINK option --freq and haplotype frequencies were 
calculated using MIDAS (Gaunt et al., 2006). 
Meta-analysis of ECG traits 
The summary statistics of ECG meta-analysis were used (Gaunt et al., 2012). The analysis 
results of PR interval, QRS duration and QTc interval were used here. All the significant SNPs 
for this meta-analysis were listed in Table 8-5.  
GIANT BMI meta-analysis summary statistics 
The GIANT consortium released the summary data for their meta-analysis of GWASs. For 
BMI meta-analysis, this includes approximately 2.8 million SNPs in up to 123856 individuals 
in discovery panel and additional 125931 individuals in the follow-up study. The summary 
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results of this meta-analysis were downloaded from the consortium webpage 
(http://www.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_fil
es). The summary results were consisted of the following information for each SNP: marker 
ID, allele 1, allele2, allele frequency of Allele 1, p values and number of observations. The 
standard errors of the betas were not included in the summary results so were calculated 
analytically. 
Meta-analysis of GBD outcomes 
The meta-analysis of GBD genotyped 15213 women of European ancestry (3216 cases and 
11997controls) using the Human cardiovascular disease (HumanCVD) BeadChip (Illumina, 
San Diego, CA), which containing up to ~53000SNPs. The odds ratios with p values for 
development of GBD were generated (Rodriguez et al., 2014).  
3.2.2. Applying SSS-RAP to meta-analysis of 
ECG traits and performance comparison 
of SSS-RAP in group level 
Fine mapping of ECG traits 
The SSS-RAP program was applied to the summary statistics of the meta-analysis on the ECG 
traits (Gaunt et al., 2012). I selected three quantitative ECG traits (PR interval, QRS duration 
and QTc interval) and decide to fine map three gene regions containing SNPs associated (p< 
5x10-4) with these traits.  
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Performance comparison of SSS-RAP using meta-analysis data 
and different reference panels 
Utilizing these meta-analysis data, I generated four data-sets using different combinations of: 
BWHHS individual level data (as the “in-house” component of the meta-analysis, individual 
level data were available), meta-analysis summary data (i.e. group-level betas and standard 
errors) and HapMap LD information (haplotype frequency X11 from HapMap individual level 
data). The compositions of these data-sets are described in Table 3-2.  
Number of 
data-set 
beta and SE MAF Haplotype freq (X11) 
1 
BWHHS individual level 
data 
BWHHS individual level 
data 
BWHHS individual level 
data 
2 Meta-analysis  
BWHHS individual level 
data 
BWHHS individual level 
data 
3 Meta-analysis  
BWHHS individual level 
data 
HapMap 
4 Meta-analysis  HapMap HapMap 
Table 3-2. Content of combination of different data-sets, X11 represents the haplotype 
frequencies of two major alleles of pair-wise SNPs. Meta-analysis means data selected from 
meta-analysis summary data. Internal data means a single study was involved in the 
meta-analysis. HapMap means data calculated using HapMap CEU individual level data. 
3.2.3. Applying SSS-RAP to GIANT 
meta-analysis of BMI  
To utilise the summary statistics of GIANT meta-analysis of BMI, I need to find a way to 
simulate the betas and the standard errors of betas, which is not listed in the original 
summary results.  
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Simulation of the standard errors 
As explained in Chapter 3.3.1, there is a clear positive correlation between minor allele 
frequency and standard error of beta (Figure 2-7). Fortunately, the standard errors of betas 
of 32 significant SNPs were found from the BMI meta-analysis paper (Speliotes et al., 2010). 
Using these data, I was able to simulate a relationship between SE and MAF for these 32 
SNPs (Figure 3-3). Identifying the general relationship between SE and MAF will be an 
interesting follow up topic.  
As shown in Figure 3-3, a power function fitted the relationship between SE and MAF with 
the least error (R2 = 0.6486). Since I only found SE for a relative small number of SNPs for the 
GIANT BMI dataset, I expected a relatively noisy relationship between MAF and SE. However, 
it is an interesting attempt for meta-analysis with missing data. Using this power function, I 
simulated the standard errors of betas for the 2,284,195 SNPs using the minor allele 
frequencies provided by the database. 
 
Figure 3-3. Predicting standard error using minor allele frequency. X-axis is the minor allele 
frequencies of obtained from the meta-analysis. Y-axis is the standard error. The relationship 
















The P-value provided in the GIANT BMI dataset was transformed from the t statistic. Here I 
use the reverse process to get the t statistic from the p-value (degree of freedom is N-2, 
where N is the number of individuals). Then I was able to simulate Beta directly using the 
existing data:  
beta = 	t	statistics	X	SE	of	beta	 
Where the standard error of beta were calculated using the prediction formula in Figure 3-3. 
The flow chat of the whole beta prediction process was illustrated in Figure 3-4.  
 
Figure 3-4. Flow chart of the beta prediction  
Using the above process, I simulated Betas with their standard errors in order to run SSS-RAP 
(See discussion for details). In addition, I used the R package “NCBI2R” 
(http://cran.r-project.org/web/packages/NCBI2R/index.html) to estimate LD correlation (r2) 
from HapMap and used Biomart web tool (http://www.biomart.org/) to find the coordinates 
for the SNPs. I then performed SSS-RAP on the remaining SNPs. T test p-value of 0.1 was set 
as the threshold of elimination for this dataset. 
The SSS-RAP program was applied to the adjusted summary statistics of this meta-analysis. 
32 significant SNPs for BMI were selected as 32 top hits. To take into account the possibility 
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of long distance LD, all SNPs inside the region of ±5Mb (million base pair) away from each 
top hit were picked out for a further SNP independent test.  
3.2.4. SSS-RAP analysis of GBD traits and 
identifying of relationship between GBD 
associated SNPs and lipids associated 
SNPs 
Independent SNP identification 
Within the ABCG5-8 region 360 SNPs were analyzed. After excluded SNPs with perfect LD 
(r2=1), a total of 118 SNPs remained in the model. I analyzed the remaining SNPs using 
SSS-RAP. Using this approach 10 out of the 118 SNPs remained significant as signals in the 
meta-analysis (Table 8-6). Both HapMap and BWHHS individual level genotypes were used as 
reference panel for performance comparison. 
Relationship of GBD associated SNPs and lipids associated SNPs 
Since most gallstones are formed of cholesterol, I investigate the relationship between GBD 
and plasma lipids level in this section. From the 95 loci previously reported to be 
independently associated with blood lipid levels (28), it was possible to subject 63 to a test 
using IBC array data (Table 8-7).  
The quantile-quantile (QQ) plots for GBD meta-analysis p value of these 63 were performed 
in R using the ‘ggplot2’ package 
(http://cran.r-project.org/web/packages/ggplot2/index.html). 
To test whether the relationship between GBD and blood lipids traits was not by random 
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chance, I designed a simulation. The null hypothesis was that in QQ plots and compared 
with appropriate random sampling of equivalent numbers of SNPs in the IBC chip, the 
distribution of significance values would be no different for a trait-selected set of SNPs 
compared with a random set. However, considering the association of gallstones with 
obesity and their constitution of cholesterol, I hypothesized either a general difference of 
distribution, and/or that the leading SNPs for the trait would also show nominal significance 
for GBD. 
For the simulation, I firstly ordered the 63 p-values ascendingly and then I calculated the 
observed p value and expected p value:  





Where N is total the number of SNPs and n represent the current SNP inside 1 to N. Obsn is 
the observed p value of SNP n, Exptn is the expected p value of SNP n.  





In comparison with this median, I drew a distribution of median log10p values generated by 
10,000 simulations using random sampling of 63 loci for each set of simulations. These 
simulations were performed in R. Representations of the histogram of median estimates was 





3.3.1. Applying SSS-RAP program to ECG 
meta-analysis summary results and four 
data combinations 
After applying SSS-RAP to meta-analysis of ECG traits, I found that generally the results of 
SSS-RAP are highly consistent with conditional analysis results using group-level results.  
NOS1AP associated with QTc interval 
For SNPs associated with QTc interval in NOS1AP region, conditional analysis of the 
meta-analysis selected 3 SNPs from 3 different LD blocks. In individual-level, SSS-RAP only 
detected two SNPs. In group-level, SSS-RAP return same SNPs model using meta-analysis 
results with BWHHS MAF and haplotype frequencies. When using HapMap MAF and 
haplotype frequencies instead of BWHHS ones, 3 more SNPs were detected, showing some 




Figure 3-5. Comparison between SSS-RAP and conditional analysis using meta-analysis data 
in ECG traits. Linkage disequilibrium and haplotype block structure were linked to related 
SNPs in NOS1AP SNPs associated with QTc interval. For both methods, cross (x) denotes 
inclusion in the best model. 
SCN5A associated with PR interval and QRS duration 
In SCN5A region, there were four SNPs associated with PR interval after conditioning on the 
top significant signal. SSS-RAP using any data sets did not select SNP rs1805126. I have 
explained the reason of this departure in Chapter 3.4.1. For the remaining three SNPs, 
SSS-RAP also selected them in group level. In individual-level, SSSRAP only selected two of 
them (Figure 3-6 a).  
128 
 
For SNPs associated with QRS duration in SCN5A region, first round conditional analysis 
selected 5 SNPs. Using meta-analysis summary statistics, SSS-RAP detect four of them: SNP 
rs11710077 was omitted by SSS-RAP, which have been explained in Chapter 3.4.1. In contrast, 
SSS-RAP only selected 2 SNPs using individual-level data (Figure 3-6 b).  
 
Figure 3-6. Comparison between SSSRAP and conditional analysis using meta-analysis data 
in ECG traits. Linkage disequilibrium and haplotype block structure were linked to related 
SNPs in (a) and (b), SCN5A loci associated with PR interval and QTc interval respectively. 
Cross (x) denotes inclusion in the best model for each data combination. 
3.3.2. SSS-RAP analysis of GIANT 
meta-analysis of BMI 
As mentioned in Chapter 4.2.3, I tested the independence of SNPs near the 32 significant 
signals identified by the original meta-analysis paper. The results for the regions with 
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secondary signals are shown in Table 3-3. SSS-RAP identified 5 regions with more than one 
association signals inside each region.  
SNP NOTE GENE CHR POS_37 REF_ALLELE FREQ SSS-RAP_P 
rs887912 top hit FANCL 2 59305625 T 0.325 0 
rs12986742 independent snp1 FANCL 2 58975143 C 0.5 3.00E-08 
rs11688816 independent snp2 FANCL 2 63053048 A 0.5417 2.54E-08 
rs206936 top hit NUDT3 6 34828553 T 0.7417 0 
rs2033529 independent snp1 NUDT3 6 40348653 G 0.2583 8.78E-09 
rs10767664 top hit BDNF 11 27694241 G 0.825 0 
rs1519480 independent snp1 BDNF 11 27675712 C 0.3667 3.52E-10 
rs12444979 top hit GPRC5B 16 19935389 A 0.1333 0 
rs11074446 independent snp1 GPRC5B 16 20255123 C 0.175 1.14E-09 
rs571312 top hit MC4R 18 57838401 A 0.2833 0 
rs17773471 independent snp1 MC4R 18 57977377 T 0.3333 4.39E-08 
rs7227255 independent snp2 MC4R 18 58055731 G 0.9833 1.75E-10 
Table 3-3. Genes that found extra independent effect SNPs by SSS-RAP program in GIANT BMI database. 
Top hits are found from previous paper, 2nd-6th means the second to sixth independent effect SNPs. 
3.3.3. SSS-RAP analysis of GBD associated 
SNPs and analysis of loci associated with 
lipids traits 
LD pattern of SNPs significantly associated with GBD 
For the ten SNPs significantly associated with GBD, I sketched the LD pattern among them 
and try to find out the relationship between correlation coefficient (r2) and effect size (and r2 
vs p values as well).  
The top associated SNP rs4953023 is in perfect LD (r2=1) with the coding variant rs11887534 
(representing an Aspartic acid to Histidine change at amino acid residue 19: D19H) that was 
associated with cholesterol gallbladder stones in previous GWAS and linkage studies 
(Grünhage et al., 2007) (Katsika et al., 2010). Rs4953023 is in intron 3 of ABCG8. It yields 
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both the highest significance (P=3.57x10-48) and the highest effect size (beta=0.763) in the 
meta-analysis study. Figure 3-7A shows r2 between each of the ABCG5 and 8 SNPs 
significantly associated with GBD in meta-analysis and the top hit rs4953023. As shown in 
the figure, there are almost no LD between them. In addition, the effect sizes and p values of 
the other 9 SNPs are not comparable to those of the top hit. This observations support 
rs4953023 is likely independent of the other ABCG8 SNPs that are significantly associated 
with GBD in the meta-analysis study.  
One of the ABCG8 SNPs, rs4299376, was found to be significantly associated with GBD (P= 
3.10 x 10-18) in our study with a lower effect size (beta=0.283) observed. This SNP is in some 
LD with a coding SNP rs4148211 (BWHHS r2 =0.209). Rs4148211 (a Cysteine to Tyrosine 
change at residue 54: C54Y) is reported to be associated with GBD in a Taiwanese study (Kuo 
et al., 2008). Moreover, in HapMap CEU population, the observed LD between this pair of 
SNPs is r2=0.161, D’=1. Our results support that these two SNPs may be in one LD block and 
may represent the same functional mechanism or (unknown) causal SNP. 
Identifying the LD pattern step wisely, I removed the top hit from the SNPs model. Figure 
3-7B shows LD between rs10439467 in intron 10 of ABCG5, and other ABCG5/8 SNPs except 
top hit rs4953023. Rs10439467 appears to mark a novel independent effect that does not 
appear to have been directly represented or captured in earlier chip-based analyses. There is 
essentially no LD between this SNP with rs6720173 E604Q (r2 = 0.095 in Europeans in 
HapMap), which is the only reported coding SNP for GBD in ABCG5. This confirmed its 
independence of effect on GBD. Besides, four other significant SNPs in the ABCG5 region 
were no longer retained as independent predictors, respectively rs4953019 (p=4.61x10-11, 
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effect size=0.3406, r2=0.352), rs10208987 (p=4.77x10-14, effect size=-0.3782, r2=0.352), 
rs10201851 (p=1.54x10-09, effect size=-0.2629, r2=0.196) and rs4148189 (p=8.66x10-09, effect 
size=0.2538, r2=0.196).  
Figure 3-7C shows LD between the remaining three SNPs with rs6720173 (E604Q) (P=3.23 x 
10-11, beta = 0.256). Two significant SNPs rs2278357 (r2=1, P=1.10 x 10-9, beta =0.233) and 
rs4245786 (r2=0.234, P=1.88 x 10-5, beta = -0.142) are in LD with E604Q. The previous 
possible independent SNP rs10439467, is in very low LD with E604Q (r2 = 0.095 in 
Europeans in HapMap).  
 
Figure 3-7. Comparison between r2 values and P values and between r2 values and effect 
sizes for key SNPs associated with GBD 
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(A) LD between the top hit rs4953023 and the ABCG5 and 8 SNPs significantly associated 
with GBD in meta-analysis 
 












SSS-RAP analysis of SNPs associated with GBD 
Here I compared the performance of SSS-RAP in individual-level and group-level using GBD 
outcomes. As shown in Table 3-4, when applying SSS-RAP to individual-level data, only two 
SNPs were detected. In addition, as shown in Chapter 4.3.3 LD pattern section, I found four 
SNPs, rs4953023, rs4299376, rs10439467, rs6720173, as possible independent effect variants. 
Similarly, SSS-RAP detected the same four SNPs as independent in ABCG5 and 8 region when 
using BWHHS individual-level genotypes as reference panel (Table 3-4). Moreover, when 
using meta-analysis summary statistics and HapMap genotypes as reference panel, five SNPs 
were detected. The extra SNP rs4953019 is in modest LD (HapMap CEU D’ =1, r2 =0.312) with 
the coding SNP rs6720173. This result suggest that these two SNPs are in one LD block and 
may represent the same functional mechanism. 
dataset reference panel phase 1 phase 2 phase 3 phase 4 phase 5 
BWHHS BWHHS rs4953023 rs4299376    
meta-analysis BWHHS rs4953023 rs4299376 rs10439467 rs6720173  
meta-analysis HapMap rs4953023 rs6720173 rs10439467 rs4299376 rs4953019 
Table 3-4. Comparison of performance of SSS-RAP in individual-level, meta-analysis level and 
different reference panels in GBD traits. 
Detecting relationship between GBD and blood lipids 
Figure 3-8A shows the QQ plots for the meta-analysis p value of 63 SNPs listed in Table 8-7. 
These SNPs represents 63 independent loci previously reported to associate with plasma 
lipid levels. The observed p values was significantly different than the expectations. Out of 
63 SNPs, 59 showed an observed p value above the expected p value in a QQ plot. This is in 




To test whether the significant of the 63 SNPs were not by random chance, I simulated a 
median distribution (Chapter 4.2.4) Figure 3-8B shows results for simulations analysing the 
median log10p value of 10,000 samples of groups of 63 random SNPs in IBC. The 10000 
random simulations got a distribution with mean of 1.07 (median =1.06) and standard 
deviation of 0.19. In contrast, the observed median value for the 63 lipid-associated loci was 
1.494. A median p value greater than that observed for the lipid loci set, was only appeared 
in 1.7% of random samplings. So the histogram in Figure 3-8B conformed the significance of 
p values I observed by the QQ plot shown in Figure 3-8A.  
Further linkage between GBD and blood lipids can be found in Table 8-7. The loci influencing 
either LDLc or triglycerides showed the most outstanding associations with GBD. Specifically, 
these were rs4299376 in ABCG5/ABCG8; rs2081687 in CYP7A1 (the proxy SNP in the 
meta-analysis rs8192870 has an r2 = 0.925 with rs2081687, P=0.0031 for GBD); rs1260326 in 
GCKR (P=0.00013); rs5756931 in PLA2G6 (the proxy SNP in the meta-analysis rs4820314 r2 = 
0.8 P=0.0048 for GBD); rs2479409 in PCSK9 (P=0.021) and rs1532085 in LIPC (P=0.036). 
This analysis is quite similar to a Mendelian Randomization (MR) approach, which is a 
method of using measured variation in genes of known function to examine the causal effect 
of a modifiable exposure on disease in non-experimental studies (Davey Smith and Ebrahim, 
2003). So there is a possibility to process a formal MR to further corroborate the causal gene. 





Figure 3-8. Pathway analysis relating GBD with SNPs associated with plasma lipid levels  
(A). GBD QQ plot for SNPs representing 63 independent loci reported in a published study to 





(B). Simulation of the median log10 p value when sampling 63 SNPs at random from the IBC 
array meta-analysis, 10,000 random samplings. The observed median was 1.49. The median 
observed for the lipid set was 1.06 (mean = 1.07, SD = 0.19). 
3.4. Discussion 
3.4.1. Comparing the performance of SSS-RAP 
using different resources 
I compared the performance of SSS-RAP using data-sets generated with parameters from 
different resources.  
When applying SSS-RAP to individual-level data of both quantitative traits (ECG) and binary 
outcomes (GBD), only part of the strong independent signals were detected compare to the 
conditional analysis results of meta-analysis. Flister et al suggested that single GWAS lack of 
power to test whether multiple causal SNPs underlie the same genomic region (Flister et al., 
2013). The result of the current analysis support such suggestion.  
As I have explained in the Chapter 3.2, the input data set of SSS-RAP contains four 
parameters: betas, standard errors of betas (SE), minor allele frequencies (MAF) and 
haplotype frequencies betas. Beta and SEs will normally be included in the meta-analysis 
summary results. However, MAFs and the haplotype frequencies (i.e. X11) will rarely be 
provided by the meta-analysis, especially the haplotype frequency. So I mimicked three 
group level situation (Table 3-2), where the meta-analysis betas and standard errors were 
available, but MAF and haplotype frequency (X11) need to be calculated from either internal 
(BWHHS) or external sources (HapMap). SSS-RAP results were closer to the conditional 
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analysis results when using BWHHS individual-level genotypes. On the other hand, this 
performance comparison also shown that results using HapMap individual-level genotypes 
as reference panel are less accurate than results using BWHHS genotypes as reference panel. 
The reason of such difference is because open access data (HapMap and 1000 Genome) 
have a limited sample sizes (less than 200 for each population) 
(http://hapmap.ncbi.nlm.nih.gov/groups.html) 
(http://www.1000genomes.org/category/frequently-asked-questions/population). Based on 
our simulation, we suggest the sample size of 1000 can lead us to an accurate LD estimation.  
Besides, in all cases, it is important that the allele and haplotype frequencies are from a 
population ancestrally matched to those in the meta-analysis. 
3.4.2. SSS-RAP analysis of ECG traits 
NOS1AP associated with QTc interval 
Numerous studies have reported association of common variation in NOS1AP with QTc 
interval (Newton-Cheh et al., 2009), and my fine mapping results suggest 3 independent 
effect SNPs. NOS1AP gene encodes a cytosolic protein that binds to neuronal nitric oxide 
synthase (nNOS). The protein has a carboxyl-terminal (C-terminal) PDZ binding domain. 
C-terminal PDZ binding domain interacts with NOS1 to accelerate cardiac repolarization by 
inhibition of L-type calcium channels in the heart and ventricular cells (Chang et al., 2008). 
SCN5A associated with PR interval and QRS duration 
Using the meta-analysis results of the European population, I identified 4 and 5 possible 
independent effect SNPs in the voltage-gated, sodium channel type V, alpha subunit 
139 
 
(SCN5A) gene are associated with PR interval and QRS duration respectively, broadly 
consistent with previous reports (Pfeufer et al., 2009) (Newton-Cheh et al., 2009) (Pfeufer et 
al., 2010). 
The two top SNPs with most significances, rs7372712 and rs7374540 for PR interval and QRS 
duration respectively, were not in LD (r2=0.02 in HapMap Europeans). Rs7372712 is located 
in an LD block in the 5’ region of SCN5A, which was replicated by the original meta-analysis 
(Gaunt et al., 2012). Additionally, rs7372712 is in very weak LD with the coding variants in 
SCN5A reported to influence ECG traits, specifically rs1805126 (D1819) and rs1805124 
(H558R) in Europeans (HapMap r2=0.003 and r2=0.011, respectively). This finding replicated 
the claim that variations in the 5’ end of SCN5A may influence on both PR interval and QRS 
duration.  
The secondary independent SNP associated with PR interval is SNP rs12053903. It share a LD 
block with other previously reported SNP (rs6763048) effects in the 3’ end of SCN5A (Bulter 
et al, 2012).The D’ between these two SNPs are 1 and the r2 between them are 0.068 (the 
1000 Genome CEU population).  
3.4.3. Meta-analysis of GIANT BMI dataset 
Among all the significant SNPs I tested for BMI association using GIANT database, at least 
two independent effects have been observed previously for MC4R (Speliotes et al., 2010): 
top hit rs571312 and a coding SNP rs2229616 (V103I). In a separate gene-focused study, 
Loos et al (Loos et al., 2008) reported another MC4R SNP, rs17700633, as an independent 
effect SNP additional to the top hit, rs17782313 (HapMap r2=1 to rs571312), for an 
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association of obesity. Rs17700633 is essentially in linkage equilibrium with the coding SNP 
rs2229616 in MC4R. These 3 SNPs were also detected by SSS-RAP program (Table 3-3), which 
again proves the accuracy of SSS-RAP program.  
In addition, Speliotes EK et al (Speliotes et al., 2010) reported that several BMI-significant 
SNPs explained a substantial proportion of the association with the most significant SNP for 
the gene transcript in conditional analyses. These significant associations included 
TMEM160, SLC39A8 and SH2B1. The SSS-RAP program did not identify any other 
independent SNPs except the top hit for these genes as well, which conformed the previous 
finding.   
Fine mapping of ABCG5/8 region 
GBD is a common disease in western countries, with more than 700,000 cholecystectomies 
performed in the U.S.A per year at a cost of ~ $6.5 billion (Shaffer, 2006). This fine mapping 
analysis, using both LD pattern and SSS-RAP, shows that a multiple number of SNPs are 
independently associate with GBD risk in women of European ancestry. The pathway 
analysis shows that a huge amount of genotypes which associate with plasma lipid levels 
also associate with risk of GBD.  
The leading SNP, rs4953023 (P=3.87x10-38, effect size=0.7003) is in perfect LD with the 
previously studied SNP rs11887534 (D19H in ABCG8). The coding variant D19H is believed to 
be a functional SNP which increases cholesterol secretion and hence the risk of 
super-saturation of bile (Katsika et al., 2010). The second SNP in ABCG8, rs4299376, tags an 
independent effect, probably reflecting a previously reported coding variant on GBD in 
Taiwanese, C54Y (r2=0.2 between rs4299376 and rs4148211 in Europeans) (Liu et al., 2002). 
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Two other independent SNPs were identified in ABCG5, rs10439467 in intron 10 and 
rs6720173 (coding variant E604Q). The ABCG5/ABCG8 transporter is the most proximal 
element of the cholesterol regulatory system to biliary cholesterol, and the identification of 
further new functional alleles at this locus emphasizes that any approach which might 
reduce cholesterol secretion without compromising TC and LDLc levels, could be useful in 
GBD prevention. 
The comparison analysis of 63 independent loci for blood lipid levels and GBD, shows that a 
huge amount of SNPs influencing blood lipid levels influence GBD risk as well. I further 
analysis this finding separately by principal trait, LDLc, total cholesterol, HDLc or triglycerides. 
I found that a large number of loci influencing either LDLc or triglycerides, indicates the most 
prominent associations with GBD (rs4299376 in ABCG5/ABCG8; rs2081687 in CYP7A1; 
rs1260326 in GCKR; rs5756931 in PLA2G6; rs2479409 in PCSK9 and rs1532085 in LIPC). 
Relationship between correlation coefficient, beta and p value 
I found it difficult to find a simple mathematical relationship between r2, beta and p value 
through the LD pattern of ABCG5-8 region. But this piece of work became the start point of 
developing novel fine mapping methods using group-level data. The idea of utilizing LD 
pattern and processing stepwise selection were used to the development of SSS-RAP and 
another novel method I should explained in Chapter 5.  
3.4.4. Conclusion  
Firstly, when applied SSS-RAP to meta-analysis summary statistics, the results of SSS-RAP is 
highly consistent with the conditional analysis results, which proved its accuracy in 
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meta-analysis level. Moreover, I detected totally 12 SNPs (in NOS1AP and SCN5A) associated 
with QTc interval and PR interval. For the GIANT BMI meta-analysis, I found a suitable way to 
transform meta-analysis p values to meta-analysis betas and identified 17 regions with 
multiple association to BMI. For the ABCG5-8 region associated with GBD, I identified four 
possible independent signals using both LD pattern and SSS-RAP. Last but not least, the idea 
of utilizing LD pattern and processing stepwise selection were used to the development of a 
novel fine mapping method which I should explain in the next chapter.   
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CHAPTER 4. HAPLOTYPE-BASED 
GROUP-LEVEL ASSOCIATION 
ANALYSIS USING AN E-M 
ALGORITHM 
4.1. Introduction 
In Chapter 3, I illustrated the limitation of GWASs and difficulties of fine mapping analysis in 
the current meta-analysis system. This motivated the development of the novel fine 
mapping method, SSS-RAP. It can detect SNPs with independent effects which are 
conditional on the strongest associated signal. The data used by SSS-RAP includes regression 
coefficients (betas), standard errors of the coefficient (SE) and minor allele frequencies (MAF) 
from meta-analysis and pairwise haplotype frequencies (X11) from a reference genotype 
panel (Zheng et al., 2013). I demonstrated its power and accuracy to detect secondary 
association signals in real life meta-analyses in Chapter 4. However, SSS-RAP is only 
applicable to pair-wise SNP comparisons and thus fine mapping multiple association loci at a 
group-level remains a problem.  
4.1.1. Multiple regression 
The classic method of testing multiple signals associated with a specific trait is multiple 
regression analysis (the term was first used by Pearson in 1908). The general purpose of 
multiple regression analysis is to understand the relationship between several predictor 
variables (also known as independent variables) and one criterion variable (dependent 
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variable).  In the genetic fine mapping field, multiple regression is focused on testing the 
association between one trait and multiple genetic variants, especially SNPs. The regression 
model will be: 
Y = 	βT +	βU ∗ HU +	S* ∗ H* …	S∂ ∗ H∂ + /	(0) 
Where Y is the phenotype, HU …H∂ are the n covariates (SNPs) in the model. βU …β∂ are 
the beta coefficients of the n SNPs. “e” is the error of the regression model.  
As explained in Chapter 1.3.2, single regression uses least squares approach to estimate the 
regression line. Multiple regression uses the same approach to find the regression line 
amongst multiple variants, but the regression line cannot be visualized in the two 
dimensional space.   
Assumptions of multiple regression 
There are several assumptions for multiple regression:  
Firstly, the general assumption is that the relationship between SNPs is linear. This 
assumption can hardly be confirmed. Fortunately, multiple regression analyses are not 
mainly affected by minor deviations from this assumption.  
Secondly, the residuals should be normally distributed. So it is necessary to check the 
distributions of the phenotypes of interest.  
Thirdly, as illustrated in Equation (0), for a multiple SNPs model, it is quite common that any 
of the SNPs are strongly correlated with each other, or even if one SNP is in perfect LD with 
other SNPs. In this situation, the genotype matrix will suffer the wrong condition due to the 
presence of collinearity. The covariates will be confounded with one or more of the others 
and the precision of the estimation will become very poor.  
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The variance inflation factor (VIF) quantifies the severity of multi-collinearity in an linear 
least squares regression analysis. It provides an index that measures how much the variance 
(the square of the estimate's standard deviation) of an estimated regression coefficient is 
increased because of collinearity (Kutner et al, 2004).  
Consider a linear model with k independent variables:  
Y = β0 + β1 X1 + β2 X2 + ... + βj X j + ... + βk Xk + ε. 






Where Rj2 is the multiple R2 for the regression of Xj on the other covariates (a regression that 
does not involve the response variable Y). This identity separates the influences of several 
distinct factors on the variance of the coefficient estimate (Kutner et al, 2004). A large VIF 
value, for example bigger than 10, will indicate a collinearity problem in the regression 
model.  
Finally, since the entire individual-level data is needed to process the multiple regression, it 
is not applicable for meta-analysis level data. Novel statistical methodology is needed to 
process approximate multiple regression using meta-analysis summary statistics directly. 
4.1.2. Current state of art: GCTA conditional 
and joint effect analysis  
To extend the scope of multiple regression to meta-analysis level, Yang J et al developed 
GCTA conditional and joint effect analysis (Yang et al., 2012). Since GCTA contains many 
functions, I only focused on its conditional and joint effect analysis, so GCTA in this chapter 
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only represent the GCTA conditional and joint effect analysis.  
To process multiple regression at the group-level, GCTA separated the task into two steps. 
Firstly, GCTA built a linkage between the multiple regression and the single regression. It 
creates equations to convert the marginal effects (and SEs of marginal effects) to joint 
effects (and SEs of joint effects) using single SNP regression summary statistics and 
individual-level genotype data. Then for a meta-analysis of multiple studies, pooled 
individual-level genotypes of the whole discovery set are normally unavailable. So GCTA 
builds the approximate variance-covariance matrix of SNP genotypes using the allele 
frequencies from meta-analysis and LD correlations (r) between pair-wise SNPs from a 
reference panel. This variance-covariance matrix is then used by the least-squares approach 
to calculate the approximate joint SNP effects.  
Assumptions and limitations of GCTA conditional and joint 
effect analysis 
There are several assumptions for GCTA: firstly, the quantitative traits or disease outcomes 
are affected by multiple genetic variants. Secondly, the assumption of additive model of the 
genotypes was made. Moreover, the genotype matrix was adjusted by MAF. This is under 
the assumption that rarer variants have a larger effect size. In addition, the method also 
assumes HWE for all SNPs in the model. Finally, the method assumes that the LD correlation 
between a pair of SNPs should be similar in the meta-analysis and the reference panel (Ke et 
al., 2004).  
For the final assumption, it has been demonstrated that combination of allele frequencies 
and pair-wise LD correlation may not always be biologically possible at the multiple-loci level, 
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since three-locus systems may place additional constrains on the maximum and minimum 
values for the pair-wise LD terms (Robinson et al., 1991).  
4.1.3. Haplotypes and haplotype phasing 
In Chapter 1, I gave a brief overview of haplotypes. In this chapter, I should describe how to 
utilize haplotype information and how to phase the haplotypes using 
statistical/computational tools.  
In population genetics, haplotype information can be used in many analyses, for example, 
disease/quantitative traits mapping (Rieder et al., 1999) and inferring population histories 
(Harding et al., 1997).   
Current genotyping methods such as microchip or next generation sequencing do not 
provide haplotype information. The cost of experimental haplotype phasing is very 
expensive (Browning and Browning, 2009). So haplotypes are normally phased by statistical 
algorithms. Two major algorithms have been used for haplotype phasing in this Chapter are 
Expectation-Maximization (E-M) algorithm and approximate coalescent and hidden Markov 
model (HMM) algorithm.  
Since the novel method I developed is an E-M algorithm approach, I will explain the details 
of the E-M algorithm in the next section. For haplotype inferring, E-M algorithm is one of the 
earliest statistical approach (Excoffier and Slatkin, 1995). PLINK (Purcell S et al, 2007) 
contains a haplotype phasing function using an E-M algorithm. The E-M approach runs well 
for a small number of genetic variants, for example 10 SNPs. However, for a large numbers of 
markers, the E-M algorithm becomes time consuming and suffers a loss of accuracy by using 
suboptimal model for haplotype frequencies. Some examples of haplotype phasing software 
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using the E-M algorithm include Arlequin (Excoffier and Lischer, 2010) and PL-EM (Qin et al., 
2002). 
Moreover, the approximate coalescent model (McVean and Cardin, 2005) assumes that 
novel haplotypes are derived from old haplotypes by mutation and recombination, so that 
haplotypes in a small region tend to look similar. Furthermore, the HMM is a model in which 
the observations are conducted by an unobserved probabilistic process (Eddy, 2004). The 
coalescent-based methods and HMMs were applied by many statistical phasing approaches 
such as PHASE (Stephens et al., 2001), MACH (Li et al., 2010), IMPUTE2 (Howie et al., 2012) 
and BEAGLE (Browning and Browning, 2007). In each of these methods, the approximate 
coalescent are lead to an HMM, and the parameters are estimated using iterative algorithms 
such as E-M algorithm. Along with all of these HMM methods, MACH outperformed other 
methods for smaller sample sizes and BEAGLE outperform for large sample size (Browning 
and Browning, 2011).  
As illustrated in Figure 4-1, for a specific population, the coinheritance of SNP alleles on the 
haplotypes leads to linkage disequilibrium amongst multiple loci (International HapMap 
Consortium, 2003). So theoretically, haplotypes are a better representation of LD than 




Figure 4-1. Example of haplotypes among four loci for different populations. In this example, 
four SNPs within 1 MB are selected. The above haplotype is the ancestral haplotype for 
these four SNPs. The four bottom haplotypes are the existing haplotypes of the ancestral 
haplotype after N generations. The haplotype frequencies are represented in the left side. 
As illustrated, the LD information for different populations is represented by the haplotypes.  
4.1.4. Expectation-Maximization algorithm 
In the statistical field, an E-M algorithm is an iterative method for detecting the value of the 
unobserved parameters that maximize the likelihood of the observed incomplete data 
(Dempster et al., 1977). Typically the models will involve latent variables except the 
unknown parameters and known observations.  
The E-M algorithm can be applied in two respects. In the first case, if I cannot directly 
calculate the parameters directly due to the problems or limitations of the analysis, I have to 
use latent variables to link the observations and unknown parameters. In the second 
situation, I can calculate the unknown parameters but the latent variables can be simplified 
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with the likelihood function.  
As illustrated in Figure 4-2, the E-M algorithm starts with setting random initial values for the 
unobserved variables. Then a numerical equation is built between the observed and 
unobserved variables. This process is called expectation (E step), which is usually the most 
difficult step of the E-M algorithm. The computational efficiency of the whole algorithm will 
highly depend on this step. Then I found the maximum likelihood of the expectation. This 
process is called maximization (M step). For the E step and M step, the expected values and 
the maximization do not need to be completed explicitly, but rather need only compute 
sufficient statistics for the completions. The E-M process will be kept until the latent 




Figure 4-2. An overview of the E-M algorithm. After initialization, the E-step and the M-step 
are iterated until the unobserved values have converged. Iteration “i” means the iteration 
number.  
Advantages and limitations of E-M algorithm 
Compared to other optimization methods such as gradient descent (Yuan, 1999) or 
Newton-Raphson method (Ypma, 1995), the EM algorithm is simple and easy to implement. 
It does not usually require heavy preparatory analytical work and it is easy to program. Since 
the E-M algorithm is simple, it is computationally fast which is a very important 
characteristic for mining large datasets and only requires modest computer memory 
compared to other methods. In addition, the EM algorithm is numerically very stable. 
Moreover, the fitted values for the complete data are usually conducted during the E step, 
so there is no need of further calculation.  
The E-M algorithm can only provide a local maximum of the objective parameter after 
converged. So it will always be helpful to process the E-M algorithm using multiple initial 
starting values to find the global maximum. For similar reasons, random initial parameters 
are useful to break symmetry in models as well. 
4.1.5. Aims and Objectives 
At the time I wrote this chapter, multiple regression (with a step-wise procedure) was still 
the gold standard of identifying SNP independence in individual-level. In meta-analysis level, 
the development of methods such as SSS-RAP (Zheng et al, 2013) and GCTA conditional and 
joint SNP effect analysis (Yang et al, 2012) fill the blank of process approximate conditional 
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analysis using meta-analysis summary statistics. The core concept of these methods are 
rebuilding LD structure using the allele frequencies in meta-analysis and LD correlations 
between pair-wise SNPs from a reference sample. However, I have a concern that utilizing 
allele frequencies and pair-wise LD correlation may lose LD information at the multiple-loci 
level since three-locus systems may place additional constraints on the maximum and 
minimum values for the pair-wise LD terms (Robinson et al., 1991). In contrast, haplotypes, 
which represent a specific sets of alleles observed on part of a chromosome, are the best 
way to represent LD among multiple loci. Fine mapping using haplotypes may pick up the LD 
information that is not detected using pairwise LD measures. However, it will be a challenge 
to develop such a fine mapping tool since the statistical system of haplotype is not as well 
established as the pair-wise correlation system. I should introduce an E-M style algorithm to 
utilise haplotype information as latent variables to link marginal SNP effects to joint SNP 
effects using meta-analysis summary statistics and develop the method using a E-M style 
algorithm (Dempster et al., 1977) definitely has the advantage of being simple, robust and 
easy to implement.   
In this chapter, I shall describe the development of the E-M style algorithm haplotype 
regional association program (HAPRAP, pronounced (hap-rap)) software: a step-wise 
elimination program to detect the independent effect SNPs of a genomic region. The joint 
effects of the independent SNPs will be conducted after the best model is decided. The 
method shall be applicable to both individual-level data and meta-analysis summary 
statistics. When applying HAPRAP to meta-analysis summary statistics, the haplotypes will 
be phased from reference panel with individual-level genotypes. In addition, the method 
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shall be applicable to both quantitative traits and binary (disease) outcomes.  
Objectives 
l Develop a haplotype-based fine mapping method using an E-M style algorithm in 
complex quantitative / disease traits meta-analysis 
l Compare the performance of the algorithm against the performance of existing fine 
mapping methods using sample datasets from 1) BWHHS individual-level data, 2) 1000 
Genome individual-level data, 3) simulated meta-analysis data. 
4.2. Methods and Materials 
4.2.1. Overview of the methodology 
The article presents an empirical method, HAPRAP, to estimate partial SNP effects using 
meta-analysis summary results. Given the assumption that haplotypes and haplotype 
frequencies in the reference panel are the same as those in the GWAS meta-analysis, 
HAPRAP uses haplotype effects to transform summary level marginal SNP effects to partial 
SNP effects. 
To achieve the goal, HAPRAP has four steps (Figure 4-3): firstly, we initialize, generating 
random starting values for the partial SNP effects Jo(0)(S) and resulting haplotype effects 
Q(0)(H) (step 1).  In step 2, we built an equation to adjust marginal SNP effects E(g)(S) based 
on haplotype effects Q(g)(H) and haplotype frequencies p(H). In step 3, the estimated 
haplotype effects Q(g)(H) are themselves adjusted based on the deviation between the 
adjusted marginal SNP effects E(g)(S) and the observed marginal SNP effects O(S). The 
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program iterates between Step 2 and Step 3 until the adjusted marginal SNP effects E(g)(S) 
are equal to the observed marginal SNP effects O(S) within 10 decimal places. In the last step, 
we inverse transform the final estimated haplotype effects Q(g)(H) to the partial SNP effects 
Jo(g)(S). The notation of the HAPRAP algorithm is described in Table 4-1. 
 
Figure 4-3. Schematic diagram of HAPRAP.   
Assumptions 
1. An additive model accounts for haplotype effects. For each SNP, the common allele is 
assigned as the baseline allele (with respect to trait); the rare allele is assigned as the 
“effect” allele. 
2. The reference panel represents the same LD structure as the meta-analysis sample 
Definitions 
Constant vectors and matrix –observed data and inputs 
S = {Sj} is the set of j SNPs. 
H = {Hn} is the set of n haplotypes. 
M represents the n x j haplotype matrix, where M= {Mnj}.  
p(H) represents the n x 1 vector of the haplotype frequencies of the n haplotypes.  
O(S) represents the observed marginal SNP effects from GWAS / meta-analysis  
Random initial values for the iteration 
Jo(0)(S) is a j x 1 vector which represents the random initial partial SNP effects of the j SNPs.  
Q(0)(H) represents a n x 1 vector of the random initial haplotype effects of the n haplotypes.  
Variables in the g iteration – output for the g iteration 
E(g)(S) represents the j x 1 vector of the adjusted marginal SNP effects of the j SNPs in the g 
iteration. Whereas g represents the number of the current iteration and g+1 is the next 
iteration.  
Q(g)(H) represents the n x 1 vector of the adjusted haplotype effects of the N haplotypes in 
the g iteration.  
Jo(g)(S) represents the partial SNP effects for the j SNPs on the g iteration.  
X(g) is the SNP with the greatest deviation between the observed marginal SNP effect and 
the estimated marginal SNP effect in the g iteration 
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Table 4-1. Notation of HAPRAP algorithm 
Step 1. Initial values for partial SNP effects and transformation to haplotype effects: We 
set up a random set of initial partial effects for ‘j’ SNPs in the model, denoted Jo(0)(S1), 
Jo(0)(S2)… Jo(0)(Sj). They are then transformed to the initial haplotype effects of the ‘n’ 
haplotypes, Q(0)(H1), Q(0)(H2)…Q(0)(Hn), using the following matrix multiplication: 
M ∗ Jo(T)(S) = Q(T)(H)	(1) 
Where M represents the n x j haplotype matrix. These initial haplotype effects are used as 
starting values in the first cycle of the iteration. 
 
Figure 4-4. The SNPs-haplotypes matrix for HAPRAP. The iteration of HAPRAP is built based on a 
matrix summarising the haplotypes and haplotype frequencies for a certain population. “0” in the 
matrix means the haplotype contains the common allele for the relevant SNP, whereas “1” means 
the haplotype contains the rare allele for the relevant SNP. The small arrow (from left to right) is the 
marginal SNP effects estimation step shown in equation (2). The large arrow (from right to left) is the 
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haplotype effects adjustment step shown in equation (3) (4) and (5). 
 
Step 2. The marginal SNP effects adjustment step: In a typical allelic association analysis 
(additive model), we treat the common allele as the “baseline” allele (with respect to trait) 
whereas the rare allele is the “effect” allele. The marginal SNP effect is the mean difference 
in phenotypes between the “effect” and “baseline”. Extending this idea to an additive 
haplotype model, for a certain SNP (called SNP A), we can divide haplotypes into two groups: 
“rare allele haplotypes”, Hrare, are haplotypes containing the rare allele of SNP A, which 
have real effects on the trait; “common allele haplotypes”, Hcommon, are haplotypes 
containing the common allele of SNP A, which represent the baseline. As in the single-SNP 
model, the difference in between the phenotypic mean in individuals with haplotypes 
containing the rare allele (the rare haplotype effect) and the phenotypic mean in those with 
the common allele (the common haplotype effect) is calculated. We get: 
Marginal SNP effect of SNP A= Effect of Hrare – Effect of Hcommon 
We adjust the haplotypic effects in each group to account for their relative frequencies.  
For Hrare, the adjustment is as follows: 1) Rare haplotypes with (relatively) higher 
frequencies are expected to have larger influence, each haplotype effect (Q) is weighted by 
its frequency. 2) The weighted rare allele haplotype effects are summed. 3) The weighted 
sum of the rare allele haplotype effects is then normalised by the sum of the frequencies of 
the rare allele haplotypes. The effect of Hcommon is constructed in the same way. 
In HAPRAP iteration “g”, the marginal SNP effect, E(g)(S), is adjusted by taking into account 
the haplotype effects, Q(g)(H) and the haplotype frequencies p(H). For a certain SNP ‘i’, the 
haplotypes are divided into two groups: Q(g)(Hrare) and Q(g)(Hcommon). The adjusted 
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marginal SNP effect of SNP “i”, E(g)(Si), is computed by taking the difference between 








We tested the reliability of equation (2) by a simulation and found that given any set of 
partial SNP effects, application of equation (2) never generated nonzero effect estimates for 
SNPs that were simulated to have truly null effects (Text S2).    
 
Step 3. The haplotype effects adjustment step: In this step, the adjusted marginal SNP 
effects E(g)(S) are compared to the observed marginal SNP effects (called O(S)). Reconciling 
the difference between E(g)(S) and O(S) is important because it equates the marginal SNP 
effects observed from the meta-analytic data with those that would arise under the 
distribution of haplotypes in the reference panel. The SNP-note as X(g)-with the greatest 
deviation is adjusted for the next iteration g+1: 
E(¬óU)√Sê(¬)ƒ = E
(¬)√Sê(¬)ƒ − O√Sê(¬)ƒ	(3) 
The other SNP effects remain the same to the next iteration: 
E(¬óU)(Se) = E
(¬)(Se)	Where	i	 ≠	X(g) (4) 
Then the haplotype effect Q(g+1)(H) for SNP SX(g) will be weighted based on the above 




Step 4. Convergence and the inverse matrix approach: After the adjusted marginal SNP 
effects, E(g)(S) are approaching the observed SNP effects, O(S), within 10 decimal places, 




YõU ∗ Q(¬)(H) = Jo(¬)(S)	(6) 
We call these estimated partial SNP effects Jo(g)(S) “HAPRAP betas”.  
 
4.2.2. Estimating the standard error of HAPRAP 
betas using simulation based HAPRAP 
Pre-test of SNP significances 
Generating bootstrap standard errors can use computational resources intensively. To 
improve computational efficiency, we first pre-test the significance of the candidate SNPs 
using the HAPRAP betas and the standard errors of the meta-analysis betas (since the 
uncertainty of the effect of a given SNP is larger in a multivariate model than that in a single 
SNP model). SNPs with the highest p value will be step-wise eliminated from the model until 
all SNPs reach the p value threshold we set.  
For a model with multiple SNPs, the standard error of a specific SNP taken from an individual 
regression analysis is usually smaller than the multiple regression standard error for the 
same SNP, since multiple SNP models will create more uncertainties than signal SNP ones. 
Based on this assumption, a pre-significant test was processed to improve the 
computational time of HAPRAP.   
The pre-significant test uses HAPRAP betas and the standard errors of the observed SNP 







The t-statistics were transformed to t test p values using R code: 
2 x pt (-abs (t-statistics), df=N-1) 
Where pt is the code to convert t-statistics to p-value, “df” is the degree of freedom, N is the 
sample size.  
After the t test p values were calculated, a hypothesis test is conducted to see whether the p 
value is smaller than the p value threshold, i.e. 5 x 10-8, if so, it will be very rare that the SNP 
is significant by chance. So the null hypothesis is that the SNP is significant and will be 
accepted. 
For the pre-significant test, the SNP with highest p value will be backwards eliminated from 
the model until every SNP in the model reaches the p value threshold after multiple testing 
correction. The problem of such pre-significant test is that the p value here will be more 
stringent than it should be so some SNPs with p values near the threshold will be eliminated.  
To calculate the standard errors of the remaining SNPs in the model after the pre-significant 
test, I developed a simulation based HAPRAP program (simHAPRAP).  
Population simulation using simHAPRAP 
As illustrated in Figure 4-5, the simulation starts by simulating a population with sample size 
equal to the total number of participants in the studies / meta-analysis. Genotypes are 
randomly generated based on the haplotypes and haplotype frequencies. For a quantitative 
trait, phenotypes are selected from a normal distribution with mean equal to zero and 
standard error equal to the deviation of the trait. For a disease outcome, binary phenotypes 
are selected from a binomial distribution which fits the probability of cases and controls of 




Figure 4-5. Population simulation for simHAPRAP. 
SimHAPRAP program 
As illustrated in Figure 4-6, the simHAPRAP program is similar to HAPRAP except for several 
differences: Firstly, since genotypes and phenotypes are simulated, the haplotype effects are 
no longer used as latent variables. The random initial values of the marginal SNP effects are 
used directly to estimate joint SNP effects. The E-M algorithm is processed between 
estimated joint SNP effects and estimated marginal SNP effects. This means the E-step 
become linear regressions between the phenotype and genotype of each SNP respectively, 
whereas the M-step remains the same. After the estimated joint SNP effects converge, these 




Figure 4-6. Flowchart for simHAPRAP. 
Stepwise backwards elimination  






P values are transformed using the same way explained above. The SNP with the highest p 
value will be eliminated one by one until the optimal model is selected.  
4.2.3. Flowchart of HAPRAP program 
Figure 4-7 illustrates the workflow of the HAPRAP program in. The core of the program is the 
E-M algorithm. Other methods used in the program include: haplotype phasing tools, 




Figure 4-7. Workflow of HAPRAP program. 
4.2.4. HAPRAP web-based tool 
A web-based implementation of the HAPRAP program was developed using HTML and CSS 
language (Figure 4-8). The source code for this program is available to academic users on 
application to the authors. The webpage has been tested on an Ubuntu server running 





Figure 4-8. HAPRAP web-based tool 
4.2.5. Sample datasets 
BWHHS individual-level dataset 
As described in the Chapter 2, 1980 BWHHS samples, which were genotyped by Illumina 
Cardio-MetaboChip were used for performance comparison (Shah et al., 2013b). I selected 
three genes associated with ECG traits and 14 genes associated with blood plasma traits. All 
the regions and associated traits are listed in Table 4-2. In total, 117 SNPs were selected 
within these regions. To prepare the input dataset for GCTA and HAPRAP, signal SNP model 
regression was conducted in R (code lm). MAF of the 117 SNPs were estimated using PLINK.  
Genomic regions Associated traits 
LIPC and LPL HDLc 
APOE, PVRL2, TOMM40, LDLR, SMARCA4, CELSR2 and APOB LDLc 
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APOE, LDLR, SMARCA4, PVRL2 and APOB TC 
NOS1AP QTc interval 
SCN5A and SCN10A PR interval 
Table 4-2. List of phenotypes and genotypes selected from BWHHS.  
To avoid the collinearity of the above multiple SNPs models, VIFs within each of the above 
genomic regions were estimated using R package 'car' (http://www.r-project.org/). All SNPs 
with VIF higher than 10 were eliminated one by one from the regression model until all 
remaining SNPs reached the VIF threshold.   
I phased the BWHHS unphased individual-level genotypes using PLINK. The haplotype letter 
(A, G, C or T) format was converted to numeric format (0 or 1) format using a python script I 
conducted (the script was attached in Chapter 9.5).  
1000 Genome individual-level dataset 
I used 1000 Genome individual-level data here for performance comparison. To increase the 
sample size, I combined 1000 Genome CEU unrelated individuals and British in England and 
Scotland (GBR) individuals. From the 117 selected SNPs, I removed SNPs not existing in 1000 
Genome and SNPs with VIF higher than 10. After filtering, 67 SNPs remained for the 
performance comparison. The principal-component analysis (PCA) of the 67 SNPs is 
illustrated in Figure 4-9. The PCA suggested that there is no population stratification 




Figure 4-9. The Multidimensional Scaling Plot of 1000 Genome CEU and GBP Population 
Together with BWHHS Individuals. Points in green are from the CEU population, points in red 
are from the GBR population and points in blue are from BWHHS. The three populations 
cluster together which suggests no population stratification between the populations.  
Simulations of artificial meta-analysis 
To conduct a performance comparison among existing methods and HAPRAP, simulations 
are needed.  
I conducted 2-SNPs models and 3-SNPs models for this simulation. There is no need to build 
any model containing more than 3 SNPs since no additional constraints on pair-wise 
disequilibrium values exist in a four loci situation, except those executed by the three loci 
combinations containing the two loci of interest (Robinson et al., 1991).   
The simulation starts with setting the parameters. To mimic complex three SNP models here, 
I firstly assumed that SNP1 is a top hit with independent effect of 1. SNP2 was set as 
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negative control without any independent effect. I used it to test whether the method can 
eliminate the bystander SNP. Moreover, SNP3 was set as a secondary signal with a small 
independent effect of 0.3. I set this effect size to test whether HAPRAP can detect this small 
effect even if the secondary SNP (SNP3) is in high LD to the top hit (SNP1). Since this 
approach is designed for common variants analysis, I set the MAFs as 0.4, 0.38 and 0.3 
respectively for SNP 1, 2 and 3 so that it will be easier to set different LD correlations 
between these SNPs.  
Using the same way described in Chapter 5.2.2 simHAPRAP section, I simulated the 
genotypes and phenotypes for 100,000 individuals for each model (Table 4-3) as a 
meta-analysis of 100,000 people. To calculate the marginal SNP effects (with standard 
errors), I conducted signal SNP model association test for each of the SNP. The MAF counts 
were estimated using PLINK. To mimic the situation that individual-level data sharing is 
unavailable for this meta-analysis. I only used meta-analysis summary statistics: the marginal 
SNP effects (with SE) and MAFs here. To test whether sample size of the reference genotype 
panel will affect the results, I randomly picked 10000, 5000, 1000, 500, 200, 175 or 150 
individual-level genotypes from the population pool. I used them as reference panel. The 
haplotypes were phased using PLINK function:  
plink	– file	data	– hap	mySNP. hlist	– hap − freq 
“data” file is the plink format data.ped and data.map file maintaining genotype information 
and mySNP.hlist as the following format:  
∗ ÀQ∑1	ÀQ∑2	ÀQ∑3 
Where the first character is an asterisk*, followed by a tab-delimited list of SNPs in the same 
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order as data.map.  
A. 2 SNPs Model 






B. 3 SNPs Model 
model r2 between SNP1 and SNP2 r2 between SNP 1 and SNP3 
1 0.8 0.5 
2 0.8 0.3 
3 0.8 0.1 
4 0.5 0.5 
5 0.5 0.3 
6 0.5 0.1 
Table 4-3. Assumptions of Pair-Wise LD (r2) of SNPs Models for Population Simulations. A, 
four 2-SNPs models with different pair-wise r2 between SNP1 and SNP2. B, six 3-SNPs 
models with different pair-wise r2 between SNP1 & SNP2 and SNP1 & SNP3. 
4.2.6. Performance comparisons 
I tested the performance of HAPRAP against other existing methods, i.e. multiple regression 
(Generalized Linear Models coded as “glm” in R) and GCTA joint SNP effect analysis 
(http://www.complextraitgenomics.com/software/gcta/index.html). These approaches were 
applied to the following datasets.  
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BWHHS individual-level data 
I applied multiple regression, GCTA version1.2 and HAPRAP to BWHHS individual-level data.  
BWHHS summary statistics (marginal SNP effects, standard errors and MAFs) of the 117 SNPs 
and individual-level genotypes are used to process GCTA and HAPRAP. For multiple 
regression, which is the most established method for fine mapping, the joint SNP effects 
were estimated using the whole individual-level phenotypes and genotypes. For this reason, 
the results of multiple regression were assumed to be the “gold standard” for this 
comparison. I conducted two two-tailed t tests: the first one compared the HAPRAP betas to 
gold standard and second compared GCTA betas to gold standard. I drew histograms to 
check the distribution of these two sets of t-statistics. To compare the accuracy of HAPRAP 
and GCTA, I drew a QQ plot for the sorted and unsorted t-statistics.  
Moreover, I calculated the concordance correlation coefficients (noted as CCC) (Lin and 
Torbeck, 1998) between HAPRAP betas (or GCTA betas) and multiple regression joint SNP 
effects using a function in R package called “epiR” 
(http://cran.r-project.org/web/packages/epiR/epiR.pdf). CCC measures the agreement 
between two methods. It combines measures of both precision and accuracy to determine 
how far the betas deviate from the line of perfect concordance (the y=x line) 23. The method 
(HAPRAP or GCTA) with CCC estimates were closer to 1 got More tightly correlated with the 
gold standard. In addition, pair plots were drew between each pair of betas to compare the 
agreement between HAPRAP (GCTA) and multiple regression using a famous R graphic 
package “ggplot2” (http://cran.r-project.org/web/packages/ggplot2/index.html). 
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BWHHS summary statistics and 1000 Genome individual-level 
data 
I further compared the performance of HAPRAP and GCTA in the circumstance that only 
external genotypes are available. I used the BWHHS summary statistics (marginal SNP effects, 
standard errors and MAFs) of 67 SNPs and selected 1000 Genome CEU and GBP 
individual-level genotypes as reference panel. The same t test described in the above 
paragraph was conducted. Histograms and QQ plots were drawn for two sets of t-statistics 
as well. Scatter plots, CCC estimates and pair plots comparing multiple regression joint 
effects and HAPRAP betas or GCTA betas were conducted. 
An independent benchmark using simulated meta-analysis data 
I then compared the performance of HAPRAP and GCTA using the artificial meta-analysis I 
described in Chapter 5.1.5.  
In fact, the independent SNP effect I set (1, 0 and 0.3 for SNP1, 2 and 3 respectively) did not 
take into account the impact of sampling errors of the simulation, so I used multiple 
regressions joint SNP effects for the 100,000 individuals as gold standards in this comparison. 
For each model, I applied HAPRAP and GCTA using the summary statistics and the genotype 
reference panel for a specific sample size. Since multiple regression is not applicable to 
group-level data, so I applied multiple regression using individual-level phenotypes and 
genotypes from the reference panel. For each method, I repeated the process 1000 times. 
The mean and standard deviation of the 1000 replications were calculated. The difference 
between the mean of 1000 replications and the gold standards were noted as error of each 
method. The standard deviation of the 1000 replications was used to conduct the 95% CI. 
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Performance comparison for rarer variants using simulated 
meta-analysis data 
To test the performance of HAPRAP in rarer variant analysis, I performed a simulation for 
two SNPs with MAF < 0.1. I assumed that SNP1 has an independent SNP effect of 1 and SNP2 
is a bystander SNP without own effect. The minor allele frequencies of SNP1 and SNP2 are 
0.093 and 0.083 respectively. The pair-wise LD (r2) between the two SNPs is 0.9, which is 
extremely high. Sample size of the reference panel will be 10000, 5000, 1000, 500 and 100 
respectively.  
4.3. Results 
4.3.1. The independent benchmark of HAPRAP, 
GCTA and multiple regression using 
simulated meta-analysis data 
I compared the performance of three methods using simulated meta-analysis data. The 
comparison results were represented in Figure 4-10, Figure 8-1 and Table 8-8. These 
comparisons show that the sample size of the reference panel will affect the accuracy of all 
the methods. I found that with the increase of sample size of the reference genotype panel 
(N), the mean of the errors are nearer zero and the 95% CI of errors are narrower. A sample 
size of 500 or more will return relatively accurate results. When sample size is lower than 
175, which is the approximate number of Caucasians in the 1000 Genome project, the errors 
deviated too widely and it will be risky to rely on the conclusion of any analysis. In addition, 
the correlation between two SNPs increases with the increase of their pair-wise r2. This 
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increased difficulty of eliminating the bystander SNP will cause the mean and 95%CI of 
errors to become more deviated and wider.  
For the two SNPs models (Figure 4-10A, Figure 8-1A), the accuracies were similar between 
HAPRAP and GCTA when r2 is low to modest. When r2 is high (i.e. r2=0.8 and r2=0.9), HAPRAP 
outperforms GCTA in among different sample sizes of reference panels.  
For the three SNPs models (Figure 4-10B, Figure 8-1B), HAPRAP outperforms GCTA in almost 
all kinds of simulations I did. HAPRAP has major advantages against GCTA to estimate the 
independent effect of the secondary signal (SNP3) when r2 is high or modest.  
When comparing HAPRAP and GCTA results to multiple regression results using 
individual-level data of the reference panel (Figure 4-10C, Figure 8-1C), HAPRAP and GCTA 





Figure 4-10. Performance Comparison of HAPRAP, GCTA and Multiple Regression Using 
Meta-Analyses of the Simulated Populations. Error (represented as a bar) is defined as the 
difference between the multiple regression joint SNP effect and the mean (with 95% CI) of 
1000 replications. N is the number of individuals in the reference panel. (A) An example of 
the comparison between HAPRAP and GCTA for 2 SNPs with r2=0.8. (B) The comparison 
between HAPRAP and GCTA for3 SNPs, r2=0.8 between SNP1 and SNP2, and r2=0.5 between 
SNP1 and SNP3. (C) The comparison between HAPRAP, GCTA using meta-analysis data and 
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multiple regression using individual-level data from the reference panel. Two SNPs with r2 of 
0.5 were used here as an example. 
Performance comparison of rarer variants 
On the other hand, I compared the performance of HAPRAP against GCTA in rarer variants 
analysis. In the example of two SNPs with MAF < 0.1 and r2 = 0.9, HAPRAP outperform GCTA 
in different sample sizes (Table 4-4).  
SNP1 
 r2=0.9 
 HR_MEAN HR_SD Mreg_MEAN Mreg_SD GCTA_MEAN GCTA_SD 
10K 0.002579 0.011049 0.000874 0.239421 0.003993 0.03148 
5K 0.003626 0.015617 0.023512 0.344624 0.001064 0.04715 
1k 0.005342 0.038019 0.002425 0.804111 0.010605 0.112993 
500 0.014124 0.055718 0.001902 1.15045 0.052179 0.217501 
100 0.014404 0.122847 0.069349 2.682938 0.057968 0.292097 
SNP2 
 r2=0.9 
 HR_MEAN HR_SD Mreg_MEAN Mreg_SD GCTA_MEAN GCTA_SD 
10K 0.002847 0.012574 0.001868 0.249512 0.004604 0.03517 
5K 0.003952 0.017793 0.020453 0.359565 0.000881 0.052533 
1k 0.005489 0.043123 0.012581 0.843051 0.01035 0.124852 
500 0.014384 0.062825 0.013464 1.204385 0.054212 0.237283 
100 0.013037 0.154193 0.050376 2.783836 0.054051 0.324903 
Table 4-4. Performance Comparison of HAPRAP, GCTA and Multiple Regression Using a 
Simulated Population with Two Rare Variants. R2 is the pair-wise LD r2. N is the number of 
individuals in the genotypes reference panel. HR_MEAN (and HR_SD) are the means (and standard 
deviations (SD)) for differences between HAPRAP betas and multiple regression joint SNP effects. 
Mreg_MEAN (and Mreg_SD) are the means (and SDs) for differences between multiple regression 
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joint SNP effects of the reference panel and multiple regression joint SNP effects of the whole 
population. GCTA_MEAN (and GCTA_SD) are the means (and SDs) for differences between GCTA 
betas and multiple regression joint SNP effects.	
4.3.2. A performance comparison of HAPRAP 
against GCTA using BWHHS genotype 
data 
I conducted a performance comparison between HAPRAP and GCTA using the BWHHS 
individual-level data for 1980 individuals. As illustrated in Figure 4-11 A and B, the t-statistics 
for both HAPRAP against multiple regression and GCTA against multiple regression are 
normally distributed. The means of both t-statistics were near zero. The most deviated 
t-statistics were around 0.3 for both methods. After I converted t-statistics to t test p values, 
the most deviated p values were 0.746 and 0.785 for HAPRAP and GCTA respectively (Table 
8-9). This suggests that the results of HAPRAP and GCTA have no statistical differences 
compared to multiple regression results when individual-level data is available. As shown on 
the scatter plots in Figure 4-11 C and D, most of the t-statistics and p values were near the 
X=Y line, which means HAPRAP and GCTA are performing at approximately the same level 





Figure 4-11. Performance comparison against HAPRAP and GCTA joint effect analysis using 
BWHHS unphased genotypes. I conducted a two tailed t-test to compare the difference 
between multiple regression (Mreg) joint SNP effects and HAPRAP / GCTA betas for all 117 
SNPs inside the region listed in Table 8-9. The entire BWHHS individual-level genotypes and 
phenotypes were used for the comparison. A histogram of T-statistics for Mreg betas vs 
GCTA betas (called GCTA T-statistics). B, histogram of T-statistics for Mreg betas vs HAPRAP 
betas (called HAPRAP T-statistics). C, QQ plot for GCTA T-statistics against HAPRAP 
T-statistics. D, QQ plot of GCTA against HAPRAP using -log10 (P) as a scale. The red line in C 
and D is the X=Y line. Detailed results were listed in Table 8-9. 
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Moreover, as shown in Figure 4-12 A and B, all the points of the scatter plots were close to 
the X=Y line, which suggests good correlations amongst the three methods. Mining further, I 
compared the concordance correlation coefficient analysis results. As illustrated in Table 4-5, 
HAPRAP had a slightly better agreement to multiple regression than GCTA (CCC estimate 
0.9982 for HAPRAP and 0.9978 for GCTA). The bias correction factor of HAPRAP is also closer 
to 1 than that of GCTA (bias correction factor 0.9997 for HAPRAP and 0.9996 for GCTA). For 
the pair plots shown in Figure 4-12 C (and results in Table 8-9), I found that most of HAPRAP 
betas are very close to gold standards (multiple regression joint SNP effects), whereas some 
of GCTA betas were apart from gold standards (multiple regression joint SNP effects). The 
above comparisons suggest that HAPRAP performs slightly better than GCTA when the 




Figure 4-12. Performance Comparison of HAPRAP and GCTA Joint Effect Analysis Using 
BWHHS Unphased Genotypes.  
I drew scatter plots and pair plots to compare the differences between multiple regression 
(noted as Mreg), joint SNP effects and HAPRAP / GCTA betas for all 117 SNPs inside the 
region listed in Table 8-9. The entire BWHHS individual-level genotypes and phenotypes 
were used for the comparison. (A) Scatter plot of Mreg betas vs GCTA betas. (B) Scatter plot 
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of Mreg betas vs HAPRAP betas. The red line in (A) and (B) is the Y=X line. (C) Pair plot of 
Mreg betas, HAPRAP betas and Mreg betas. SNPs were sorted by Mreg betas in ascending 
order. The full circles represent the Mreg betas, clear triangles represent the HAPRAP betas 
and cross represent the GCTA betas. Detailed results were listed in Table 8-9. 
Methods Cohorts CCC  95% CI of CCC C.b 
HAPRAP vs Mreg BWHHS 0.9982 0.9975~0.9987 0.9997 
GCTA vs Mreg BWHHS 0.9978 0.9971~0.9984 0.9996 
HAPRAP vs Mreg 1000G 0.9922 0.9887~0.9946 0.9964 
GCTA vs Mreg 1000G 0.6129 0.5159~0.6944 0.7562 
Table 4-5. The Results of Concordance Correlation Coefficient Analysis. Notations: CCC 
represents the centre estimate of concordance correlation coefficient and 95% CI of CCC is 
the 95% confidence interval of the centre estimate. Closer the CCC estimates the better 
agreement of two methods. C.b refers to the bias correction factor, which is a measurement 
of how far the best-fit line deviates from a line at 45 degrees. No deviation from the 45 
degree line occurs when C.b = 1. 
4.3.3. A performance comparison of HAPRAP 
versus GCTA using 1000 Genome 
genotype data 
After further analysing the performance of HAPRAP and GCTA using BWHHS summary 
statistics and public available genotype data from 1000 Genome, I found that the t-statistics 
for both methods were normally distributed with means near zero. But the t-statistics 
deviated substantially this time (Figure 4-13 A and B). After I converted t-statistics to t test p 
values, the most deviated p value for HAPRAP was 0.412, which suggests that there are no 
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statistical differences between HAPRAP results and multiple regression results. In contrast, 
the most deviated t test p value for GCTA was 3.15x10-8, which suggests a significant 
difference between GCTA beta and multiple regression joint SNP effect of this SNP (Table 
8-10). So the GCTA results are not reliable in some cases when using 1000 Genome 
genotypes as reference panel.   
  
 
Figure 4-13. Performance comparison between HAPRAP and GCTA joint effect analysis using 
1000 Genome phased genotypes. The entire BWHHS summary statistics and 1000 Genome 
phased individual-level genotypes of 174 people (CEU and GBP) were used for the 
comparison. The histogram of T-statistics for GCTA and HAPRAP are normal distributed. 
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From C and D, some of the SNPs are apart from the X=Y line (red line), where HAPRAP got 
much larger t-test p values than HAPRAP. This suggests that when a small number of phased 
individual-level genotypes are available, HAPRAP performance better than GCTA. Detailed 
results were listed in Table 8-10. 
Furthermore, I found that the line of best fit for HAPRAP against multiple regression was 
again close to the Y=X line (Figure 4-14 A). In contrast, the line of best fit for GCTA against 
multiple regression had a large angle to the Y=X line (Figure 4-14 B). As the pair plots 
showed in Figure 4-13 C (and results in Table 8-10), HAPRAP betas were closer to multiple 
regression joint SNP effects than GCTA betas were. As represented in Table 4-5, CCC analysis 
results also suggest that HAPRAP got a much better agreement to multiple regression than 
GCTA (CCC estimate 0.9922 for HAPRAP and 0.6129 for GCTA). The bias correction factor of 
HAPRAP is much closer to 1 than that of GCTA as well (bias correction factor 0.9964 for 
HAPRAP and 0.7562 for GCTA). I then estimated the mean square error of the three 
methods (deviation between points and Y=X line). As shown in Table 8-10, HAPRAP’s mean 
square error (phased by SHAPEIT) is 10.84% lower than that of GCTA-COJO.  
These comparisons suggest that HAPRAP is much more reliable than GCTA when utilizing the 




Figure 4-14. Performance Comparison Against HAPRAP and GCTA Joint Effect Analysis Using 
1000 Genome Phased Genotypes. (A) Scatter plot of Mreg t-statistics vs HAPRAP (SHAPEIT) 
t-statistics. (B) Scatter plot of Mreg t-statistics vs GCTA-COJO t-statistics. In (A) and (B), the 
longer light line is the Y=X line, the shorter dark line is the line of best fit. Inner zone and 
outer zone are the 95% confidence interval and prediction interval of the line of best fit 
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respectively. The full circles represent the Mreg betas, clear triangles represent the HAPRAP 
betas and cross represent the GCTA betas. Detailed results were listed in Table 8-10. 
4.4. Discussion 
In this chapter, I presented an EM style method, HAPRAP, which provides a new angle to 
perform regional association analysis using meta-analysis results. This method is built on the 
underlying biology of haplotypes, which lead to 3 significant advantages against GCTA-COJO: 
It is more accurate when LD measure r2 is high (i.e. r2 > 0.8) and sample size in the reference 
panel is low (i.e. N < 500). It is more accurate when analysing rare variants (i.e. MAF < 0.01) 
than methods using pair-wise LD; low MAF presents no barrier to performance 
Haplotype-based analyses lead to identification of the most informative SNP. The 
independent association SNP need not be the most strongly associated SNP within the 
genomic region.  
4.4.1. Advantages of HAPRAP 
From our independent benchmark, we proved that the performance of HAPRAP is 
comparable to multiple regression when all the individual-level phenotypes and genotypes 
are available.  
As mentioned in the introduction, most of the individual-level data will be not available 
when conducting a meta-analysis of published consortial data. We have proved in the 
independent benchmark that applying multiple regression to the available individual-level 
data, in a single accessible cohort, will return much less accurate results than using HAPRAP 
and GCTA-which utilize the same individual-level genotypes from one cohort but also make 
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use of the overall meta-analysis summary statistics. My performance comparison using the 
1000 Genomes Project data showed that HAPRAP’s mean square error was on average 10% 
lower than that of GCTA-COJO. Furthermore, the major difference between the two 
methods is that HAPRAP utilizes phased haplotypes whereas GCTA utilizes unphased 
genotypes.  
As I have mentioned in the introduction section, haplotypes contain more information than 
unphased genotypes. Thus, HAPRAP should have a theoretical advantage over GCTA for 
analysing individuals with accurate phased haplotypes. For instance, the 1000 Genome 
consortium (1000 Genomes Project Consortium et al., 2010) used Segmented HAPlotype 
Estimation and Imputation Tool (SHAPEIT) (Delaneau et al., 2013) to phase the genotypes 
with family information. I proved this advantage by using the admixture European 
population from the 1000 Genome data. Since the sample size of 1000 Genome data is still 
small (around 200 individuals for each major ethnic group), the risk of using it as a reference 
panel is relatively high. The errors of using the 1000 Genomes Project data as a reference 
panel are relatively high since the sample size is currently small (under the null, variance of 
LD correlation is 1/n with n being the sample size. Given n=200, the standard error of LD 
correlation estimate is ~0.07). However, for researchers not involved in the meta-analysis or 
those yet to use the data, it is still meaningful to use 1000 Genome data as a test dataset to 
get a general pattern for the multiple potentially associated SNPs in the region(s) of interest. 
With the development of open access genotype databases such as 1000 Genomes Project 
and HAPMAP phase 3 (International HapMap 3 Consortium et al., 2010), more and more 
free data will be available. HAPRAP’s accuracy advantage against GCTA will increase.  
In addition, GCTA adjusts genotypes based on MAFs of SNPs. The genotype for a certain SNP 
under the additive model will be 0-2p, 1-2p and 2-2p, where p is the reference allele 
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frequency of this SNP. This adjustment is due to the assumption that SNPs with lower MAF 
will have higher effects (Park et al., 2011), which will mislead the regression if this is the case. 
In contrast, HAPRAP uses haplotype frequencies instead of allele frequencies, which does 
not rely on the above assumption. This suggests that HAPRAP may have an advantage over 
GCTA for rare variants. The performance comparison of rarer variants also suggest that 
HAPRAP may have advantage against GCTA when MAF < 0.1. Moreover, we highlighted a 
rare variant in Apolipoprotein B (APOB), rs41288783, as an example in real world (Table S2). 
The SNP had a MAF of 0.0018 in BWHHS individuals. The joint SNP effect of this SNP 
estimated by HAPRAP is near to the gold standard comparing to the effect estimated by 
GCTA-COJO (gold standard: 0.731, HAPRAP: 0.705, GCTA-COJO: 0.449). 
4.4.2. Assumptions and limitations for HAPRAP 
There is an uncertainty when phasing haplotypes from genotypes. The haplotype phasing 
approach I selected is an E-M algorithm. It is not accurate especially when there are more 
than 10 SNPs in the model (Browning and Browning, 2011).  In fact, in the same paper, 
Browning SR et al illustrate that the phasing accuracy can be increased up to 98% by using 
hidden Markov model (HMM) haplotype phasing tools such as BEAGLE (Browning and 
Browning, 2009), IMPUTE2 (Howie et al., 2009) and MACH (Li et al., 2010). However, these 
tools are computationally expensive. I have opted to use empirical E-M algorithm here for 
two reasons. Firstly, the method is computationally fast. Secondly, it is almost impossible to 
identify 10 or more multiple associated SNPs in a specific genomic region and the errors 
caused by haplotype uncertainty are a minor issue in the step-wise elimination process.  
Moreover, if SNPs with a very high variance inflation factor (VIF) are included, HAPRAP will 
return extremely large betas for a pair of SNPs. So it is necessary to remove SNPs with VIF 
185 
 
higher than 10 step-wisely before applying HAPRAP.     
HAPRAP needs more time to finish the analysis than GCTA. The reasons for this are listed 
below. Firstly, HAPRAP needs time to phase haplotypes if the genotypes are unphased; 
secondly, it is time consuming to conduct the standard errors of the independent SNP effects 
using simHAPRAP. To improve the efficiency of HAPRAP, I developed the pre-significant test 
system to exclude insignificant SNPs from the model so that the only SNPs within the 
optimal model will be conducted.  For the 6 SNPs model of ABCG5-8 regions (Chapter 6), 
HAPRAP finished the pre-significant test within only 10 seconds but took another 622 
seconds (approximately 10 minutes) to calculate the standard errors of the remaining SNPs 
using simHAPRAP. I think it is still reasonable to use 10 minutes for a fine mapping analysis of 
a genomic region.  
Normally, two SNPs are unlikely to be in a strong LD if they are far away from each other. 
However, long-distance LD may occur during an extreme reduction in population size (note 
as a population bottleneck) (Zhang et al., 2004). For example, long-distance LD had been 
found over a few hundred kb in unrelated population (Sabeti et al., 2002). For convenience 
of analysis and simplicity of SNP models, I set a threshold of genomic regions of 1MB for 
HAPRAP so that it can process regional association analysis more efficiently. In some specific 
cases, two SNPs can be in strong LD even if they are more than 1MB to each other (Yang J et 
al, 2012). So I suggest checking long distance LD inside each chromosome after the optimal 
SNP models were identified by HAPRAP.  
4.4.3. Conclusion 
In this chapter, I have described the novel fine mapping method HAPRAP which I developed. 
This method uses haplotypes instead of genotypes to represent the LD correlation among 
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multiple SNPs. The method can be applied to both quantitative traits and disease outcomes. 
Compared to other related methods, the results of HAPRAP are highly consistent with 
multiple regression results using individual-level data. Moreover, HAPRAP consistently 
outperforms GCTA joint SNP effect analysis at group-level meta-analysis across different 
linkage disequilibrium (LD) correlations (r2) and sample sizes of reference panels. The E-M 
algorithm I have developed is computational fast but the standard error simulation needs 
time but still acceptable. This method is developed for region association analysis for SNPs 
within 1Mb.  
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CHAPTER 5. FINE MAPPING OF 
META-ANALYSIS 
GROUP-LEVEL DATA USING 
HAPRAP 
5.1. Introduction 
In Chapter 3, I have introduced the cardiovascular disease and the genetic variants 
associated with some CVD related phenotypes such as ECG traits and GBD traits. Other traits 
such as blood lipids traits and coagulation traits are also related to CVD risks. Identifying the 
genetic variants associated with these traits and interpreting the causality are of equal 
importance.  
5.1.1. Blood lipids traits  
Plasma lipids are mostly transported in a protein capsule. The major content of blood lipids 
are cholesterol and fatty acids. Cholesterol is an organic molecule which is an essential 
structural component of animal cell membranes that is required to establish proper 
membrane permeability and fluidity. Cholesterol also works as a precursor for the synthesis 
of steroid hormones, bile acids, and vitamin D (Hanukoglu, 1992). The liver cells normally 
produces more cholesterols than other cells in humans.  
Fatty acids are a kind of carboxylic acid with a long aliphatic tail. The tail can be either 
saturated or unsaturated. Most naturally synthesizing fatty acids have a chain of an even 
number of carbon atoms, from 4 to 28. Two important source of fatty acids are triglycerides 
and phospholipids. Fatty acids are important sources of energy for human beings since they 
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can yield large quantities of Adenosine triphosphate (ATP) when they metabolized. ATP is 
the most important element for intracellular energy transfer (Knowles, 1980). Many cell 
types can accept fatty acids as a source of energy, particularly, heart and skeletal muscle 
prefer fatty acids. The brain can use fatty acids as well (Marin-Valencia et al., 2013) 
Since lipids are not absorbed in water (such as bloodstream), lipoprotein molecules enable 
the transportation of cholesterol and triglycerides. In order of molecular size, lipoprotein 
can be categorized into chylomicrons, very low-density lipoprotein (VLDL), 
intermediate-density lipoprotein (IDL), low-density lipoprotein (LDL) and high-density 





Figure 5-1. Cholesterol and lipoprotein transport pathways. Figure from PharmGKB 
(http://www.pharmgkb.org/pathway/PA2031) 
Blood lipids are modifiable risk factors for coronary artery disease (KANNEL et al., 1961) 
(Castelli, 1988). High lipid levels are also a leading cause of death (Lloyd-Jones et al., 2010). 
A lot of evidences have shown the association between lipid concentrations and 
cardiovascular disease incidence worldwide (Law et al., 2003) (Kuulasmaa et al., 2000) 
(Clarke et al., 2007). Plasma concentrations of total cholesterol (TC), low-density lipoprotein 
cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and triglycerides (TG) are 
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heritable risk factors for cardiovascular disease and targets for therapeutic intervention 
(Kathiresan et al., 2007). Environmental factors such as smoking, diet and physical activity all 
play a role in determining individual lipid profiles. Moreover, previous family studies suggest 
that genetic constitutions may contribute to half of the variation in these traits in many 
populations (Pilia et al., 2006) (Pollin et al., 2004). A previous GWAS study identified 95 loci 
associated with blood lipids, accounting for 10%~12% of total trait variance (Teslovich et al., 
2010). Recently meta-analysis of even more GWASs combining European and 
non-European-ancestry individuals identified 157 loci associated with lipid levels at P < 5 x 
10-8 (Global Lipids Genetics Consortium et al., 2013). 
HDL cholesterol 
Ranked by size, HDL is the smallest particles of the lipoprotein. HDL particles move fat acids 
and cholesterol out from cells, including within artery wall atheroma and transport it back 
to the liver for excretion or re-utilization. So the cholesterol carried within HDL particles 
(HDL-C) is sometimes called "good cholesterol". A person with higher levels of HDL-C tend to 
have a better cardiovascular health (Sirtori and Fumagalli, 2006), while those with low 
HDL-C cholesterol levels (especially less than 40 mg/dL or about 1 mmol/L) have increased 
rates for heart disease (Toth, 2005). Epidemiological studies have highlighted the 
antiatherogenic function of HDLC and showed that an increase of 1 mg/dL in HDLC levels is 
associated with a 2% and 3% decrease in risk of coronary artery disease in men and women, 
respectively. 
As shown in Table 8-11, previous GWASs have identified 107 SNPs associated with HDL-C. 
Some well-known gene such as Cholesteryl ester transfer protein (CETP), lipase hepatic (LIPC) 
and lipoprotein lipase (LPL) were fine mapped. CETP, which located on chromosome 16q21, 
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transfers cholesteryl esters between lipoproteins. CETP could be targeted in CETP deficient 
individuals to increase HDL-C levels (Agerholm-Larsen et al., 2000). To be able to identify 
suitable targets, it will be necessary to fine map these genomic regions. Multiple associated 
SNPs were identified using both European-descent based and African-descent based 
meta-analysis (Teslovich et al., 2010) (Buyske et al., 2012). LPL encodes lipoprotein lipase. It 
is expressed in cell types such as heart, muscle, and adipose tissue. LPL functions as a 
homodimer, and has the dual functions of triglyceride hydrolase and ligand/bridging factor 
for receptor-mediated lipoprotein uptake. LIPC, which encodes hepatic triglyceride lipase, is 
an important enzyme in HDL metabolism. It is mostly expressed in liver.  
LDL cholesterol 
LDL molecules can transport their content of many fat molecules into artery walls, attract 
macrophages, and thus drive atherosclerosis. So they are often noted as bad cholesterol for 
human beings. High concentrations of LDL cholesterol are associated with increased risk of 
coronary artery disease (CAD) and the leading cause of death in United States (Roger et al., 
2012). LDL-C level is influenced by the environment factors and genetic factors. Among the 
total variation, approximately 40%–50% of them is heritable (de Miranda Chagas et al., 
2011).  
As shown in Table 8-12, previous GWASs have identified 73 loci associated with LDL, which 
only explained 10%-12% of the total variance in LDL-C (Teslovich et al., 2010).  
A recently fine mapping study of five LDL cholesterol associated loci claimed that variants 
with the strongest association were often substantially different in effect allele frequencies 
and effect sizes from those identified by GWAS (Sanna et al., 2011). To explain the missing 
heritability and to replicate the GWASs results, fine mapping is needed for candidate gene 
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regions such as Apolipoprotein E (APOE), Poliovirus Receptor Related 2 (PVRL2), Translocase 
Of Outer Mitochondrial Membrane 40 Homology (TOMM40), Low-Density Lipoprotein 
Receptor (LDLR), Cadherin, EGF LAG Seven-Pass G-Type Receptor 2 (CELSR2) - 
Proline/Serine-Rich Coiled-Coil 1 (PSRC1) region and Apolipoprotein B (APOB).  
APOE is a gene with three major isoforms: ApoE2 (cys112, cys158), ApoE3 (cys112, arg158), 
and ApoE4 (arg112, arg158) (Ghebranious et al., 2005). These isoforms are defined by the 
combinations of two SNPs rs429458 and rs7412 (Table 5-1).  
  rs429358 rs7412 
E2 T T 
E3 T C 
E4 C C 
Table 5-1. Three major isoforms of APOE gene 
E2 can be found in approximately 7% of the population 
(http://www.alzgene.org/meta.asp?geneID=83). E2 is associated with increased risk for 
atherosclerosis and Parkinson’s disease (Breslow et al., 1982) (Feussner et al., 1998) (Civeira 
et al., 1996) (Huang et al., 2004). For E3, it is the most common APOE genotype which can 
be found in approximately 79% of the population 
(http://www.alzgene.org/meta.asp?geneID=83). More important, E4 has been associated 
with disorders such as atherosclerosis (Federoff et al., 2012), Alzheimer's disease (Mahley, 
1988) (Corder et al., 1993), impaired cognitive function (Strittmatter et al., 1993) (Deary et 




LDLR is a protein coding gene located in chromosome 19p3.2. It binds LDL and transport it 
into cells by endocytosis. Mutation in LDLR is also associated with hypercholesterolemia 
(http://www.genecards.org/cgi-bin/carddisp.pl?gene=LDLR).  
In addition, APOB is a protein-coding gene of Apolipoprotein B, which is a major protein 
constituent of chylomicrons, LDL and VLDL 
(http://www.genecards.org/cgi-bin/carddisp.pl?gene=APOB).   
Triglycerides (TG) 
TG is an ester derived from glycerol and three fatty acids. As a part of the plasma lipid, it 
helps enable the double sided transference of adipose fat and blood glucose from the liver. 
As other blood lipids, TG level is heritable risk factors for cardiovascular disease (Namboodiri 
et al., 1985) (KANNEL et al., 1961) (Miller and Miller, 1975).  
As shown in Table 8-13, totally 79 SNPs were found to be associated with TG from previous 
GWASs. I will fine mapping candidate genes such as Zinc Finger Protein 259 (ZNF259), 
Apolipoprotein A-V (APOA5), BUD13 Homolog (BUD13), LINC00900 long intergenic 
non-protein coding RNA 900 (LOC283143) and LPL (which is associated with HDL-C level as 
well) in this chapter. For example, the common LPL nonsense mutation S477X (rs328) in this 
region is known to be associated with TG. And multiple associated signals were found by the 
previous GWASs (Table 8-13).   
Total cholesterol (TC) 
Until now, 62 SNPs were proved to be associated with TC which explained 12.4% of the total 
heritability (Global Lipids Genetics Consortium, 2013). Table 8-14 listed the most recent 15 
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SNPs found to be associated with TC. Candidate genes such as APOE, LDLR, PVRL2 and APOB 
need further fine mapping.  
5.1.2. Coagulation 
Plasma levels of coagulation factors such as VII (FVII), VIII (FVIII) and von Willebrand factor 
(vWF) is the basis of hemostasis, which prevents life-threatening blood loss from damaged 
blood vessels. Both coagulation factors VII and VIII are produced in liver and play a key role 
in the initiation and propagation of fibrin formation (Smith et al., 2010b). Increased 
circulating levels of FVIII and vWF will increase risk of several thrombosis (Koster et al., 
1995) (Folsom, 2001). Deficiency in FVII and vWF are causality of Hemorrhagic complications 
(Cooper et al., 1997) (Acharya et al., 2004). X-linked deficiency in FVIII, which is called 
haemophilia A clinically, is associated with hemorrhagic complications as well (Antonarakis 
et al., 1987). Plasma levels of these factors will be influenced by both environmental and 
genetic factors (Conlan et al., 1993) (de Lange et al., 2001).  
Factor VII 
In the tissue-factor pathway, activated FVII is a catalyst for factor X (FX) activation, which 
converts prothrombin to thrombin. The heritability estimate of FVII is from 0.53 to 0.63 
(Smith NL et al, 2010). Table 8-15 shown 4 SNPs associated with FVII from previous GWASs.  
Factor VIII 
During the propagation process, activated FVIII can activates FX when the activated factor IX 
present. The heritability estimate of FVIII is from 0.4 to 0.61 (Smith et al., 2010b). Table 8-16 
shown 11 SNPs associated with FVII from previous GWASs.  
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Von Willebrand (vWF) 
Von Willebrand factor is produced by endothelial cells and megakaryocytes, andplays 
multiple roles in hemostasis. Firstly, it acts as an adhesion molecule that anchors platelets to 
exposed collagen after endothelial cell damage. Secondly, serves as a carrier protein for 
FVIII, therefore extending the half-life of FVIII. The heritability estimate of vWF is from 0.31 
to 0.75 (Smith et al., 2010b). Table 8-17 shown 11 SNPs associated with vWF from previous 
GWASs. 
To sum up, there are only a limited number of SNPs reported to be associated with 
coagulation factors. I will fine map the following genomic regions using HAPRAP and GCTA: 
F7, F10, PROCR, TRPC4AR and MYH7B for FVII; ABO, OBP2B, SURF4, C9orf96, ADAMTS13, 
CACFD1 and GBGT1 for FVIII; ABO, OBP2B, SURF4, C9orf96, ADAMTS13, CACFD1, MED22, 
SLC2A6 and GBGT1 for vWF.  
5.1.3. Other CVD related traits 
C-reactive protein (CRP) 
C-reactive protein, which is found in blood, is a pattern-recognition molecule of innate 
immunity. Low level of plasma concentrations of CRP is an independent predictor of 
diseases such as incident metabolic syndrome, type 2 diabetes, myocardial infarction, and 
stroke in both men and women (Ridker et al., 1997) (Pradhan et al., 2001) (Laaksonen et al., 
2004) (Ridker et al., 2002) (Han et al., 2002). CRP levels will be affected by both 
environmental factors, such as obesity, smoking and hormone-replacement therapy, and 
genetic factors (Hage and Szalai, 2007). Previous GWASs have provided insight into 
mechanisms underlying relationships between CRP, insulin resistance, metabolic syndrome, 
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and vascular events (Table 8-18). Further analysis is need for candidate genes such as APOE, 
CRP, NHF1A and C12orf43.  
Interleukin 6 (IL6) 
Interleukin 6 encodes a cytokine that works in inflammation and maturation of B cells. So its 
function is associated with several inflammation diseases such as diabetes mellitus and 
systemic juvenile rheumatoid arthritis 
(http://www.genecards.org/cgi-bin/carddisp.pl?gene=IL6).  
Bilirubin 
Bilirubin is a major component of bile and it is the breakdown product of heme catabolism.  
Increased levels of serum bilirubin is associated diseases such as gallstone disease. 
Moreover, the inverse correlation between bilirubin levels and atherosclerosis risk had been 
found and supported by meta-analysis (Hunt et al., 2001) (Djoussé et al., 2001) (Novotný 
and Vítek, 2003), which suggests that it can be protective.  
The heritability of bilirubin levels had been identified by family-based studies (Kronenberg 
et al., 2002) (Lin et al., 2003) (Clementi et al., 2007). Furthermore, linkage analyses 
identified the UGT region on chromosome 2q37.1 as the major genomic region for bilirubin 
levels (Kronenberg et al., 2002) (Lin et al., 2003).  
Pervious GWASs found 38 SNPs associated bilirubin, which is listed in Table 8-19. UGT and 
USP40 will be extremely interesting regions to follow-up.  
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Serum urate (surate) 
Uric acid is a heterocyclic compound with the formula C5H4N4O3. It is the end product of 
purine metabolism in humans. Urate is known as the salts forms from uric acid. 
Approximately 70% of urate disposal occurs via the kidneys. Impaired renal excretion leads 
to hyperuriccemia in 5~25% of the human population (Becker and Jolly, 2006). 
Hyperuricemia will lead to development of gout, which is an inflammatory arthritis, in about 
10% of the population.  
Until now, 68 SNPs were identified to be associated with urate by previous GWASs (Table 
8-20). SLC2A9 gene, which is the first gene to be found by GWASs, is a known fructose 
transporter (Manolescu et al., 2007).  
5.1.4. Atopic Dermatitis 
Atopic dermatitis, also called eczema, is a common chronic inflammatory skin diseases with 
prevalence of 20% in children and 3% in adults. It is commonly starts during infancy. Food 
allergy, asthma and rhinitis are often occurs in eczema patients. Its clinical characters 
includes dry skin, intense pruritus and age-related inflammatory lesisons (Bieber, 2008). Key 
components affecting the development of atopic dermatitis include change in skin barrier 
function and immunologic abnormalities. Further research is needed to identify the exact 
molecular mechanisms of atopic dermatitis.  
Atopic dermatitis is strongly inherited. Until now, 28 SNPs were reported to be associated 
with atopic dermatitis (Table 5-21). Specific genomic regions such as FLG in chromosome 1, 
C11orf30 in chromosome 11 need further investigation. 
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5.1.5. Aims and Objectives 
In the above section, I have listed the traits and their associated genomic regions I am 
interested in. I would conduct fine mapping to these candidate genes using meta-analysis 
summary results directly. In Chapter 5, I have presented the novel fine mapping method 
HAPRAP and compare its performance with other methods. In this chapter, I will focus on 
the application of HAPRAP and GCTA joint SNP effect analysis to these traits. Secondary 
association signals will be identified using meta-analysis summary results directly.   
Objectives 
l Further fine mapping the ECG traits and GBD traits  
l Fine mapping the four major blood lipids traits 
l Fine mapping coagulation traits 
l Fine mapping other CVD related traits including  
l Fine mapping another binary traits, atopic dermatitis.  
l Compare the difference of meta-analysis results between using fix effect model and 
random effect model  
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5.2. Methods and Materials 
5.2.1. Sample datasets 
BWHHS individual-level data 
BWHHS individual-level genotypes of 1980 elder ladies from 60-79 years old were used in 
this chapter as the reference genotype panel. The individual-level genotypes were 
genotyped using the Metabochip chip for these ladies. The BWHHS cohort was pre-phased 
using MACH (Li et al., 2010) and imputed using the 1000 Genomes CEU reference panel on 
the imputation tool minimac (Howie et al., 2012). 
UCLEB Meta-analysis of CVD related traits 
I used summary statistics of UCLEB meta-analysis on totally 14959 individuals.  
The UCLEB meta-analysis of ECG traits included three participating studies on totally 7106 
individuals: the BWHHS (Lawlor et al., 2003), the British Regional Heart Study (BRHS) 
(Shaper et al., 1981) and the Whitehall II study (WHII) (Marmot et al., 1991).  
The UCLEB meta-analysis of blood lipids traits included eight participating studies on totally 
14959 individuals: MRC NSHD (Wadsworth et al., 2006), ELSA (Marmot et al., 2003), ET2DS 
(Price et al., 2008), EAS (Fowkes et al., 1991), CAPS (Bainton et al., 1992), BWHHS, BRHS and 
WHII.  
The UCLEB meta-analysis of vWF and FVII included five participating studies on totally 9009 
individuals: EAS, CAPS, BWHHS, BRHS and WHII. Besides, FVIII meta-analysis included four 
independent studies on totally 5872 individuals: EAS, CAPS, BWHHS and BRHS. 
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For other traits, CRP included seven studies on totally 11545 individuals: ELSA, ET2DS, EAS, 
CAPS, BWHHS, BRHS and WHII. IL6 included six studies on totally 9541 individuals: ET2DS, 
EAS, CAPS, BWHHS, BRHS and WHII. Bilirubin included four studies on totally 6530 
individuals: ET2DS, CAPS, BWHHS and BRHS. Serum urate included two studies on 4242 
individuals: BWHHS, BRHS 
Meta-analysis of GBD 
I used meta-analysis summary statistics of a consortium analysis of gallbladder disease (GBD) 
(Rodriguez et al., 2014). The meta-analysis included three individual studies from both UK 
and USA: the Atherosclerosis Risk in Communities Study (ARIC) (The ARIC investigators, 
1989), the Whitehall I (WHI) (The Women’s Health Initiative Study Group, 1998) and the 
BWHHS. Totally 15213 individuals were included in this meta-analysis.  
EAGLE consortium meta-analysis of atopic dermatitis 
The EGALE consortium meta-analysis of atopic dermatitis was used in this section 
(Paternoster et al., 2012). Totally 119496 European individuals were involved in the 
meta-analysis. Details of individual studies involved in this meta-analysis were listed in 
Chapter 2.1.7).  
5.2.2. Fine mapping for GBD outcomes 
HAPRAP is appropriate to case-control studies. I demonstrated this by using meta-analysis 
summary statistics of the consortium analysis of gallbladder disease (GBD) and 
individual-level genotypes using the HumanCVD chip for 3078 BWHHS individuals. I selected 
two head to head genes, ABCG5 and ABCG8, as an example. This region has been previously 
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shown to contain multiple associated SNPs with GBD (Buch et al., 2007). Based on the 
summary statistics from the meta-analysis, eight SNPs were significantly associated with 
GBD in this region. Two of them were removed because of high VIF. I applied HAPRAP and 
GCTA to the remaining six SNPs with meta-analysis p values smaller than 5x10-5 (Table 8-22).   
5.2.3. Fine mapping for UCLEB meta-analysis of 
CVD related traits 
I applied HAPRAP using summary statistics from the UCLEB meta-analysis on totally 13 
different traits. I used 1980 BWHHS individuals of recent European ancestry, which is 
genotyped using MetaboChip, as a reference genotype panel. As I have mentioned above, 
BWHHS cohort is part of the UCLEB meta-analysis. The meta-analysis significant p value 
cut-off is 1 x 10-5. For quality control of SNPs, I used the most likely genotypes of the 
imputed SNPs and excluded SNPs with MAF <0.05. SNPs with VIF < 10 were selected for 
further fine mapping. 
For ECG traits, I focused on the NOS1AP region, which has been previously reported to be 
associated with QTc interval and SCN5A-SCN10A region associated with PR interval.  
For plasma lipids traits, I selected three regions associated with HDL-C: CETP-HERPUD1, LIPC 
and LPL associated with HDL; seven regions associated with LDL-C: APOE, PVRL2, TOMM40, 
LDLR-SMARCA4, CELSR2, APOB and PCSK9; five regions associated with TG: ZNF259, APOA5, 
BUD13, LOC283143 and LPL; four regions associated with TC: APOE, LDLR-SMARCA4, PVRL2 
and APOB.   
For coagulation traits, I chose five regions associated with FVII: F7, F10, PROCR, TRPC4AP 
and MYH7B; seven regions associated with FVIII: ABO, OBP2B, SURF4, C90rf96, ADAMTS13, 
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CACFD1 and GBGT1; nine regions associated with vWF: ABO, OBP2B, SURF4, C9orf96, 
ADAMTS13, CACFD1, MED22, SLC2A6 and GBGT1.  
For other traits, I selected IL6 gene associated with IL6; SLC2A9 gene associated with sUrate; 
four genes associated with CRP: APOE, CRP, HNF1A and C12orf43; three regions associated 
with bilirubin: UGT, USP40 and SLC22A3.   
Totally 394 meta-analysis significant SNPs passed the quality control process for the above 
regions. The SNPs, their genomic regions and their relative traits were listed in Table 8-23.  
For all the above traits, the p value threshold of the fine mapping analysis was 5 x10-5. 
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5.2.4. Fine mapping for Atopic Dermatitis  
I applied HAPRAP to summary statistics from the EAGLE genome-wide association 
meta-analysis of atopic dermatitis, made available to me by the EAGLE consortium. The 
meta-analysis was conducted using European only individuals and a fixed effect model. All 
SNPs reach the meta-analysis significance of p value < 5 x 10 -8 were selected for the further 
fine mapping analysis.  
9233 ALSPAC individuals were use as the genotype reference panel for HAPRAP. The EAGLE 
consortium aim to set more accurate conditional analysis p value threshold in each 
candidate region. To achieve that, the EAGLE consortium used the SNP spectral 
decomposition (SNPSpD) method to calculate the number of effective tests in each region 
(Nyholt, 2004) and the conditional analysis p-value threshold for each region were then 
calculated based on the number of effective tests. The p-value threshold provided by the 
EAGLE consortium were listed in Table 5-2.  
       Chr P value threshold       Start region End region 
1 6.45E-06 150250000 154500000 
2 9.29E-05 102777103 103277103 
3 9.85E-05 112180000 112641174 
3 9.82E-05 52838790 53338790 
4 1.30E-04 122993592 123493592 
5 0.00012 131741085 132150000 
6 6.31E-06 32325524 32825524 
6 1.14E-05 31216217 31716217 
8 1.60E-04 81090000 81340000 
10 7.34E-05 6020000 6288853 
10 8.03E-05 64119999 64619999 
204 
 
11 9.26E-05 65309266 65809266 
11 7.52E-05 76031593 76531593 
11 2.20E-04 128040000 128190000 
14 9.32E-05 35309126 35809126 
16 6.27E-05 10979589 11479589 
17 1.00E-04 40278131 40778131 
19 6.91E-05 8539722 9039722 
20 5.24E-05 62053115 62553115 
Table 5-2. P value threshold for each atopic dermatitis candidate region.  
5.3. Results 
5.3.1. Fine mapping of GBD outcomes 
I conducted the fine mapping analysis of loci associated with GBD using both HAPRAP and 
GCTA. Both methods identified rs4299376 and rs4953023 as independent effect SNPs (Table 
5-3). Besides, both methods return similar joint SNP effects and standard errors, which 
proved the suitability of HAPRAP in the case-control study.  
SNP 
          HAPRAP   GCTA 
 CHR POS   MAF    BETA SE p value   BETA SE p value 
rs4299376  2  43926080   0.315  
 
-0.223 0.033 8.86x10-12 
 
-0.221 0.033 1.92x10-11 
rs4953023  2  43927504   0.066    0.688 0.054 5.87x10-38   0.712 0.053 5.50x10-41 
 Table 5-3. HAPRAP and GCTA joint effect analysis of identifying two independent effect 
SNPs associated with gallbladder disease in ABCG 5 and 8 regions. 
5.3.2. Fine mapping for ECG traits 
I processed the fine mapping analysis using UCLEB meta-analysis results of ECG traits. For 
NOS1AP gene associated with QTc interval, I identified three jointly associated SNPs: 
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rs10429888, rs16857031 and rs10918859 using HAPRAP (Table 5-4). In contrast, GCTA only 
detected the top hit, rs12143842, as independent. 
For SCN5A-10A region associated with PR interval, I identified three independent effect 
SNPs: rs12635898, rs73056438, rs6801957 using HAPRAP. In comparison, GCTA identified 
the same three SNPs as HAPRAP.  
5.3.3. Fine mapping for lipids traits 
I performed the fine mapping analysis using UCLEB meta-analysis results of plasma lipids 
traits. As shown in Table 5-5, totally 41 SNPs in 14 loci have multiple association SNPs for 
four lipids traits: 5 SNPs in 2 loci associated with HDL-C; 9 SNPs in 4 loci associated with 
LDL-C; 19 SNPs in 4 loci associated with TG and 8 SNPs in 3 loci associated with TC. 
5.3.4. Fine mapping for coagulation traits 
I conducted the fine mapping analysis using UCLEB meta-analysis results of coagulation 
traits. As shown in Table 5-6, totally 50 SNPs in 15 loci have multiple association SNPs for 
four lipids traits: 2 SNPs in F7 gene associated with FVII; 13 SNPs in 5 loci associated with 
FVIII and 35 SNPs in 9 loci associated with vWF. 
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SNP Chr. Location (bp) Nearest gene Ref Allele MAF 
UCLEB meta-analysis   HAPRAP, haplotypes from BWHHS 
BETA Std Err P   BETA Std Err P 
rs10429888 1 162024987 NOS1AP A 0.1291 4.0402 0.6642 1.18x10-9  3.7071 0.642 8.07x10
-9 
rs16857031 1 162112910 NOS1AP G 0.1469 2.8277 0.6276 6.61x10-6 
 
2.8386 0.6082 3.104x10-6 
rs10918859 1 162169268 NOS1AP A 0.1784 3.5747 0.5825 8.41x10-10   2.5991 0.5553 2.913x10-6 
             
rs12635898 3 38601069 SCN5A-10A A 0.3909 2.5793 0.4753 5.73x10-8  2.9567 0.4916 1.84x10-9 
rs73056438 3 38646478 SCN5A-10A A 0.3572 2.6866 0.5318 4.38x10-7  3.7213 0.5575 2.66x10-11 
rs6801957 3 38742319 SCN5A-10A A 0.4526 3.9874 0.4243 5.61x10-21  4.4573 0.4492 4.69x10-23 
Table 5-4. Summary of multiple associated SNPs at NOS1AP for QTc interval and SCN5A-10A for PR interval. The UCLEB meta-analysis betas 
are the marginal SNPs effects of the SNPs. For the HAPRAP analysis, UCLEB meta-analysis summary statistics and individual-level haplotypes 
from 1980 BWHHS individuals were used. The HAPRAP betas are the independent SNP effects of the SNPs. Chr represents the chromosomes 
of the SNPs. MAF represent the minor allele frequencies of the SNPs. The Standard errors are noted as Std Err and the P values are noted as P. 
207 
 
Locus Chr independent SNP traits Allele Freq Beta P HAPRAP Beta HAPRAP P GCTA Beta GCTA P 
CETP 16 rs12708967 HDL C 0.3016 -0.0617 1.87E-33 -0.0386 5.89E-07 -0.0367 7.25E-12 
CETP 16 rs3764261 HDL A 0.4449 0.0822 7.35E-80 0.0795 1.42E-36 0.0589 1.26E-36 
CETP 16 rs5883 HDL A 0.1264 0.0566 7.49E-10 0.095 7.52E-15 0.0913 1.35E-21 
LIPC 15 rs1077834 HDL G 0.2593 0.049 2.54E-23 0.0327 0.002136 0.033149 1.26E-05 
LIPC 15 rs261338 HDL A 0.2205 0.0517 3.35E-21 0.0225 0.055035 0.023354 0.006117 
LPL 8 chr8:19868772 HDL G 0.3227 0.0399 3.98E-19 0.0377 3.42E-10 0.037656 9.08E-17 
LPL 8 chr8:19959564 HDL G 0.3155 0.0302 1.88E-11 0.0271 4.02E-06 0.027087 2.11E-09 
APOE 19 rs769449 LDL A 0.2098 0.2097 9.61E-32 0.1671 7.52E-18 0.1739 6.03E-22 
APOE 19 chr19:50103919 LDL A 0.1762 -0.484 9.00E-107 -0.4606 2.02E-79 -0.4603 1.17E-93 
PVRL2 19 rs7254892 LDL A 0.1303 -0.4105 3.84E-34 -0.3762 1.27E-19 -0.39478 3.45E-31 
PVRL2 19 rs6857 LDL A 0.2414 0.2042 1.37E-35 0.1912 1.25E-26 0.196799 6.18E-33 
TOMM40 19 rs2075650 LDL G 0.2243 0.2018 3.40E-33 0.1917 3.04E-26 0.205764 2.38E-34 
TOMM40 19 chr19:50092587 LDL A 0.2384 -0.3502 2.98E-24 -0.3207 3.36E-15 -0.35984 3.56E-25 
LDLR 19 rs6511720 LDL A 0.202 -0.1922 3.59E-27 -0.1868 2.58E-19 -0.18776 1.08E-25 
LDLR 19 rs2738447 LDL A 0.4291 -0.0608 7.68E-07 -0.0525 0.000205 -0.05341 1.48E-05 
CELSR2 1 chr1:109618715 LDL G 0.2823 -0.1502 7.73E-26 -0.1264 5.73E-08 -0.12102 3.09E-09 
CELSR2 1 chr1:109618768 LDL G 0.3629 -0.1127 5.66E-19 -0.0279 0.17683 -0.0364 0.044382 
APOB 2 rs41288783 LDL A 0.2504 0.9996 1.36E-06 0.9255 1.46E-05 0.993053 4.29E-05 
APOB 2 rs1367117 LDL A 0.369 0.1163 1.15E-20 0.0819 2.95E-08 0.090326 3.44E-12 
APOB 2 chr2:21124828 LDL A 0.2278 -0.1629 7.52E-23 -0.1286 1.93E-11 -0.13141 2.64E-14 
ZNF259 11 rs6589566 TG G 0.2199 0.1362 7.91E-27 0.1458 8.76E-36 0.144344 1.30E-29 
ZNF259 11 chr11:116160810 TG A 0.2184 0.1387 7.02E-27 0.1485 3.61E-35 0.146956 9.83E-30 
APOA5 11 chr11:116167541 TG A 0.2187 0.1359 1.74E-26 0.1449 1.71E-34 0.144304 3.62E-29 
APOA5 11 chr11:116168917 TG G 0.211 0.1444 4.18E-27 0.1539 7.29E-34 0.153089 6.94E-30 
BUD13 11 chr11:116137710 TG A 0.2205 0.1311 1.19E-25 0.1408 3.76E-32 0.139785 1.03E-28 
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BUD13 11 rs10790162 TG A 0.2194 0.1356 1.23E-26 0.1452 2.02E-35 0.14429 1.43E-29 
LOC283143 11 chr11:116031077 TG A 0.2293 0.09 2.32E-14 0.1855 1.69E-16 0.154655 6.24E-23 
LOC283143 11 chr11:116038377 TG C 0.3288 0.0775 2.34E-06 -0.442 1.67E-27 0.490813 2.87E-85 
LOC283143 11 chr11:116063637 TG A 0.3275 0.0442 2.25E-09 0.0611 1.41E-07 0.036298 6.22E-05 
LOC283143 11 chr11:116083427 TG G 0.3533 0.0507 6.44E-06 -0.1791 1.01E-17 0.317944 3.31E-81 
LOC283143 11 rs7350481 TG A 0.212 0.1193 2.62E-19 -0.1867 1.92E-05 -0.06491 0.026156 
LOC283143 11 chr11:116099040 TG A 0.1983 0.1556 1.36E-13 0.2278 2.07E-11 0.427106 4.90E-47 
LOC283143 11 chr11:116109242 TG G 0.2243 0.1175 1.46E-22 -0.1986 8.31E-07 0.026689 0.369999 
LOC283143 11 chr11:116112578 TG A 0.2171 0.1298 1.16E-24 0.319 1.03E-18 0.183769 1.55E-12 
LOC283143 11 chr11:116115504 TG G 0.3046 -0.0494 1.13E-08 -0.0685 9.05E-11 -0.05613 1.92E-08 
LOC283143 11 chr11:116116667 TG A 0.2301 0.1178 1.19E-16 0.3036 1.15E-13 0.221831 1.15E-22 
LOC283143 11 chr11:116117338 TG G 0.2297 0.1125 2.27E-21 0.1353 7.93E-06 0.146775 3.02E-07 
LPL 8 rs10096633 TG A 0.2527 -0.0939 1.39E-23 -0.0606 6.76E-10 -0.06653 7.81E-11 
LPL 8 chr8:19914551 TG A 0.3402 -0.074 1.26E-24 -0.0527 2.80E-13 -0.05441 3.59E-12 
APOE 19 rs769449 TC A 0.2102 0.2101 2.87E-26 0.1397 3.55E-09 0.157471 2.54E-14 
APOE 19 chr19:50103919 TC A 0.1763 -0.3898 2.38E-56 -0.4014 4.10E-44 -0.38812 9.75E-53 
APOE 19 rs439401 TC A 0.3931 -0.0605 9.87E-06 -0.0827 1.03E-06 -0.06557 4.79E-06 
LDLR 19 rs6511720 TC A 0.2019 -0.2254 7.35E-30 -0.2194 2.68E-21 -0.2206 3.44E-28 
LDLR 19 rs2738447 TC A 0.4287 -0.0664 1.31E-06 -0.0563 0.000179 -0.05779 2.57E-05 
PVRL2 19 rs7254892 TC A 0.131 -0.3109 1.05E-16 -0.2778 4.58E-10 -0.29576 4.04E-15 
PVRL2 19 rs6857 TC A 0.2435 0.1949 1.05E-26 0.1852 3.83E-20 0.189344 3.29E-25 
APOB 2 rs41288783 TC A 0.2021 1.0301 8.06E-07 0.9495 2.16E-05 1.02417 1.40E-05 
APOB 2 rs1367117 TC A 0.3691 0.1195 6.62E-18 0.0842 6.50E-08 0.092005 1.54E-10 
APOB 2 rs541041 TC G 0.2491 -0.1635 7.42E-22 -0.133 9.29E-13 -0.13569 1.25E-14 
Table 5-5. Independent effect SNPs identified by HAPRAP in four lipids traits. 
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Locus Chr independent SNP traits Allele Freq Beta P HAPRAP Beta HAPRAP P GCTA Beta GCTA P 
F10 13 rs563964 FVII A 0.4867 4.9929 1.42E-34 4.2915 2.07E-14 4.30832 3.01E-24 
F10 13 rs547138 FVII A 0.5802 3.9481 1.09E-20 2.8342 9.25E-07 2.82781 1.24E-10 
ABO 9 chr9:135138971 FVIII A 0.2984 16.206 1.49E-36 19.6925 1.28E-42 18.6836 7.26E-46 
ABO 9 rs507666 FVIII A 0.3517 14.3829 7.07E-74 16.0027 1.26E-70 15.5104 3.64E-82 
OBP2B 9 rs12554449 FVIII A 0.4635 5.6209 5.41E-06 11.8967 9.28E-16 9.82115 1.27E-14 
OBP2B 9 chr9:135112913 FVIII G 0.2947 15.9482 2.54E-35 9.5292 9.64E-10 13.2242 1.11E-22 
OBP2B 9 chr9:135118367 FVIII A 0.4615 -7.5723 1.17E-31 -14.4936 2.72E-51 -11.0948 2.05E-52 
OBP2B 9 chr9:135118593 FVIII G 0.3745 -5.3952 4.94E-13 -10.2517 1.06E-26 -9.19467 5.49E-29 
ADAMTS13 9 chr9:135282263 FVIII A 0.3108 13.2123 6.50E-08 15.3184 2.07E-09 14.2103 7.82E-09 
ADAMTS13 9 chr9:135294712 FVIII G 0.2858 10.6838 6.04E-12 12.5936 7.69E-13 11.6782 7.58E-14 
ADAMTS13 9 rs4962153 FVIII A 0.3336 9.4932 3.28E-24 10.4451 5.90E-26 10.0274 1.48E-26 
CACFD1 9 chr9:135319775 FVIII A 0.3352 9.4455 6.10E-24 9.5931 1.84E-21 9.5006 3.98E-24 
CACFD1 9 chr9:135323177 FVIII A 0.2165 15.3003 5.37E-06 16.7279 1.97E-05 15.7311 3.12E-06 
GBGT1 9 chr9:135032145 FVIII A 0.3639 5.0703 3.71E-11 6.2262 2.47E-12 5.94377 1.50E-14 
GBGT1 9 chr9:135055347 FVIII A 0.2985 10.7287 7.37E-21 12.117 2.72E-21 11.7318 6.86E-24 
ABO 9 rs8176725 vWF A 0.2909 0.127 2.03E-47 0.1334 3.10E-49 0.131433 1.89E-47 
ABO 9 chr9:135123327 vWF A 0.3427 -0.0661 1.98E-26 -0.0681 6.32E-19 -0.07385 2.81E-28 
ABO 9 chr9:135126784 vWF A 0.4653 -0.0982 4.34E-85 -0.0812 1.24E-26 -0.08735 5.44E-46 
ABO 9 chr9:135142543 vWF A 0.3462 -0.0683 7.66E-29 -0.0879 8.96E-15 -0.07837 2.31E-20 
ABO 9 chr9:135146954 vWF A 0.4419 0.0731 7.12E-49 0.123 1.94E-55 0.10824 2.35E-70 
ABO 9 chr9:135171669 vWF G 0.3879 -0.0555 5.55E-24 -0.0402 2.26E-11 -0.04406 6.97E-15 
OBP2B 9 chr9:135106483 vWF A 0.2786 -0.0439 3.59E-07 -0.0612 4.49E-06 -0.06161 2.83E-10 
OBP2B 9 chr9:135111124 vWF A 0.31 0.0755 5.82E-25 -0.091 6.53E-09 -0.02766 0.00478 
OBP2B 9 chr9:135118367 vWF A 0.4551 -0.0945 1.03E-77 -0.1723 1.88E-123 -0.1428 7.27E-129 
OBP2B 9 chr9:135118379 vWF G 0.2806 0.1838 2.85E-74 0.1443 2.19E-15 0.141907 6.01E-30 
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OBP2B 9 chr9:135118558 vWF C 0.3619 -0.076 1.58E-38 -0.17 1.26E-100 -0.1399 2.07E-94 
SURF4 9 chr9:135225708 vWF A 0.285 -0.0589 2.71E-13 -0.0369 7.95E-06 -0.03924 1.72E-06 
SURF4 9 chr9:135227493 vWF A 0.3191 0.1338 2.41E-77 0.1291 4.25E-82 0.128935 4.86E-68 
C9orf96 9 chr9:135244970 vWF A 0.3044 -0.0601 9.39E-15 -0.0656 9.88E-16 -0.05218 2.94E-10 
C9orf96 9 chr9:135254869 vWF A 0.2796 -0.0545 2.33E-09 -0.0627 3.28E-11 -0.05006 1.25E-07 
C9orf96 9 chr9:135256970 vWF A 0.3159 0.1284 1.42E-68 0.103 1.82E-21 0.087128 9.29E-19 
C9orf96 9 chr9:135257905 vWF A 0.403 0.04 8.99E-14 -0.0437 6.80E-10 -0.01397 0.024119 
C9orf96 9 chr9:135258289 vWF C 0.3085 -0.0364 7.95E-07 -0.0413 1.01E-07 -0.03377 1.56E-05 
C9orf96 9 chr9:135260359 vWF C 0.2954 0.138 1.18E-55 0.0607 3.04E-07 0.066674 2.04E-09 
ADAMTS13 9 chr9:135282263 vWF A 0.2832 0.1803 5.03E-21 0.2063 5.97E-28 0.192827 3.43E-23 
ADAMTS13 9 chr9:135294712 vWF G 0.2728 0.106 1.91E-17 0.131 2.27E-25 0.119081 2.67E-21 
ADAMTS13 9 rs4962153 vWF A 0.3155 0.1248 8.98E-66 0.1357 5.01E-77 0.130568 1.82E-70 
CACFD1 9 rs739468 vWF A 0.3141 0.1241 2.83E-65 0.1255 1.99E-70 0.124649 4.92E-65 
CACFD1 9 chr9:135323177 vWF A 0.2176 0.1434 2.62E-07 0.1619 8.25E-09 0.150061 8.16E-08 
MED22 9 rs621907 vWF A 0.276 -0.0497 1.48E-07 -0.044 4.72E-06 -0.04566 1.60E-06 
MED22 9 chr9:135201989 vWF A 0.2708 0.1688 1.81E-32 0.1653 1.20E-30 0.166274 5.45E-31 
SLC2A6 9 chr9:135326625 vWF A 0.287 0.1811 3.99E-21 0.1763 5.26E-21 0.177274 4.93E-19 
SLC2A6 9 chr9:135328419 vWF A 0.2654 -0.0623 1.63E-10 -0.0596 1.95E-08 -0.06953 2.09E-12 
SLC2A6 9 chr9:135329780 vWF G 0.3176 -0.0421 3.94E-09 -0.0649 3.86E-05 -0.03313 0.008265 
SLC2A6 9 chr9:135330021 vWF A 0.3823 0.0437 8.94E-15 0.096 8.40E-39 0.077087 1.94E-31 
SLC2A6 9 chr9:135333468 vWF C 0.3361 -0.0512 7.70E-15 -0.06 8.89E-06 -0.07193 9.20E-11 
SLC2A6 9 chr9:135337653 vWF G 0.2576 -0.0502 2.19E-06 -0.0479 1.32E-05 -0.05566 2.23E-07 
SLC2A6 9 chr9:135338906 vWF C 0.341 -0.0375 3.18E-09 -0.0276 1.95E-05 -0.03408 1.05E-07 
GBGT1 9 chr9:135032145 vWF A 0.3536 0.0588 1.90E-22 0.071228 1.26E-31 0.067896 4.75E-29 
GBGT1 9 chr9:135055347 vWF A 0.2828 0.1144 1.97E-36 0.130282 7.80E-45 0.125969 1.35E-41 
Table 5-6. Independent effect SNPs identified by HAPRAP in three coagulation traits. 
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5.3.5. Fine mapping for other CVD related 
traits 
I run the fine mapping analysis using UCLEB meta-analysis results of other CVD 
related traits. For il6 and surate, I did not find any additional signals expect the top 
hits rs7518199 (associated with il6) and rs9998811 (associated with surate). 
As shown in Table 5-7, totally 10 SNPs in 4 loci have multiple association SNPs for 
bilirubin and crp: 3 SNPs in UGT region associated with bilirubin and 7 SNPs in 3 loci 
associated with crp. 
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Locus Chr independent SNP  traits Allele Freq Beta P HAPRAP Beta HAPRAP P GCTA Beta GCTA P 
UGT 2 rs28899170 bilirubin A 0.4362 2.4878 9.74E-157 1.2848 1.29E-13 1.29489 2.54E-12 
UGT 2 rs17862875 bilirubin A 0.4291 2.5304 5.68E-159 1.3552 9.75E-15 1.37247 2.24E-13 
UGT 2 rs11568318 bilirubin A 0.3609 -1.5878 1.31E-17 -0.7261 3.71E-05 -1.22312 1.21E-10 
CRP 1 rs1205 crp A 0.3857 -0.1662 1.60E-26 -0.0781 2.44E-05 -0.08849 1.30E-06 
CRP 1 rs3091244 crp A 0.4039 0.1865 1.33E-34 0.1412 3.77E-15 0.140156 3.72E-15 
CRP 1 rs11579148 crp A 0.1826 -0.3538 2.16E-08 -0.247 4.73E-05 -0.31971 6.32E-07 
HNF1A 12 chr12:119901371 crp G 0.3712 -0.1649 1.20E-25 -0.1834 3.87E-30 -0.17498 2.29E-28 
HNF1A 12 rs2245407 crp A 0.197 -0.1345 4.47E-06 -0.1959 1.98E-10 -0.17043 7.74E-09 
C12orf43 12 chr12:119926624 crp A 0.187 -0.1428 6.71E-06 -0.1957 6.41E-09 -0.17379 5.01E-08 
C12orf43 12 chr12:119927499 crp G 0.3574 -0.1581 6.83E-23 -0.1729 5.46E-27 -0.16637 5.30E-25 
Table 5-7. Independent effect SNPs identified by HAPRAP in crp and bilirubin.  
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5.3.6. Fine mapping for Atopic Dermatitis 
For the fine mapping analysis of Atopic Dermatitis, I applied HAPRAP to 
meta-analysis results. Four genomic regions with more than one independent SNPs 
were determined: six SNPs were identified in chromosome 1 (region from 
150250000 to 154500000); two independent SNPs in chromosome 4 (region from 
122993592 to 123493592), chromosome 5 (region from 131741085 to 132150000) 
and chromosome 10 (region from 6020000 to 6288853) (Table 5-21). Other twelve 
regions showed no evidence for secondary signals.  
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Chr SNP beta SE pval N HAPRAP beta HAPRAP SE HAPRAP pval 
Chr1 1q21.2_SNP1 -0.0771 0.012585032 9.20E-10 102760 -0.06658198 0.0125 1.00301E-07 
Chr1 1q21.3_SNP1 0.2755 0.030093897 5.75E-20 96795 0.162593083 0.033 8.36123E-07 
Chr1 1q21.3_SNP2 -0.1139 0.015825028 6.31E-13 102760 -0.07749054 0.0161 1.48835E-06 
Chr1 1q21.3_SNP3 0.4764 0.042608896 5.55E-29 93326 0.469246255 0.0428 5.94072E-28 
Chr1 1q21.3_SNP4 0.2961 0.031383212 4.12E-21 96795 0.169504985 0.035 1.28091E-06 
Chr1 1q21.3_SNP5 0.0783 0.012288311 1.93E-10 102760 0.073674469 0.0122 1.55707E-09 
Chr4 4q27_SNP1 0.0758 0.012616106 1.94E-09 102761 0.054018999 0.0135079 6.36371E-05 
Chr4 4q27_SNP2 -0.0897 0.015254395 4.20E-09 102762 -0.0673655 0.0163327 3.71707E-05 
Chr5 5q31.1_SNP1 0.1271 0.015100459 4.03E-17 102761 0.10440521 0.018192895 9.56E-09 
Chr5 5q31.1_SNP2 0.0986 0.014370354 7.14E-12 101294 0.072118769 0.016450248 1.17E-05 
Chr10 10p15.1_SNP1 0.0736 0.012177861 1.54E-09 103065 0.058452566 0.014549342 5.89E-05 
Chr10 10p15.1_SNP2 0.1778 0.03176829 2.23E-08 97099 0.146938916 0.034499725 2.05E-05 
Table 5-21. Genomic regions with multiple SNPs associated with Atopic Dermatitis using fixed effect model meta-analysis results. I used 




5.4.1. Fine mapping of ABCG5-8 region 
The analysis I conducted for ABCG5 and 8 region associated with GBD replicated the 
conclusion in the previous meta-analysis (Rodriguez et al., 2014). Rs4953023, which is the 
top hit of the GBD meta-analysis, is in perfect LD with a previously associated SNP 
rs11887534 (Buch et al., 2007). Rs4299376 is only 1424 base pair apart from the top hit. 
These two SNPs are in weak LD with r2 equal to 0.047 (1000 Genome CEU population). 
5.4.2. Fine mapping of NOS1AP region 
For NOS1AP associated with QTc interval, the first independent SNP rs10429888 is in strong 
LD with a previously associated SNP rs12143842 (r2=0.646 in 1000 Genome CEU), this SNP 
was indicated as the most significant SNP in two previous reports (Newton-Cheh et al., 
2009; Pfeufer et al., 2009). Meanwhile, the second independent SNP rs10918859 is in 
moderate LD with two previously reported SNPs rs4657178 (r2=0.467 in 1000 Genome CEU) 
and rs12029454 (r2=0.168 in 1000 Genome CEU). Moreover, conditional on rs12143842, 
both were reported to be secondary signals in separate studies: rs4657178 in Pfeufer’s 
study (Pfeufer et al., 2009) and rs12029454 in Newton-Cheh’s study (Newton-Cheh et al., 
2009). In addition, there is evidence of correlations between the third independent SNP, 
rs16057031, and two different previously reported SNPs rs10494366 (r2=0.168 in 1000 
Genome CEU) and rs288058 (r2=0.152 in 1000 Genome CEU) (Arking et al., 2006; Marroni et 
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al., 2009). SNP rs10494366 was the first well-replicated NOS1AP SNP reported to be 
associated with QT interval. 
5.4.3. Fine mapping of SCN5A-10A region 
For SCN5A-10A region associated with PR interval, the top associated SNP rs6801957 was 
identified as significant SNP by a previous GWAS study (Butler et al., 2012). Other two SNPs 
are not included in 1000 Genome project, but one of them, rs73056438 was genotyped by 
the ALSPAC in 8365 individuals. So I used ALSPAC individual-level genotype data to calculate 
the LD between rs73056438 and other 6 SNPs reported to be associated with PR interval in 
SCN5A-10A region (the 6 SNPs were listed in Table 8-2). None of the previous reported SNPs 
were in LD with this SNP which suggest that it may represent a novel independent 
associated SNP.  
5.4.4. Fine mapping of candidate regions 
associated with Atopic Dermatitis 
As listed in the introduction section, previous GWAS have identified 28 SNPs associated with 
Atopic Dermatitis (Table 8-21). The region of chromosome 1 where HAPRAP identifies 6 
independent signals is a locus known to be associated with atopic dermatitis. Several rare 
loss of function FLG mutations have been shown to be strongly associated with atopic 
dermatitis (Palmer et al., 2006) (Rodríguez et al., 2009) and previous GWAS signals in this 
region have been shown to be tagging these Loss-of-Function variants (Paternoster et al., 
2012). The variants identified by HAPRAP may therefore tag the haplotypes that these rare 
FLG mutations fall on, or could represent additional independent signals. The EAGLE 
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consortium is carrying out further analysis in this region to determine if there are any novel 
independent associations. In chromosome 4, there was only one SNP, rs17389664, was 
found to be associated with atopic dermatitis (Ellinghaus et al., 2013). In this study, I found 
that 4q27_SNP1 is in modest LD to rs17389664 (ALSAPC r2=0.55). There is almost no LD 
between the other SNP 4q27_SNP2 and rs17389664 (ALSAPC r2=0.079), which suggest a 
secondary signal in this region. On the other hand, there are 2 known independent signals in 
chromosome 5: rs2897442 and rs848 (Paternoster et al., 2012). In this study, I found two 
proxy SNPs which replicated these two signals: 5q31.1_SNP1 is in modest LD with rs848 
(ALSAPC r2=0.281), 5q31.1_SNP2 is in modest LD with rs848 (ALSAPC r2=0.186) and 
5q31.1_SNP2 is in strong LD with rs2897442 (ALSAPC r2=0.912). Moreover, two independent 
SNPs in chromosome 10 are novel findings in this meta-analysis. Further replication analysis 
is needed to test these two signals.  
The SNPs consisted with previous findings confirm the accuracy of the meta-analysis results 
and fine mapping using HAPRAP program. Further analysis is necessary for new findings in 
chromosome 1, 4 and 10.  
5.4.5. Conclusion  
In this chapter, I focused on applying the method I developed, HAPRAP, to meta-analysis 
results of several quantitative traits and diseases outcomes. The fine mapping of ECG traits 
and GBD outcomes are highly consistent to previous conditional analysis of meta-analysis. 
The fine mapping of blood lipids traits, coagulations traits and other CVD related traits 
found some novel independent effect SNPs. The fine mapping of atopic dermatitis outcomes 
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confirmed the previous evidences and enhanced the understanding of its genetic and 
molecular mechanisms of atopic dermatitis. 
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CHAPTER 6. CONCLUSIONS 
AND FUTURE DIRECTION 
There has been an increasing number of national and international collaborations in the 
field of complex disease genetics. The collaboration of large consortia have resulted in an 
increasing number of large-scale meta-analyses to be carried out for a range of complex 
traits such as BMI (Speliotes et al, 2010), lipids traits (Rodriguez et al, 2015) and ECG traits 
(Gaunt et al, 2012). These meta-analyses have successfully increased the statistical power to 
detect novel genetic variants associated with complex human traits. Moreover, an 
increasing number of the world’s leading international consortia such as the GIANT 
consortium, are willing to share their meta-analysis summary statistics, either through 
making the data publicly available or by sharing the data in a collaborative basis. Table 6-1, I 
lists a set of consortia which provide meta-analysis summary data publicly. These summary 
data are unique and informative resources which can lead us to better understand the 









Consortium Fritsche et al, 2013, Nat Genet 77100 
Rheumatoid Arthritis  BIRAC and YEAR Stahl et al, 2010, Nat Genet 25708 
Coronary artery disease CARDIOGRAM Schunkert, et al, 2011, Nat Genet 76995 
Atopic Dermatitis EAGLE Lavinia, et al, 2015 Nat Genet 40835 
Birth Head Circumference EGG Taal, et al, 2012, Nat Genet 10768 
Asthma GABRIEL Moffatt, et al, NEJM, 2010 26475 
BMI GIANT Yang, et al, 2012, Nature 169811 
Extrem_BMI GIANT Berndt, et al, 2013, Nat Genet 263407 
Extrem_height GIANT Berndt, et al, 2013, Nat Genet 263407 
Extrem_WHR GIANT Berndt, et al, 2013, Nat Genet 263407 
Height GIANT Wood, et al, 2014,Nat Genet 253288 
hip circumference GIANT Shungin, et al, 2015, Nature 224459 
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Obesity GIANT Berndt, et al, 2013, Nat Genet 263407 
Overweight GIANT Berndt, et al, 2013, Nat Genet 263407 
waist circumference GIANT Shungin, et al, 2015, Nature 224459 
waist-to-hip ratio (WHR) GIANT Shungin, et al, 2015, Nature 224459 
Lipids GLGC Willer, et al, 2013, Nat Genet 188577 
Crohn's disease. IBD Franke, et al, 2010, Nat Genet 21389 
Ulcerative colitis  IBD Anderson, et al, 2011, Nat Genet 25865 
Celiac Disease  ImmunoBase Trynka, et al, 2011, Nat Genet 24242 
Juvenile Idiopathic Arthritis  ImmunoBase Hinks, et al, 2013, Nat Genet 15872 
narcolepsy ImmunoBase Faraco, et al, 2013, PLoS Genet 12307 
Primary Biliary Cirrhosis  ImmunoBase Liu JZ, et al, 2012, Nat Genet 11375 
Psoriasis  ImmunoBase Tsoi LC, et al, 2012, Nat Genet 33394 
Multiple Sclerosis  
ImmunoBase / 
IMSGC 
International Multiple Sclerosis Genetics 
Consortium, 2013, Nat Genet 38589 
Metabolites MuTHER Shin, et al, 2014, Nat Genet 7824 
Sporadic amyotrophic lateral 
sclerosis SLAGEN Fogh, et al, 2014, HMG 13225 
Type 1 Diabetes T1D Base Copper, Unpublished 13254 
Table 6-1. A list of consortium with public available meta-analysis summary data  
As explained in Chapter 1, utilising publicly available summary statistics has become 
widespread in the complex trait genetics field. The below are some of the well-known and 
widely used examples – as mentioned in the previous chapter: 
1. LD score regression using meta-analysis summary statistics for heritability analysis 
(Bulik-Sullivan BK et al, 2015 a) and genetic correlation analysis (Bulik-Sullivan BK et al, 
2015 b). 
2. Mendelian randomisation approach which can be applied to identify causal relationship 
using public available data (Burgess et al, 2015).  
3. GCTA conditional and joint SNP effect analysis (Yang et al, 2012) using meta-analysis 
summary statistics to process an approximately conditional analysis 
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Under such trend of utilising meta-analysis summary statistics, I developed two user-friendly 
statistical methods, namely SSS-RAP (Zheng et al, 2013) and HAPRAP (Zheng et al, 2015), 
which are two model selection approaches using meta-analysis summary statistics directly. I 
then applied these two methods to certain complex traits and compared them to existing 
state-of-the-art tools. As described in chapter 2 and 4, these two method make better use 
of the meta-analysis summary statistics and their accuracy and performance are better than 
the existing state-of-the-art tools.  
6.1. Selecting independent SNPs using Sequential 
Sentinel SNP Regional Association Plot  
In this thesis, I designed and developed the Sequential Sentinel SNP Regional Association 
Plot (SSS-RAP) program (Zheng et al, 2013) which utilises the concept of pair-wise LD to 
calculate SNP effects conditional on the most significant signals (defined as ones with the 
lowest p values). It was our first try to filling the holes present in fine mapping analysis using 
meta-analysis summary results. The performance of SSS-RAP is comparable to other model 
selection methods at individual-level. Although the method has been published few years 
ago, it is still valuable since 1) it only requires summary-level meta-analysis data and 
summary LD information, which is an advantage over all other model selection methods at 
current; 2) it is computationally fast, which only need a few seconds to finish an 
approximately step-wise regression procedure. So it is a quick, convenient and a visually 
presented method for testing SNP ‘independence’ . 
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6.2. Haplotype based model selection using 
Haplotype regional association analysis 
Program. 
The bulk of this thesis concerns itself with the design and development of Haplotype 
regional association analysis (HAPRAP). This method incorporates the biological concept of 
haplotypes and an empirical expectation-maximisation (E-M) algorithm incorporating the 
relationship between marginal SNP effects and joint SNP effects. The results of HAPRAP 
were highly consistent with multiple regression results using individual-level data. In 
meta-analysis level, it is the most accurate approach for identifying SNP independence at 
current. I summarise below its advantages over other tools, both in biological and statistical 
point of view:  
In a biological point of view, HAPRAP inherits the core concept of using haplotypes to 
represent LD from SSS-RAP and extend it to multiple loci situation. The core advantage of 
HAPRAP is that it is the first approach to insert haplotype based analysis concepts to SNP 
based analysis and utilizes this nested design to identify SNP independence – using 
meta-analysis summary results. In fact, in individual level, haplotype based association 
analysis has already proved its advantage against single marker analysis. As demonstrated 
by previous simulation studies, statistical approaches based on haplotypes can be a more 
powerful method to characterize the genetic background of complex diseases compare to 
single maker LD analysis (Akey J et al, 2001). In meta-analysis level, HAPRAP, showed its 
accuracy advantage against GCTA-COJO, which inherits the pair-wise correlation concept 
from multiple regression. Moreover, from a statistical point of view, the core formula of 
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HAPRAP (see Chapter 5.2.1, equation 2) starts from a very simple concept of a single 
regression between a SNP and a trait, which assumes an additive model, treats the common 
allele as the “baseline” allele (with respect to trait) and assumes the rare allele is the “effect” 
allele. HAPRAP then extends this concept to a more complex SNP-haplotype matrix. 
However, the model is an EM style algorithm which is empirical. Although it is possible that 
the EM algorithm may not convergence may not be possible, so I cannot exclude the 
situation that HAPRAP will not converge. However, in hundreds of thousands of simulation 
and real case examples we performed, I did not find any situation where HAPRAP did not 
converge. Algorithms are often used effectively where the biological model is well 
understood, but the statistical model is too complex to generalise to all scenarios. For 
instance, a recent fine mapping method, probability identification of causal SNPs (PICS), 
used an empirical constant in its core algorithm to estimate the expected mean of the 
association signal at a SNP (Farh et al., 2015). I believe, with further development of 
haplotype-based analyses - especially with advancements on including haplotypes in 
appropriate statistical models - the importance of HAPRAP algorithm will increase in the 
future. 
6.3. Future directions  
In this section, I will describe possible extension of SSS-RAP and HAPRAP programme and 
potential extensions of the fine mapping approaches.   
224 
 
6.3.1. Further development of SSS-RAP: fine 
mapping for untyped SNPs  
In an association analysis of a specific region, the real causal SNP may not be directly 
genotyped because of chosen SNP array coverage. Nowadays, imputation is a widely used 
method that increases the density of SNP data available from an array. But the quality of 
imputation is highly dependent on the density of the original genotype data and the quality 
of the reference panel being used (Marchini and Howie, 2010). The causal SNP may still not 
be detected, even after imputation. Therefore, to test whether there is an untested and 
“significant” SNP associated with a trait, and to determine how it relates to directly 
genotyped SNPs that show significance, I am working on an idea that develops a “hidden 
sentinel SNP shadow LD pattern” approach using the SSS-RAP program. This method will 
extend our knowledge of the associations between typed/imputed SNPs in a region and 
phenotypes, to all SNPs in a genomic region. More importantly, there will be no extra 
genotyping cost, which makes this method more attractive.  
6.3.2. Further development of HAPRAP 
As I alluded to before, HAPRAP can be a useful tool in four aspects. In this section, I will 
describe the possible extension of HAPRAP in these aspects:  
1) HAPRAP provides a good platform for the functional annotation of casual variants using 
variant prediction tools such as FATHMM (Shihab et al., 2015). One of the key purposes of 
fine mapping is to select the variant that is most likely to be the casual SNP for further 
functional studies. Therefore, a logical follow-up to HAPRAP would be to find biological links 
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for those SNPs that are reported to be associated with complex traits (Schaub et al., 2012). 
Ideally, this process should be an automated procedure and be feasibly carried out on 
multiple SNPs. To identify possible functional consequences of the independent SNPs, 
functional prediction tools such as FATHMM (Shihab et al., 2013) and RegulomeDB (Boyle et 
al., 2012) can be used to functionally annotate the SNPs with independent effects (as 
identified by HAPRAP). This process can be further extend to SNPs with very high LD (eg: 
r2 >= 0.8) to the independent SNPs identified using tools such as SNAP (Johnson et al., 2008).  
2) HAPRAP provides an automated model selection procedure, which can be used for allelic 
score estimating. Although HAPRAP is developed for analysing meta-analysis summary data, 
it can be used using individual-level too. As mentioned in Chapter 7.2, haplotype-based 
analysis maintain advantages over multiple regression using individual-level data, so 
HAPRAP can be used as a convenient automated step-wise selection procedure in 
individual-level as well. As mentioned in Chapter 1, allele scores (also called genetic risk 
scores, gene scores, or genotype scores) are a convenient way of summarizing a large 
number of genetic variants associated with a risk factor. It is calculated as the total number 
of risk factor increasing alleles for an individual (unweighted score), or the sum of weights 
for each allele corresponding to estimated genetic effect sizes (weighted score) (Burgess S 
et al, 2012). The most important procedure of allelic score estimating is to select a subset of 
SNPs which represents most of the total variance explained while keeping with the 
stringency criteria. Furthermore, HAPRAP is also a suitable model selection approach for the 
genome-wide allelic score of biological intermediates and mining the phenome (Evans et al., 
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2013), which can be used in Mendelian randomization and will lead to “Hypothesis-Free” 
causality (Evans and Davey Smith, 2015).  
3) HAPRAP provides a good SNP selection procedure for two-sample Mendelian 
randomisation (MR) approach using publicly available data to estimate the causal effect of 
the risk factor on an outcome (Burgess et al, 2015). In the current two-sample MR 
framework, if the test SNPs are in LD with each other, their effects are merged together to 
build a combined effect using the LD correlation matrix (cite). HAPRAP provides an 
alternative way, which can be used as a SNP selection procedure and only the best fit model 
are then be used for the MR. Compared to other model selection approaches, HAPRAP 
requires the same summary information, which will have been corrected for the two-sample 
MR already. As presented in Chapter 5.4, HAPRAP is the most accurate method when using 
public available genotypes (such as the 1000 Genome project data) as a reference panel. So 
combining HAPRAP with MR will lead to a more accurate and robust causal relationship 
between two or more traits. 
4) HAPRAP’s unique function of identifying SNP independence for rare variants. As explained 
in Chapter 1, rare variants tends to have larger effects than common variants (Bodmer and 
Bonilla, 2008). One limitation of rare variant analysis is the lack of a rare variant catalog with 
reference genotypes. For common variants, publicly available genotype resources such as 
the HapMap (www.hapmap.org/) and 1000 Genome Project 
(http://www.1000genomes.org/) databases exist. These reference genotypes help identify 
‘tag SNPs’ within a group of SNPs in high LD. I believe that, with further additions to the 
1000 Genomes Project (1000 Genomes Project Consortium et al., 2010) with other publicly 
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available whole genome sequencing projects, the reference genotypes for rare variants will 
be better established in the future (Asimit and Zeggini, 2010). For example, the UK10K 
project (http://www.uk10k.org/) is another publicly available whole genome sequencing 
dataset that can be used as an LD reference. UK10K has a larger sample size than the 1000 
Genome datasets, and may have better LD structure (Timpson et al., 2014; Taylor et al., 
2015). The novel genotype reference panel for rare variants will provide a good foundation 
for further statistical and bioinformatics analysis, especially for fine mapping of rare variants.  
6.4. Conclusion 
For many complex human traits and diseases (e.g. cardiovascular disease, atopic dermatitis), 
GWAS studies and meta-analysis of multiple GWAS studies have successfully identified 
multiple loci associated with common traits. Using the two methods I developed, we can 
carry out fine mapping in genomic regions with possible secondary signals using 
meta-analysis summary results. As explained in this chapter, future development of this 
work will focus on three aspects: i) Genetic refinement of association signals, fine mapping 
of rare variants will be possible in the near future when we have a fuller understanding of 
haplotype pattern pertaining to rare variants, ii) Phenotypic refinement of association 
signals, improved phenotype definition by increasing the specificity of phenotype (e.g. 
detailed metabolic phenotypes instead of lipid traits) which will increase the power of 
detecting association signals; and iii) Following up association signals with functional 
analysis, since correlated loci are not necessarily a biological agent for disease. Functional 
data, such as expression information and functional annotation, can certainly support and 
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inform the efforts of finding casual signals. New methodologies and approaches in these 
three aspects will improve our understanding of common complex human diseases.  
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CHAPTER 8. APPENDIX 
8.1. Supplementary Notes 
8.1.1. Codes for LiftOver 
The code to run liftOver is as follows: 
liftOver input.bed hg18ToHg19.over.chain.gz output.bed unlifed.bed 
Where input.bed is the input file, hg18ToHg19.over.chain.gz is the chain file and output.bed 
is the output file with SNP information after lift over.  
8.1.2. R codes used for model selection 
methods 
Firstly, I created a data frame called “dataframe”, which contain genotype and phenotype 
information. Then I created a linear model called “linear” using the following code: 
linear <- lm(phenotype~., dataframe) 
The R packages I used for the first four model selection approaches are “leap” and 
“bestglm”. The R codes are:  
1. AIC:  bestglm(dataframe, IC=”AIC”) 
2. BIC:  bestglm(dataframe, IC=”BIC”)  
3. Cross Validation:  bestglm(dataframe, IC=”CV”)  
4. LOOCV:  bestglm(dataframe, IC=”LOOCV”) 
The R package I used for the next two methods is called “leap”. I created a regression model 
using the following code:  
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subset <- regsubsets(y~., dataframe,nvmax=snpno.,really.big=T) 
5. Mallows Cp:  plot(subset, scale=”Cp”) 
6. Adjusted r2:  plot(subset, scale=”adjr2”) 
For the next three methods, I used the basic R code “step” 
7. StepwiseAIC: step(linear, dataframe, direction=”both”, k=2, trace=0) 
8. stepwiseBIC: step(linear, dataframe, direction=”both”, k=log(nrow(dataframe)), 
trace=0) 
9. stepwiseCp:  step(linear, dataframe, direction=”both”, 
scale=(summary(linear)$sigma)^z, trace=0) 
For the last methods, I used the basic linear model “lm” 
10. stepwise regression with p value threshold = 0.05:  
model_0 <- lm (phenotype~., dataframe) 
summary(model_0) and knock out the SNP with highest p value (i.e. snp1) 
model_1 <- update(model_0,~.-snp1) 
summary(model_1)  
 and so on 
Until all reminding SNPs in the model reach the p value threshold of 0.05 
8.1.3. Funding section of the samples 
BWHHS 
BWHHS (British Women's Heart and Health Study). BWHHS is supported by funding from the 
British Heart Foundation and the Department of Health Policy Research Programme 
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(England). We thank the BWHHS data collection team, General Practitioners who helped 
with recruitment of participants and the participants. We thank all of the participants and 
the general practitioners, research nurses, and data management staff who supported data 
collection and preparation. The BWHHS is coordinated by Shah Ebrahim (PI), D.L., and J.-P.C., 
with genotyping funded by the BHF (PG/07/131/24254, PI T.G.). This work was carried out in 
a Centre that receives core funding from the UK Medical Research Council (G0600705) and 
the University of Bristol. 
HapMap 
The USA National Institutes of Health, the National Human Genome Research Institute, the 
National Institute on Deafness and Other Communication Disorders and the Wellcome Trust 
for supporting the majority of this work. Funding was also provided by the Louis-Jeantet 
Foundation and the NCCR ‘Frontiers in Genetics’ (Swiss National Science Foundation). 
1000 Genomes 
This research was supported in part by Wellcome Trust grants WT098051 to R.M.D., M.E.H. 
and C.T.S.; WT090532/Z/09/Z, WT085475/Z/08/Z and WT095552/Z/11/Z to P.Do.; 
WT086084/Z/08/Z andWT090532/Z/09/Z to G.A.M.;WT089250/Z/09/Z to I.M.; 
WT085532AIA to P.F.; Medical Research Council grant G0900747(91070) to G.A.M.; British 
Heart Foundation grant RG/09/12/28096 to C.A.A.; the National Basic Research Program of 
China (973 program no.2011CB809201, 2011CB809202 and 2011CB809203); the Chinese 
863 program (2012AA02A201); the National Natural Science Foundation of China 
(30890032,31161130357); the Shenzhen Key Laboratory of Transomics Biotechnologies 
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(CXB201108250096A); the Shenzhen Municipal Government of China (grants 
ZYC200903240080A and ZYC201105170397A); Guangdong Innovative Research Team 
Program (no. 2009010016); BMBF grant 01GS08201 to H.Le.; BMBF grant 0315428A to R.H.; 
the Max Planck Society; Swiss National Science Foundation 31003A_130342 to E.T.D.; Swiss 
National Science Foundation NCCR ‘Frontiers in Genetics’ grant to E.T.D.; Louis Jeantet 
Foundation grant to E.T.D.; Biotechnology and Biological Sciences Research Council (BBSRC) 
grantBB/I021213/1 to A.R.-L.; German Research Foundation (Emmy Noether Fellowship KO 
4037/1-1) to J.O.K.; Netherlands Organization for Scientific Research VENI grant 
639.021.125 to K.Y.; Beatriu de Pinos Program grants 2006BP-A 10144 and 2009BP-B 00274 
to M.V.; Israeli Science Foundation grant 04514831 to E.H.; Genome Que´bec and the 
Ministry of Economic Development, Innovation and Trade grant PSR-SIIRI-195 to P.Aw.; 
National Institutes of Health (NIH) grants UO1HG5214, RC2HG5581 and RO1MH84698 to 
G.R.A.; R01HG4719 and R01HG3698 to G.T.M; RC2HG5552 and UO1HG6513 to G.R.A. and 
G.T.M.; R01HG4960 and R01HG5701 to B.L.B.; U01HG5715 to C.D.B. and A.G.C.; 32GM8283 
to D.Cl.; U01HG5208 to M.J.D.; U01HG6569 to M.A.D.; R01HG2898 and R01CA166661 
to .E.D.; UO1HG5209, UO1HG5725 and P41HG4221 to C.Le.; P01HG4120 to E.E.E.; 
U01HG5728 to Yu.F.; U54HG3273 and U01HG5211 to R.A.G.; R01HL95045 to S.B.G.; 
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to E.G.B.; RC2HL102925 to S.B.G. and D.M.A.; R01GM59290 to L.B.J. and M.A.B.; 
U54HG3067 to E.S.L. and S.B.G.; T15LM7033 to B.K.M.; T32HL94284 to J.L.R.-F.; DP2OD6514 
and BAA-NIAID-DAIT-NIHAI2009061 to P.C.S.; T32GM7748 to X.S.; U54HG3079 to R.K.W.; 
UL1RR024131 to R.D.H.; HHSN268201100040C to the Coriell Institute for Medical Research; 
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a Sandler Foundation award and an American Asthma Foundation award to E.G.B.; an IBM 
Open Collaborative Research Program award to Y.B.; an A.G. Leventis Foundation 
scholarship to D.K.X.; a Wolfson Royal Society Merit Award to P.Do.; a Howard Hughes 
Medical Institute International Fellowship award to P.H.S.; a grant from T. and V. Stanley to 
S.C.Y.; and a Mary Beryl Patch Turnbull Scholar Program award to K.C.B. E.H. is a faculty 
fellow of the Edmond J. Safra Bioinformatics program at Tel-Aviv University. E.E.E. and D.H. 
are investigators of the Howard Hughes Medical Institute. M.V.G. is a long-term fellow of 
EMBO. 
ALSPAC 
The UK Medical Research Council (Grant ref:74882), the Wellcome Trust (Grant  ref:  
076467), and the University of Bristol provide core support for the Avon Longitudinal  
Study of Parents and their Children (ALSPAC). The Sample Logistics and Genotyping Facilities 
at the Wellcome Trust Sanger Institute and 23andMe generated the ALSPAC GWA data. The 
Wellcome Trust and Swiss National Science Foundation funded the expression data. 
UCLEB 
UCLEB (University College London-London School of Hygiene and Tropical 
Medicine-Edinburgh-Bristol). The UCLEB consortium is funded by a British Heart Foundation 




The following parent studies, funded by the listed National Institutes of Health grants, have 
contributed parent study data, ancillary study data, and DNA samples through the Broad 
Institute (N01-HC-65226) to create this genotype/phenotype database for wide 
dissemination to the biomedical research community: Atherosclerotic Risk in Communities: 
University of North Carolina at Chapel Hill (N01-HC-55015, N01-HC-55018). 
GIANT 
US National Institutes of Health grants CA65725, CA87969, CA49449, CA67262, CA50385, 
DK062370, DK072193, DK075787, HG02651, HL084729, HL087679 (through STAMPEED, 
1RL1MH083268), 5UO1CA098233, 1Z01 HG000024, 1RL1MH083268, T32 DK07191, F32 
DK079466, K23 DK080145, K23 DK067288, CIDR NIH Contract Number N01-HG-65403, NIA 
contract NO1-AG-1-2109; the Intramural Research Program of the Division of Cancer 
Epidemiology and Genetics; contracts from the Division of Cancer Prevention, National 
Cancer Institute and EU FP6 funding (contract no LSHM-CT-2003-503041); GlaxoSmithKline; 
the Faculty of Biology and Medicine of Lausanne, Switzerland; the Intramural Research 
Program of the National Institute on Aging (NIA); Cancer Research United Kingdom; the UK 
Medical Research Council (including grants G0000649, G0000934 and G0601261); the 
Wellcome Trust (including Strategic Award 076113, grants 068545/Z/02 and 
076467/Z/05/Z); the NIHR through the Biomedical Research Centres at Oxford, King's 
College London; Guys and St. Thomas' Foundation Hospitals' Trust; the British Heart 
Foundation (including grant FS/05/061/19501), European Community's Seventh Framework 
Programme (ENGAGE:HEALTH-F4-2007-201413); Diabetes UK; Unilever Corporate Research; 
American Diabetes Association including a Smith Family Foundation Pinnacle Program 
Project Award #7-03-PPG-04R; the Academy of Finland (grants 118065 and 124243); 
National Genome Research Net Germany; Munich Center of Health Sciences (MC Health) as 
part of LMUinnovativ; the Helmholtz Center Munich; the Sigrid Juselius Foundation; 
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University of Bristol; Linné grant from Swedish Research Council; Wallenberg Foundation; 
Folkhälsan Research Foundation; University of Southampton; Netherlands Organisation of 
Scientific Research NWO (nr. 175.010.2005.011); Erasmus Medical Center and Erasmus 
University, Rotterdam; Netherlands Organization for the Health Research and Development 
(ZonMw); the Research Institute for Diseases in the Elderly (RIDE); the Netherlands Ministry 
of Education, Culture and Science; the Netherlands Ministry for Health, Welfare and Sports; 
the European Commision (DG XII) and the Municipality of Rotterdam. G.R.A. and K.L.M. are 
Pew Scholars for the Biomedical Sciences; A.L.E. is supported by a Sarnoff Cardiovascular 
Research Foundation Fellowship; C.M.L. is a Nuffield Department of Medicine Scientific 
Leadership Fellow; S.A.M. is supported by a Life Sciences Research Fellowship; M.K. is 
supported by the Finnish Cultural Foundation; N.J.S. holds a BHF Chair; M.N.W. is a 
Vandervell Foundation Research Fellow; C.J.W. is supported by an American Diabetes 
Association postdoctoral fellowship; and E.Z. is a Wellcome Trust-RD Fellow (grant number 
079557). 
8.2. Supplementary Tables 
rs ID Gene related traits BP p value beta SE A1 A2 MAF 
rs301 LPL TG 19861214 0.000315 -0.14132 0.029565 G A 0.2334 
rs320 LPL TG 19863357 0.000167 -0.13672 0.028204 C A 0.2665 
rs327 LPL TG 19863816 0.000211 -0.13304 0.028075 C A 0.2709 
rs328 LPL TG 19864004 6.60E-05 -0.23155 0.042525 G C 0.09638 
rs331 LPL TG 19864685 0.000228 -0.1378 0.028386 A G 0.2608 
rs12679834 LPL TG 19864713 7.30E-05 -0.22967 0.042504 G A 0.09654 
rs3208305 LPL TG 19867928 0.000179 -0.13575 0.027777 T A 0.2819 
rs3735964 LPL TG 19868325 3.23E-05 -0.22732 0.041032 A C 0.1033 
rs13702 LPL TG 19868772 0.000244 -0.13271 0.027704 G A 0.283 
rs17482753 LPL TG 19876926 8.99E-05 -0.22475 0.042387 A C 0.09685 
rs263 LPL HDL-C 19857092 9.61E-05 0.127327 0.033651 A G 0.1682 
rs320 LPL HDL-C 19863357 2.56E-06 0.127149 0.028236 C A 0.2665 
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rs327 LPL HDL-C 19863816 2.16E-06 0.126428 0.028103 C A 0.2709 
rs328 LPL HDL-C 19864004 7.80E-06 0.179427 0.042637 G C 0.09638 
rs331 LPL HDL-C 19864685 1.08E-06 0.131653 0.028414 A G 0.2608 
rs12679834 LPL HDL-C 19864713 8.11E-06 0.179219 0.042613 G A 0.09654 
rs3208305 LPL HDL-C 19867928 3.05E-07 0.135128 0.027797 T A 0.2819 
rs3735964 LPL HDL-C 19868325 8.40E-06 0.174595 0.041142 A C 0.1033 
rs13702 LPL HDL-C 19868772 2.81E-07 0.135123 0.02772 G A 0.283 
rs17482753 LPL HDL-C 19876926 1.23E-05 0.175461 0.042493 A C 0.09685 
rs12708967 CETP HDL-C 55550712 7.31E-08 -0.17187 0.033029 G A 0.1834 
rs3764261 CETP HDL-C 55550825 2.41E-19 0.251125 0.027175 A C 0.3318 
rs12720918 CETP HDL-C 55551713 2.74E-08 -0.1521 0.028181 G A 0.2272 
rs17231506 CETP HDL-C 55552029 6.07E-19 0.249239 0.027296 G A 0.2774 
rs1800775 CETP HDL-C 55552737 5.09E-11 0.174275 0.025822 A C 0.4913 
rs711752 CETP HDL-C 55553712 1.97E-11 0.182519 0.026059 A G 0.4376 
rs708272 CETP HDL-C 55553789 1.67E-11 0.182834 0.026028 A G 0.4377 
rs1864163 CETP HDL-C 55554734 1.31E-11 -0.19809 0.029044 A G 0.258 
rs11508026 CETP HDL-C 55556829 4.95E-11 0.179469 0.026061 A G 0.4379 
rs12720922 CETP HDL-C 55558386 6.87E-12 -0.22576 0.033227 A G 0.1807 
rs9939224 CETP HDL-C 55560233 6.36E-11 -0.20887 0.031698 A C 0.2044 
rs1532625 CETP HDL-C 55562802 1.93E-12 0.18948 0.025966 A G 0.4448 
rs1532624 CETP HDL-C 55562980 1.76E-12 0.1897 0.025959 A C 0.4446 
rs11076175 CETP HDL-C 55563879 1.76E-11 -0.22426 0.033539 G A 0.175 
rs7499892 CETP HDL-C 55564091 1.51E-11 -0.22431 0.0335 A G 0.175 
rs11076176 CETP HDL-C 55564947 3.81E-07 -0.16652 3.36E-02 C A 0.1708 
rs289714 CETP HDL-C 55564952 6.75E-06 -0.14556 0.033076 G A 0.1784 
Table 8-1A. Significant SNPs for lipids traits in BWHHS individual level data. Beta is 
standardized by Z score: Z = (beta – mean of beta) / SD of beta  
rs ID Gene related traits BP p value beta SE A1 A2 MAF 
rs4657139 NOS1AP QTC  160296531 1.43E-05 0.132798 0.028522 A T 0.3382 
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rs10918594 NOS1AP QTC  160297312 2.67E-06 0.148328 0.028922 C G 0.32295 
rs16847548 NOS1AP QTC  160301898 7.57E-09 0.199317 0.033488 G A 0.20365 
rs6702936 NOS1AP QTC  160303783 7.60E-05 0.134953 0.030263 G A 0.28235 
rs10918602 NOS1AP QTC  160304324 5.95E-05 0.145625 0.030414 G A 0.27585 
rs10800279 NOS1AP QTC  160304902 1.88E-05 0.142141 0.030371 G A 0.2768 
rs1415257 NOS1AP QTC  160328668 4.42E-05 0.11301 0.028231 G A 0.3483 
rs11579850 NOS1AP QTC  160333846 3.36E-05 0.112479 0.028182 C A 0.34905 
rs10494365 NOS1AP QTC  160350613 2.41E-06 0.19626 0.042214 C G 0.1154 
rs10494366 NOS1AP QTC  160352309 4.66E-05 0.112812 0.028241 C A 0.3487 
rs12733821 NOS1AP QTC  160353315 3.33E-05 0.118197 0.028416 G C 0.3438 
rs4657154 NOS1AP QTC  160374743 7.54E-05 0.11784 0.030417 A G 0.26455 
rs1932933 NOS1AP QTC  160384670 6.42E-05 0.116762 0.028077 A G 0.3524 
rs945708 NOS1AP QTC  160385526 6.35E-05 0.121033 0.02806 A G 0.3556 
rs7534004 NOS1AP QTC  160413333 2.36E-09 0.221772 0.037865 A G 0.15135 
rs12039600  NOS1AP QTC  160426106 3.42E-09 0.256379 0.042757 A G 0.11575 
rs4657166 NOS1AP QTC  160427963 7.96E-06 0.12918 0.029425 C G 0.30135 
rs10918859 NOS1AP QTC  160435892 2.89E-07 0.181159 0.035478 A G 0.1802 
rs10800352 NOS1AP QTC  160439313 2.60E-07 0.171028 0.032977 G A 0.21555 
rs6664702 NOS1AP QTC  160471531 3.30E-06 0.14518 0.031613 G A 0.2444 
rs10399680 NOS1AP QTC  160480119 1.86E-06 0.151172 0.031224 G A 0.2552 
rs6427664 NOS1AP QTC  160481097 7.15E-07 0.161283 0.031781 A G 0.2435 
rs7522678  NOS1AP QTC  160487168 2.05E-06 0.162986 0.03369 A C 0.201 
rs10919035 NOS1AP QTC  160510636 3.38E-05 0.16676 0.039938 A G 0.1357 
rs12053903    SCN5A PR interval 38568397 0.000971 0.092152 0.028258 G     A        0.3177 
rs10154914      SCN5A PR interval 38607634 0.002144 -0.09657 0.033078 A     T        0.19625 
rs7374540    SCN5A PR interval 38609146 0.00347 0.077644 0.02672 C     A         0.3872 
rs1805124    SCN5A PR interval 38620424 0.008284 -0.07446 0.030758 G     A        0.2386 
rs13084981    SCN5A PR interval 38621003 0.003756 0.125451 0.042554 A     G        0.109 
rs7372712    SCN5A PR interval 38661196 0.001374 0.100148 0.033059 A     G        0.19695 
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rs7374540 SCN5A QRS duration 38609146 0.00023 0.100261 0.026201 C A 0.3849 
rs9861242 SCN5A QRS duration 38584338 0.000387 0.122806 0.029793 A G 0.24415 
rs1805126 SCN5A QRS duration 38567410 0.000849 0.099815 0.027581 G A 0.32195 
rs10154914 SCN5A QRS duration 38607634 0.000907 -0.11625 0.032319 A T 0.1987 
rs9833086 SCN5A QRS duration 38585475 0.001754 0.103007 0.028261 G A 0.279 
rs7624535 SCN5A QRS duration 38640206 0.002231 -0.09719 0.031806 C A 0.2022 
rs12053903 SCN5A QRS duration 38568397 0.003086 0.087244 0.027786 G A 0.31575 
rs11710077 SCN5A QRS duration 38632903 0.003849 -0.10804 0.031893 A T 0.2097 
rs12491987 SCN5A QRS duration 38624048 0.00536 -0.10805 0.043181 A G 0.1018 
Table 8-1B. Significant SNPs for ECG traits in BWHHS individual level data. Effect sizes are 
shown as beta estimates from linear regression models for increasing copy of the coded 
allele and are on the standard deviation scale. 
Chr Position Gene lead SNP Risk Allele beta p-Value 
1 40433771 MFSD2 rs3103778 G 6.3 9.00E-06 
2 66756976 MEIS1 rs3891585 A 2.13 1.00E-11 
2 66772000 MEIS1 rs11897119 C 1.36 5.00E-11 
2 215341890 VWC2L rs7604827 C 6.54 5.00E-06 
3 37574024 ITGA9 rs267567 A 2.73 4.00E-11 
3 38624253 SCN5A rs3922844 T 4.54 5.00E-43 
3 38633923 SCN5A rs11708996 C 3.04 6.00E-26 
3 38681394 SCN5A rs6763048 A 2.62 4.00E-12 
3 38767315 SCN10A rs6801957 T 3.36 9.00E-09 
3 38774832 SCN10A rs6800541 C 3.77 2.00E-74 
3 65486388 MAGI1 rs1524976 A 8 8.00E-06 
3 187456709 BCL6 rs3733017 G 10.07 6.00E-06 
4 86641149 ARHGAP24 rs7692808 A 2.01 6.00E-20 
4 86683560 ARHGAP24 rs11732231 C 2.28 3.00E-09 
5 172480336 NKX2-5, C5orf41 rs251253 C 1.49 9.00E-13 
6 130550063 Intergenic rs10447419 A 8.65 2.00E-06 
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7 116186241 CAV1, CAV2 rs3807989 A 2.3 4.00E-28 
7 116191301 CAV1 rs11773845 A 2.29 4.00E-12 
10 26294828 MYO3A rs16926523 A 9.55 4.00E-06 
11 12159661 MICAL2 rs1994318 A 6.79 2.00E-06 
11 75909619 WNT11 rs4944092 G 1.19 3.00E-08 
12 24788339 SOX5, C12orf67 rs11047543 A 2.09 3.00E-13 
12 114802138 TBX5 rs1895585 A 3.19 1.00E-19 
12 115346424 TBX5, TBX3 rs1896312 C 1.95 3.00E-17 
15 39573535 Intergenic rs12595668 G 6.26 9.00E-06 
15 39576560 Intergenic rs746265 C 6.27 8.00E-06 
Table 8-2. Previous GWAS findings of PR interval 
Chr Position Gene lead SNP Risk Allele beta p-Value 
1 185794883 HMCN1 rs13375391 A 5.82 9.00E-06 
4 100137494 ADH6;LOC100507053 rs6820368 C 9.9 6.00E-06 
5 101403586 OR7H2P - SLCO4C1 rs6861497 A 2.34 5.00E-06 
6 124951063 NKAIN2 rs504008 C 2.7 3.00E-06 
6 128194473 THEMIS rs12194062 T 5.16 5.00E-06 
11 67715028 RPS3AP40 - OR7E1P rs308309 C 4.39 5.00E-06 
12 69523923 CPM - CPSF6 rs10784762 T 2.38 6.00E-06 
14 85737169 RNU7-51P - RNU3P3 rs1867082 A 2.82 1.00E-06 
16 85961562 IRF8 - FENDRR rs17444745 A 6.4 7.00E-06 
Table 8-3. Previous GWAS findings of QRS interval 
Chr Position Gene lead SNP Risk Allele beta p-Value 
1 6279370 RNF207 rs846111 C 1.75 1.00E-16 
1 162033890 OLFML2B - MIR4654 rs12143842 T 3.15 2.00E-78 
1 162085685 NOS1AP rs10494366 ? 4.9 1.00E-10 
1 162112910 NOS1AP rs16857031 G 2.63 1.00E-34 
1 162133117 NOS1AP rs12029454 A 2.98 3.00E-45 
1 162195738 NOS1AP rs4657175 ? 1.71 1.00E-09 
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1 162210610 NOS1AP rs4657178 T 2.19 7.00E-33 
1 169073346 RPL29P7 - ATP1B1 rs1320976 A 2.06 2.00E-10 
1 169099483 ATP1B1 rs10919071 A 2.05 1.00E-15 
2 40757791 SLC8A1 - LDHAP3 rs13017846 G 0.07 8.00E-14 
2 46176962 PRKCE rs6751349 A 1.22 8.00E-06 
2 179248420 OSBPL6 rs7580640 C 3.64 3.00E-06 
3 3147981 IL5RA rs17879755 C 5.64 2.00E-06 
3 8250790 GRM7 - LMCD1-AS1 rs9866825 A 1.18 8.00E-06 
3 38589163 SCN5A rs11129795 A 1.27 5.00E-14 
3 38593393 SCN5A rs12053903 C 1.23 1.00E-14 
3 71115751 FOXP1 rs7616330 A 1.72 6.00E-06 
3 73540618 PDZRN3 rs4557101 C 1.72 4.00E-06 
4 15964863 FGFBP2 rs4698433 T 7.23 6.00E-06 
4 16893893 LDB2 rs1483012 G 6.02 7.00E-06 
4 16908004 LDB2 - MTND5P4 rs6819013 A 6.06 6.00E-06 
4 27194071 STIM2 - MRPL51P1 rs13149020 A 10.69 8.00E-06 
4 72126889 SLC4A4 rs2579330 C 1.36 1.00E-06 
4 76030921 PARM1 - RCHY1 rs1426063 A 1.18 8.00E-06 
4 95643957 PDLIM5 - BMPR1B rs10027628 C 1.81 6.00E-06 
5 3092192 C5orf38 - IRX1 rs6873793 C 1.47 1.00E-06 
5 64417678 CWC27 - RPEP1 rs7729539 C 2.59 1.00E-06 
5 73276903 ARHGEF28 - ENC1 rs6894385 C 9.92 1.00E-06 
5 102759658 C5orf30 - NUDT12 rs17155315 G 4.73 7.00E-06 
5 126032964 RPLP1P7 - LMNB1 rs1546498 C 7.69 2.00E-06 
6 67885919 NUFIP1P - BAI3 rs9342616 A 6.92 1.00E-06 
6 118653204 SLC35F1 - BRD7P3 rs12210810 C 3.13 2.00E-17 
6 118680374 SLC35F1 - BRD7P3 rs11970286 T 1.64 2.00E-24 
6 118788652 CEP85L rs11752626 G 1.56 2.00E-06 
6 118993632 CEP85L rs11756438 A 1.4 5.00E-22 
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7 100881403 CLDN15 rs3757458 A 8 2.00E-06 
7 150622162 ABP1 - KCNH2 rs2968864 C 1.4 8.00E-16 
7 150623137 ABP1 - KCNH2 rs2968863 T 1.35 2.00E-15 
7 150637863 ABP1 - KCNH2 rs4725982 T 1.58 5.00E-16 
7 150669976 KCNH2 rs3778872 C 1.77 3.00E-06 
7 154509324 DPP6 - PAXIP1 rs12666280 C 8.93 2.00E-06 
10 30834632 HNRNPA1P32 - LYZL2 rs11008099 A 2.74 9.00E-06 
11 2484803 KCNQ1 rs2074238 T 7.88 3.00E-17 
11 2486120 KCNQ1 rs16928297 G 1.25 2.00E-06 
11 2489342 KCNQ1 rs12296050 T 1.44 3.00E-17 
11 2502319 KCNQ1 rs12576239 T 1.75 1.00E-15 
11 2752609 KCNQ1 rs231906 A 1.51 2.00E-06 
13 63436800 RPL32P28 - OR7E156P rs2204037 A 1.38 5.00E-07 
13 102553248 FGF14 rs9557754 G 1.23 8.00E-06 
15 50873344 TRPM7 rs2414059 A 1.24 2.00E-06 
16 8503222 RPS26P51 - TMEM114 rs8045405 G 11.38 9.00E-06 
16 11691753 LITAF - SNN rs8049607 T 1.23 5.00E-15 
16 58566304 CNOT1 rs37060 ? 1.52 1.00E-07 
16 58567238 CNOT1 rs37062 G 1.75 3.00E-25 
16 58622178 CNOT1 rs7188697 A 1.66 7.00E-25 
17 15193056 MIR4731 - TEKT3 rs1380181 A 1.97 3.00E-07 
17 33324382 LIG3 rs2074518 T 1.05 6.00E-12 
17 68494992 CALM2P1 - SOX9 rs17779747 T 1.02 6.00E-12 
18 74735135 MBP rs11663697 G 13.71 9.00E-06 
20 47982128 ZFAS1 - KCNB1 rs237450 A 6.86 5.00E-06 
21 37935669 CLDN14 rs9984896 A 2.85 5.00E-06 
Table 8-4 A. Previous GWAS findings of QTc interval. QTc = QT / SQRT (RR interval) 
 
Chr Position Gene lead SNP Risk Allele beta p-Value 
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1 162014632 OLFML2B - MIR4654 rs2880058 G 0.19 2.00E-10 
1 162033890 OLFML2B - MIR4654 rs12143842 T 0.18 1.00E-83 
2 157552860 GPD2 - RPLP0P7 rs7601713 A 0.16 2.00E-06 
2 179641975 TTN rs12476289 A 0.29 2.00E-06 
3 61794054 PTPRG rs652889 A 0.15 8.00E-07 
3 122368347 PARP15 - EIF4BP8 rs2650951 A 0.29 1.00E-06 
3 194327098 TMEM44 rs789852 A 0.25 7.00E-07 
4 35410631 RPL31P31 - SEC63P2 rs1533317 A 0.14 2.00E-06 
4 118332255 TRAM1L1 - RPSAP35 rs4318720 A 0.28 8.00E-07 
4 148974602 ARHGAP10 rs6845865 G 0.19 7.00E-07 
5 5897694 KIAA0947 - HMGB3P3 rs7728043 G 0.14 1.00E-06 
6 118667522 SLC35F1 - BRD7P3 rs11153730 C 0.09 2.00E-29 
7 37076854 ELMO1 rs10488031 A 0.26 2.00E-06 
12 20531756 PDE3A rs1348582 G 0.2 1.00E-06 
13 48162558 GNG5P5 - NAP1L4P3 rs2478333 A 0.17 4.00E-08 
14 96122408 TCL6 rs8015016 G 0.18 5.00E-07 
Table 8-4 B. Previous GWAS findings of QT interval. Betas were calculated using unadjusted 
QT interval. 
rs ID Gene related traits BP p value beta SE Ancestral allele 
rs12039600 NOS1AP QTC 160426106 7.12E-23 0.256379 0.042757 G 
rs7534004 NOS1AP QTC 160413333 7.89E-22 0.221772 0.037865 G 
rs10918859 NOS1AP QTC 160435892 3.48E-20 0.181159 0.035478 G 
rs10800352 NOS1AP QTC 160439313 6.12E-20 0.171028 0.032977 A 
rs10918594 NOS1AP QTC 160297312 4.49E-18 0.148328 0.028922 C 
rs7522678 NOS1AP QTC 160487168 5.44E-18 0.162986 0.03369 C 
rs4657139 NOS1AP QTC 160296531 3.80E-17 0.132798 0.028522 A 
rs6664702 NOS1AP QTC 160471531 1.28E-16 0.14518 0.031613 T 
rs12733821 NOS1AP QTC 160353315 4.92E-16 0.118197 0.028416 C 
rs10494366 NOS1AP QTC 160352309 1.70E-15 0.112812 0.028241 T 
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rs11579850 NOS1AP QTC 160333846 3.66E-15 0.112479 0.028182 G 
rs1415257 NOS1AP QTC 160328668 4.10E-15 0.11301 0.028231 C 
rs1415262 NOS1AP QTC 160312759 1.07E-14 0.094877 0.028348 C 
rs5000342 NOS1AP QTC 160319684 1.24E-14 0.103484 0.029562 A 
rs945708 NOS1AP QTC 160385526 1.50E-14 0.121033 0.02806 T 
rs1932933 NOS1AP QTC 160384670 1.69E-14 0.116762 0.028077 T 
rs6660701 NOS1AP QTC 160307530 2.28E-14 0.11512 0.028491 C 
rs4657166 NOS1AP QTC 160427963 1.26E-13 0.12918 0.029425 C 
rs880296 NOS1AP QTC 160395070 1.63E-13 0.137104 0.033702 C 
rs4233385 NOS1AP QTC 160314369 1.63E-13 0.0956 0.02914 C 
rs10918762 NOS1AP QTC 160385608 1.96E-13 0.136572 0.033563 A 
rs4657154 NOS1AP QTC 160374743 5.03E-12 0.11784 0.030417 N/A 
rs7515045 NOS1AP QTC 160310334 2.00E-11 0.097078 0.030498 C 
rs6427664 NOS1AP QTC 160481097 2.97E-10 0.161283 0.031781 G 
rs6702936 NOS1AP QTC 160303783 3.06E-10 0.134953 0.030263 A 
rs4531275 NOS1AP QTC 160453174 2.08E-09 0.082086 0.029558 C 
rs6659759 NOS1AP QTC 160304233 3.26E-09 0.133713 0.030227 T 
rs12128479 NOS1AP QTC 160534747 3.33E-09 0.156116 0.046353 A 
rs10800366 NOS1AP QTC 160470520 4.75E-09 0.075289 0.029399 C 
rs10800397 NOS1AP QTC 160503714 1.14E-08 0.049591 0.033375 C 
rs10918602 NOS1AP QTC 160304324 1.16E-08 0.145625 0.030414 T 
rs10458392 NOS1AP QTC 160358734 1.47E-08 0.112882 0.033224 N/A 
rs10399680 NOS1AP QTC 160480119 1.57E-08 0.151172 0.031224 T 
rs3923368 NOS1AP QTC 160463154 3.10E-08 0.061292 0.028797 T 
rs10800404 NOS1AP QTC 160521736 3.26E-08 0.053004 0.033504 G 
rs16860185 NOS1AP QTC 160560694 6.37E-08 0.150212 0.044952 G 
rs7513132 NOS1AP QTC 160432057 7.03E-08 0.080609 0.028532 A 
rs10800279 NOS1AP QTC 160304902 7.03E-08 0.142141 0.030371 T 
rs10918936 NOS1AP QTC 160469112 7.57E-08 0.073848 0.028029 A 
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rs16857031 NOS1AP QTC 160379534 8.78E-08 0.101452 0.037934 C 
rs10800409 NOS1AP QTC 160527339 1.23E-07 0.156484 0.039781 C 
rs16847548 NOS1AP QTC 160301898 1.34E-07 0.199317 0.033488 T 
rs4657161 NOS1AP QTC 160422913 1.81E-07 0.065083 0.027944 G 
rs12135795 NOS1AP QTC 160416389 1.98E-07 0.065083 0.027944 A 
rs3927640 NOS1AP QTC 160422437 2.71E-07 0.065326 0.027953 A 
rs10753765 NOS1AP QTC 160418397 3.86E-07 0.06545 0.027937 G 
rs4557949 NOS1AP QTC 160477578 4.44E-07 0.047958 0.027479 A 
rs12734991 NOS1AP QTC 160461200 4.65E-07 0.066225 0.027712 C 
rs12026452 NOS1AP QTC 160396910 6.12E-07 0.129928 0.039262 G 
rs12022557 NOS1AP QTC 160322208 6.64E-07 0.086869 0.032799 G 
rs10918615 NOS1AP QTC 160316051 7.21E-07 0.084062 0.03284 G 
rs4145621 NOS1AP QTC 160485312 1.44E-06 0.041182 0.027544 C 
rs12742393 NOS1AP QTC 160491210 1.95E-06 0.047436 0.027862 A 
rs2661818 NOS1AP QTC 160531438 2.35E-06 0.043966 0.027617 C 
rs10919035 NOS1AP QTC 160510636 3.32E-06 0.16676 0.039938 C 
rs7540690 NOS1AP QTC 160380841 1.08E-05 0.116906 0.033688 G 
rs4298709 NOS1AP QTC 160503206 1.19E-05 0.040409 0.027957 G 
rs12729882 NOS1AP QTC 160508661 1.45E-05 0.037635 0.027877 A 
rs12733377 NOS1AP QTC 160519067 2.60E-05 0.035871 0.027888 G 
rs16857019 NOS1AP QTC 160379274 8.82E-05 0.098496 0.045361 G 
rs7372712 SCN5A PR interval 38661196 6.21E-10 0.00302 0.000488 C 
rs12053903 SCN5A PR interval 38568397 4.59E-09 0.002158 0.000368 C 
rs7374540 SCN5A PR interval 38609146 9.50E-08 0.001864 0.000349 A 
rs1805126 SCN5A PR interval 38567410 2.07E-06 0.001745 0.000368 A 
rs7624535 SCN5A PR interval 38640206 4.33E-06 -0.00194 0.000421 T 
rs6768664 SCN5A PR interval 38659470 4.75E-06 -0.00156 0.00034 A 
rs7373102 SCN5A PR interval 38655632 5.32E-06 -0.00155 0.00034 C 
rs7374540 SCN5A QRS  38609146 5.87E-09 0.100261 0.026201 A 
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rs9861242 SCN5A QRS  38584338 1.59E-08 0.122806 0.029793 A 
rs1805126 SCN5A QRS  38567410 6.93E-08 0.099815 0.027581 A 
rs11710077 SCN5A QRS  38632903 1.80E-07 -0.10804 0.031893 A 
rs9833086 SCN5A QRS  38585475 2.05E-07 0.103007 0.028261 A 
rs12053903 SCN5A QRS  38568397 1.97E-06 0.087244 0.027786 C 
rs6797133 SCN5A QRS  38631037 8.73E-06 -0.05357 0.026626 G 
rs7624535 SCN5A QRS  38640206 5.17E-05 -0.09719 0.031806 T 
rs9832895 SCN5A QRS  38636537 5.60E-05 -0.02167 0.025544 C 
rs7373102 SCN5A QRS  38655632 6.45E-05 -0.05577 0.025538 C 
Table 8-5. Significant SNPs for ECG traits in meta-analysis 
Marker Name Allele1 Allele2 beta SE P-value 
rs4953023 a g 0.7003 0.0542 3.87E-38 
rs10439467 t c 0.4272 0.0585 2.81E-13 
rs4148191 a c 0.511 0.0759 1.61E-11 
rs4953019 a g 0.3652 0.0544 1.84E-11 
rs6720173 c g 0.2636 0.0407 9.75E-11 
rs2278357 t c 0.2424 0.0406 2.30E-09 
rs6756629 a g 0.5371 0.0966 2.71E-08 
rs4148189 t c 0.2521 0.0465 5.96E-08 
rs4299376 t g 0.194 0.0359 6.44E-08 
rs10208987 t g -0.2704 0.0527 2.90E-07 
rs4077440 a g -0.2483 0.0526 2.38E-06 
rs6709904 a g -0.3612 0.0779 3.58E-06 
rs10201851 t c -0.2083 0.046 6.04E-06 
Table 8-6. The significant SNPs of the GBD meta-analysis. 
rsID Locus lipids effect size CA effect size  direction leading trait  CA p value MAF proxy r2 with proxy 
rs1084651 LPA 1.95 0.0443 same direction HDL 0.2921 0.16 (A) (A) 
rs11869286 STARD3 -0.48 -0.0176 same direction HDL 0.5955 0.34 (A) (A) 
rs12967135 MC4R -0.42 0.0333 opposite direction HDL 0.5422 0.23 rs1943226 0.188 
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rs1532085 LIPC 1.45 -0.1122 opposite direction HDL 0.03656 0.39 (A) (A) 
rs16942887 LCAT 1.27 -0.0259 opposite direction HDL 0.7018 0.12 rs2292318 0.915 
rs1800961 HNF4A -1.88 0.1497 opposite direction HDL 0.0848 0.03 (A) (A) 
rs1883025 ABCA1 -0.94 0.0031 opposite direction HDL 0.9312 0.25 (A) (A) 
rs2652834 LACTB -0.39 0.0507 opposite direction HDL 0.1896 0.2 rs11071721 0.442 
rs2972146 IRS1 0.46 0.0329 same direction HDL 0.3256 0.37 rs2943634 0.774 
rs3136441 LRP4 0.78 -0.0428 opposite direction HDL 0.3594 0.15 rs2070850 1 
rs3764261 CETP 3.39 0.0259 same direction HDL 0.444 0.32 (A) (A) 
rs386000 LILRA3 0.83 -0.0491 opposite direction HDL 0.2069 0.2 rs103294 0.832 
rs4129767 PGS1 -0.39 -0.0364 same direction HDL 0.2487 0.49 rs4082919 0.967 
rs4846914 GALNT2 -0.61 -0.0608 same direction HDL 0.05724 0.4 (A) (A) 
rs6065906 PLTP -0.93 0.071 opposite direction HDL 0.07487 0.18 rs6073952 0.877 
rs7134375 PDE3A 0.4 0.0187 same direction HDL 0.5553 0.42 rs10841495 0.243 
rs7134594 MVK -0.44 0.0057 opposite direction HDL 0.9127 0.47 (A) (A) 
rs7241918 LIPG -1.31 -0.0521 same direction HDL 0.2255 0.17 rs2156552 0.948 
rs7255436 ANGPTL4 -0.45 -0.036 same direction HDL 0.253 0.47 rs2278236 1 
rs838880 SCARB1 0.61 -0.0323 opposite direction HDL 0.352 0.31 rs838878 0.961 
rs11220462 ST3GAL4 1.95 -0.0629 opposite direction LDL 0.2014 0.14 rs8177375 0.121 
rs1367117 APOB 4.05 -0.0311 opposite direction LDL 0.358 0.3 (A) (A) 
rs1800562 HFE -2.22 0.016 opposite direction LDL 0.801 0.06 (A) (A) 
rs2479409 PCSK9 2.01 0.0776 same direction LDL 0.02155 0.3 (A) (A) 
rs3757354 MYLIP -1.43 -0.0129 same direction LDL 0.8653 0.22 rs7770341 0.157 
rs4299376 ABCG5/8 2.75 0.194 same direction LDL 6.44E-08 0.3 (A) (A) 
rs4420638 APOE 7.14 0.0002 same direction LDL 0.9977 0.17 (A) (A) 
rs6029526 TOP1 1.39 -0.0186 opposite direction LDL 0.5594 0.47 rs753381 0.818 
rs629301 SORT1 -5.65 -0.0196 same direction LDL 0.7141 0.22 (A) (A) 
rs6511720 LDLR -6.99 -0.0318 same direction LDL 0.5239 0.11 (A) (A) 
rs7206971 OSBPL7 0.78 0.0457 same direction LDL 0.1569 0.49 rs7214993 0.493 
rs8017377 NYNRIN 1.14 0.0315 same direction LDL 0.4356 0.47 rs6573766 0.118 
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rs10128711 SPTY2D1 -1.04 -0.0163 same direction TC 0.6457 0.28 rs11024739 1 
rs10401969 CILP2 -4.74 -0.0488 same direction TC 0.6094 0.07 (A) (A) 
rs11065987 BRAP -0.96 0.0334 opposite direction TC 0.2933 0.42 rs17696736 0.696 
rs1169288 HNF1A 1.42 0.045 same direction TC 0.4132 0.33 (A) (A) 
rs12027135 LDLRAP1 -1.22 -0.0305 same direction TC 0.5597 0.45 (A) (A) 
rs12916 HMGCR 2.84 0.0003 same direction TC 0.9914 0.39 (A) (A) 
rs2000999 HPR 2.34 0.0878 same direction TC 0.02439 0.2 (A) (A) 
rs2072183 NPC1L1 2.01 -0.0326 opposite direction TC 0.3871 0.25 (A) (A) 
rs2081687 CYP7A1 1.23 0.0976 same direction TC 0.003077 0.35 rs8192870 0.925 
rs2290159 RAF1 -1.42 -0.0382 same direction TC 0.3466 0.22 rs9817675 0.857 
rs2902940 MAFB -1.38 0.0111 opposite direction TC 0.7313 0.29 rs6029247 0.108 
rs3177928 HLA 2.31 -0.0547 opposite direction TC 0.2847 0.16 rs17496549 0.646 
rs492602 FLJ36070 1.27 -0.063 opposite direction TC 0.2218 0.49 (A) (A) 
rs6882076 TIMD4 -1.98 0.0602 opposite direction TC 0.2622 0.35 (A) (A) 
rs1042034  -5.99 -0.0172 same direction TG 0.6511 0.22 (A) (A) 
rs11613352 LRP1 -2.7 -0.045 same direction TG 0.2571 0.23 rs11172134 0.802 
rs11649653 CTF1 -2.13 -0.0179 same direction TG 0.5786 0.4 (A) (A) 
rs11776767 PINX1 2.01 -0.0367 opposite direction TG 0.249 0.37 rs4841317 0.125 
rs1260326 GCKR 8.76 -0.123 opposite direction TG 0.0001345 0.41 (A) (A) 
rs12678919 LPL -13.64 0.0592 opposite direction TG 0.5069 0.12 (A) (A) 
rs1495741 NAT2 2.85 -0.0047 opposite direction TG 0.893 0.22 rs1961456 0.524 
rs17145738 MLXIPL -9.32 0.0747 opposite direction TG 0.1188 0.12 (A) (A) 
rs174546 FADS1-2-3 3.82 0.0526 same direction TG 0.3409 0.34 (A) (A) 
rs2068888 CYP26A1 -2.28 -0.0309 same direction TG 0.3302 0.46 rs4418728 1 
rs2131925 ANGPTL3 -4.94 0.0662 opposite direction TG 0.04468 0.32 rs1748197 1 
rs2247056  -2.99 -0.004 same direction TG 0.8998 0.25 rs2523589 0.563 
rs2929282 FRMD5 5.13 -0.0737 opposite direction TG 0.1577 0.05 rs10438303 0.237 
rs2954029 TRIB1 -5.64 -0.0283 same direction TG 0.3696 0.47 (A) (A) 
rs439401  -5.5 0.0116 opposite direction TG 0.7225 0.36 (A) (A) 
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rs442177 KLHL8 -2.25 -0.0484 same direction TG 0.1333 0.41 rs3775214 0.964 
rs5756931 PLA2G6 -1.54 0.0932 opposite direction TG 0.004772 0.4 rs4820314 0.802 
rs645040 MSL2L1 -2.22 -0.0516 same direction TG 0.3991 0.22 (A) (A) 
rs964184 APOA1 16.95 0.0248 same direction TG 0.6875 0.13 rs12286037 0.588 
Table 8-7. Associations between GBD and 63 independent loci previously reported to be 




2 SNPs Model 
SNP1, independent effect =1 
 N 10K 5K 1k 500 100 
r2=0.9 
HR_MEAN 0.001666247 0.002327979 0.007662525 0.008899966 0.148657148 
HR_95%CI 0.03435748 0.052061965 0.118976878 0.192076277 1.452488811 
Mreg_MEAN 0.0011124 0.003888542 0.017189593 0.019894365 0.037589728 
Mreg_95%CI 0.302178051 0.438952618 0.977343389 1.423197341 3.544468234 
GCTA_MEAN 0.006184591 0.007119836 0.003234032 0.006265411 0.145259253 
GCTA_95%CI 0.04179361 0.06197972 0.146828738 0.226757081 0.832076091 
       
r2=0.8 
HR_MEAN 0.002121781 0.002142119 0.001136835 0.005149754 0.077632799 
HR_95%CI 0.026408551 0.037983395 0.090456528 0.131271477 0.974071684 
Mreg_MEAN 0.002743894 0.002354297 0.010080058 0.008472605 0.033431403 
Mreg_95%CI 0.206969633 0.303471321 0.70384088 0.987939529 2.321674632 
GCTA_MEAN 0.002421276 0.002634457 0.000516333 0.007229987 0.061184005 
GCTA_95%CI 0.029119613 0.042309561 0.1012824 0.144272179 0.469159452 
       
r2=0.5 
HR_MEAN 0.02039984 0.021877524 0.022225636 0.023238884 0.039157148 
HR_95%CI 0.015308343 0.02207482 0.050166436 0.07516596 0.189840069 
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Mreg_MEAN 0.018866975 0.022878874 0.026078252 0.018654087 0.018842517 
Mreg_95%CI 0.130271489 0.192942335 0.433039972 0.626248877 1.396102366 
GCTA_MEAN 0.020159147 0.021325037 0.021749437 0.024257734 0.044669467 
GCTA_95%CI 0.01746593 0.024185728 0.056048713 0.083885424 0.212847225 
       
r2=0.2 
HR_MEAN 0.000736617 0.001160796 0.002188218 0.002976302 0.01212241 
HR_95%CI 0.008099122 0.011357692 0.027778145 0.036623104 0.102899236 
Mreg_MEAN 0.000237719 0.000323408 0.00609236 0.002675935 0.006000273 
Mreg_95%CI 0.102455541 0.150891858 0.341759957 0.515294816 1.165054397 
GCTA_MEAN 0.000550163 0.000216059 0.00114004 0.001770056 0.012727879 
GCTA_95%CI 0.008818049 0.01245593 0.02935433 0.039496618 0.104033652 
       
SNP2 independent effect =0 
  N 10K 5K 1k 500 100 
r2=0.9 
HR_MEAN 0.001835105 0.002595134 0.007604252 0.008275996 0.089215875 
HR_95%CI 0.036466382 0.055232839 0.125693975 0.202003308 1.554200319 
Mreg_MEAN 0.002038094 0.004222709 0.023000853 0.020897789 0.002356261 
Mreg_95%CI 0.304112805 0.448800685 1.001041864 1.432890469 3.554742134 
GCTA_MEAN 0.006633267 0.007693014 0.002847673 0.005344696 0.146204386 
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GCTA_95%CI 0.044497118 0.065976995 0.155660822 0.239707121 0.859037502 
      
 
r2=0.8 
HR_MEAN 0.002449701 0.002529292 0.00067627 0.004615229 0.032919587 
HR_95%CI 0.029803049 0.042859084 0.101745378 0.146867437 1.076762496 
Mreg_MEAN 0.002580834 0.001357546 0.007358458 0.003344505 0.032221692 
Mreg_95%CI 0.209929017 0.301991991 0.712796003 0.980119523 2.362155958 
GCTA_MEAN 0.002797201 0.0031074 0.000142086 0.006755521 0.060804859 
GCTA_95%CI 0.032917926 0.047824888 0.114117941 0.161942213 0.504183156 
      
 
r2=0.5 
HR_MEAN 0.013077255 0.015084665 0.014951476 0.015361469 0.029779187 
HR_95%CI 0.021624925 0.03108006 0.070312245 0.105250278 0.255825539 
Mreg_MEAN 0.01525414 0.012402253 0.024679445 0.023732623 0.038305434 
Mreg_95%CI 0.135916085 0.201657702 0.446067545 0.646961436 1.424609007 
GCTA_MEAN 0.012707242 0.014261407 0.014023917 0.016310952 0.035405846 
GCTA_95%CI 0.024676355 0.034059399 0.078691106 0.117506658 0.285186833 
      
 
r2=0.2 
HR_MEAN 0.001519921 0.002343901 0.003135982 0.003716353 0.007051808 
HR_95%CI 0.018636056 0.026023183 0.06388167 0.083218802 0.217541001 
Mreg_MEAN 0.000155018 0.000107109 0.004444034 0.007841599 0.017722129 
Mreg_95%CI 0.102218767 0.151394016 0.35169023 0.510821493 1.110035301 
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GCTA_MEAN 0.001474759 0.00089392 0.000461927 0.000195873 0.007573781 
GCTA_95%CI 0.020460327 0.028823312 0.06784384 0.090931083 0.220967026 
 
3 SNPs model, r^2 between SNP1 and SNP2 is 0.8, r^2 between SNP1 and SNP3 are showed below 
SNP1, independent effect = 1 
 
SNP1 and SNP3 r2=0.5 
 
SNP1 and SNP3 r2=0.3 
 
SNP1 and SNP3 r2=0.1 
N HR_MEAN HR_95%CI Mreg_MEAN Mreg_95%CI GCTA_MEAN GCTA_95%CI 
 
HR_MEAN HR_95%CI Mreg_MEAN Mreg_95%CI GCTA_MEAN GCTA_95%CI 
 
HR_MEAN HR_95%CI Mreg_MEAN Mreg_95%CI GCTA_MEAN GCTA_95%CI 
10K 0.071443 0.01935 0.078972 0.213202 0.081914 0.021935 
 
0.001721 0.020938 0.000277 0.215446 0.002296 0.024751 
 
0.005022 0.018532 0.001694 0.208788 0.004359 0.022345 
5K 0.070608 0.028433 0.074086 0.310041 0.081747 0.032022 
 
0.001092 0.032178 0.002968 0.306323 0.00073 0.037117 
 
0.003776 0.028718 0.001068 0.297912 0.003042 0.034279 
1k 0.06793 0.068689 0.088521 0.741105 0.077826 0.080734 
 
0.004513 0.07476 0.001779 0.666349 0.005727 0.086409 
 
0.00339 0.063829 0.006353 0.672172 0.000589 0.075138 
500 0.063203 0.101107 0.069358 1.067519 0.071937 0.111674 
 
0.005411 0.10432 0.031336 0.989216 0.007633 0.121729 
 
7.15E-05 0.094294 0.007536 0.992912 0.002123 0.11466 
200 0.022049 0.203736 0.012563 1.573526 0.02683 0.240872 
 
0.021471 0.185104 0.009987 1.584888 0.02954 0.224464 
 
0.012762 0.160332 0.028184 1.598921 0.023415 0.19711 
175 0.03782 0.232971 0.005792 1.77176 0.044612 0.273101 
 
0.021517 0.193962 0.018654 1.679401 0.025672 0.228139 
 
0.014471 0.170772 0.013852 1.682086 0.02369 0.209402 
150 0.02396 0.25229 0.007221 1.914583 0.032194 0.294921 
 
0.045519 0.92051 0.002511 1.921594 0.038327 0.262136 
 
0.025197 0.236012 0.023125 1.906707 0.040697 0.286419 
100 0.004375 0.852442 0.063161 2.372521 0.013907 0.420461   0.08198 1.688698 0.090395 2.348012 0.050037 0.357962   0.097025 0.268564 0.059514 1.952315 0.096202 0.296018 
                     
SNP2, independent effect = 0 
 
SNP1 and SNP3 r2=0.5 
 
SNP1 and SNP3 r2=0.3 
 
SNP1 and SNP3 r2=0.1 
N HR_MEAN HR_95%CI Mreg_MEAN Mreg_95%CI GCTA_MEAN GCTA_95%CI 
 
HR_MEAN HR_95%CI Mreg_MEAN Mreg_95%CI GCTA_MEAN GCTA_95%CI 
 
HR_MEAN HR_95%CI Mreg_MEAN Mreg_95%CI GCTA_MEAN GCTA_95%CI 
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10K 0.085864 0.024096 0.09158 0.260677 0.092715 0.030336 
 
0.00245 0.026358 0.000652 0.230533 0.002878 0.031761 
 
0.006713 0.022435 0.002014 0.212812 0.005322 0.027041 
5K 0.084704 0.035927 0.083006 0.368303 0.092962 0.045254 
 
0.001911 0.040477 0.005273 0.32278 0.001516 0.047413 
 
0.0054 0.034904 0.002654 0.315865 0.003957 0.041322 
1k 0.082365 0.086355 0.088306 0.863651 0.090444 0.11312 
 
0.003393 0.09166 0.000757 0.733818 0.004959 0.107433 
 
0.006199 0.077115 0.005876 0.707974 0.002631 0.09041 
500 0.078792 0.122422 0.07441 1.24979 0.085522 0.154602 
 
0.002934 0.131336 0.030136 1.094274 0.005001 0.154346 
 
0.004201 0.11365 0.015362 1.045262 0.001601 0.13792 
200 0.019562 0.236565 0.027676 1.879106 0.018457 0.303018 
 
0.015501 0.220523 0.023563 1.75621 0.022655 0.271515 
 
0.006207 0.188442 0.043528 1.671417 0.017751 0.231827 
175 0.036375 0.267425 0.012954 2.084913 0.037855 0.346152 
 
0.0148 0.234985 0.026581 1.852227 0.016841 0.281142 
 
0.00682 0.203172 0.010224 1.790115 0.016837 0.24819 
150 0.019694 0.287601 0.000411 2.289741 0.023012 0.367297 
 
0.0092 0.970629 0.008168 2.065278 0.031093 0.313083 
 
0.017137 0.267554 0.03141 1.982361 0.033987 0.324516 
100 0.057824 0.920113 0.002247 2.803695 0.046178 0.493073   0.034349 1.896017 0.108352 2.51097 0.03735 0.42203   0.125322 0.306481 0.084049 2.064166 0.120576 0.345898 
                     
SNP3, independent effect = 0.3 
 
SNP1 and SNP3 r2=0.5 
 
SNP1 and SNP3 r2=0.3 
 
SNP1 and SNP3 r2=0.1 
N HR_MEAN HR_95%CI Mreg_MEAN Mreg_95%CI GCTA_MEAN GCTA_95%CI 
 
HR_MEAN HR_95%CI Mreg_MEAN Mreg_95%CI GCTA_MEAN GCTA_95%CI 
 
HR_MEAN HR_95%CI Mreg_MEAN Mreg_95%CI GCTA_MEAN GCTA_95%CI 
10K 0.000559 0.013875 0.001203 0.167766 0.005967 0.020456 
 
0.001627 0.017335 0.000217 0.129061 8.87E-05 0.021013 
 
0.003715 0.017521 0.000383 0.109942 0.000112 0.019982 
5K 0.000168 0.020337 0.006579 0.244004 0.005478 0.029927 
 
0.00189 0.026149 0.001215 0.181278 0.000721 0.030983 
 
0.003571 0.027068 0.000398 0.15904 7.9E-05 0.029661 
1k 0.000423 0.048175 0.004815 0.559304 0.00439 0.07414 
 
0.001874 0.057104 0.00599 0.440201 0.000268 0.067839 
 
0.005076 0.05987 0.003218 0.358797 0.00135 0.066914 
500 0.001545 0.065773 0.006644 0.793359 0.003692 0.103288 
 
0.002031 0.085586 0.003048 0.613382 7.44E-05 0.103486 
 
0.006198 0.087614 0.000279 0.523932 0.001958 0.099037 
200 0.002655 0.109118 0.03065 1.28247 0.006053 0.169914 
 
0.00746 0.134306 0.001086 0.982017 0.005463 0.162139 
 
0.00419 0.140486 0.001762 0.82159 0.002676 0.157305 
175 0.002338 0.119988 0.012632 1.394103 0.004393 0.193872 
 
0.006821 0.144407 0.003303 1.010778 0.004826 0.177088 
 
0.009793 0.146709 0.023451 0.891007 0.001172 0.165214 
150 0.003984 0.119375 0.004589 1.529762 0.004772 0.191016 
 
0.006389 0.15406 0.021492 1.140249 0.002143 0.184736 
 
0.008203 0.160133 0.000956 1.003118 0.002862 0.179848 
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100 0.019004 0.16694 0.067913 1.793368 0.016858 0.25738   0.007147 0.315199 0.02881 1.349366 0.004199 0.232238   0.019815 0.148227 0.021706 1.095973 0.018954 0.181625 
                     
                     
3 SNPs model, r^2 between SNP1 and SNP2 is 0.5, r^2 between SNP1 and SNP3 are showed below 
SNP1, independent effect = 1 
 
SNP1 and SNP3 r2=0.5 
 
SNP1 and SNP3 r2=0.3 
 
SNP1 and SNP3 r2=0.1 
N HR_MEAN HR_95%CI Mreg_MEAN Mreg_95%CI GCTA_MEAN GCTA_95%CI 
 
HR_MEAN HR_95%CI Mreg_MEAN Mreg_95%CI GCTA_MEAN GCTA_95%CI 
 
HR_MEAN HR_95%CI Mreg_MEAN Mreg_95%CI GCTA_MEAN GCTA_95%CI 
10K 0.002967 0.011306 0.003693 0.14216 0.00134 0.013487 
 
0.002058 0.010132 0.000282 0.13391 0.001713 0.012016 
 
0.005049 0.011402 0.001047 0.136532 0.000869 0.014064 
5K 0.003593 0.01675 0.000196 0.216511 0.000826 0.018758 
 
0.002526 0.014923 0.001695 0.189744 0.001344 0.017683 
 
0.004687 0.016598 0.005547 0.202362 0.001253 0.020857 
1k 0.004979 0.03748 0.009001 0.478326 0.001466 0.042888 
 
0.003308 0.033886 0.000837 0.42827 0.00066 0.039691 
 
0.005785 0.037467 0.018376 0.451182 2.84E-05 0.046784 
500 0.008366 0.053872 0.030902 0.680628 0.004171 0.061572 
 
0.005471 0.05152 0.002232 0.611297 0.002761 0.057796 
 
0.007548 0.054742 0.010261 0.619745 0.002957 0.068763 
200 0.015664 0.091586 0.035961 1.111772 0.016034 0.109201 
 
0.008398 0.080934 0.00407 0.976986 0.007091 0.098099 
 
0.010459 0.091034 0.008501 1.005677 0.011382 0.115428 
175 0.020079 0.102031 0.000426 1.175271 0.020785 0.115194 
 
0.01516 0.088932 0.005235 1.078919 0.015724 0.10892 
 
0.011194 0.096569 0.007069 1.102921 0.01206 0.121923 
150 0.023365 0.121295 0.006161 1.217457 0.023712 0.137196   0.014484 0.096039 0.009355 1.177267 0.014081 0.115882   0.013506 0.105475 0.003759 1.146685 0.015483 0.134107 
                     
SNP2, independent effect = 0 
  
SNP1 and SNP3 r2=0.5 
 
SNP1 and SNP3 r2=0.3   
 
SNP1 and SNP3 r2=0.1   
N HR_MEAN HR_95%CI Mreg_MEAN Mreg_95%CI GCTA_MEAN GCTA_95%CI 
 
HR_MEAN HR_95%CI Mreg_MEAN Mreg_95%CI GCTA_MEAN GCTA_95%CI 
 
HR_MEAN HR_95%CI Mreg_MEAN Mreg_95%CI GCTA_MEAN GCTA_95%CI 
10K 0.005335 0.031744 0.001524 0.165943 0.002171 0.032676 
 
0.002866 0.020751 0.002963 0.204698 0.005029 0.031283 
 
0.008174 0.01927 0.002284 0.162963 0.001701 0.024635 
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5K 0.006336 0.047868 0.002997 0.242945 0.001022 0.048058 
 
0.003519 0.030284 0.003015 0.284677 0.004683 0.04391 
 
0.007256 0.02827 0.001465 0.238482 0.002656 0.036918 
1k 0.00701 0.100369 0.004341 0.537551 0.001246 0.104788 
 
0.003705 0.067285 0.006813 0.627475 0.004252 0.100525 
 
0.007309 0.063579 0.010852 0.519195 0.00314 0.08256 
500 0.013831 0.148917 0.019065 0.786398 0.002959 0.15037 
 
0.005697 0.10332 0.009217 0.936886 0.003919 0.14763 
 
0.007902 0.091604 0.00081 0.775495 0.001821 0.119975 
200 0.022976 0.243415 0.027964 1.245634 0.011116 0.25225 
 
0.002403 0.161332 0.018789 1.500344 0.009981 0.244727 
 
0.005543 0.150336 0.009055 1.174585 0.002733 0.198077 
175 0.031973 0.261772 0.012531 1.399636 0.020975 0.274807 
 
0.013452 0.180892 0.000335 1.563804 0.002154 0.271318 
 
0.0045 0.157985 0.018221 1.301526 0.001541 0.20679 
150 0.027984 0.310561 0.018124 1.475033 0.017212 0.304352   0.010222 0.192267 0.021124 1.701797 0.005019 0.280361   0.007534 0.172231 0.029494 1.374553 0.005823 0.226009 
                     
SNP3, independent effect = 0.3 
 
SNP1 and SNP3 r2=0.5   
 
SNP1 and SNP3 r2=0.3   
 
SNP1 and SNP3 R r2sq=0.1   
N HR_MEAN HR_95%CI Mreg_MEAN Mreg_95%CI GCTA_MEAN GCTA_95%CI 
 
HR_MEAN HR_95%CI Mreg_MEAN Mreg_95%CI GCTA_MEAN GCTA_95%CI 
 
HR_MEAN HR_95%CI Mreg_MEAN Mreg_95%CI GCTA_MEAN GCTA_95%CI 
10K 0.002248 0.024303 0.000444 0.17825 0.000404 0.026254 
 
0.000519 0.019124 0.000176 0.178497 0.003276 0.030012 
 
0.006345 0.017912 0.001184 0.134354 9.21E-05 0.023356 
5K 0.002591 0.037651 0.005817 0.259285 0.001128 0.04049 
 
0.000342 0.026012 0.005459 0.255805 0.003267 0.041753 
 
0.00581 0.027432 0.002536 0.18532 0.000138 0.035817 
1k 0.002004 0.079591 0.002428 0.567777 0.001139 0.091392 
 
0.000241 0.062349 0.006501 0.572443 0.004311 0.09958 
 
0.003768 0.061173 0.004633 0.417322 0.003319 0.076687 
500 0.006028 0.118724 0.052431 0.815189 0.001748 0.125692 
 
0.000414 0.090867 0.01073 0.855641 0.004453 0.143809 
 
0.002437 0.085001 0.003017 0.631975 0.004808 0.112559 
200 0.008509 0.186178 0.007775 1.316778 0.000498 0.208051 
 
0.004602 0.139791 0.03704 1.347114 0.012931 0.221147 
 
0.001143 0.140412 0.000993 0.947095 0.002521 0.179897 
175 0.012829 0.20391 0.042233 1.423342 0.003982 0.232144 
 
0.00199 0.154465 0.024355 1.380328 0.011807 0.251986 
 
0.00372 0.15131 0.007127 0.992171 0.004315 0.195721 
150 0.006318 0.238321 0.0112 1.621696 0.001548 0.255486   0.00227 0.17163 0.011046 1.476126 0.014893 0.267052   0.001402 0.158987 0.012859 1.161024 0.002415 0.203338 
Table 8-8. Performance Comparison of HAPRAP, GCTA and Multiple Regression using Artificial Meta-Analyses of the Simulated Populations. A, 
errors of HAPRAP, GCTA and multiple regression in 2-SNPs models; B, errors of HAPRAP, GCTA and multiple regression in 3-SNPs models. “r2”is 
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the pair-wise LD r2. N is the number of individuals in the genotypes reference panel. HR_MEAN (and HR_95%CI) are the means (and width of 95% 
confidence intervals (CI)) for differences between HAPRAP betas and multiple regression joint SNP effects. Mreg_MEAN (and Mreg_95%CI) are 
the means (and width of 95% CIs) for differences between multiple regression joint SNP effects of the reference panel and multiple regression 
joint SNP effects of the whole population. GCTA_MEAN (and GCTA_95%CI) are the means (and width of 95% CIs) for differences between GCTA 
betas and multiple regression joint SNP effects. 
 
BWHHS individual-level data 
 







genomic regreions and traits SNP beta SE pavl N   beta SE pval   beta SE pavl   beta SE pavl 
APOE_TC rs769449 0.148  0.058  1.09E-02 1962 
 
0.097  0.058  9.60E-02 
 
0.102  0.060  8.78E-02 
 
0.104  0.059  7.65E-02 
APOE_TC chr19:50103919 -0.516  0.072  1.08E-12 1951 
 
-0.504  0.072  4.23E-12 
 
-0.502  0.071  2.05E-12 
 
-0.501  0.073  8.26E-12 
APOE_LDL rs769449 0.174  0.053  9.81E-04 1909 
 
0.111  0.052  3.34E-02 
 
0.117  0.053  2.80E-02 
 
0.120  0.053  2.44E-02 
APOE_LDL chr19:50103919 -0.632  0.065  6.35E-22 1898 
 
-0.617  0.065  6.66E-21 
 
-0.615  0.065  1.48E-20 
 
-0.615  0.067  3.67E-20 
NOS1AP_QTc chr1:160291611 6.169  1.193  2.55E-07 1981 
 
4.530  1.663  6.50E-03 
 
4.368  1.747  1.25E-02 
 
4.420  1.676  8.36E-03 
NOS1AP_QTc chr1:160297312 3.235  0.840  1.21E-04 1980 
 
-2.122  1.822  2.44E-01 
 
-2.394  1.989  2.29E-01 
 
-1.976  1.807  2.74E-01 
NOS1AP_QTc rs12143842 5.299  0.919  9.41E-09 1981 
 
4.262  1.928  2.71E-02 
 
4.583  2.119  3.06E-02 
 
4.056  1.900  3.28E-02 
NOS1AP_QTc rs16857031 3.098  1.111  5.36E-03 1981 
 
2.815  1.591  7.70E-02 
 
2.926  1.676  8.10E-02 
 
2.797  1.595  7.95E-02 
NOS1AP_QTc rs10918740 3.168  0.818  1.12E-04 1981 
 
-1.167  1.619  4.71E-01 
 
-1.202  1.721  4.85E-01 
 
-1.053  1.631  5.19E-01 
NOS1AP_QTc chr1:160426106 5.868  1.242  2.49E-06 1981 
 
-0.817  2.945  7.82E-01 
 
-0.775  3.383  8.19E-01 
 
-0.408  2.817  8.85E-01 
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NOS1AP_QTc chr1:160427963 3.544  0.855  3.55E-05 1981 
 
0.893  1.421  5.30E-01 
 
0.715  1.597  6.54E-01 
 
0.922  1.419  5.16E-01 
NOS1AP_QTc chr1:160431793 4.938  1.103  8.04E-06 1981 
 
-0.610  2.413  8.01E-01 
 
-0.644  2.666  8.09E-01 
 
-0.793  2.362  7.37E-01 
NOS1AP_QTc chr1:160435892 5.306  1.038  3.48E-07 1981 
 
3.019  2.295  1.89E-01 
 
3.135  2.662  2.39E-01 
 
2.824  2.259  2.11E-01 
NOS1AP_QTc chr1:160477234 4.295  0.898  1.86E-06 1981 
 
2.069  1.773  2.43E-01 
 
2.135  1.993  2.84E-01 
 
2.047  1.758  2.44E-01 
NOS1AP_QTc rs10919024 4.615  1.163  7.44E-05 1981 
 
-0.738  1.948  7.05E-01 
 
-0.861  2.137  6.87E-01 
 
-0.574  1.940  7.67E-01 
SCN5A10A_PR chr3:38619266 -3.379  0.977  5.53E-04 1896 
 
-2.881  0.983  3.41E-03 
 
-2.922  0.972  2.67E-03 
 
-2.953  0.987  2.77E-03 
SCN5A10A_PR chr3:38634956 2.607  0.867  2.68E-03 1895 
 
2.132  0.876  1.50E-02 
 
2.123  0.862  1.39E-02 
 
2.110  0.881  1.66E-02 
SCN5A10A_PR chr3:38719374 2.460  0.814  2.55E-03 1895 
 
0.707  1.040  4.96E-01 
 
0.738  1.045  4.80E-01 
 
0.735  1.046  4.83E-01 
SCN5A10A_PR chr3:38742319 3.283  0.825  7.13E-05 1896 
 
2.670  1.196  2.57E-02 
 
2.719  1.210  2.48E-02 
 
2.627  1.199  2.84E-02 
SCN5A10A_PR chr3:38762595 -2.398  0.824  3.64E-03 1894 
 
0.075  1.156  9.48E-01 
 
0.158  1.173  8.93E-01 
 
0.040  1.162  9.72E-01 
LIPC_HDL rs1077834 0.064  0.017  1.86E-04 1963 
 
0.010  0.039  7.90E-01 
 
0.023  0.039  5.49E-01 
 
0.018  0.036  6.08E-01 
LIPC_HDL rs8033940 0.055  0.015  3.45E-04 1963 
 
0.017  0.028  5.44E-01 
 
0.010  0.029  7.38E-01 
 
0.014  0.027  6.04E-01 
LIPC_HDL rs12914035 -0.066  0.020  1.29E-03 1955 
 
-0.048  0.021  2.45E-02 
 
-0.050  0.021  1.73E-02 
 
-0.048  0.021  2.51E-02 
LIPC_HDL rs261338 0.070  0.019  1.73E-04 1964 
 
0.073  0.044  9.66E-02 
 
0.065  0.046  1.54E-01 
 
0.063  0.043  1.40E-01 
LIPC_HDL rs261336 0.053  0.019  4.96E-03 1963 
 
-0.040  0.038  2.89E-01 
 
-0.038  0.040  3.33E-01 
 
-0.035  0.038  3.52E-01 
LPL_HDL chr8:19852310 0.041  0.021  4.45E-02 1963 
 
0.002  0.035  9.57E-01 
 
0.000  0.039  9.94E-01 
 
0.006  0.034  8.63E-01 
LPL_HDL chr8:19855067 0.046  0.027  8.27E-02 1964 
 
0.046  0.044  2.98E-01 
 
0.044  0.048  3.59E-01 
 
0.034  0.043  4.28E-01 
LPL_HDL chr8:19857947 0.060  0.019  1.58E-03 1963 
 
-0.009  0.038  8.07E-01 
 
-0.009  0.041  8.34E-01 
 
-0.004  0.037  9.14E-01 
LPL_HDL chr8:19861214 0.035  0.017  4.01E-02 1963 
 
0.018  0.047  6.92E-01 
 
0.016  0.051  7.58E-01 
 
0.006  0.046  8.95E-01 
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LPL_HDL chr8:19862322 0.027  0.016  8.48E-02 1964 
 
-0.061  0.036  8.84E-02 
 
-0.063  0.040  1.19E-01 
 
-0.053  0.035  1.31E-01 
LPL_HDL chr8:19868772 0.050  0.016  1.60E-03 1963 
 
-0.011  0.046  8.11E-01 
 
-0.008  0.052  8.81E-01 
 
-0.003  0.045  9.43E-01 
LPL_HDL rs1569209 0.029  0.027  2.95E-01 1962 
 
-0.159  0.067  1.76E-02 
 
-0.149  0.081  6.62E-02 
 
-0.134  0.062  3.07E-02 
LPL_HDL rs10096633 0.076  0.022  7.17E-04 1964 
 
0.206  0.059  5.30E-04 
 
0.204  0.069  3.27E-03 
 
0.188  0.057  9.22E-04 
LPL_HDL chr8:19914551 0.050  0.016  2.54E-03 1964 
 
0.041  0.047  3.86E-01 
 
0.041  0.052  4.32E-01 
 
0.039  0.047  4.13E-01 
LPL_HDL chr8:19919284 0.051  0.014  3.78E-04 1963 
 
0.041  0.020  4.30E-02 
 
0.041  0.020  4.13E-02 
 
0.040  0.020  4.81E-02 
LPL_HDL chr8:19959564 0.009  0.016  5.69E-01 1952 
 
0.007  0.022  7.62E-01 
 
-0.003  0.022  8.77E-01 
 
0.004  0.022  8.52E-01 
LPL_HDL rs9644568 0.036  0.022  9.96E-02 1964 
 
-0.013  0.037  7.34E-01 
 
-0.003  0.040  9.49E-01 
 
-0.006  0.036  8.65E-01 
LPL_HDL chr8:19983329 0.009  0.028  7.53E-01 1964 
 
-0.063  0.046  1.66E-01 
 
-0.066  0.054  2.20E-01 
 
-0.070  0.045  1.22E-01 
LDLR_TC rs6511720 -0.059  0.060  3.31E-01 1967 
 
0.171  0.105  1.02E-01 
 
0.179  0.109  1.01E-01 
 
0.170  0.104  1.03E-01 
LDLR_TC chr19:11067575 0.019  0.038  6.25E-01 1967 
 
-0.036  0.047  4.47E-01 
 
-0.028  0.047  5.46E-01 
 
-0.026  0.046  5.70E-01 
LDLR_TC chr19:11068516 -0.140  0.097  1.47E-01 1968 
 
0.021  0.125  8.69E-01 
 
0.025  0.121  8.34E-01 
 
0.020  0.122  8.67E-01 
LDLR_TC rs2228671 -0.139  0.059  1.79E-02 1967 
 
-0.314  0.129  1.52E-02 
 
-0.313  0.131  1.72E-02 
 
-0.300  0.126  1.74E-02 
LDLR_TC rs2738447 -0.006  0.039  8.76E-01 1937 
 
-0.033  0.052  5.20E-01 
 
-0.030  0.051  5.57E-01 
 
-0.027  0.051  6.00E-01 
LDLR_TC rs5742911 -0.044  0.042  2.91E-01 1967 
 
0.016  0.056  7.73E-01 
 
0.010  0.056  8.61E-01 
 
0.008  0.055  8.82E-01 
SMARCA4_TC rs8099996 -0.039  0.040  3.27E-01 1968 
 
-0.044  0.085  6.04E-01 
 
-0.037  0.086  6.69E-01 
 
-0.034  0.083  6.84E-01 
SMARCA4_TC rs8102273 -0.034  0.041  4.05E-01 1967 
 
-0.050  0.118  6.70E-01 
 
-0.063  0.121  6.01E-01 
 
-0.067  0.116  5.62E-01 
SMARCA4_TC chr19:11044837 -0.016  0.044  7.21E-01 1968 
 
0.095  0.095  3.20E-01 
 
0.101  0.095  2.88E-01 
 
0.104  0.095  2.73E-01 
SMARCA4_TC chr19:11056030 -0.036  0.049  4.58E-01 1968 
 
0.041  0.079  6.02E-01 
 
0.049  0.081  5.41E-01 
 
0.047  0.078  5.49E-01 
282 
 
SMARCA4_TC chr19:11059187 -0.071  0.061  2.46E-01 1967 
 
-0.116  0.104  2.66E-01 
 
-0.123  0.107  2.51E-01 
 
-0.121  0.103  2.41E-01 
PVRL2_TC rs7254892 -0.333  0.115  3.80E-03 1968 
 
-0.311  0.115  7.06E-03 
 
-0.313  0.118  7.89E-03 
 
-0.317  0.115  6.01E-03 
PVRL2_TC rs6857 0.124  0.052  1.62E-02 1961 
 
0.115  0.052  2.58E-02 
 
0.113  0.053  3.35E-02 
 
0.115  0.052  2.59E-02 
APOB_TC chr2:21079258 -0.124  0.050  1.31E-02 1968 
 
-0.054  0.082  5.09E-01 
 
-0.045  0.080  5.71E-01 
 
-0.039  0.081  6.33E-01 
APOB_TC chr2:21085700 -0.104  0.039  8.33E-03 1968 
 
0.048  0.085  5.77E-01 
 
0.039  0.091  6.67E-01 
 
0.043  0.081  5.95E-01 
APOB_TC chr2:21091291 -0.118  0.077  1.24E-01 1968 
 
0.144  0.157  3.58E-01 
 
0.082  0.189  6.63E-01 
 
0.085  0.150  5.71E-01 
APOB_TC rs41288783 0.743  0.464  1.09E-01 1968 
 
0.760  0.463  1.01E-01 
 
0.704  0.686  3.05E-01 
 
0.766  0.467  1.01E-01 
APOB_TC rs10199768 0.126  0.040  1.84E-03 1968 
 
-0.045  0.096  6.38E-01 
 
-0.034  0.105  7.43E-01 
 
-0.035  0.089  6.95E-01 
APOB_TC chr2:21099811 -0.175  0.074  1.81E-02 1968 
 
-0.185  0.186  3.21E-01 
 
-0.145  0.273  5.94E-01 
 
-0.128  0.169  4.49E-01 
APOB_TC rs1367117 0.187  0.042  7.31E-06 1968 
 
0.084  0.104  4.20E-01 
 
0.096  0.130  4.59E-01 
 
0.083  0.103  4.22E-01 
APOB_TC chr2:21119728 -0.160  0.172  3.52E-01 1968 
 
-0.040  0.214  8.51E-01 
 
0.019  0.268  9.43E-01 
 
-0.035  0.209  8.66E-01 
APOB_TC chr2:21120715 -0.240  0.054  9.67E-06 1962 
 
-0.144  0.147  3.27E-01 
 
-0.121  0.224  5.91E-01 
 
-0.155  0.133  2.43E-01 
APOB_TC rs17398765 0.249  0.070  4.15E-04 1968 
 
0.186  0.088  3.52E-02 
 
0.177  0.090  4.87E-02 
 
0.186  0.088  3.54E-02 
APOB_TC rs541041 -0.198  0.051  9.80E-05 1967 
 
0.004  0.142  9.76E-01 
 
-0.003  0.183  9.85E-01 
 
-0.008  0.135  9.55E-01 
APOB_TC chr2:21158700 0.169  0.042  5.45E-05 1967 
 
0.092  0.107  3.93E-01 
 
0.047  0.123  7.04E-01 
 
0.083  0.106  4.29E-01 
APOB_TC chr2:21162840 -0.257  0.071  3.15E-04 1967 
 
-0.059  0.179  7.42E-01 
 
-0.033  0.242  8.90E-01 
 
-0.039  0.167  8.16E-01 
APOB_TC chr2:21181140 -0.153  0.042  3.28E-04 1968 
 
0.082  0.126  5.16E-01 
 
0.015  0.171  9.30E-01 
 
0.058  0.121  6.30E-01 
APOB_TC chr2:21254166 0.119  0.041  3.29E-03 1967 
 
-0.078  0.103  4.51E-01 
 
-0.057  0.145  6.93E-01 
 
-0.072  0.099  4.66E-01 
APOB_TC chr2:21257334 -0.104  0.045  2.05E-02 1968 
 
-0.026  0.113  8.18E-01 
 
0.001  0.146  9.96E-01 
 
-0.001  0.108  9.95E-01 
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APOB_TC chr2:21284866 0.160  0.045  3.79E-04 1960 
 
-0.076  0.121  5.30E-01 
 
-0.067  0.152  6.61E-01 
 
-0.089  0.115  4.42E-01 
APOB_TC chr2:21300158 -0.191  0.052  2.66E-04 1968 
 
-0.117  0.122  3.38E-01 
 
-0.084  0.156  5.92E-01 
 
-0.112  0.120  3.51E-01 
APOB_TC chr2:21305109 -0.077  0.050  1.27E-01 1968 
 
0.164  0.109  1.33E-01 
 
0.147  0.135  2.77E-01 
 
0.159  0.104  1.25E-01 
APOB_TC chr2:21305192 -0.185  0.050  2.25E-04 1966 
 
-0.057  0.087  5.12E-01 
 
-0.077  0.089  3.89E-01 
 
-0.049  0.084  5.58E-01 
APOB_TC chr2:21305332 0.168  0.041  4.45E-05 1966 
 
0.090  0.109  4.10E-01 
 
0.068  0.128  5.97E-01 
 
0.088  0.101  3.85E-01 
APOB_TC rs10198972 -0.099  0.096  3.03E-01 1968 
 
0.063  0.138  6.48E-01 
 
0.089  0.208  6.68E-01 
 
0.071  0.135  5.99E-01 
APOB_TC rs312049 0.143  0.039  2.89E-04 1967 
 
0.012  0.086  8.85E-01 
 
0.031  0.102  7.58E-01 
 
0.023  0.082  7.79E-01 
APOB_TC rs7571647 -0.243  0.063  1.14E-04 1968 
 
-0.084  0.112  4.54E-01 
 
-0.093  0.117  4.28E-01 
 
-0.097  0.109  3.74E-01 
PVRL2_LDL rs6859 0.061  0.036  8.97E-02 1914 
 
0.012  0.039  7.65E-01 
 
0.012  0.038  7.51E-01 
 
0.010  0.039  7.88E-01 
PVRL2_LDL rs283813 -0.113  0.069  9.96E-02 1911 
 
0.066  0.090  4.61E-01 
 
0.073  0.095  4.43E-01 
 
0.067  0.090  4.56E-01 
PVRL2_LDL rs7254892 -0.464  0.104  9.18E-06 1915 
 
-0.503  0.135  1.92E-04 
 
-0.509  0.144  4.16E-04 
 
-0.505  0.135  1.73E-04 
PVRL2_LDL rs6857 0.151  0.047  1.36E-03 1909 
 
0.126  0.051  1.44E-02 
 
0.123  0.051  1.72E-02 
 
0.126  0.052  1.45E-02 
TOMM40_LDL rs157580 -0.139  0.036  1.41E-04 1905 
 
-0.146  0.039  1.99E-04 
 
-0.146  0.038  1.13E-04 
 
-0.144  0.040  2.93E-04 
TOMM40_LDL rs2075650 0.147  0.050  3.02E-03 1915 
 
0.066  0.053  2.16E-01 
 
0.064  0.054  2.36E-01 
 
0.072  0.053  1.79E-01 
TOMM40_LDL chr19:50092587 -0.503  0.107  2.49E-06 1915 
 
-0.554  0.108  2.88E-07 
 
-0.550  0.112  9.89E-07 
 
-0.550  0.109  4.21E-07 
TOMM40_LDL chr19:50095056 0.109  0.108  3.13E-01 1914 
 
0.051  0.109  6.37E-01 
 
0.045  0.111  6.87E-01 
 
0.052  0.110  6.34E-01 
LDLR_LDL rs6511720 -0.061  0.055  2.63E-01 1914 
 
0.163  0.094  8.25E-02 
 
0.172  0.097  7.80E-02 
 
0.164  0.094  8.08E-02 
LDLR_LDL chr19:11068102 -0.098  0.043  2.35E-02 1914 
 
-0.024  0.067  7.20E-01 
 
-0.036  0.066  5.89E-01 
 
-0.032  0.066  6.22E-01 
LDLR_LDL rs2228671 -0.142  0.053  7.89E-03 1914 
 
-0.267  0.112  1.74E-02 
 
-0.253  0.115  2.80E-02 
 
-0.248  0.111  2.54E-02 
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LDLR_LDL rs2738447 -0.002  0.036  9.52E-01 1885 
 
-0.019  0.041  6.48E-01 
 
-0.018  0.042  6.75E-01 
 
-0.016  0.041  6.91E-01 
LDLR_LDL rs5742911 -0.037  0.038  3.23E-01 1914 
 
0.019  0.048  6.95E-01 
 
0.011  0.049  8.29E-01 
 
0.011  0.048  8.25E-01 
SMARCA4_LDL rs1529729 0.028  0.035  4.21E-01 1914 
 
0.006  0.045  8.97E-01 
 
0.005  0.046  9.11E-01 
 
0.006  0.045  8.89E-01 
SMARCA4_LDL rs3786725 -0.041  0.038  2.80E-01 1915 
 
-0.052  0.084  5.36E-01 
 
-0.051  0.084  5.40E-01 
 
-0.053  0.085  5.29E-01 
SMARCA4_LDL chr19:11044837 -0.030  0.040  4.52E-01 1915 
 
0.047  0.089  5.98E-01 
 
0.045  0.087  6.03E-01 
 
0.049  0.088  5.77E-01 
SMARCA4_LDL chr19:11056030 -0.060  0.044  1.80E-01 1915 
 
-0.008  0.074  9.15E-01 
 
-0.007  0.074  9.20E-01 
 
-0.008  0.072  9.15E-01 
SMARCA4_LDL chr19:11059187 -0.079  0.055  1.56E-01 1914 
 
-0.067  0.096  4.85E-01 
 
-0.069  0.097  4.78E-01 
 
-0.069  0.094  4.65E-01 
CELSR2_LDL chr1:109600244 -0.051  0.036  1.59E-01 1914 
 
0.067  0.052  1.97E-01 
 
0.066  0.052  2.11E-01 
 
0.063  0.051  2.17E-01 
CELSR2_LDL rs4970834 -0.135  0.045  2.96E-03 1915 
 
0.012  0.084  8.85E-01 
 
0.016  0.086  8.48E-01 
 
0.011  0.084  8.99E-01 
CELSR2_LDL chr1:109618715 -0.150  0.043  5.04E-04 1915 
 
-0.091  0.087  2.92E-01 
 
-0.095  0.090  2.91E-01 
 
-0.092  0.086  2.87E-01 
CELSR2_LDL chr1:109618768 -0.120  0.038  1.65E-03 1914 
 
-0.096  0.069  1.65E-01 
 
-0.094  0.071  1.85E-01 
 
-0.093  0.069  1.75E-01 
CELSR2_LDL chr1:109622407 -0.165  0.062  8.07E-03 1914 
 
-0.065  0.083  4.34E-01 
 
-0.070  0.081  3.87E-01 
 
-0.069  0.083  4.08E-01 
APOB_LDL chr2:21079258 -0.148  0.046  1.22E-03 1915 
 
-0.084  0.073  2.50E-01 
 
-0.088  0.077  2.52E-01 
 
-0.076  0.073  2.99E-01 
APOB_LDL chr2:21085700 -0.117  0.036  1.10E-03 1915 
 
0.034  0.074  6.42E-01 
 
0.045  0.077  5.59E-01 
 
0.027  0.072  7.10E-01 
APOB_LDL chr2:21093423 0.139  0.037  1.43E-04 1915 
 
-0.022  0.074  7.62E-01 
 
0.003  0.076  9.67E-01 
 
-0.019  0.072  7.88E-01 
APOB_LDL rs12713956 -0.114  0.065  7.89E-02 1915 
 
0.088  0.129  4.97E-01 
 
0.046  0.174  7.91E-01 
 
0.090  0.122  4.61E-01 
APOB_LDL rs41288783 0.797  0.416  5.54E-02 1915 
 
0.807  0.416  5.23E-02 
 
0.715  0.493  1.47E-01 
 
0.806  0.419  5.42E-02 
APOB_LDL chr2:21103221 -0.204  0.089  2.27E-02 1915 
 
0.108  0.119  3.66E-01 
 
0.100  0.134  4.56E-01 
 
0.100  0.120  4.06E-01 
APOB_LDL rs1367117 0.194  0.038  3.34E-07 1915 
 
0.215  0.086  1.29E-02 
 
0.198  0.096  3.81E-02 
 
0.199  0.085  1.91E-02 
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APOB_LDL rs17398765 0.231  0.064  3.26E-04 1915 
 
0.159  0.081  5.03E-02 
 
0.149  0.084  7.42E-02 
 
0.156  0.080  5.10E-02 
APOB_LDL chr2:21124828 -0.224  0.049  5.29E-06 1914 
 
-0.138  0.125  2.70E-01 
 
-0.099  0.180  5.85E-01 
 
-0.138  0.118  2.42E-01 
APOB_LDL chr2:21162840 -0.243  0.065  1.77E-04 1914 
 
0.009  0.143  9.49E-01 
 
0.001  0.199  9.98E-01 
 
0.009  0.137  9.46E-01 
APOB_LDL chr2:21167284 0.141  0.040  3.93E-04 1915 
 
-0.057  0.086  5.07E-01 
 
-0.050  0.095  5.95E-01 
 
-0.050  0.084  5.49E-01 
APOB_LDL chr2:21181140 -0.142  0.039  2.25E-04 1915 
 
0.102  0.090  2.56E-01 
 
0.079  0.117  5.01E-01 
 
0.083  0.087  3.41E-01 
APOB_LDL rs4635554 0.098  0.037  8.83E-03 1904 
 
-0.091  0.081  2.60E-01 
 
-0.072  0.110  5.13E-01 
 
-0.077  0.078  3.26E-01 
APOB_LDL chr2:21257334 -0.119  0.041  3.50E-03 1915 
 
-0.042  0.108  6.99E-01 
 
-0.049  0.128  7.02E-01 
 
-0.035  0.103  7.37E-01 
APOB_LDL chr2:21292834 -0.200  0.048  2.79E-05 1915 
 
-0.189  0.109  8.24E-02 
 
-0.163  0.135  2.28E-01 
 
-0.174  0.107  1.05E-01 
APOB_LDL chr2:21303769 0.136  0.041  9.21E-04 1910 
 
0.021  0.088  8.07E-01 
 
0.009  0.119  9.40E-01 
 
0.010  0.085  9.03E-01 
APOB_LDL chr2:21305109 -0.130  0.046  4.37E-03 1915 
 
0.063  0.094  4.99E-01 
 
0.066  0.112  5.52E-01 
 
0.058  0.090  5.22E-01 
APOB_LDL chr2:21305192 -0.181  0.045  7.10E-05 1913 
 
-0.042  0.073  5.63E-01 
 
-0.055  0.072  4.42E-01 
 
-0.042  0.072  5.54E-01 
APOB_LDL rs7571647 -0.228  0.057  6.79E-05 1915   -0.041  0.095  6.66E-01   -0.039  0.111  7.24E-01   -0.039  0.094  6.76E-01 
Table 8-9. Performance Comparison of HAPRAP and GCTA Using BWHHS Summary Statistics and BWHHS Individual-level Genotypes.
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BWHHS summary statistics together with 1000 Genome individual-level data 
 







genomic region and traits SNP beta SE pavl N   beta SE pavl   beta SE pavl   beta SE pavl 
NOS1AP_QTc rs4657166 3.544  0.855  3.55E-05 1981 
 
1.347  1.084  2.14E-01 
 
1.160  0.992  2.42E-01 
 
8.923  1.030  4.54E-18 
NOS1AP_QTc rs16857031 3.098  1.111  5.36E-03 1981 
 
2.434  1.388  7.97E-02 
 
1.985  1.294  1.25E-01 
 
7.895  1.272  5.38E-10 
NOS1AP_QTc rs10918859 5.306  1.038  3.48E-07 1981 
 
3.234  1.201  7.16E-03 
 
3.277  1.152  4.51E-03 
 
8.062  1.179  8.14E-12 
LPL_HDL rs10096633 0.076  0.022  7.17E-04 1964 
 
0.149  0.044  7.59E-04 
 
0.123  0.047  8.56E-03 
 
0.249  0.062  6.45E-05 
LPL_HDL rs35237252 0.050  0.016  2.54E-03 1964 
 
0.065  0.047  1.65E-01 
 
0.023  0.046  6.12E-01 
 
0.108  0.048  2.53E-02 
NOS1AP_QTc rs10429888 6.169  1.193  2.55E-07 1981 
 
4.297  1.739  1.35E-02 
 
4.084  1.639  1.28E-02 
 
6.636  1.740  1.37E-04 
LPL_HDL rs343 0.046  0.027  8.27E-02 1964 
 
-0.001  0.046  9.77E-01 
 
-0.001  0.040  9.90E-01 
 
0.059  0.049  2.26E-01 
TOMM40_LDL rs157580 -0.139  0.036  1.41E-04 1905 
 
-0.169  0.037  5.49E-06 
 
-0.164  0.037  8.61E-06 
 
-0.124  0.037  6.94E-04 
CETP_HDL rs5880 -0.058  0.031  6.25E-02 1964 
 
0.036  0.034  2.80E-01 
 
0.001  0.034  9.83E-01 
 
0.040  0.038  2.95E-01 
TOMM40_LDL rs61679753 -0.503  0.107  2.49E-06 1915 
 
-0.572  0.102  2.69E-08 
 
-0.568  0.107  1.24E-07 
 
-0.470  0.108  1.22E-05 
CETP_HDL rs11076174 -0.104  0.025  4.59E-05 1964 
 
-0.079  0.032  1.44E-02 
 
-0.082  0.029  4.75E-03 
 
-0.064  0.032  4.22E-02 
LDLR_TC rs2738447 -0.006  0.039  8.76E-01 1937 
 
-0.003  0.049  9.45E-01 
 
-0.033  0.052  5.20E-01 
 
-0.009  0.053  8.63E-01 
APOB_LDL rs17398765 0.231  0.064  3.26E-04 1915 
 
0.131  0.080  1.00E-01 
 
0.114  0.070  1.05E-01 
 
0.143  0.069  3.89E-02 
HERPUD1_HDL rs3764261 0.103  0.015  2.29E-11 1963 
 
0.075  0.021  4.83E-04 
 
0.077  0.020  1.23E-04 
 
0.084  0.020  3.66E-05 
LDLR_TC rs6511721 0.019  0.038  6.25E-01 1967 
 
-0.014  0.046  7.54E-01 
 
-0.036  0.047  4.47E-01 
 
-0.021  0.047  6.56E-01 
HERPUD1_HDL rs2562126 -0.021  0.021  3.09E-01 1963 
 
0.011  0.022  6.06E-01 
 
0.005  0.022  8.10E-01 
 
0.012  0.022  5.95E-01 
287 
 
HERPUD1_HDL rs7205692 -0.046  0.020  2.01E-02 1964 
 
-0.044  0.023  5.21E-02 
 
-0.035  0.023  1.27E-01 
 
-0.029  0.024  2.29E-01 
LPL_HDL rs301 0.035  0.017  4.01E-02 1963 
 
0.008  0.020  7.08E-01 
 
-0.009  0.045  8.46E-01 
 
0.001  0.023  9.61E-01 
LDLR_TC rs6511720 -0.059  0.060  3.31E-01 1967 
 
0.237  0.124  5.56E-02 
 
0.171  0.105  1.02E-01 
 
0.196  0.108  7.07E-02 
HERPUD1_HDL rs12920974 -0.077  0.016  1.38E-06 1963 
 
-0.058  0.020  4.58E-03 
 
-0.056  0.020  4.97E-03 
 
-0.051  0.019  8.47E-03 
APOB_TC rs17398765 0.249  0.070  4.15E-04 1968 
 
0.134  0.083  1.06E-01 
 
0.142  0.077  6.73E-02 
 
0.158  0.075  3.61E-02 
PVRL2_LDL rs7254892 -0.464  0.104  9.18E-06 1915 
 
-0.443  0.101  1.29E-05 
 
-0.444  0.105  2.41E-05 
 
-0.424  0.106  6.32E-05 
LDLR_LDL rs2228671 -0.142  0.053  7.89E-03 1914 
 
-0.137  0.066  3.73E-02 
 
-0.149  0.060  1.33E-02 
 
-0.140  0.057  1.37E-02 
CETP_HDL rs1864163 -0.105  0.016  1.71E-10 1964 
 
-0.047  0.028  9.18E-02 
 
-0.054  0.024  2.56E-02 
 
-0.051  0.027  5.86E-02 
SMARCA4_TC rs8099996 -0.039  0.040  3.27E-01 1968 
 
-0.033  0.083  6.87E-01 
 
-0.044  0.085  6.04E-01 
 
-0.032  0.087  7.11E-01 
LIPC_HDL rs261338 0.070  0.019  1.73E-04 1964 
 
0.060  0.020  2.47E-03 
 
0.059  0.019  1.88E-03 
 
0.062  0.019  1.11E-03 
LDLR_TC rs73015030 -0.140  0.097  1.47E-01 1968 
 
0.014  0.138  9.17E-01 
 
0.021  0.125  8.69E-01 
 
0.034  0.125  7.88E-01 
SMARCA4_TC rs73015007 -0.016  0.044  7.21E-01 1968 
 
0.096  0.098  3.31E-01 
 
0.095  0.095  3.20E-01 
 
0.105  0.097  2.79E-01 
PVRL2_TC rs7254892 -0.333  0.115  3.80E-03 1968 
 
-0.315  0.113  5.44E-03 
 
-0.311  0.115  7.06E-03 
 
-0.299  0.116  1.03E-02 
APOB_TC rs1367117 0.187  0.042  7.31E-06 1968 
 
0.108  0.049  2.70E-02 
 
0.109  0.048  2.24E-02 
 
0.113  0.046  1.51E-02 
APOE_LDL rs769449 0.174  0.053  9.81E-04 1909 
 
0.123  0.053  2.03E-02 
 
0.111  0.052  3.34E-02 
 
0.115  0.053  3.04E-02 
APOE_TC rs769449 0.148  0.058  1.09E-02 1962 
 
0.107  0.060  7.49E-02 
 
0.097  0.058  9.60E-02 
 
0.100  0.059  8.77E-02 
SCN5A10A_PR rs6801957 3.283  0.825  7.13E-05 1896 
 
3.244  0.851  1.42E-04 
 
3.061  0.824  2.08E-04 
 
3.106  0.832  1.90E-04 
SMARCA4_TC rs11668477 -0.036  0.049  4.58E-01 1968 
 
0.041  0.075  5.87E-01 
 
0.041  0.079  6.02E-01 
 
0.045  0.075  5.43E-01 
APOE_LDL rs7412 -0.632  0.065  6.35E-22 1898 
 
-0.614  0.069  1.57E-18 
 
-0.617  0.065  6.66E-21 
 
-0.614  0.067  4.45E-20 
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APOE_TC rs7412 -0.516  0.072  1.08E-12 1951 
 
-0.500  0.076  6.55E-11 
 
-0.504  0.072  4.23E-12 
 
-0.501  0.073  9.25E-12 
LDLR_TC rs2228671 -0.139  0.059  1.79E-02 1967 
 
-0.343  0.134  1.07E-02 
 
-0.314  0.129  1.52E-02 
 
-0.310  0.126  1.39E-02 
CELSR2_LDL rs7528419 -0.150  0.043  5.04E-04 1915 
 
-0.127  0.054  1.79E-02 
 
-0.125  0.053  1.80E-02 
 
-0.124  0.050  1.34E-02 
SMARCA4_TC rs17248720 -0.071  0.061  2.46E-01 1967 
 
-0.111  0.108  3.06E-01 
 
-0.116  0.104  2.66E-01 
 
-0.115  0.094  2.21E-01 
APOB_TC rs1800481 -0.240  0.054  9.67E-06 1962 
 
-0.186  0.053  4.69E-04 
 
-0.181  0.057  1.36E-03 
 
-0.182  0.057  1.40E-03 
APOB_LDL rs1713222 -0.224  0.049  5.29E-06 1914 
 
-0.164  0.049  8.21E-04 
 
-0.159  0.051  1.86E-03 
 
-0.161  0.052  1.86E-03 
SMARCA4_LDL rs11668477 -0.060  0.044  1.80E-01 1915 
 
-0.034  0.056  5.45E-01 
 
-0.026  0.067  7.01E-01 
 
-0.027  0.057  6.29E-01 
SMARCA4_LDL rs17248720 -0.079  0.055  1.56E-01 1914 
 
-0.037  0.082  6.51E-01 
 
-0.043  0.084  6.13E-01 
 
-0.048  0.070  4.92E-01 
SMARCA4_LDL rs3786725 -0.041  0.038  2.80E-01 1915 
 
-0.021  0.042  6.15E-01 
 
-0.019  0.043  6.47E-01 
 
-0.023  0.041  5.75E-01 
CETP_HDL rs289715 0.038  0.022  7.88E-02 1964 
 
0.010  0.025  6.92E-01 
 
0.014  0.022  5.32E-01 
 
0.011  0.022  6.30E-01 
SCN5A10A_PR rs55824920 2.607  0.867  2.68E-03 1895 
 
2.088  0.872  1.68E-02 
 
2.171  0.868  1.25E-02 
 
2.048  0.877  1.95E-02 
LIPC_HDL rs12914035 -0.066  0.020  1.29E-03 1955 
 
-0.054  0.020  7.87E-03 
 
-0.051  0.021  1.37E-02 
 
-0.054  0.021  8.60E-03 
APOB_LDL rs1367117 0.194  0.038  3.34E-07 1915 
 
0.103  0.046  2.41E-02 
 
0.126  0.043  3.65E-03 
 
0.119  0.043  5.82E-03 
CELSR2_LDL rs11577931 -0.165  0.062  8.07E-03 1914 
 
-0.056  0.080  4.84E-01 
 
-0.060  0.076  4.29E-01 
 
-0.074  0.072  3.03E-01 
SMARCA4_TC rs8102273 -0.034  0.041  4.05E-01 1967 
 
-0.066  0.115  5.64E-01 
 
-0.050  0.118  6.70E-01 
 
-0.074  0.119  5.35E-01 
PVRL2_TC rs6857 0.124  0.052  1.62E-02 1961 
 
0.112  0.054  3.67E-02 
 
0.115  0.052  2.58E-02 
 
0.104  0.052  4.57E-02 
SCN5A10A_PR rs62242769 -3.379  0.977  5.53E-04 1896 
 
-3.450  1.064  1.21E-03 
 
-2.931  0.979  2.79E-03 
 
-3.197  0.983  1.15E-03 
PVRL2_LDL rs6857 0.151  0.047  1.36E-03 1909 
 
0.134  0.049  6.08E-03 
 
0.138  0.047  3.17E-03 
 
0.123  0.048  9.94E-03 
CETP_HDL rs118146573 -0.098  0.022  5.60E-06 1964 
 
-0.075  0.036  3.54E-02 
 
-0.056  0.032  8.53E-02 
 
-0.067  0.035  5.20E-02 
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LDLR_LDL rs5742911 -0.037  0.038  3.23E-01 1914 
 
-0.010  0.042  8.07E-01 
 
0.012  0.043  7.87E-01 
 
-0.004  0.040  9.29E-01 
HERPUD1_HDL rs9938160 0.022  0.015  1.60E-01 1964 
 
-0.019  0.017  2.79E-01 
 
-0.012  0.016  4.67E-01 
 
-0.019  0.017  2.65E-01 
LPL_HDL rs74304285 0.041  0.021  4.45E-02 1963 
 
-0.028  0.043  5.13E-01 
 
-0.003  0.034  9.24E-01 
 
-0.024  0.042  5.70E-01 
LPL_HDL rs4333617 0.051  0.014  3.78E-04 1963 
 
0.045  0.020  2.15E-02 
 
0.040  0.019  4.17E-02 
 
0.029  0.019  1.25E-01 
LDLR_TC rs5742911 -0.044  0.042  2.91E-01 1967 
 
-0.023  0.051  6.55E-01 
 
0.016  0.056  7.73E-01 
 
-0.016  0.052  7.52E-01 
CETP_HDL rs5883 0.118  0.031  1.64E-04 1962 
 
0.089  0.029  2.39E-03 
 
0.090  0.032  4.26E-03 
 
0.070  0.033  3.32E-02 
APOB_LDL rs41288783 0.797  0.416  5.54E-02 1915 
 
0.705  0.206  6.39E-04 
 
0.731  0.413  7.70E-02 
 
0.449  0.429  2.96E-01 
LPL_HDL rs9644568 0.036  0.022  9.96E-02 1964 
 
-0.010  0.036  7.76E-01 
 
-0.012  0.035  7.19E-01 
 
-0.040  0.044  3.64E-01 
LPL_HDL rs269 0.060  0.019  1.58E-03 1963 
 
0.024  0.045  5.94E-01 
 
0.023  0.035  5.07E-01 
 
-0.006  0.042  8.89E-01 
NOS1AP_QTc rs12143842 5.299  0.919  9.41E-09 1981 
 
1.610  1.441  2.64E-01 
 
1.586  1.332  2.34E-01 
 
0.540  1.369  6.93E-01 
LPL_HDL rs13702 0.050  0.016  1.60E-03 1963 
 
-0.013  0.050  7.91E-01 
 
0.013  0.044  7.73E-01 
 
-0.026  0.046  5.66E-01 
LPL_HDL rs314 0.027  0.016  8.48E-02 1964 
 
-0.079  0.032  1.30E-02 
 
-0.041  0.034  2.39E-01 
 
-0.087  0.032  6.74E-03 
LPL_HDL rs7015766 0.009  0.028  7.53E-01 1964   -0.113  0.043  8.72E-03   -0.106  0.042  1.17E-02   -0.232  0.061  1.28E-04 
Table 8-10. Performance Comparison of HAPRAP and GCTA Using BWHHS Summary Statistics and 1000 Genome Individual-Level Genotypes.
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Chr Position Gene lead SNP Risk Allele beta p-Value 
1 40028180 MACF1,PABPC4 rs4660293 G 0.48 4.00E-10 
1 182168885 ZNF648 rs1689800 G 0.47 3.00E-10 
1 230294916 GALNT2 rs2144300 T 1.11 3.00E-14 
1 230295691 GALNT2 rs4846914 G 0.61 4.00E-21 
1 230304988 GALNT2 rs10489615 G 0.02 4.00E-09 
2 21198900 APOB rs11902417 G 0.02 4.00E-07 
2 21206183 APOB rs6754295 C 0.07 4.00E-08 
2 21225281 APOB rs1042034 C 0.9 1.00E-30 
2 165540800 COBLL1 rs12328675 C 0.68 3.00E-10 
2 227100698 IRS1 rs2972146 C 0.46 2.00E-09 
4 103188709 SLC39A8 rs13107325 T 0.84 7.00E-11 
5 53298025 ARL15 rs6450176 A 0.49 5.00E-08 
6 34552797 C6orf106 rs2814944 A 0.49 4.00E-09 
6 139829666 CITED2 rs605066 C 0.39 3.00E-08 
6 161089817 LPA rs1084651 A 0.56 3.00E-08 
7 72982874 MLXIPL rs17145738 T 0.57 1.00E-09 
7 80340622 CD36 rs2366858 C 0.03 6.00E-10 
7 130433384 KLF14 rs4731702 T 0.59 1.00E-15 
8 9183358 PPP1R3B rs9987289 A 1.21 6.00E-25 
8 9185146 PPP1R3B rs2126259 A 0.11 1.00E-06 
8 9187242 PPP1R3B rs1461729 T 0.04 7.00E-09 
8 19819328 LPL rs325 T 0.05 8.00E-26 
8 19819439 LPL rs326 T 0.02 1.00E-08 
8 19819724 LPL rs328 G 0.17 9.00E-23 
8 19832646 LPL rs17482753 T 2.02 3.00E-11 
8 19844222 LPL rs12678919 G 2.25 1.00E-97 
8 19847690 LPL rs10503669 T 0.04 8.00E-43 
8 19865175 LPL rs2083637 G 0.11 6.00E-18 
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8 116599199 TRPS1 rs2293889 T 0.44 6.00E-11 
8 126490972 TRIB1 rs2954029 T 0.61 6.00E-19 
9 15289578 TTC39B rs471364 C 0.08 3.00E-10 
9 15296034 TTC39B rs643531 C 0.01 7.00E-09 
9 15305378 TTC39B rs581080 C 0.72 1.00E-13 
9 107620835 NIPSNAP3A,NIPSNAP3B,ABCA1 rs9282541 A 0.37 6.00E-26 
9 107647220 ABCA1 rs4149268 C 0.82 1.00E-10 
9 107647655 ABCA1 rs3890182 A 0.1 3.00E-10 
9 107653426 ABCA1 rs12686004 T 0.02 2.00E-18 
9 107657070 ABCA1 rs3905000 G 0.11 9.00E-13 
9 107664301 ABCA1 rs1883025 T 0.94 2.00E-33 
11 10388782 ADM,AMPD3 rs2923084 G 0.41 5.00E-08 
11 46743247 LRP4,NR1H3 rs3136441 C 0.78 3.00E-18 
11 47286290 NR1H3 rs7120118 G 0.04 4.00E-08 
11 48518893 MADD, FOLH1 rs7395662 G 0.07 6.00E-11 
11 61569830 FADS1,FADS2,FADS3 rs174546  T 0.73 2.00E-22 
11 61570783 FADS1, FADS2, FADS3 rs174547 C 0.09 2.00E-12 
11 61571348 FADS1 rs174548 G 0.01 1.00E-12 
11 61597212 FADS2, FADS3 rs174570 G 0.06 4.00E-06 
11 116617240 Intergenic rs11216126 C 0.03 3.00E-34 
11 116648917 APOA1,APOC3,APOA4,APOA5 rs964184 G 1.5 5.00E-47 
11 122522375 UBASH3B rs7941030 G 0.31 3.00E-08 
12 20473758 PDE3A rs7134375 A 0.4 4.00E-08 
12 57792580 LRP1 rs11613352 T 0.46 2.00E-08 
12 109840940 MYO1H,KCTD10,UBE3B,MMAB,MVK rs9943753 G 0.02 3.00E-06 
12 109895168 MMAB,MVK rs2338104 C 0.07 1.00E-10 
12 110000193 MMAB,MVK rs7134594 C 0.44 7.00E-15 
12 111414461 MYL2 rs12229654 G 0.03 3.00E-23 
12 112645401 C12orf51 rs2074356 T 0.04 7.00E-37 
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12 113409176 OAS3 rs2072134 A 0.02 6.00E-06 
12 123796238 SBNO1 rs4759375 T 0.86 8.00E-09 
12 124460167 CCDC92,ZNF664 rs4765127 T 0.44 3.00E-10 
12 125261593 SCARB1 rs838880 C 0.61 3.00E-14 
15 58674695 LIPC rs4775041 C 1.38 3.00E-20 
15 58678512 LIPC rs10468017 T 0.1 8.00E-23 
15 58683366 LIPC rs1532085 A 1.45 3.00E-96 
15 58694020 Intergenic rs16940212 T 0.02 1.00E-24 
15 58723426 LIPC rs1077835 A 0.17 2.00E-14 
15 58723675 LIPC rs1800588 T 0.14 2.00E-32 
15 58726744 LIPC rs261334 G 0.03 5.00E-22 
15 63396867 LACTB rs2652834 A 0.39 9.00E-09 
16 56985139 CETP rs9989419 G 0.04 1.00E-32 
16 56988044 CETP rs173539 T 0.25 4.00E-75 
16 56990716 CETP rs247617 A 0.06 1.00E-44 
16 56993324 CETP rs3764261 A 3.39 7E-380 
16 56995236 CETP, NUP93, SLC12A3, HERPUD1 rs1800775 A 3.09 4.00E-93 
16 56997233 CETP rs1864163 G 4.12 7.00E-39 
16 57005479 CETP rs1532624 C 0.21 9.00E-94 
16 57012379 CETP rs12708980 C 0.04 2.00E-28 
16 67708897 GFOD2,LCAT rs12449157 G 0.02 2.00E-07 
16 67902070 CTCF, PRMT8 rs2271293 G 0.13 8.00E-16 
16 67928042 LCAT rs16942887 A 1.27 8.00E-33 
16 68013471 LCAT rs255049 G 0.05 3.00E-08 
16 68024995 LCAT rs255052 A 0.74 1.00E-07 
16 81534790 CMIP rs2925979 T 0.45 2.00E-11 
17 2428508 Intergenic rs9891572 A 0.05 2.00E-07 
17 37813856 STARD3 rs11869286 C 0.51 3.00E-14 
17 66875294 ABCA8 rs4148008 G 0.42 2.00E-10 
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17 76403984 PGS1 rs4129767 G 0.4 5.00E-09 
18 47159090 LIPG rs7240405 A 2.27 5.00E-10 
18 47160953 LIPG rs7241918 G 1.31 3.00E-49 
18 47167214 LIPG rs4939883 T 0.14 7.00E-15 
18 47181668 LIPG rs2156552 T 0.03 2.00E-12 
18 57849023 RPS3A,MC4R rs12967135 A 0.42 7.00E-09 
19 8433196 ANGPTL4 rs7255436 C 0.45 3.00E-08 
19 8469738 ANGPTL4 rs2967605 T 0.12 1.00E-08 
19 11342703 LOC55908 rs12979813 T 0.02 2.00E-09 
19 11347493 DOCK6,LOC55908 rs737337 C 0.64 3.00E-09 
19 11350488 
TSPAN16,SPC24,RAB3D,LOC55908,KANK
2,DOCK6 rs2278426 ? 0.14 3.00E-09 
19 45376284 PVRL2, TOMM40, APOE rs519113 C 0.02 8.00E-11 
19 45395266 TOMM40, APOE rs157580 G 0.06 4.00E-07 
19 45422946 APOE,APOC1,APOC2 rs4420638 G 1.06 4.00E-21 
19 54792761 LILRA3,LILRB2 rs386000 C 0.83 4.00E-16 
20 43042364 HNF4A rs1800961 T 1.88 1.00E-15 
20 44554015 PLTP rs6065906 C 0.93 2.00E-22 
20 44576502 PLTP rs7679 C 0.07 4.00E-09 
21 32060490 Intergenic rs13046373 C 0.02 4.00E-06 
22 21932068 UBE2L3 rs181362 T 0.46 1.00E-08 
Table 8-11. Genetic variants reported to be associated with HDL-C by previous GWASs 
Chr Position Gene lead SNP Risk Allele beta p-Value 
1 25775733 TMEM57,LDLRAP1 rs12027135 A 1.1 1.00E-10 
1 55496039 PCSK9 rs11206510 T 3.04 4.00E-11 
1 55504650 PCSK9 rs2479409 G 2.01 2.00E-28 
1 55505647 PCSK9 rs11591147 T 0.47 2.00E-44 
1 55625548 PCSK9 rs17111684 A 9.01 2.00E-17 
1 63025942 ANGPTL3,DOCK7 rs2131925 G 1.59 3.00E-18 
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1 63118196 DOCK7 rs10889353 C 0.06 8.00E-06 
1 109817590 CELSR2, PSRC1, SORT1 rs12740374 T 0.23 2.00E-42 
1 109817838 CELSR2 rs660240 A 0.04 1.00E-26 
1 109818306 CELSR2,PSRC1,SORT1 rs629301 G 5.65 1.00E-170 
1 109818530 CELSR2,PSRC1,SORT1 rs646776 C 0.16 3.00E-29 
1 109822166 CELSR2,PSRC1 rs599839 G 0.16 1.00E-33 
1 207875175 CR1L rs4844614 A 0.1 2.00E-07 
1 220973563 MOSC1 rs2642442 T 1.09 6.00E-11 
1 234858597 IRF2BP2,TOMM20 rs514230 A 1.13 9.00E-12 
2 21232195 APOB rs693 A 0.12 1.00E-21 
2 21241505 APOB rs12713956 G 4.86 4.00E-08 
2 21263900 APOB rs1367117 A 4.05 4.00E-114 
2 21286057 APOB rs515135 T 0.16 5.00E-29 
2 21288321 APOB rs562338 G 4.89 6.00E-22 
2 44065090 ABCG5 rs6756629 G 0.16 3.00E-10 
2 44072576 ABCG5,ABCG8 rs4299376 G 2.75 2.00E-47 
2 44073881 ABCG8 rs6544713 T 0.15 2.00E-20 
2 44074431 ABCG8 rs4245791 G 5.97 1.00E-09 
5 74625487 HMGCR rs7703051 A 18 1.00E-08 
5 74648603 HMGCR rs12654264 T 0.1 1.00E-20 
5 74651084 HMGCR rs3846662 G 0.08 2.00E-11 
5 74655726 HMGCR rs3846663 T 0.07 8.00E-12 
5 74656539 HMGCR rs12916 C 2.45 5.00E-45 
5 156390297 TIMD4,HAVCR1 rs6882076 T 1.67 2.00E-22 
5 156398169 TIMD4, HAVCR1 rs1501908 G 0.07 1.00E-11 
6 16127407 IDOL rs3757354 T 1.43 1.00E-11 
6 16197194 MYLIP,GMPR rs2142672 C 0.01 2.00E-08 
6 26093141 HFE,HIST1H4C rs1800562 A 2.22 6.00E-10 
6 32412435 HLA rs3177928 A 1.83 2.00E-15 
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6 33143948 B3GALT4 rs2254287 G 1.91 5.00E-08 
6 116312893 FRK rs9488822 T 0.89 3.00E-09 
6 160578860 LPA rs1564348 C 1.95 2.00E-17 
7 21607352 DNAH11 rs12670798 C 1.26 7.00E-10 
7 44579180 NPC1L1 rs2072183 A 1.17 4.00E-11 
8 9183358 PPP1R3B rs9987289 T 2.22 7.00E-15 
8 59388565 CYP7A1 rs2081687 A 0.95 4.00E-09 
8 145043543 PLEC1 rs11136341 G 1.4 4.00E-13 
10 113933886 GPAM rs2255141 A 1.08 2.00E-09 
11 61569830 FADS1,FADS2,FADS3 rs174546 T 1.71 1.00E-21 
11 61597212 FADS2, FADS3 rs174570 G 0.11 4.00E-13 
11 116603724 APOA1, APOA4, APOA5, APOC3 rs12272004 C 0.18 5.00E-13 
11 116607437 BUD13, ZNF259, APOA5,APOA4,APOC3,APOA1 rs1558861 T 0.03 2.00E-06 
11 116648917 APOA1,APOC3,APOA4,APOA5 rs964184 G 2.85 1.00E-26 
11 126243952 ST3GAL4 rs11220462 A 1.95 1.00E-15 
12 112072424 BRAP rs11065987 G 0.97 2.00E-09 
12 121388962 HNF1A rs2650000 A 0.07 2.00E-08 
12 121416650 HNF1A rs1169288 C 1.42 1.00E-15 
14 24883887 CBLN3,KIAA0323 rs8017377 T 1.17 4.00E-11 
16 56993324 CETP rs3764261 T 1.45 9.00E-13 
16 72108093 HP,HPR,DHX38 rs2000999 A 2 2.00E-22 
17 45425115 OSBPL7 rs7206971 T 0.87 4.00E-09 
19 11195030 LDLR rs11668477 G 0.13 2.00E-07 
19 11200008 LDLR rs17249141 T 32.93 2.00E-17 
19 11202306 LDLR rs6511720 T 6.99 4.00E-117 
19 11210912 LDLR rs2228671 G 0.14 4.00E-14 
19 11238473 LDLR rs2738459 C 0.02 7.00E-06 
19 19407718 CSPG3,CILP2,PBX4 rs10401969 C 3.11 7.00E-22 
19 19658472 NCAN,CILP2 rs16996148 G 3.32 3.00E-09 
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19 19789528 NCAN rs2304130 G 0.12 3.00E-06 
19 45395266 TOMM40, APOE rs157580 G 0.11 2.00E-19 
19 45403412 APOE rs1160985 C 6.77 2.00E-21 
19 45412079 APOE rs7412 ? 12.3 2.00E-09 
19 45422946 APOE,APOC1,APOC2 rs4420638 G 7.14 9.00E-147 
20 39091487 MAFB rs2902940 G 0.98 1.00E-08 
20 39228784 MAFB rs6102059 T 0.06 4.00E-09 
20 39672618 TOP1 rs6029526 T 1.41 3.00E-19 
23 66942625 AR rs5031002 A 0.3 2.00E-07 
Table 8-12. Genetic variants reported to be associated with LDL-C by previous GWASs 




1 62931632 DOCK7 rs1167998 C 0.09 2.00E-12 
1 62996838 DOCK7,ANGPTL3 rs1168013 G 0.04 6.00E-08 
1 63025942 ANGPTL3,DOCK7 rs2131925 G 4.94 9.00E-43 
1 63049593 ANGPTL3 rs1748195 C 7.12 2.00E-10 
1 63118196 ANGPTL3 rs10889353 C 0.13 2.00E-09 
1 63191777 ANGPTL3, DOCK7, ATG4C rs12130333 T 0.11 2.00E-08 
1 230294916 GALNT2 rs2144300 C 4.25 8.00E-07 
1 230295691 GALNT2 rs4846914 G 0.08 7.00E-15 
2 21204025 APOB rs6544366 T 0.04 2.00E-07 
2 21206183 APOB rs6754295 C 0.08 3.00E-08 
2 21208211 APOB rs7557067 G 0.08 9.00E-12 
2 21225281 APOB rs1042034 C 5.99 1.00E-45 
2 21232195 APOB rs693 A 0.08 2.00E-07 
2 27598097 GCKR rs4665972 T 0.07 1.00E-08 
2 27730940 GCKR rs1260326 T 8.76 6.00E-133 
2 27741237 GCKR rs780094 T 8.59 6.00E-32 
2 27743154 GCKR rs780092 G 0.05 5.00E-27 
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2 27748624 GCKR rs1260333 C 0.05 2.00E-19 
2 165513091 COBLL1 rs10195252 C 2.01 2.00E-10 
2 227100698 IRS1 rs2972146 C 1.89 2.00E-08 
3 135926622 MSL2L1 rs645040 G 2.22 3.00E-08 
4 88030261 AFF1,KLHL8 rs442177 G 2.25 9.00E-12 
5 55854153 C5orf35 rs6867983 T 0.02 3.00E-06 
5 55861786 ANKRD55,MAP3K1 rs9686661 T 2.57 1.00E-10 
5 156390297 TIMD4,HAVCR1 rs6882076 G 2.63 4.00E-12 
6 31265490 HLA rs2247056 T 2.99 2.00E-15 
7 72129667 TYW1B rs13238203 T 7.91 1.00E-09 
7 72856269 MLXIPL rs2240466 G 0.14 1.00E-12 
7 72856430 BAZ1B, BCL7B, TBL2, MLXIPL rs1178979 A 0.05 2.00E-12 
7 72864869 MLXIPL rs714052 G 0.16 3.00E-15 
7 72982874 MLXIPL rs17145738 G 7.91 9.00E-59 
7 72987354 TBL2, MLXIPL rs2286276 T 0.07 1.00E-15 
7 73020337 MLXIPL rs3812316 C 10.5 1.00E-10 
8 10683929 PINX1,XKR6 rs11776767 C 2.01 1.00E-08 
8 11045161 XKR6, AMAC1L2 rs7819412 G 0.04 3.00E-08 
8 18272881 NAT2 rs1495741 G 2.97 4.00E-14 
8 19819724 LPL rs328 G 0.19 2.00E-28 
8 19827848 LPL rs10105606 C 0.07 4.00E-26 
8 19830921 LPL rs10096633 G 0.17 2.00E-18 
8 19844222 LPL rs12678919 G 13.64 2.00E-115 
8 19847690 LPL rs10503669 T 0.09 7.00E-39 
8 19848080 LPL rs17410962 G 0.11 7.00E-09 
8 126477978 Intergenic rs2001945 C 0.04 1.00E-20 
8 126486409 TRIB1 rs17321515 G 0.08 4.00E-17 
8 126490972 TRIB1 rs2954029 T 5.64 3.00E-55 
10 65027610 JMJD1C rs10761731 T 2.38 3.00E-12 
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10 94839642 CYP26A1 rs2068888 A 2.28 2.00E-08 
11 61569830 FADS1,FADS2,FADS3 rs174546 T 3.82 5.00E-24 
11 61570783 FADS1, FADS2, FADS3 rs174547 C 0.06 2.00E-14 
11 61571348 FADS1 rs174548 G 0.03 5.00E-14 
11 116584987 BUD13,ZNF259,APOA5,APOA4,APOC3,APOA1 rs4938303 T 0.07 4.00E-21 
11 116586283 APOA1,APOC3,APOA4,APOA5 rs7350481 G 0.24 1.00E-49 
11 116603724 APOA1, APOA4, APOA5, APOC3 rs12272004 C 0.18 5.00E-13 
11 116607437 LOC440069, MGC13125 rs1558861 C 17 2.00E-26 
11 116619073 APOA1, APOC3, APOA4, APOA5, ZNF259, BUD13 rs28927680 G 0.26 2.00E-17 
11 116648917 APOA1,APOC3,APOA4,APOA5 rs964184 G 16.95 7.00E-240 
11 116652207 APOA5, APOA4, APOC3, APOA1 rs12286037 T 25.82 1.00E-26 
11 116652423 APOA,APOC rs6589566 C 0.21 5.00E-14 
11 116654435 ZNF259, APOA1, APOC3, APOA4, APOA5, BUD13 rs603446 T 0.09 2.00E-86 
11 116732512 APOA1,KIAA0999,LOC645044 rs2075292 G 8.7 5.00E-08 
12 57792580 LRP1 rs11613352 T 2.7 4.00E-10 
12 124460167 CCDC92,ZNF664 rs4765127 G 2.42 1.00E-08 
15 42683787 CAPN3 rs2412710 A 7 2.00E-08 
15 44245931 FRMD5 rs2929282 T 5.13 2.00E-11 
15 58674695 LIPC rs4775041 C 3.62 2.00E-08 
15 58683366 LIPC rs1532085 G 2.99 2.00E-13 
16 30918487 CTF1 rs11649653 G 2.13 3.00E-08 
16 56993324 CETP rs3764261 A 2.88 1.00E-12 
16 56995236 CETP rs1800775 C 2.1 3.00E-13 
19 19407718 CSPG3,CILP2,PBX4 rs10401969 C 7.83 2.00E-29 
19 19658472 NCAN,CILP2 rs16996148 G 6.1 3.00E-09 
19 19662220 NCAN,CILP2,PBX4 rs17216525 T 0.11 4.00E-11 
19 19789528 CILP2,ZNF101 rs2304130 G 0.07 4.00E-08 
19 45414451 APOE,APOC1,APOC2 rs439401 T 5.5 1.00E-30 
19 45422587 APOC1 rs12721054 G 0.1 3.00E-19 
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19 45422946 APOE cluster rs4420638 G 2.4 3.00E-13 
20 44554015 PLTP rs6065906 C 3.32 5.00E-18 
20 44576502 PLTP rs7679 C 0.07 7.00E-11 
22 38546033 PLA2G6 rs5756931 C 1.54 4.00E-08 
Table 8-13. Genetic variants reported to be associated with triglycerides by previous GWAS 
studies 
Chr Position Gene lead SNP Risk Allele beta p-Value 
1 23.77 ASAP3 rs1077514 C −0.03 6.00E-09 
2 169.83 ABCB11 rs2287623 G 0.027 4.00E-12 
2 203.53 FAM117B rs11694172 G 0.028 2.00E-09 
2 234.68 UGT1A1 rs11563251 T 0.037 1.00E-09 
3 58.38 PXK rs13315871 A −0.036 4.00E-08 
6 39.25 KCNK17 rs2758886 A 0.023 3.00E-08 
6 135.41 HBS1L rs9376090 C −0.025 3.00E-09 
7 1.08 GPR146 rs1997243 G 0.033 3.00E-10 
9 2.64 VLDLR rs3780181 G −0.044 7.00E-10 
10 17.26 VIM-CUBN rs10904908 G 0.025 3.00E-11 
11 118.49 PHLDB1 rs11603023 T 0.022 1.00E-08 
12 9.08 PHC1-A2ML1 rs4883201 G −0.035 2.00E-09 
17 7.09 DLG4 rs314253 C −0.023 3.00E-10 
22 35.71 TOM1 rs138777 A 0.021 5.00E-08 
22 46.63 PPARA rs4253772 T 0.032 1.00E-08 
Table 8-14. Novel genetic variants reported to be associated with total cholesterol by 
previous GWASs 
Chr Position Gene lead SNP Risk Allele beta p-Value 
7 4411209 SDK1 - SNORD13P2 rs10488360 ? NR 7.00E-06 
1 4315204 C1orf174 - AJAP1 rs966321 ? NR 8.00E-06 
3 7982827 GRM7 - LMCD1-AS1 rs4591494 ? NR 9.00E-06 
13 113760034 F7 rs561241 ? NR 5.00E-16 
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Table 8-15. Genetic variants reported to be associated with FVII by previous GWASs 
Chr Position Gene lead SNP Risk Allele beta p-Value 
3 1.85E+08 VPS8 rs4686760 G 0.15 1.00E-06 
5 1.12E+08 EPB41L4A rs379440 G 0.34 1.00E-06 
12 90609017 dessert rs10745527 G 0.16 5.00E-06 
19 5582535 SAFB2 rs732505 A 0.25 9.00E-06 
2 30526780 LBH rs6708166 A 0.17 1.00E-06 
9 1.37E+08 VAV2 rs12344583 G 0.2 8.00E-06 
17 31737421 ACCN1 rs1354492 A 0.16 2.00E-06 
6 90310966 ANKRD6 rs6454764 T 0.31 5.00E-06 
9 81310680 KRT18P24 rs1757948 G 0.15 7.00E-06 
18 25569058 CDH2 rs2298574 G 0.27 6.00E-06 
12 1.04E+08 STAB2 rs7306642 A 0.3 3.00E-06 
Table 8-16. Genetic variants reported to be associated with FVIII by previous GWASs 
Chr Position Gene lead SNP Risk Allele beta p-Value 
3 1.85E+08 VPS8 rs4686760 G 0.15 1.00E-06 
5 1.12E+08 EPB41L4A rs379440 G 0.34 1.00E-06 
12 90609017 dessert rs10745527 G 0.16 5.00E-06 
19 5582535 SAFB2 rs732505 A 0.25 9.00E-06 
2 30526780 LBH rs6708166 A 0.17 1.00E-06 
9 1.37E+08 VAV2 rs12344583 G 0.2 8.00E-06 
17 31737421 ACCN1 rs1354492 A 0.16 2.00E-06 
6 90310966 ANKRD6 rs6454764 T 0.31 5.00E-06 
9 81310680 KRT18P24 rs1757948 G 0.15 7.00E-06 
18 25569058 CDH2 rs2298574 G 0.27 6.00E-06 
12 1.04E+08 STAB2 rs7306642 A 0.3 3.00E-06 
Table 8-17. Genetic variants reported to be associated with vWF by previous GWASs 
Chr Position Gene lead SNP Risk Allele beta p-Value 
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1 40064961 PABPC4 rs12037222 A 0.05 6.00E-11 
1 66086194 LEPR rs10889569 T 0.05 9.00E-09 
1 66089782 LEPR rs6700896 T 14.8 3.00E-14 
1 66102257 LEPR rs1805096 A 0.11 2.00E-09 
1 66105944 LEPR rs1892534 A 0.17 7.00E-21 
1 66161461 LEPR rs4420065 C 0.09 4.00E-62 
1 154418879 IL6R rs4537545 T 11.5 2.00E-14 
1 154426264 IL6R rs4129267 C 0.08 2.00E-48 
1 154426970 IL6R rs8192284 ? 0.1 2.00E-08 
1 159649700 CRP, APCS, DARC, FCER1A, DUSP23, OR10J1, OR10J5, OR10J3, OLFML2B, IFI16, FCRL6 rs16827466 T 0.42 4.00E-73 
1 159655518 CRPP1, CRP rs726640 ? 0.44 2.00E-13 
1 159674933 CRP rs876537 C 0.29 1.00E-09 
1 159676171 CRP rs16842559 T 0.11 4.00E-21 
1 159678816 CRP rs2794520 C 0.16 2.00E-186 
1 159684665 CRP rs3091244 ? 0.2 6.00E-28 
1 159685136 CRP rs3093059 G 0.16 4.00E-21 
1 159692573 CRP, APCS, DARC, FCER1A, DUSP23, OR10J1, OR10J5, OR10J3, OLFML2B, IFI16, FCRL6 rs2808634 T 0.15 3.00E-10 
1 159698549 CRP rs7553007 A 20.7 8.00E-44 
1 247601595 NLRP3 rs12239046 C 0.05 1.00E-15 
2 27730940 GCKR rs1260326 T 0.07 5.00E-40 
2 27741237 GCKR rs780094 A 0.14 7.00E-15 
2 113841030 IL1F10, IL1RN rs6734238 G 0.11 9.00E-10 
2 113841030 IL1F10 rs6734238 G 0.05 2.00E-17 
5 131839618 IRF1 rs4705952 G 0.04 1.00E-08 
6 93852252 NR rs1408282 A 0.41 1.00E-06 
6 117114025 GPRC6A rs6901250 A 0.04 5.00E-08 
7 22732839 IL6 rs2097677 A 0.1 4.00E-11 
7 72971231 BCL7B rs13233571 C 0.05 4.00E-09 
8 9183358 PPP1R3B rs9987289 A 0.07 3.00E-13 
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12 103483094 ASCL1 rs10745954 A 0.04 2.00E-11 
12 103495151 Unknown rs10778213 G 0.12 1.00E-10 
12 121402932 HNF1A rs7305618 T 0.27 1.00E-08 
12 121420260 HNF1A rs7979473 A 0.12 1.00E-10 
12 121420807 HNF1A rs1183910 G 0.15 2.00E-124 
12 121424861 HNF1A rs7310409 A 0.15 7.00E-17 
12 121435587 HNF1A, OASL, C12orf43 rs2259816 T 0.14 3.00E-10 
12 121439433 HNF1A rs1169310 A 0.13 2.00E-08 
14 73019236 RGS6 rs4903031 G 0.03 5.00E-06 
15 60894965 RORA rs340029 T 0.03 4.00E-09 
16 51158710 SALL1 rs10521222 C 0.1 9.00E-13 
18 12821593 PTPN2 rs2847281 A 0.03 2.00E-08 
19 45395619 APOE rs2075650 G 0.12 2.00E-21 
19 45403412 TOMM40 rs1160985 C 0.13 4.00E-13 
19 45410002 APOE rs769449 ? 0.26 9.00E-21 
19 45422946 APOC1 rs4420638 A 0.24 9.00E-139 
20 43042364 HNF4A rs1800961 C 0.09 2.00E-09 
21 40465534 PSMG1 rs2836878 G 0.03 2.00E-07 
Table 8-18. Genetic variants reported to be associated with CRP by previous GWASs. 
Chr Position Gene lead SNP Risk Allele beta p-Value 
1 64868352 RNU7-62P rs11208446 A 0.12 9.00E-06 
1 82074852 RP5-837I24.4 rs11809789 A 0.4 6.00E-06 
1 159856429 CCDC19 rs2501324 ? 0.14 2.00E-10 
2 81872922 AC013262.1 rs12052359 A 0.22 7.00E-06 
2 88315793 KRCC1 rs12714207 T 0.03 5.00E-07 
2 160867059 PLA2R1 rs2667011 ? 0.04 2.00E-13 
2 190643649 ORMDL1 rs7606224 ? 0.1 2.00E-06 
2 234264848 DGKD rs1550532 ? 0.04 3.00E-19 
2 234406655 USP40 rs6704644 ? 0.08 8.00E-08 
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2 234639310 UGT1A1 rs11891311 ? 0.14 1.00E-41 
2 234668570 UGT1A1 rs887829 T 0.57 1.00E-69 
2 234669144 UGT1A1 rs4148323 ? 0.14 3.00E-139 
2 234672639 UGT1A1 rs6742078 T 0.23 5E-324 
2 234673309 UGT1A rs4148325 ? 0.17 5.00E-62 
2 234698790 LOC339766 rs2361502 ? 0.1 7.00E-23 
3 72023700 RP11-648C16.1 rs2135319 A 0.19 4.00E-06 
4 125993502 Intergenic rs1986655 A 0.02 2.00E-06 
4 155389247 DCHS2 rs17031671 ? 0.12 6.00E-11 
6 26116982 HIST1H2BC rs12206204 T 0.18 8.00E-07 
6 33060822 Intergenic rs6928954 ? 0.08 1.00E-06 
7 22756463 AC073072.5 rs10155981 T 0.13 2.00E-07 
7 80599357 SEMA3C rs4236644 A 0.02 2.00E-06 
8 445601 C8orf42 rs17665859 ? 0.09 5.00E-07 
8 112976141 AC068954.1, RP11-58O3.2 rs12549576 G 0.3 1.00E-06 
8 137768892 Intergenic rs16906293 ? 0.09 6.00E-06 
9 16034538 Intergenic rs3008706 ? 0.06 5.00E-07 
9 133765656 Intergenic rs10901296 ? 0.09 3.00E-07 
11 2936952 SLC22A18 rs16928809 A 0.06 1.00E-07 
12 21017875 SLCO1B3 rs2417940 ? 0.06 7.00E-19 
12 21074122 SLCO1B3 rs2117032 C 0.13 3.00E-14 
12 21331549 SLCO1B1,LST-3TM12,SLCO1A2 rs4149056 C 0.05 7.00E-13 
12 21368722 SLCO1B1 rs4363657 ? 0.06 5.00E-08 
13 70454960 KLHL1 rs11843309 T 0.21 7.00E-06 
13 111818832 ARHGEF7 rs4773330 A 0.04 8.00E-06 
14 46029687 Intergenic rs7140958 ? 0.09 2.00E-07 
16 14045399 ERCC4 rs4781563 A 0.16 2.00E-06 
21 34168573 C21orf49 rs2154427 ? 0.1 1.00E-06 
23 153554404 G6PD rs766420 G 0.18 9.00E-09 
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Table 8-19. Genetic variants reported to be associated with Bilirubin by previous GWASs. 
Chr Position Gene lead SNP Risk Allele beta p-Value 
1 145723645 PDZK1 rs1967017 T 3.33 4.00E-08 
1 145723739 PDZK1 rs1471633 A 0.06 1.00E-29 
1 150950062 ARNT rs4970988 A 0.03 1.00E-07 
1 155151493 TRIM46, PKLR rs11264341 T 0.05 6.00E-19 
2 27730940 GCKR rs1260326 T 0.07 1.00E-44 
2 27741237 GCKR rs780094 T 0.07 5.00E-06 
2 27742603 GCKR rs780093 T 5.15 4.00E-17 
2 121306440 INHBB rs17050272 A 0.04 2.00E-10 
2 148716428 ORC4L, ACVR2A rs2307394 T 0.03 2.00E-08 
2 170204846 LRP2 rs2544390 C 0.08 4.00E-08 
2 203337001 BMPR2 rs12468226 A 0.04 3.00E-06 
3 53100214 SFMBT1, MUSTN1 rs6770152 T 0.04 3.00E-16 
4 9915741 SLC2A9 rs11722228 T 0.16 7.00E-24 
4 9922167 SLC2A9 rs16890979 T 0.34 7.00E-168 
4 9926967 SLC2A9 rs13129697 G 22.21 2.00E-242 
4 9934744 SLC2A9 rs737267 C 0.88 3.00E-09 
4 9935910 GLUT9 rs6855911 A 0.32 2.00E-16 
4 9944052 SLC2A9 rs12498742 A 0.37 1E-700 
4 9966380 SLC2A9 rs7442295 C 0.35 3.00E-70 
4 9966380 SLC2A9,WDR1 rs7442295 A 0.02 2.00E-15 
4 81169912 FGF5 rs11099098 T 0.03 7.00E-07 
4 89052323 ABCG2 rs2231142 T 0.22 1.00E-134 
4 89054667 ABCG2 rs4148155 G 0.12 1.00E-13 
5 39902365 DAB2 rs11954519 A 0.03 4.00E-06 
5 55811092 ANKRD55 rs456867 T 0.04 3.00E-06 
5 72431482 TMEM171 rs17632159 C 0.04 4.00E-11 
6 7102084 RREB1 rs675209 T 0.06 1.00E-23 
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6 25813150 SLC17A1 rs1165196 G 6.21 5.00E-25 
6 25821616 SLC17A1, SLC17A3 rs1165151 T 0.09 7.00E-70 
6 25870542 SLC17A3 rs1165205 ? 0.09 4.00E-29 
6 43272188 SLC22A7 rs4149178 A 0.03 1.00E-06 
6 43804571 VEGFA rs729761 T 0.05 8.00E-16 
6 116310287 FRK rs1933737 T 0.03 7.00E-07 
6 134773554 Intergenic rs9321453 T 0.14 1.00E-09 
7 72857049 BAZ1B, MLXIPL rs1178977 A 0.05 1.00E-12 
7 151406005 PRKAG2 rs10480300 T 0.04 4.00E-09 
8 23777006 STC1 rs17786744 A 0.03 1.00E-08 
8 76478768 HNF4G rs2941484 T 0.04 4.00E-17 
9 33180362 B4GALT1 rs10813960 T 0.03 4.00E-07 
10 52646093 A1CF, ASAH2 rs10821905 A 0.06 7.00E-17 
10 61469538 SLC16A9 rs1171614 T 0.08 2.00E-28 
11 64334114 SLC22A11 rs2078267 T 0.07 9.00E-38 
11 64359221 SLC22A12 rs12800450 T 1.19 3.00E-16 
11 64440920 SLC22A12 rs506338 C 0.23 2.00E-31 
11 64478063 NRXN2, SLC22A12 rs478607 A 0.05 4.00E-11 
11 64525216 Intergenic rs589691 T 0.15 9.00E-08 
11 64546391 MEN1,SF1,MAP4K2,PYGM,RASGRP2,CDC42BPG,NRXN2 rs606458 T 0.18 6.00E-11 
11 64557054 MAP4K2 rs493573 A 0.8 2.00E-17 
11 65560620 OVOL1, LTBP3 rs642803 T 0.04 3.00E-13 
11 119235404 USP2 rs2195525 T 0.03 2.00E-06 
12 48173352 HDAC7 rs4760636 T 0.03 6.00E-06 
12 52251272 ACVR1B, ACVRL1 rs7976059 T 0.03 2.00E-09 
12 57809456 R3HDM2,INHBC rs1106766 T 5.16 2.00E-11 
12 57844049 INHBC, INHBE rs3741414 T 0.07 2.00E-25 
12 112007756 ATXN2, PTPN11 rs653178 T 0.04 7.00E-12 
12 121416988 HNF1A rs2244608 A 0.04 8.00E-08 
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12 122625992 B3GNT4 rs7953704 A 0.03 3.00E-08 
13 72345505 DACH1 rs584480 T 0.02 9.00E-06 
15 73082366 ADPGK rs4777542 T 0.03 2.00E-07 
15 76158983 UBE2Q2, NRG4 rs1394125 A 0.04 3.00E-13 
15 99271135 IGF1R rs6598541 A 0.04 5.00E-15 
16 69563890 NFAT5 rs7193778 T 0.05 8.00E-10 
16 79734987 MAF rs7188445 A 0.03 2.00E-09 
17 53364788 HLF rs7224610 A 0.04 5.00E-17 
17 59465697 BCAS3, C17orf82 rs2079742 T 0.04 1.00E-08 
17 74283669 QRICH2, PRPSAP1 rs164009 A 0.03 2.00E-07 
18 57872989 MC4R rs12955983 A 0.04 2.00E-06 
19 7199803 INSR rs1035942 A 0.03 1.00E-07 
Table 8-20. Genetic variants reported to be associated with urate by previous GWASs. 
Chr Position Gene lead SNP Risk Allele beta p-Value 
1 152300817 FLG rs3126085 A 1.22 6.00E-12 
1 152442289 FLG rs6661961 T 0.34 9.00E-11 
2 102971865 IL1RL1, IL18R1, IL18RAP rs13015714 G 1.27 8.00E-18 
2 112003867 LOC100505634 rs2271404 G 1.17 3.00E-07 
3 33065339 GLB1 rs7613051 A 1.29 6.00E-21 
3 112376308 CCDC80, LOC100630917 rs12634229 G 1.29 2.00E-19 
5 131995843 IL13, RAD50 rs1295686 A 1.38 2.00E-17 
5 132049027 KIF3A rs2897442 C 1.11 4.00E-08 
6 31272321 HLA-C rs9368677 G 1.36 1.00E-17 
6 31499603 BAT1 rs3853601 G 1.13 2.00E-06 
6 32074804 CREBL1, TNXB, rs12153855 T 1.58 3.00E-14 
6 32158319 GPSM3 rs176095 T 1.4 8.00E-20 
6 32308908 C6orf10 rs9469099 G 1.61 5.00E-19 
7 3128789 CARD11 rs4722404 G 1.18 8.00E-09 
8 81308150 ZBTB10 rs7000782 A 1.09 1.00E-06 
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8 129427518 MIR1208 rs7815944 A 1.16 4.00E-07 
10 64398466 ZNF365 rs10995251 C 1.28 6.00E-20 
10 64560470 ADO, EGR2 rs1444418 A 1.17 2.00E-07 
11 7968359 OR10A3, NLRP10 rs878860 G 1.31 2.00E-22 
11 65513107 OVOL1 rs593982 C 1.23 6.00E-07 
11 65551957 OVOL1 rs479844 G 1.14 1.00E-13 
11 76270683 C11orf30,LRRC32 rs7130588 G 1.29 4.00E-13 
11 76301316 C11orf30 rs7927894 A 1.22 8.00E-10 
11 76332210 C11orf30 rs11236809 G 1.24 3.00E-06 
16 11210415 CLEC16A rs9923856 A 1.17 6.00E-06 
19 8789381 ACTL9 rs2164983 A 1.16 7.00E-09 
20 52807221 CYP24A1, PFDN4 rs16999165 T 1.19 2.00E-08 
22 37258503 NCF4 rs4821544 C 1.09 6.00E-06 
Table 8-21. Genetic variants reported to be associated with atopic dermatitis by previous 
GWASs. 
SNP     A1  A2      freq    b       se      p      N 
rs6720173 C G 0.1583 0.2561 0.0386 3.23E-11 15213 
rs10208987 C A 0.0799 0.3782 0.0502 4.77E-14 15213 
rs4148189 A G 0.1139 0.2538 0.0441 8.66E-09 15213 
rs4245786 G A 0.2425 0.1423 0.0333 1.88E-05 15213 
rs4299376 C A 0.3154 -0.2829 0.0325 3.10E-18 15213 
rs4953023 A G 0.0658 0.7625 0.0523 3.57E-48 15213 
Table 8-22. SNPs significantly associated with GBD in the GBD meta-analysis 
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Marker ID A1 A2 Freq beta StdErr P.value N CHR traits Gene 
rs10429888 A G 0.3558 4.0061 0.6687 2.09E-09 7105 1 QTC interval OLFML2B(dist=31343),NOS1AP(dist=14594) 
rs10918594 C G 0.5689 2.8147 0.4769 3.59E-09 7101 1 QTC interval OLFML2B(dist=37044),NOS1AP(dist=8893) 
rs12143842 T C 0.4025 3.726 0.517 5.70E-13 7097 1 QTC interval OLFML2B(dist=40246),NOS1AP(dist=5691) 
rs16857031 C G 0.6309 2.8037 0.6321 9.19E-06 7104 1 QTC interval NOS1AP 
rs10918740 T C 0.4521 2.78 0.4663 2.49E-09 7105 1 QTC interval NOS1AP 
rs12039600 A G 0.3555 4.2885 0.709 1.46E-09 7106 1 QTC interval NOS1AP 
rs4657166 C G 0.5729 2.3324 0.4936 2.30E-06 7105 1 QTC interval NOS1AP 
rs72633699 T C 0.3724 3.6318 0.6375 1.22E-08 7105 1 QTC interval NOS1AP 
rs10918859 A G 0.3783 3.5549 0.5865 1.35E-09 7106 1 QTC interval NOS1AP 
rs4657178 T C 0.4091 2.5549 0.5192 8.61E-07 7103 1 QTC interval NOS1AP 
rs10919024 A C 0.6366 3.3784 0.6591 2.97E-07 7105 1 QTC interval NOS1AP 
rs7645178 A G 0.5828 1.9978 0.4512 9.51E-06 6902 3 PR interval SCN5A 
rs41312411 C G 0.6545 2.8977 0.5877 8.18E-07 6904 3 PR interval SCN5A 
rs12635898 A C 0.3909 2.5793 0.4753 5.73E-08 6807 3 PR interval SCN5A 
rs62242769 A G 0.3687 -2.3914 0.5032 2.01E-06 6902 3 PR interval SCN5A 
rs55824920 T C 0.4144 2.4975 0.4449 1.97E-08 6898 3 PR interval SCN5A 
rs6795580 C G 0.4609 -2.271 0.4298 1.27E-07 6902 3 PR interval SCN5A 
rs9818148 T G 0.6118 -2.4408 0.4792 3.52E-07 6883 3 PR interval SCN5A 
rs41312045 C G 0.2839 5.4286 1.179 4.14E-06 6903 3 PR interval SCN5A 
rs73056438 T C 0.3572 2.6866 0.5318 4.38E-07 6902 3 PR interval SCN5A 
rs6599230 T C 0.3604 -2.6812 0.5272 3.66E-07 6894 3 PR interval SCN5A 
rs6773331 A T 0.1946 -8.1823 1.5691 1.84E-07 6903 3 PR interval SCN5A 
rs4131768 A G 0.5796 -2.0936 0.4482 2.99E-06 6904 3 PR interval SCN5A(dist=4010),SCN10A(dist=43663) 
rs182475051 T C 0.388 -2.6333 0.4812 4.46E-08 6902 3 PR interval SCN5A(dist=34328),SCN10A(dist=13345) 
rs11129800 T C 0.4677 2.9887 0.4149 5.86E-13 6902 3 PR interval SCN10A 
rs9990137 A G 0.5727 -2.4132 0.441 4.45E-08 6902 3 PR interval SCN10A 
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rs73062575 T G 0.2642 5.2862 1.1925 9.29E-06 6900 3 PR interval SCN10A 
rs6801957 T C 0.4526 3.9874 0.4243 5.61E-21 6903 3 PR interval SCN10A 
rs10428168 T C 0.5829 -2.499 0.4411 1.46E-08 6902 3 PR interval SCN10A 
rs12636123 T G 0.528 -2.5996 0.423 7.98E-10 6902 3 PR interval SCN10A 
rs7553796 A C 0.4426 -0.0635 0.0093 8.14E-12 9528 1 il6 IL6R 
rs7518199 A C 0.5524 0.0883 0.0092 9.49E-22 9533 1 il6 IL6R 
rs4072391 T C 0.2896 -0.0581 0.0119 1.03E-06 9540 1 il6 IL6R 
rs9998811 A G 0.4517 -0.0226 0.0023 5.53E-23 4242 4 sUrate SLC2A9 
rs7696092 A C 0.5487 -0.0203 0.0023 3.40E-19 4241 4 sUrate SLC2A9 
rs2741029 T G 0.5653 2.0051 0.0955 5.84E-98 6521 2 bilirubin UGT1A8 
rs7608713 A G 0.4166 -0.9284 0.1042 5.11E-19 6530 2 bilirubin UGT1A10,UGT1A8 
rs17868322 A G 0.3576 1.603 0.2346 8.36E-12 6526 2 bilirubin UGT1A10,UGT1A8 
rs28899170 A C 0.4362 2.4878 0.0933 9.74E-157 6522 2 bilirubin UGT1A10,UGT1A6,UGT1A7,UGT1A8,UGT1A9 
rs1604144 T C 0.4403 -1.1735 0.0988 1.58E-32 6493 2 bilirubin UGT1A10,UGT1A6,UGT1A7,UGT1A8,UGT1A9 
rs17862875 A G 0.4291 2.5304 0.0942 5.68E-159 6530 2 bilirubin UGT1A10,UGT1A3,UGT1A4,UGT1A5,UGT1A6,UGT1A7,UGT1A8,UGT1A9 
rs11568318 A C 0.3609 -1.5878 0.1859 1.31E-17 6501 2 bilirubin UGT1A10,UGT1A3,UGT1A4,UGT1A5,UGT1A6,UGT1A7,UGT1A8,UGT1A9 
rs11563251 T C 0.3683 -1.237 0.1435 6.64E-18 6518 2 bilirubin UGT1A1,UGT1A10,UGT1A3,UGT1A4,UGT1A5,UGT1A6,UGT1A7,UGT1A8,UGT1A9 
rs7586006 T G 0.6176 -0.7347 0.1316 2.39E-08 6529 2 bilirubin UGT1A10(dist=3576),HJURP(dist=59959) 
rs10209214 T C 0.554 -0.9548 0.0953 1.24E-23 6523 2 bilirubin UGT1A10(dist=5632),HJURP(dist=57903) 
rs1115381 T C 0.4221 -0.9004 0.1025 1.53E-18 6483 2 bilirubin USP40(dist=35418),UGT1A8(dist=21006) 
rs2741027 A G 0.4346 2.0055 0.0954 3.60E-98 6530 2 bilirubin USP40(dist=48144),UGT1A8(dist=8280) 
rs491098 C G 0.199 -21.5146 0.5994 3.64E-282 8737 13 FVII F7 
rs3093253 A G 0.1906 -22.3575 0.6249 2.33E-280 8739 13 FVII F7 
rs563964 T C 0.4867 4.9929 0.4071 1.42E-34 8735 13 FVII F10 
rs547138 A T 0.5802 3.9481 0.4233 1.09E-20 8733 13 FVII F10 
rs867186 A G 0.8115 7.3879 0.724 1.89E-24 8738 20 FVII PROCR 
rs17406518 A C 0.8102 5.5107 0.7059 5.85E-15 8737 20 FVII PROCR(dist=34011),MMP24(dist=15280) 
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rs1058003 A G 0.5948 2.1242 0.4231 5.16E-07 8739 20 FVII TRPC4AP 
rs6060230 T C 0.187 7.3503 0.7349 1.50E-23 8738 20 FVII TRPC4AP(dist=8690),EDEM2(dist=13852) 
rs11906160 A G 0.1953 5.4717 0.6851 1.38E-15 8738 20 FVII MYH7B 
rs7261167 A G 0.184 7.4098 0.7441 2.32E-23 8738 20 FVII MYH7B 
rs8176725 A G 0.3073 11.5058 1.1053 2.25E-25 5867 9 FVIII ABO 
rs2073827 C G 0.4723 -7.761 0.645 2.42E-33 5868 9 FVIII ABO 
rs8176694 T C 0.6578 -5.455 0.8213 3.10E-11 5861 9 FVIII ABO 
rs8176644 T C 0.2984 16.206 1.2834 1.49E-36 5871 9 FVIII ABO 
rs507666 A G 0.3517 14.3829 0.791 7.07E-74 5871 9 FVIII ABO 
rs630014 A G 0.4934 -8.2094 0.6295 7.19E-39 5870 9 FVIII ABO 
rs11244061 T C 0.3287 13.2379 0.9874 5.47E-41 5872 9 FVIII ABO(dist=3351),SURF6(dist=43571) 
rs633862 T C 0.5037 -7.4347 0.6316 5.49E-32 5864 9 FVIII ABO(dist=4814),SURF6(dist=42108) 
rs554710 T C 0.6048 -5.4182 0.6924 5.09E-15 5869 9 FVIII ABO(dist=31218),SURF6(dist=15704) 
rs1179011 A G 0.5708 4.8883 0.6587 1.16E-13 5860 9 FVIII ABO(dist=35753),SURF6(dist=11169) 
rs11244084 T C 0.3075 9.818 1.2502 4.07E-15 5871 9 FVIII ABO(dist=40380),SURF6(dist=6542) 
rs10901262 A G 0.3857 4.6887 0.7122 4.60E-11 5870 9 FVIII ABO(dist=41486),SURF6(dist=5436) 
rs11244034 T C 0.3318 4.119 0.8678 2.07E-06 5870 9 FVIII OBP2B 
rs12554449 T G 0.5365 5.6209 1.2358 5.41E-06 2871 9 FVIII OBP2B 
rs3761823 C G 0.3494 3.679 0.7977 3.99E-06 5864 9 FVIII OBP2B(dist=2184),ABO(dist=43751) 
rs185852900 A G 0.3202 7.1986 0.9549 4.77E-14 5869 9 FVIII OBP2B(dist=18035),ABO(dist=27900) 
rs2013075 T C 0.2941 13.6835 1.2919 3.25E-26 5859 9 FVIII OBP2B(dist=18525),ABO(dist=27410) 
rs182267720 T C 0.3206 7.2223 0.9875 2.59E-13 5869 9 FVIII OBP2B(dist=29716),ABO(dist=16219) 
rs9411470 A G 0.663 4.552 0.8636 1.36E-07 5772 9 FVIII OBP2B(dist=35357),ABO(dist=10578) 
rs10901250 A G 0.3184 6.848 0.965 1.28E-12 5869 9 FVIII OBP2B(dist=36998),ABO(dist=8937) 
rs11244049 T C 0.7053 15.9482 1.2859 2.54E-35 5855 9 FVIII OBP2B(dist=38464),ABO(dist=7471) 
rs7857390 A G 0.4615 -7.5723 0.6468 1.17E-31 5872 9 FVIII OBP2B(dist=43918),ABO(dist=2017) 
rs10901253 T C 0.6255 -5.3952 0.7465 4.94E-13 5871 9 FVIII OBP2B(dist=44144),ABO(dist=1791) 
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rs28715750 T C 0.7242 -6.9293 1.5568 8.55E-06 5871 9 FVIII SURF4 
rs3118660 A T 0.3031 -5.8465 1.0295 1.36E-08 5871 9 FVIII SURF4 
rs3758348 C G 0.3395 11.0928 0.9249 3.82E-33 5869 9 FVIII SURF4 
rs62575992 T C 0.3169 -4.8132 0.9725 7.44E-07 5871 9 FVIII C9orf96 
rs77926044 T C 0.2999 -5.4358 1.1644 3.04E-06 5871 9 FVIII C9orf96 
rs17474001 T C 0.3357 10.7113 0.9439 7.65E-30 5870 9 FVIII C9orf96 
rs3124747 A G 0.4066 3.2712 0.6822 1.62E-06 5872 9 FVIII C9orf96 
rs41302673 T G 0.6826 10.0792 1.1259 3.48E-19 5872 9 FVIII C9orf96 
rs36219252 A G 0.3108 13.2123 2.4447 6.50E-08 5872 9 FVIII ADAMTS13 
rs72779205 A G 0.3266 -5.5328 0.9186 1.71E-09 5868 9 FVIII ADAMTS13 
rs3118671 T G 0.3394 -5.567 0.8268 1.66E-11 5867 9 FVIII ADAMTS13 
rs41296094 T C 0.7142 10.6838 1.5532 6.04E-12 5872 9 FVIII ADAMTS13 
rs28645493 C G 0.683 9.6009 1.1685 2.10E-16 5869 9 FVIII ADAMTS13 
rs652600 A G 0.6 -3.8721 0.6977 2.87E-08 5869 9 FVIII ADAMTS13 
rs2769073 T C 0.3292 -3.9742 0.8797 6.25E-06 5871 9 FVIII ADAMTS13 
rs2769074 T C 0.3017 -5.1076 1.0782 2.17E-06 5872 9 FVIII ADAMTS13 
rs4962153 A G 0.3336 9.4932 0.9352 3.28E-24 5872 9 FVIII ADAMTS13 
rs3124764 T C 0.3352 9.4455 0.9361 6.10E-24 5872 9 FVIII CACFD1 
rs41302667 A G 0.3114 9.1834 1.1719 4.65E-15 5869 9 FVIII CACFD1 
rs2073936 T C 0.2165 15.3003 3.3628 5.37E-06 5871 9 FVIII CACFD1 
rs3094381 A G 0.3029 -5.0661 1.0744 2.42E-06 5872 9 FVIII CACFD1 
rs35434910 A T 0.3639 5.0703 0.7664 3.71E-11 5869 9 FVIII GBGT1(dist=3023),OBP2B(dist=38342) 
rs7022409 T C 0.4266 -3.5256 0.6606 9.47E-08 5871 9 FVIII GBGT1(dist=3969),OBP2B(dist=37396) 
rs6597604 A G 0.5998 3.5731 0.6914 2.36E-07 5870 9 FVIII GBGT1(dist=10479),OBP2B(dist=30886) 
rs186686586 T C 0.363 -3.5115 0.7691 4.98E-06 5869 9 FVIII GBGT1(dist=21428),OBP2B(dist=19937) 
rs12378537 T C 0.2985 10.7287 1.1452 7.37E-21 5872 9 FVIII GBGT1(dist=26225),OBP2B(dist=15140) 
rs11244031 A G 0.471 -4.1714 0.6391 6.71E-11 5865 9 FVIII GBGT1(dist=36863),OBP2B(dist=4502) 
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rs4783961 A G 0.5096 -0.0309 0.0041 2.74E-14 14310 16 HDL CETP 
rs1800775 A C 0.4856 0.0682 0.004 5.99E-64 14312 16 HDL CETP 
rs1864163 A G 0.3016 -0.0729 0.0045 8.18E-58 14312 16 HDL CETP 
rs9929488 C G 0.3016 -0.0549 0.0046 4.52E-33 14311 16 HDL CETP 
rs118146573 A G 0.1848 -0.081 0.0059 2.73E-42 14324 16 HDL CETP 
rs11076174 T C 0.8517 -0.0496 0.0075 2.99E-11 14326 16 HDL CETP 
rs7205804 A G 0.4449 0.0692 0.0041 2.33E-64 14315 16 HDL CETP 
rs5883 T C 0.1264 0.0566 0.0092 7.49E-10 13528 16 HDL CETP 
rs289714 A G 0.7721 -0.0628 0.0053 1.51E-32 14315 16 HDL CETP 
rs289715 A T 0.1796 0.0383 0.0063 1.06E-09 14319 16 HDL CETP 
rs289719 T C 0.3415 0.0442 0.0044 5.22E-24 14309 16 HDL CETP 
rs5880 C G 0.1224 -0.0794 0.0088 3.01E-19 14325 16 HDL CETP 
rs2562126 A G 0.1946 -0.0307 0.0058 1.52E-07 14324 16 HDL HERPUD1 
rs9938160 T C 0.6614 0.0223 0.0044 4.54E-07 14321 16 HDL HERPUD1(dist=6797),CETP(dist=11245) 
rs9989419 A G 0.4105 -0.0498 0.0042 4.67E-33 14312 16 HDL HERPUD1(dist=7346),CETP(dist=10696) 
rs193695 A G 0.3749 -0.0482 0.0043 1.10E-29 14313 16 HDL HERPUD1(dist=7363),CETP(dist=10679) 
rs72786786 A G 0.3375 0.0671 0.0044 2.36E-52 14308 16 HDL HERPUD1(dist=7721),CETP(dist=10321) 
rs12448528 A G 0.2635 -0.0581 0.0051 3.09E-30 12079 16 HDL HERPUD1(dist=7762),CETP(dist=10280) 
rs7205692 A G 0.7897 -0.035 0.0056 3.37E-10 14323 16 HDL HERPUD1(dist=9121),CETP(dist=8921) 
rs12920974 T G 0.3171 -0.0479 0.0045 3.18E-26 14318 16 HDL HERPUD1(dist=15232),CETP(dist=2810) 
rs12708967 T C 0.7623 -0.0617 0.0051 1.87E-33 14324 16 HDL HERPUD1(dist=15418),CETP(dist=2624) 
rs3764261 A C 0.3502 0.0822 0.0043 7.35E-80 14317 16 HDL HERPUD1(dist=15531),CETP(dist=2511) 
rs1077834 T C 0.7407 0.049 0.0049 2.54E-23 14322 15 HDL LIPC 
rs8033940 A G 0.3197 0.0381 0.0045 4.29E-17 14289 15 HDL LIPC 
rs12914035 A G 0.7965 -0.0299 0.0056 1.08E-07 14295 15 HDL LIPC 
rs261338 A G 0.2205 0.0517 0.0055 3.35E-21 14323 15 HDL LIPC 
rs261336 A G 0.7849 0.0463 0.0055 4.41E-17 14325 15 HDL LIPC 
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rs74304285 A G 0.1991 0.0384 0.0057 2.36E-011 14323 8 HDL LPL 
rs343 A C 0.1441 0.0503 0.0072 3.50E-012 14320 8 HDL LPL 
rs269 T G 0.7683 0.0395 0.0052 4.19E-014 14322 8 HDL LPL 
rs301 T C 0.7228 0.0396 0.0048 1.36E-016 14324 8 HDL LPL 
rs314 A G 0.3161 0.0315 0.0045 2.13E-012 14326 8 HDL LPL 
rs13702 T C 0.6773 0.0399 0.0045 3.98E-019 14324 8 HDL LPL 
rs1569209 T G 0.8564 0.0638 0.0071 2.30E-019 14319 8 HDL LPL(dist=5400),SLC18A1(dist=172196) 
rs10096633 T C 0.1833 0.059 0.006 7.51E-023 14326 8 HDL LPL(dist=6151),SLC18A1(dist=171445) 
rs35237252 A C 0.2903 0.0397 0.0047 2.32E-017 14323 8 HDL LPL(dist=45501),SLC18A1(dist=132095) 
rs4333617 A G 0.552 0.029 0.0041 2.23E-012 14323 8 HDL LPL(dist=50234),SLC18A1(dist=127362) 
rs191343955 T C 0.6845 0.0302 0.0045 1.88E-011 14279 8 HDL LPL(dist=90514),SLC18A1(dist=87082) 
rs9644568 A G 0.1878 0.0489 0.006 2.74E-016 14324 8 HDL LPL(dist=103812),SLC18A1(dist=73784) 
rs7015766 T C 0.1348 0.054 0.0077 2.44E-012 14311 8 HDL LPL(dist=114279),SLC18A1(dist=63317) 
rs405509 T G 0.4909 0.088 0.0119 1.34E-13 14056 19 LDL APOE 
rs769449 A G 0.2098 0.2097 0.0179 9.61E-32 14048 19 LDL APOE 
rs7412 T C 0.1762 -0.484 0.022 9.00E-107 13226 19 LDL APOE 
rs445925 A G 0.1951 -0.3159 0.0192 1.10E-60 14057 19 LDL APOE(dist=2990),APOC1(dist=2281) 
rs6859 A G 0.4382 0.0725 0.0119 1.22E-09 14044 19 LDL PVRL2 
rs283813 A T 0.1673 -0.1163 0.0234 6.69E-07 14007 19 LDL PVRL2 
rs7254892 A G 0.1303 -0.4105 0.0337 3.84E-34 14057 19 LDL PVRL2 
rs6857 T C 0.2414 0.2042 0.0164 1.37E-35 13154 19 LDL PVRL2 
rs157580 A G 0.5781 -0.0952 0.0124 1.32E-14 13264 19 LDL TOMM40 
rs2075650 A G 0.7757 0.2018 0.0168 3.40E-33 14057 19 LDL TOMM40 
rs61679753 A T 0.2384 -0.3502 0.0345 2.98E-24 14057 19 LDL TOMM40 
rs115881343 T C 0.1332 0.1703 0.0369 3.96E-06 14047 19 LDL TOMM40 
rs6511720 T G 0.202 -0.1922 0.0178 3.59E-27 14056 19 LDL LDLR 
rs1010679 T C 0.7191 -0.0933 0.0142 4.99E-11 14054 19 LDL LDLR 
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rs2228671 T C 0.2086 -0.1489 0.0176 2.50E-17 14053 19 LDL LDLR 
rs2738447 A C 0.4291 -0.0608 0.0123 7.68E-07 13175 19 LDL LDLR 
rs5742911 A G 0.6383 -0.069 0.0137 4.99E-07 12044 19 LDL LDLR 
rs1529729 T C 0.5331 0.0562 0.0119 2.13E-06 14056 19 LDL SMARCA4 
rs3786725 A G 0.3492 -0.0577 0.0127 5.91E-06 14055 19 LDL SMARCA4 
rs73015007 A G 0.3076 -0.0814 0.0136 1.89E-09 14055 19 LDL SMARCA4(dist=10879),LDLR(dist=16201) 
rs11668477 A G 0.7264 -0.1145 0.0144 1.58E-15 14057 19 LDL SMARCA4(dist=22072),LDLR(dist=5008) 
rs17248720 T C 0.2004 -0.1904 0.0179 1.76E-26 14056 19 LDL SMARCA4(dist=25229),LDLR(dist=1851) 
rs10858082 A G 0.5594 -0.0662 0.012 3.94E-08 14048 1 LDL CELSR2 
rs4970834 T C 0.2572 -0.1294 0.0151 1.16E-17 14055 1 LDL CELSR2 
rs7528419 A G 0.7177 -0.1502 0.0143 7.73E-26 14014 1 LDL CELSR2 
rs11102967 T C 0.6371 -0.1127 0.0127 5.66E-19 14043 1 LDL CELSR2 
rs11577931 A G 0.8197 -0.1384 0.0203 9.29E-12 14054 1 LDL CELSR2(dist=2506),PSRC1(dist=1292) 
rs1042031 T C 0.2499 -0.0934 0.0155 1.55E-09 14057 2 LDL APOB 
rs693 A G 0.5209 -0.096 0.0119 6.18E-16 14057 2 LDL APOB 
rs113549125 T G 0.4476 0.101 0.012 3.17E-17 14052 2 LDL APOB 
rs12713956 A G 0.8264 -0.0978 0.0207 2.43E-06 14056 2 LDL APOB 
rs41288783 A G 0.2504 0.9996 0.2069 1.36E-06 7498 2 LDL APOB 
rs12691202 T C 0.1406 -0.143 0.0299 1.68E-06 14057 2 LDL APOB 
rs1367117 A G 0.369 0.1163 0.0125 1.15E-20 14055 2 LDL APOB 
rs17398765 A G 0.8217 0.1077 0.0223 1.33E-06 14057 2 LDL APOB(dist=3806),LOC645949(dist=639555) 
rs1713222 A G 0.2278 -0.1629 0.0166 7.52E-23 14056 2 LDL APOB(dist=4378),LOC645949(dist=638983) 
rs71435594 T C 0.173 -0.1832 0.0223 2.34E-16 14055 2 LDL APOB(dist=42390),LOC645949(dist=600971) 
rs111526071 T C 0.3312 0.0966 0.0131 1.53E-13 14048 2 LDL APOB(dist=46834),LOC645949(dist=596527) 
rs97458 A G 0.6588 -0.0947 0.0129 1.76E-13 14057 2 LDL APOB(dist=60690),LOC645949(dist=582671) 
rs4635554 T G 0.6305 0.0755 0.0126 2.07E-09 13975 2 LDL APOB(dist=122714),LOC645949(dist=520647) 
rs507627 T C 0.3019 -0.1048 0.0137 1.83E-14 14057 2 LDL APOB(dist=136884),LOC645949(dist=506477) 
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rs365946 T G 0.2383 -0.1226 0.0157 6.44E-15 14055 2 LDL APOB(dist=172384),LOC645949(dist=470977) 
rs11900894 A C 0.704 0.0824 0.0139 2.91E-09 14024 2 LDL APOB(dist=183319),LOC645949(dist=460042) 
rs436566 T C 0.2483 -0.1014 0.0156 7.91E-11 14056 2 LDL APOB(dist=184659),LOC645949(dist=458702) 
rs35239705 A G 0.2626 -0.0955 0.0147 9.29E-11 14054 2 LDL APOB(dist=184742),LOC645949(dist=458619) 
rs7571647 A G 0.1921 -0.1497 0.0191 3.96E-15 14056 2 LDL APOB(dist=209689),LOC645949(dist=433672) 
rs769449 A G 0.245 -0.3076 0.0224 4.34E-43 11537 19 crp APOE 
rs75627662 T C 0.2961 -0.1641 0.0184 5.00E-19 11543 19 crp APOE 
rs439401 T C 0.4055 0.0986 0.0154 1.36E-10 11544 19 crp APOE(dist=1801),APOC1(dist=3470) 
rs1205 T C 0.3857 -0.1662 0.0156 1.60E-26 11538 1 crp CRP 
rs3091244 A G 0.4039 0.1865 0.0152 1.33E-34 11539 1 crp CRP 
rs11579148 T C 0.1826 -0.3538 0.0632 2.16E-08 11545 1 crp CRP(dist=35023),DUSP23(dist=31357) 
rs12815613 A G 0.6248 0.115 0.0157 2.35E-13 11542 12 crp HNF1A-AS1 
rs2244608 A G 0.6288 -0.1649 0.0157 1.20E-25 11543 12 crp HNF1A 
rs1169286 T C 0.5511 -0.1237 0.0148 5.79E-17 11541 12 crp HNF1A 
rs2245407 A C 0.197 -0.1345 0.0293 4.47E-06 11543 12 crp HNF1A 
rs12427353 C G 0.2851 0.1176 0.0186 2.46E-10 11541 12 crp HNF1A 
rs1169300 A G 0.3559 -0.1562 0.0161 2.58E-22 11543 12 crp HNF1A 
rs1169303 A C 0.504 -0.1204 0.0146 1.98E-16 11541 12 crp HNF1A 
rs1169307 T C 0.411 0.1146 0.0151 2.70E-14 11540 12 crp HNF1A 
rs3751152 C G 0.3672 0.0981 0.0158 5.29E-10 11515 12 crp C12orf43 
rs3751151 A T 0.4398 0.0924 0.0155 2.72E-09 11533 12 crp C12orf43 
rs73214128 T C 0.187 -0.1428 0.0317 6.71E-06 11542 12 crp C12orf43 
rs1169314 A G 0.6426 -0.1581 0.016 6.83E-23 11528 12 crp C12orf43 
rs2264779 T C 0.5901 0.1157 0.0151 1.66E-14 11538 12 crp C12orf43 
rs6589566 A G 0.7801 0.1362 0.0127 7.91E-27 13636 11 TG ZNF259 
rs35120633 A G 0.2184 0.1387 0.0129 7.02E-27 13636 11 TG ZNF259 
rs3741298 T C 0.6958 0.0962 0.0079 9.36E-34 13631 11 TG ZNF259 
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rs12287066 T G 0.2187 0.1359 0.0128 1.74E-26 13636 11 TG APOA5 
rs662799 A G 0.789 0.1444 0.0134 4.18E-27 13635 11 TG APOA5 
rs6589567 A C 0.2551 0.0836 0.0101 8.67E-17 13635 11 TG APOA5(dist=7540),APOA4(dist=20742) 
rs61905108 A C 0.205 0.1322 0.0149 6.09E-19 13579 11 TG BUD13 
rs180326 T G 0.5978 0.0499 0.0066 4.87E-14 13608 11 TG BUD13 
rs10488699 T C 0.2205 0.1311 0.0125 1.19E-25 13633 11 TG BUD13 
rs17440824 T C 0.2581 0.0504 0.0096 1.52E-07 13634 11 TG BUD13 
rs10790162 A G 0.2194 0.1356 0.0127 1.23E-26 13636 11 TG BUD13 
rs1263151 T C 0.5069 0.0344 0.0063 4.00E-08 13631 11 TG BUD13 
rs2041967 A G 0.7046 0.0385 0.0082 2.52E-06 13635 11 TG BUD13(dist=1435),ZNF259(dist=4127) 
rs499790 T C 0.2473 0.0766 0.0104 1.50E-13 13628 11 TG LOC283143(dist=888821),BUD13(dist=99147) 
rs481843 T C 0.2293 0.09 0.0118 2.32E-14 13610 11 TG LOC283143(dist=894949),BUD13(dist=93019) 
rs486394 A C 0.6314 0.0405 0.0069 4.31E-09 13632 11 TG LOC283143(dist=895404),BUD13(dist=92564) 
rs11820504 T C 0.71 0.0442 0.0083 8.80E-08 13614 11 TG LOC283143(dist=898524),BUD13(dist=89444) 
rs509728 C G 0.3288 0.0775 0.0164 2.34E-06 13635 11 TG LOC283143(dist=902249),BUD13(dist=85719) 
rs112064887 A T 0.4339 0.0317 0.0064 6.01E-07 13357 11 TG LOC283143(dist=903370),BUD13(dist=84598) 
rs61906105 A G 0.7955 0.1128 0.0144 4.09E-15 13635 11 TG LOC283143(dist=919610),BUD13(dist=68358) 
rs12417015 A G 0.822 0.1098 0.0216 3.79E-07 13636 11 TG LOC283143(dist=919858),BUD13(dist=68110) 
rs12799766 A G 0.3275 0.0442 0.0074 2.25E-09 13633 11 TG LOC283143(dist=927509),BUD13(dist=60459) 
rs1145210 T C 0.3881 -0.0337 0.0067 5.48E-07 13630 11 TG LOC283143(dist=928084),BUD13(dist=59884) 
rs11216103 A G 0.2102 0.1027 0.0128 1.16E-15 13636 11 TG LOC283143(dist=943570),BUD13(dist=44398) 
rs12221682 C G 0.6467 0.0507 0.0112 6.44E-06 13622 11 TG LOC283143(dist=947299),BUD13(dist=40669) 
rs11216107 T C 0.624 0.0439 0.0068 1.04E-10 13636 11 TG LOC283143(dist=948745),BUD13(dist=39223) 
rs7350481 T C 0.212 0.1193 0.0133 2.62E-19 13636 11 TG LOC283143(dist=955365),BUD13(dist=32603) 
rs75273015 A G 0.1983 0.1556 0.021 1.36E-13 13632 11 TG LOC283143(dist=962912),BUD13(dist=25056) 
rs180360 A G 0.6525 -0.0374 0.0072 1.81E-07 13603 11 TG LOC283143(dist=968070),BUD13(dist=19898) 
rs12279180 T C 0.7757 0.1175 0.012 1.46E-22 13636 11 TG LOC283143(dist=973114),BUD13(dist=14854) 
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rs1558860 A C 0.2171 0.1298 0.0127 1.16E-24 13636 11 TG LOC283143(dist=976450),BUD13(dist=11518) 
rs61905084 T C 0.6954 -0.0494 0.0086 1.13E-08 12101 11 TG LOC283143(dist=979376),BUD13(dist=8592) 
rs57232565 T C 0.2301 0.1178 0.0142 1.19E-16 12828 11 TG LOC283143(dist=980539),BUD13(dist=7429) 
rs10466533 A G 0.7703 0.1125 0.0119 2.27E-21 13613 11 TG LOC283143(dist=981210),BUD13(dist=6758) 
rs56321069 A T 0.3342 -0.0394 0.0073 7.09E-08 13630 8 TG LPL 
rs74304285 A G 0.2715 -0.0549 0.0089 7.71E-10 13633 8 TG LPL 
rs343 A C 0.2252 -0.0734 0.0113 9.07E-11 13632 8 TG LPL 
rs253 T C 0.4634 -0.0332 0.0063 1.22E-07 13634 8 TG LPL 
rs269 T G 0.7065 -0.0547 0.0081 1.92E-11 13633 8 TG LPL 
rs285 T C 0.4789 -0.0447 0.0063 1.44E-12 13564 8 TG LPL 
rs314 A G 0.3594 -0.0561 0.0069 5.50E-16 13636 8 TG LPL 
rs10096633 T C 0.2527 -0.0939 0.0094 1.39E-23 13636 8 TG LPL(dist=6151),SLC18A1(dist=171445) 
rs117604010 A G 0.2032 -0.1255 0.0243 2.41E-07 13636 8 TG LPL(dist=23626),SLC18A1(dist=153970) 
rs17411024 A G 0.2556 -0.0638 0.0094 1.37E-11 13636 8 TG LPL(dist=27364),SLC18A1(dist=150232) 
rs894210 A G 0.5217 0.0477 0.0063 3.01E-14 13634 8 TG LPL(dist=41073),SLC18A1(dist=136523) 
rs35237252 A C 0.3402 -0.074 0.0072 1.26E-24 13633 8 TG LPL(dist=45501),SLC18A1(dist=132095) 
rs7005359 A G 0.7006 -0.0444 0.0081 3.51E-08 13458 8 TG LPL(dist=45923),SLC18A1(dist=131673) 
rs4333617 A G 0.5393 -0.0448 0.0064 1.74E-12 13634 8 TG LPL(dist=50234),SLC18A1(dist=127362) 
rs10103634 A G 0.3849 -0.0381 0.0067 1.36E-08 13631 8 TG LPL(dist=65842),SLC18A1(dist=111754) 
rs6586891 A C 0.5952 0.0454 0.0067 9.34E-12 13214 8 TG LPL(dist=89828),SLC18A1(dist=87768) 
rs9644568 A G 0.2589 -0.0759 0.0093 3.46E-16 13634 8 TG LPL(dist=103812),SLC18A1(dist=73784) 
rs11985911 T C 0.4096 0.0416 0.0066 2.36E-10 13634 8 TG LPL(dist=107318),SLC18A1(dist=70278) 
rs28597716 A G 0.6981 -0.0452 0.008 1.61E-08 13636 8 TG LPL(dist=111917),SLC18A1(dist=65679) 
rs7015766 T C 0.2168 -0.0769 0.012 1.37E-10 13622 8 TG LPL(dist=114279),SLC18A1(dist=63317) 
rs80336612 T C 0.5686 0.0334 0.0065 2.33E-07 13635 8 TG LPL(dist=115452),SLC18A1(dist=62144) 
rs13265868 A G 0.4573 -0.0292 0.0064 4.52E-06 13636 8 TG LPL(dist=118257),SLC18A1(dist=59339) 
rs8176725 A G 0.2909 0.127 0.0088 2.03E-047 9004 9 vWF ABO 
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rs512770 A G 0.3427 -0.0661 0.0062 1.98E-026 9007 9 vWF ABO 
rs2073826 T G 0.4653 -0.0982 0.005 4.34E-085 9008 9 vWF ABO 
rs8176694 T C 0.6722 -0.0694 0.0065 6.58E-027 8993 9 vWF ABO 
rs8176765 A C 0.774 0.1583 0.0166 1.35E-021 9000 9 vWF ABO 
rs8176632 T C 0.3112 0.0714 0.0073 1.47E-022 9007 9 vWF ABO(dist=1917),SURF6(dist=45005) 
rs8176630 T C 0.3462 -0.0683 0.0061 7.66E-029 9003 9 vWF ABO(dist=2092),SURF6(dist=44830) 
rs11244061 T C 0.3074 0.1714 0.0077 1.07E-110 9009 9 vWF ABO(dist=3351),SURF6(dist=43571) 
rs558240 A G 0.4419 0.0731 0.005 7.12E-049 9006 9 vWF ABO(dist=6503),SURF6(dist=40419) 
rs554710 T C 0.6121 -0.0555 0.0055 5.55E-024 9006 9 vWF ABO(dist=31218),SURF6(dist=15704) 
rs75444660 A G 0.7149 0.1815 0.0112 3.90E-059 9009 9 vWF ABO(dist=31845),SURF6(dist=15077) 
rs1179011 A G 0.5773 0.0577 0.0052 2.54E-028 8986 9 vWF ABO(dist=35753),SURF6(dist=11169) 
rs11244084 T C 0.2852 0.1423 0.0098 7.65E-048 9008 9 vWF ABO(dist=40380),SURF6(dist=6542) 
rs12379461 A G 0.4368 0.0246 0.0054 5.50E-06 8249 9 vWF OBP2B 
rs12554449 T G 0.4139 -0.0488 0.0083 3.54E-09 5934 9 vWF OBP2B 
rs10793957 T G 0.679 0.0422 0.0068 5.39E-10 9008 9 vWF OBP2B(dist=3303),ABO(dist=42632) 
rs185852900 A G 0.3037 0.073 0.0075 1.78E-22 9003 9 vWF OBP2B(dist=18035),ABO(dist=27900) 
rs2013075 T C 0.2747 0.1616 0.0102 5.78E-57 8995 9 vWF OBP2B(dist=18525),ABO(dist=27410) 
rs138683771 A C 0.7267 0.1357 0.0193 1.90E-12 9007 9 vWF OBP2B(dist=20935),ABO(dist=25000) 
rs182267720 T C 0.3025 0.0839 0.0078 3.36E-27 9005 9 vWF OBP2B(dist=29716),ABO(dist=16219) 
rs11793768 A G 0.2786 -0.0439 0.0086 3.59E-07 9009 9 vWF OBP2B(dist=32034),ABO(dist=13901) 
rs7855466 T C 0.31 0.0755 0.0073 5.82E-25 9001 9 vWF OBP2B(dist=36675),ABO(dist=9260) 
rs7025839 A G 0.2864 -0.0412 0.0087 1.88E-06 9008 9 vWF OBP2B(dist=39562),ABO(dist=6373) 
rs7857390 A G 0.4551 -0.0945 0.0051 1.03E-77 9009 9 vWF OBP2B(dist=43918),ABO(dist=2017) 
rs77693339 T C 0.7194 0.1838 0.0101 2.85E-74 9006 9 vWF OBP2B(dist=43930),ABO(dist=2005) 
rs12554339 A C 0.6381 -0.076 0.0059 1.58E-38 9006 9 vWF OBP2B(dist=44109),ABO(dist=1826) 
rs1179034 T C 0.7184 -0.05 0.0088 1.62E-08 9006 9 vWF SURF4 
rs3118660 A T 0.285 -0.0589 0.0081 2.71E-13 9008 9 vWF SURF4 
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rs28406995 A G 0.2858 -0.0397 0.0089 7.41E-06 9008 9 vWF SURF4 
rs56343119 A C 0.3191 0.1338 0.0072 2.41E-77 9009 9 vWF SURF4 
rs34399743 A G 0.2879 -0.04 0.0087 4.64E-06 9008 9 vWF C9orf96 
rs62575992 T C 0.3044 -0.0601 0.0078 9.39E-15 9008 9 vWF C9orf96 
rs77926044 T C 0.2796 -0.0545 0.0091 2.33E-09 9008 9 vWF C9orf96 
rs17474001 T C 0.3159 0.1284 0.0073 1.42E-68 9007 9 vWF C9orf96 
rs3124747 A G 0.403 0.04 0.0054 8.99E-14 9008 9 vWF C9orf96 
rs190371202 T G 0.6915 -0.0364 0.0074 7.95E-07 9008 9 vWF C9orf96 
rs41302673 T G 0.7046 0.138 0.0088 1.18E-55 9009 9 vWF C9orf96 
rs34265876 T C 0.7107 -0.0394 0.0088 6.99E-06 9009 9 vWF ADAMTS13 
rs34024143 T C 0.3046 -0.0415 0.0074 2.07E-08 9009 9 vWF ADAMTS13 
rs36219252 A G 0.2832 0.1803 0.0192 5.03E-21 9009 9 vWF ADAMTS13 
rs72779205 A G 0.3121 -0.0425 0.0073 6.38E-09 9005 9 vWF ADAMTS13 
rs3118671 T G 0.3272 -0.0565 0.0065 5.52E-18 9002 9 vWF ADAMTS13 
rs41296094 T C 0.7272 0.106 0.0125 1.91E-17 9009 9 vWF ADAMTS13 
rs28645493 C G 0.7061 0.1328 0.0091 3.09E-48 9006 9 vWF ADAMTS13 
rs592514 A T 0.7019 -0.0448 0.0077 5.69E-09 9008 9 vWF ADAMTS13 
rs652600 A G 0.6075 -0.042 0.0055 2.30E-14 9005 9 vWF ADAMTS13 
rs2769073 T C 0.3147 -0.0459 0.007 4.81E-11 9007 9 vWF ADAMTS13 
rs4962153 A G 0.3155 0.1248 0.0073 8.98E-66 9009 9 vWF ADAMTS13 
rs739468 T G 0.3141 0.1241 0.0073 2.83E-65 9008 9 vWF CACFD1 
rs78534112 A G 0.2369 0.1044 0.0155 1.59E-11 9001 9 vWF CACFD1 
rs41302667 A G 0.2895 0.1276 0.0091 3.12E-44 9006 9 vWF CACFD1 
rs2073936 T C 0.2176 0.1434 0.0279 2.62E-07 9008 9 vWF CACFD1 
rs3094381 A G 0.2863 -0.0455 0.0085 8.40E-08 9009 9 vWF CACFD1 
rs621907 T C 0.276 -0.0497 0.0095 1.48E-07 9009 9 vWF MED22 
rs512050 T C 0.2782 -0.0484 0.0093 2.08E-07 9009 9 vWF MED22 
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rs117119759 A G 0.2708 0.1688 0.0142 1.81E-32 9009 9 vWF MED22 
rs41307428 T C 0.287 0.1811 0.0192 3.99E-21 9008 9 vWF SLC2A6 
rs3094378 A G 0.2828 -0.0425 0.0087 1.07E-06 9009 9 vWF SLC2A6 
rs3124762 A C 0.6735 -0.0442 0.0067 3.05E-11 9006 9 vWF SLC2A6 
rs41297217 A G 0.2982 -0.0553 0.0086 1.29E-10 8228 9 vWF SLC2A6 
rs41309954 A C 0.2654 -0.0623 0.0097 1.63E-10 9005 9 vWF SLC2A6 
rs3124760 T C 0.6824 -0.0421 0.0072 3.94E-09 9005 9 vWF SLC2A6 
rs2073935 T G 0.3823 0.0437 0.0056 8.94E-15 9002 9 vWF SLC2A6 
rs3094326 C G 0.3361 -0.0512 0.0066 7.70E-15 9008 9 vWF SLC2A6 
rs78602133 T C 0.2816 -0.0447 0.0098 5.06E-06 9009 9 vWF SLC2A6(dist=3244),TMEM8C(dist=32188) 
rs72779222 T C 0.7424 -0.0502 0.0106 2.19E-06 9007 9 vWF SLC2A6(dist=3556),TMEM8C(dist=31876) 
rs4259477 C G 0.341 -0.0375 0.0063 3.18E-09 8982 9 vWF SLC2A6(dist=4809),TMEM8C(dist=30623) 
rs3094324 T C 0.3763 0.0289 0.0056 2.92E-07 8998 9 vWF SLC2A6(dist=5874),TMEM8C(dist=29558) 
rs2157780 C G 0.6126 -0.0298 0.0055 7.73E-08 9006 9 vWF SLC2A6(dist=8845),TMEM8C(dist=26587) 
rs183925556 A G 0.3568 0.0299 0.006 7.16E-07 9007 9 vWF SLC2A6(dist=9592),TMEM8C(dist=25840) 
rs77771223 T C 0.2989 -0.0454 0.0082 3.14E-08 9008 9 vWF SLC2A6(dist=12170),TMEM8C(dist=23262) 
rs3094325 A G 0.2792 0.0797 0.0136 4.63E-09 8989 9 vWF SLC2A6(dist=16601),TMEM8C(dist=18831) 
rs186264304 A G 0.6815 0.0805 0.0072 1.00E-28 9009 9 vWF SLC2A6(dist=18859),TMEM8C(dist=16573) 
rs28615587 T G 0.3962 0.0288 0.0054 1.01E-07 9009 9 vWF SLC2A6(dist=20870),TMEM8C(dist=14562) 
rs35434910 A T 0.3536 0.0588 0.006 1.90E-22 9006 9 vWF GBGT1(dist=3023),OBP2B(dist=38342) 
rs34187118 T C 0.2956 -0.0512 0.0081 2.04E-10 9009 9 vWF GBGT1(dist=3150),OBP2B(dist=38215) 
rs7022409 T C 0.4214 -0.044 0.0052 3.11E-17 9008 9 vWF GBGT1(dist=3969),OBP2B(dist=37396) 
rs4284147 T C 0.3549 -0.0377 0.006 2.91E-10 9007 9 vWF GBGT1(dist=7838),OBP2B(dist=33527) 
rs35333961 A G 0.4014 0.0413 0.0054 2.67E-14 9006 9 vWF GBGT1(dist=16864),OBP2B(dist=24501) 
rs7028259 T C 0.6627 -0.0336 0.0064 1.65E-07 9007 9 vWF GBGT1(dist=22347),OBP2B(dist=19018) 
rs12378537 T C 0.2828 0.1144 0.0091 1.97E-36 9009 9 vWF GBGT1(dist=26225),OBP2B(dist=15140) 
rs7039497 A G 0.2845 -0.0497 0.0087 1.04E-08 9008 9 vWF GBGT1(dist=30630),OBP2B(dist=10735) 
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rs11244031 A G 0.4642 -0.0481 0.0051 1.88E-21 9002 9 vWF GBGT1(dist=36863),OBP2B(dist=4502) 
rs10901243 C G 0.4289 0.0275 0.0052 1.22E-07 8998 9 vWF GBGT1(dist=39074),OBP2B(dist=2291) 
rs405509 T G 0.4903 0.0605 0.0132 4.58E-06 14594 19 TC APOE 
rs769449 A G 0.2102 0.2101 0.0198 2.87E-26 14586 19 TC APOE 
rs7412 T C 0.1763 -0.3898 0.0246 2.38E-56 13758 19 TC APOE 
rs439401 T C 0.3931 -0.0605 0.0137 9.87E-06 14594 19 TC APOE(dist=1801),APOC1(dist=3470) 
rs445925 A G 0.1949 -0.2479 0.0214 4.71E-31 14595 19 TC APOE(dist=2990),APOC1(dist=2281) 
rs6511720 T G 0.2019 -0.2254 0.0199 7.35E-30 14594 19 TC LDLR 
rs6511721 A G 0.5154 0.0636 0.0131 1.13E-06 14591 19 TC LDLR 
rs73015030 A G 0.1544 -0.1665 0.0349 1.91E-06 14595 19 TC LDLR 
rs2228671 T C 0.208 -0.1759 0.0196 2.89E-19 14591 19 TC LDLR 
rs2738447 A C 0.4287 -0.0664 0.0137 1.31E-06 13704 19 TC LDLR 
rs5742911 A G 0.6387 -0.0735 0.0153 1.52E-06 12541 19 TC LDLR 
rs8099996 A G 0.6059 -0.0646 0.0135 1.82E-06 14590 19 TC SMARCA4(dist=1667),LDLR(dist=25413) 
rs8102273 T C 0.6486 -0.0696 0.0141 7.98E-07 14591 19 TC SMARCA4(dist=7089),LDLR(dist=19991) 
rs73015007 A G 0.3066 -0.0974 0.0151 1.03E-10 14593 19 TC SMARCA4(dist=10879),LDLR(dist=16201) 
rs11668477 A G 0.7273 -0.1431 0.016 3.08E-19 14595 19 TC SMARCA4(dist=22072),LDLR(dist=5008) 
rs17248720 T C 0.2001 -0.2253 0.0199 1.29E-29 14594 19 TC SMARCA4(dist=25229),LDLR(dist=1851) 
rs7254892 A G 0.131 -0.3109 0.0375 1.05E-16 14595 19 TC PVRL2 
rs6857 T C 0.2435 0.1949 0.0182 1.05E-26 13684 19 TC PVRL2 
rs1042031 T C 0.2505 -0.0849 0.0172 7.75E-07 14595 2 TC APOB 
rs693 A G 0.5211 -0.1044 0.0132 2.22E-15 14595 2 TC APOB 
rs2854725 T G 0.8361 -0.1384 0.0254 5.03E-08 14588 2 TC APOB 
rs41288783 A G 0.2021 1.0301 0.2088 8.06E-07 8671 2 TC APOB 
rs10199768 T G 0.4616 0.1065 0.0133 9.36E-16 14592 2 TC APOB 
rs12714102 C G 0.168 -0.1499 0.0237 2.61E-10 14592 2 TC APOB 
rs1367117 A G 0.3691 0.1195 0.0139 6.62E-18 14593 2 TC APOB 
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rs72653053 T C 0.8791 -0.2604 0.0574 5.80E-06 14595 2 TC APOB 
rs1800481 A G 0.228 -0.1779 0.0184 5.15E-22 14552 2 TC APOB 
rs17398765 A G 0.8211 0.1133 0.0247 4.55E-06 14595 2 TC APOB(dist=3806),LOC645949(dist=639555) 
rs541041 A G 0.7509 -0.1635 0.017 7.42E-22 14593 2 TC APOB(dist=28030),LOC645949(dist=615331) 
rs61539677 A G 0.6288 0.11 0.0139 3.09E-15 14589 2 TC APOB(dist=38250),LOC645949(dist=605111) 
rs71435594 T C 0.1739 -0.1728 0.0249 3.67E-12 14593 2 TC APOB(dist=42390),LOC645949(dist=600971) 
rs97458 A G 0.6576 -0.1047 0.0143 2.48E-13 14595 2 TC APOB(dist=60690),LOC645949(dist=582671) 
rs12477249 A G 0.3721 0.087 0.0139 3.49E-10 14591 2 TC APOB(dist=133716),LOC645949(dist=509645) 
rs507627 T C 0.302 -0.1082 0.0152 1.09E-12 14595 2 TC APOB(dist=136884),LOC645949(dist=506477) 
rs11903224 C G 0.2968 0.0973 0.0154 2.58E-10 14533 2 TC APOB(dist=164416),LOC645949(dist=478945) 
rs380240 T C 0.2386 -0.1425 0.0175 3.41E-16 14592 2 TC APOB(dist=179708),LOC645949(dist=463653) 
rs436566 T C 0.2488 -0.0911 0.0173 1.47E-07 14594 2 TC APOB(dist=184659),LOC645949(dist=458702) 
rs35239705 A G 0.2632 -0.1021 0.0164 5.11E-10 14592 2 TC APOB(dist=184742),LOC645949(dist=458619) 
rs386397 A G 0.3535 0.0735 0.014 1.60E-07 14591 2 TC APOB(dist=184882),LOC645949(dist=458479) 
rs10198972 A G 0.1477 -0.1453 0.0328 9.42E-06 14595 2 TC APOB(dist=186266),LOC645949(dist=457095) 
rs312049 T C 0.5705 0.0609 0.0132 4.33E-06 14592 2 TC APOB(dist=208999),LOC645949(dist=434362) 
rs7571647 A G 0.1925 -0.1547 0.0212 3.05E-13 14594 2 TC APOB(dist=209689),LOC645949(dist=433672) 
Table 8-23. 394 SNPs selected for fine mapping analysis in the UCLEB meta-analysis of CVD related traits 
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Figure 8-1. Performance comparison of HAPRAP, GCTA and multiple regression using artificial 
meta-analyses of the simulated populations. Error (represented as a bar) is defined as the 
difference between the gold standard and the mean (with 95% CI) of 1000 replications. N is 
the number of individuals in the reference panel. A, the comparison against HAPRAP and 
GCTA for the 2-SNPs models with r2=0.8. B, the comparison against HAPRAP and GCTA for 
the 3-SNPs models. C, the comparison among HAPRAP, GCTA using meta-analysis data and 
multiple regression using individual-level data from the reference panel.  
 
